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Abstract 
 
Part A: Synthesis of N-heterocycles with dual pharmacology for the treatment of 
asthma 
The most common and effective anti-inflammatory asthma treatment is carried out 
through use of steroids but these can have significant side effects.  An alternative non-
steroidal oral treatment is montelukast which targets the leukotriene inflammatory 
pathway, but is less effective at controlling asthma symptoms.  The asthma 
inflammation pathway is complex involving many inflammatory mediators, and it was 
anticipated that a compound with dual pharmacology which impacted both leukotriene 
and prostaglandin pathways simultaneously would yield compounds with an enhanced 
ability to treat asthma.  An attractive novel dual target strategy was the inhibition of the 
5-lipoxygenase activating protein (FLAP) and antagonism of the prostaglandin D2 
receptor CRTh2.  A combination of GlaxoSmithKline and literature SAR studies were 
elaborated in the design of the target compounds, incorporating known pharmacophores 
for FLAP inhibitors and CRTh2 antagonists.  Synthetic routes towards the target 
compounds were developed and their biological activity against the intended targets 
determined.   
 
Part B: Synthesis of tetrahydroisoquinolines, tetrahydrobenzazepines and profens 
and their antimycobacterial properties 
Tuberculosis (TB) is an infectious disease caused by the Mycobacterium tuberculosis 
pathogen.  The increasing prevalence of drug resistant strains of M. tuberculosis means 
there is an urgent need to develop new anti-TB drugs with novel modes of action.  
Aporphine alkaloid natural products and synthetic tetrahydroisoquinolines have 
demonstrated a specific antimycobacterial effect, as well as M. tuberculosis MurE 
inhibitory activity.  The tetrahydroisoquinoline skeleton therefore provides a unique 
template for the development of new anti-TB drugs.  Recently we developed 
biomimetic reaction conditions for the Pictet-Spengler condensation of aldehydes and 
amines into tetrahydroisoquinolines.  The reaction is mediated by phosphate and 
proceeds under mild reaction conditions.  The scope of the phosphate mediated Pictet-
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Spengler reaction was investigated in order to access novel alkaloid structures and 
identify new leads for mycobacterial growth inhibitors.  Studies into asymmetric 
versions of the reaction using chiral phosphates and extending the reaction for the 
construction of larger ring sizes were explored.   
Another interesting class of compounds recently identified as active against 
mycobacterial growth were non-steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen. Analogues of profen compounds were synthesised for evaluation as 
mycobacterial growth inhibitors.     
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Part A: Synthesis of N-heterocycles with dual pharmacology for the 
treatment of asthma 
 
1. Introduction 
 
1.1 Asthma - definition 
Asthma is a chronic inflammatory disorder of the airways.  It is typically characterised 
by airflow obstruction, airway hyper-responsiveness, infiltration of inflammatory cells 
to the airways and airway remodelling, resulting in symptoms such as coughing, 
wheezing, breathlessness and chest tightness.
1
  The symptoms are often triggered by 
stimuli such as allergens, environmental exposure, exercise, chemical irritation, viral 
illnesses or emotional stress. 
The definition of asthma is broad and describes a number of different subgroups or 
phenotypes of the disease.  Different phenotypes can be defined by either the clinical 
symptoms and response to treatment, or by the underlying chemical mechanisms which 
are still not fully understood.
2
  Recognising asthma as a heterogeneous disease is 
important with respect to the development of anti-asthma drugs, as drugs targeting 
multiple asthma pathways or tailored to specific phenotypes could be beneficial.
3
 
Asthma is a global health problem which affects over 300 million people worldwide, 
and is expected to rise to 400 million by 2025.
4
  The disease has high economic costs, 
both directly for healthcare systems and from indirect consequences such as lost time 
from work.
5
  Asthma can have a serious impact on the sufferer’s quality of life, and 
asthma attacks can be fatal, often arising from poorly controlled and undertreated 
asthma.
6
   Despite the availability of effective asthma treatments, more than half of 
patients experience poor symptom control,
7
 so there remains an unmet therapeutic need 
for many asthmatics.   
  
1.2 Asthma treatment 
There are two major classes of asthma treatment; drugs to relieve the symptoms of 
asthma and drugs which control the symptoms (Table 1.1).
8
  Reliever drugs are 
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bronchodilators which provide rapid relief from asthma attacks by stimulating widening 
of the airways.  The most widely used bronchodilators are 2-adrenoceptor agonists, 
anticholinergics and methylxanthines.  Controller drugs are designed to prevent asthma 
attacks and reduce symptoms by supressing the underlying inflammatory component. 
The most common controller drugs are inhaled corticosteroids, which are seen as the 
gold standard of asthma treatment.  Alternatives include chromones and two newer 
classes of drugs introduced in the last 30 years, the anti-IgE monoclonal antibody 
omalizumab and the anti-leukotrienes.   
 
Classification Drug type  (mode of action) Examples 
Reliever drugs Short acting inhaled 2-adrenoceptor 
agonists (bronchodilator)  
Salbutamol 
Terbutaline  
 Methylxanthines  
(bronchodilator) 
Theophylline 
 Inhaled anticholinergics 
 (bronchodilator) 
Tiotropium bromide 
Ipratropium bromide  
Controller 
drugs 
Corticosteroids  
(anti-inflammatory) 
Fluticasone propionate 
Fluticasone furoate  
Prednisolone 
Long acting inhaled 2-adrenoceptor 
agonists (bronchodilator) 
Salmeterol 
Formoterol 
 Chromones  
(anti-inflammatory) 
Sodium cromoglycate 
Nedocromil sodium 
 Anti-immunoglobin E (Anti-IgE) 
(anti-inflammatory) 
Omalizumab  
 Anti-leukotrienes 
(anti-inflammatory) 
Montelukast 
Zafirlukast 
Zileuton 
Table 1.1. Reliever and controller drugs used for the treatment of asthma. 
 
Inhaled corticosteroids provide the most effective anti-inflammatory asthma treatment, 
helping to reduce symptoms and the risk of asthma attacks and improve lung function.
9
  
For example, fluticasone furoate (Figure 1.1) acts as a glucocorticoid receptor agonist 
and was approved by the FDA for clinical use in 2007 for allergic rhinitis and in 2014 
for once-daily asthma treatment.
10
  Combination inhalers of corticosteroids and long 
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acting 2-adrenoceptor agonists (e.g. salmeterol/fluticasone) can also provide highly 
effective asthma control.
11
  Inhaled corticosteroids are relatively safe for patients with 
mild to moderate asthma, as the drug is delivered directly into the lungs so lower doses 
can be used.  Local side effects such as oral candidiasis and dysphonia can be 
problematic but rare.
12
   For patients with more severe asthma, the long term use of high 
doses of inhaled corticosteroids can lead to side effects such as cataracts, glaucoma and 
osteoporosis, and another problem is poor compliance with inhaled corticosteroids, 
leading to the poor control of symptoms.
13
  Oral treatments are generally preferred, but 
oral corticosteroids such as prednisolone (Figure 1.1) are only used to treat severe 
asthma for short periods of time due to serious systemic side effects or adverse 
reactions, and are not suitable as daily controller drugs.   
 
 
Figure 1.1. Anti-asthma drugs - corticosteroids. 
 
Anti-leukotriene drugs such as montelukast, zafirlukast and zileuton (Figure 1.2) are 
alternatives to inhaled corticosteroids.  The anti-leukotrienes target a specific 
inflammatory pathway or mediator and block part of the inflammatory response.  
Montelukast was one of the first non-steroid oral treatments available to asthma 
patients.  With its good safety profile and few side effects it is now widely used as a 
daily controller drug.  However when compared with inhaled corticosteroids, anti-
leukotrienes are less effective in controlling asthma symptoms and are generally used in 
combination with other therapies.
14
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Figure 1.2. Anti-asthma drugs - anti-leukotrienes. 
 
The monoclonal IgE antibody omalizumab was approved for asthma treatment by the 
FDA in 2003 and the EU in 2009.  Omalizumab is used specifically for the treatment of 
severe allergic asthma, and works by complexing with free immunoglobin E (IgE, a key 
mediator of inflammation), which prevents the activation of high affinity IgE receptors 
on inflammatory cells.  Since the approval of omalizumab there has been significant 
development of biologic asthma therapies, in particular those targeting pro-
inflammatory cytokines such as mepolizumab (developed by GSK), which is an anti-
interleukin 5 monoclonal antibody for the treatment of severe asthma.
15
 
Even though there are effective asthma drugs available, it has been reported that 5-10% 
of patients have inadequately controlled symptoms despite taking controller 
medications.
16
  There is still a need to develop new anti-inflammatory therapies, 
particularly oral treatments which are safe and effective at controlling symptoms.   
 
1.3 Asthma inflammation pathways 
1.3.1 Biosynthesis of leukotrienes 
Asthma inflammatory pathways are complex, and there are a number of compounds 
involved in mediating the inflammatory response.  These include amines, lipids, 
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peptides, cytokines, chemokines, proteases and other small molecules.  Each have their 
own specific receptors through which they exert their biological effects.  Eicosanoids 
are a class of lipid mediator inflammatory compounds and are bioactive oxygenated 
metabolites of fatty acids containing a 20 carbon chain length.  Leukotrienes (LTs) and 
prostaglandins (PGs) are part of the eicosanoid family, and play a key role in 
inflammatory and allergic diseases such as asthma.
17
  Both LTs and PGs are derived 
from arachidonic acid, which is released from membrane phospholipids by 
phospholipases in response to allergic or other cellular stimuli.   
The biosynthesis of leukotrienes (Schemes 1.1 and 1.2) begins with the conversion of 
arachidonic acid to the unstable epoxide leukotriene A4 (LTA4) in a two-step 
oxidation/hydrolysis process catalysed by 5-lipoxygenase (5-LO).
18
  The activity of the 
5-LO enzyme requires the integral membrane protein, 5-lipoxygenase activating protein 
(FLAP), which plays a role in the transfer of arachidonic acid to 5-LO.  LTA4 is rapidly 
converted to either leukotriene B4 (LTB4) by enzymatic hydrolysis, or to leukotriene C4 
(LTC4) by opening of the epoxide by the thiol anion of glutathione.  LTC4 is further 
converted to LTD4 and LTE4 through amide bond cleavage of the peptide side chain.  
Collectively, LTC4, LTD4 and LTE4 are known as cysteinyl leukotrienes (CysLTs) and 
all contain a thioether linkage. 
 
 
Scheme 1.1. Biosynthesis of leukotrienes. LT = leukotriene, 5-LO = 5-lipoxygenase, FLAP = 5-
lipoxygenase activating protein. 
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Scheme 1.2. Biosynthesis of leukotrienes (LTs) from  arachidonic acid. 
 
Leukotrienes are recognised by specific G protein coupled receptors (GPCRs).
19
  The 
CysLTs bind to CysLT1 and CysLT2 receptors, which are involved in mediating 
bronchoconstriction, increasing vascular permeability, airway edema and mucus 
secretion.  LTB4 binds to BLT1 and BLT2 receptors, with a particularly high specificity 
for BLT1.  BLT1 is expressed in inflammatory cells and its activation mediates 
chemoattractant and pro-inflammatory actions. 
 
1.3.2 Biosynthesis of prostaglandins 
The biosynthesis of prostaglandins (Schemes 1.3 and 1.4) begins with the conversion of 
arachidonic acid to the unstable endoperoxide intermediate prostaglandin H2 (PGH2), 
catalysed by a cyclooxygenase enzyme.  PGH2 is further metabolised to a number of 
biologically active mediators including prostaglandin D2 (PGD2), catalysed by PGD 
synthase.   
7 
 
 
Scheme 1.3. Biosynthesis of prostaglandins. PG = prostaglandin, TXA2 = Thromboxane A2, COX = 
cyclooxygenase. 
 
 
Scheme 1.4. Biosynthesis of prostaglandin D2 (PGD2). 
 
PGD2 is of particular importance because it is the major prostaglandin produced by mast 
cells, is generated in high concentrations at sites of allergic inflammation and promotes 
an inflammatory response associated with asthma and allergy.
20
    PGD2 is a ligand for 
two G protein coupled receptors, DP1 and CRTh2 (chemoattractant receptor-
homologous molecule expressed on Th2 cells, also known as DP2).  The CRTh2 
receptor is expressed on Th2 cells, eosinophils and basophils, and in vitro studies have 
shown PGD2 activation of this receptor stimulates chemotaxis of these inflammatory 
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cells and the release of pro-inflammatory Th2 cytokines.
21
  The DP1 receptor is also 
activated through binding PGD2 and mediates vasodilation and bronchodilation.  A 
number of metabolites of PGD2 retain the ability to activate CRTh2 but only have weak 
DP1 activity, suggesting the effects of CRTh2 dominate, and that CRTh2 is able to bind 
a more structurally diverse range of ligands.
20,22
 
 
1.4 Drugs targeting the arachidonic acid pathway 
1.4.1 Anti-leukotriene drugs 
There are two classes of anti-leukotriene drugs: leukotriene receptor antagonists 
(LTRAs) and inhibitors of leukotriene biosynthesis.  The LTRA montelukast (Figure 
1.2) targets the CysLT1 receptor and is widely used for the treatment of asthma.  
However, montelukast is not always effective in asthmatic patients, and the lack of 
efficacy often associated with LTRAs may arise from their mode of action to only block 
the biological effect of specific leukotrienes.   
Alternatively, anti-leukotriene drugs that target 5-LO or FLAP early on in the pathway 
inhibit the formation of all CysLTs and LTB4, so could offer better efficacy compared 
to LTRAs.  The 5-LO enzyme inhibitor zileuton (Figure 1.2) is currently the only 
leukotriene synthesis inhibitor approved clinically for asthma treatment, but is not 
widely used due to its poor safety profile and high dose requirements.
23
  FLAP is a 
protein that is essential for the cellular biosynthesis of leukotrienes and hence represents 
an attractive target for novel anti-asthma drugs.
24
  FLAP is a membrane embedded 
protein that selectively binds arachidonic acid and transfers it to the 5-LO enzyme.  It 
has also been suggested that FLAP plays a role in enhancing the activity of 5-LO in the 
oxidation/reduction sequence to convert arachidonic acid to LTA4.
25
 
There are currently no FLAP inhibitors approved for therapeutic use, but several 
compounds have advanced into clinical trials for inflammatory diseases including 
asthma.
26
  Early FLAP inhibitors include the quinoline based compound BAYX1005 1, 
indole based compound MK886 2 and a combination of these structures MK591 3 
(Figure 1.3).
27
  In 2007 the crystal structure of MK591 3 bound to human FLAP was 
determined, revealing key binding interactions, and showed the inhibitor binding site 
was located in the membrane embedded pockets and prevented the binding of 
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arachidonic acid to FLAP.
28
  The crystal structure of FLAP has enabled improved 
FLAP inhibitor design, and several compounds with different pharmacophores such as 
benzimidazoles, oxadiazoles and biaryls have been published.
29
 
 
 
Figure 1.3. FLAP inhibitors (IC50 (FLAP) refers to a FLAP binding assay.  IC50 (LTB4) refers to the 
LTB4 inhibition in human leukocytes assay). 
 
A series of selective FLAP inhibitors containing a core indole structure were recently 
developed by Amira and GlaxoSmithKline (Figure 1.4).  The compounds AM103 4 and  
AM803 5 had superior potency and pharmacokinetic and safety profiles compared to the 
indole based FLAP inhibitor MK591 3.
30
  The key structural changes from MK591 3 
were replacement of the quinoline pharmacophore with pyridine derivatives and 
incorporation of heteroaromatic biaryls in place of the 4-chlorobenzyl group.  AM803 5  
successfully completed phase I clinical studies and was advanced to phase II trials in 
asthmatic patients as an orally bioavailable FLAP inhibitor.
31
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Stock et al. reported an extensive structure-activity relationship study for this series of 
FLAP inhibitors,
32
 focusing on cyclic moieties appended to the indole core, in order to 
replace the quinoline group present in MK591 3 which has been implicated as being 
susceptible to CYP-mediated bioactivation and covalent labelling of protein.  The 
compound AM679 6 (Figure 1.4) containing a novel N-acylated-(S)-indoline group 
showed excellent potency at inhibiting LTB4 synthesis in human blood (IC50 = 154 nM) 
as well as the human leukocyte assay (IC50 = 0.6 nM) and LT inhibition in several in 
vivo models.  In addition, AM679 6 displayed better solubility and an improved CYP 
inhibition profile compared to MK591 3, through replacement of the chlorobenzyl 
group with a heteroaromatic biaryl group. 
 
 
Figure 1.4. Indole based FLAP inhibitors developed by GlaxoSmithKline and Amira (IC50 (FLAP) refers 
to FLAP binding assay.  IC50 (LTB4) refers to the LTB4 inhibition in human leukocytes assay). 
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1.4.2 Prostaglandin inhibitors and receptor antagonists 
Inhibition of the synthesis of pro-inflammatory mediator PGD2 (Scheme 1.3) could be 
achieved by targeting enzymes COX1 and COX2 using COX inhibitors (non-steroidal 
anti-inflammatory drugs).  However COX inhibitors have been found to be generally 
ineffective as anti-asthma drugs because inhibition of COX also inhibits the 
biosynthesis of PGE2, a prostaglandin with bronchodilator properties.  Therefore, to 
achieve a therapeutic benefit in asthma treatment, selective inhibition of the biological 
actions of PGD2 is needed.
20
  
There has been much interest in the last 10 years in designing small molecule 
antagonists of the PGD2 receptor CRTh2, as a target for anti-asthma drugs.  In various 
biological studies, the pro-inflammatory effects from activation of the CRTh2 receptor 
by PGD2 have been completely blocked with a CRTh2 antagonist.  In addition, a 
number of CRTh2 antagonists have entered clinical trials for the treatment of asthma, 
COPD and allergic rhinitis, with promising proof of concept results, and hence CRTh2 
is a validated drug target.
33
    
The first CRTh2 antagonist discovered was ramatroban 7 (Figure 1.5).  Ramatroban was 
marketed for allergic rhinitis in Japan as an orally bioavailable thromboxane receptor 
antagonist.  It was subsequently found to also be a potent CRTh2 receptor antagonist 
and antagonises PGD2 induced bronchoconstriction.
34
   
 
 
Figure 1.5. CRTh2 antagonist ramatoban (IC50 value refers to a CRTh2 binding assay). 
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The tricyclic core of ramatroban 7 has served as a starting point for the design of more 
potent and selective CRTh2 antagonists.  7TM Pharma demonstrated with compound 8 
(TM30089, Figure 1.6) that shortening the propionic acid side chain to an acetic acid 
and N-methylation of ramatroban 7 gave a highly potent and selective CRTh2 
antagonist.
35
  Changes to the core indole structure of ramatroban 7 such as the reverse 
indole 9 (MK7246), the aza-indole 10, and replacement of the sulfonamide side chain 
were also tolerated (Figure 1.6).
36
 
 
 
Figure 1.6. CRTh2 antagonists with a tricyclic core (Ki values refer to a CRTh2 binding assay). 
. 
Another major structural class of CRTh2 antagonists are indole acetic acids.  
Interestingly this core structure was originally inspired by indomethacin 11 (Figure 1.7), 
which is a non-steroidal anti-inflammatory drug (NSAID) that was discovered to be a 
CRTh2 receptor agonist.
37
  Oxagen developed a potent orally bioavailable CRTh2 
antagonist OC459 12 (Figure 1.7), which is a reverse indole analogue of 11 and with a 
quinoline substituent replacing the aryl ketone.  Compound 12 progressed into phase II 
clinical trials and has been found to improve lung function and asthma control in 
allergic asthmatics.
38
  A similar indole acetic acid scaffold was present in AstraZenecas 
lead CRTh2 antagonist AZD1981 13 (Figure 1.7), which progressed into phase II 
clinical studies for the treatment of asthma and COPD, but lacked efficacy and has been 
discontinued.
39
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Figure 1.7. Indole acetic acid series of CRTh2 antagonists (IC50 values refer to a CRTh2 binding assay). 
 
Phenoxy and phenyl acetic acids are other common motifs for CRTh2 antagonists.  
Amira have optimised a series of biphenylacetic acid CRTh2 selective antagonists 
(Figure 1.8).  Compounds such as 14 and 15 were highly potent in both binding and 
functional assays, and demonstrated good in vivo activity in mouse models of 
inflammatory disease after oral dosing.
40
   
 
 
Figure 1.8. Phenyl acetic acid based CRTh2 antagonists (IC50 values refer to a CRTh2 binding assay). 
 
7TM Pharma identified the first phenoxyacetic acid CRTh2 antagonists such as 
compound 16 (Figure 1.9) from virtual screening.
41
  A series of phenoxyacetic acids 
17a-c (Figure 1.9) were reported by AstraZeneca, where changes to the acetic acid side 
chain were investigated.
42
  Isosteres of the carboxylic acid were not tolerated, and 
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increasing steric bulk next to the carboxylic acid was also unfavourable with respect to 
CRTh2 binding affinity.  In general, the majority of CRTh2 antagonists in development 
contain a carboxylic acid group.  It is likely that this group mimics the carboxylic acid 
present in PGD2, the natural ligand for the CRTh2 receptor. 
 
 
Figure 1.9. Phenoxy acetic acid based CRTh2 antagonists (IC50 values refer to a CRTh2 binding assay). 
 
A recent review of CRTh2 antagonist clinical candidates has suggested increased 
potency is required for CRTh2 antagonists, as recently evaluated clinical candidates 
have failed to produce the efficacy required for them to be clinically useful for the 
treatment of asthma or allergic diseases.
43
 
 
1.4.3 Dual inhibitors 
Due to the complexity of asthma, compounds that inhibit more than one target have the 
potential to be more effective treatments than those targeting a single mediator.  Also, 
several single targeting compounds that have advanced to clinical development for the 
treatment of asthma have been discontinued due to lack of efficacy.   
Amgen have recently described the optimisation of a series of phenylacetic acid 
derivatives as potent dual antagonists of both the PGD2 receptors, CRTh2 and DP1.
44
  
Their clinical candidate AMG853 18 (Figure 1.10) was evaluated in phase II clinical 
studies for the treatment of asthma but failed to improve asthma symptoms in patients 
with poorly controlled asthma and has since been discontinued.  Dual CRTh2/DP1 
antagonists are yet to show any anti-asthma benefits over selective CRTh2 antagonists.  
15 
 
Studies of a selective DP1 antagonist (laropiprant) have indicated that antagonism of the 
DP1 receptor does not have a therapeutic benefit for the treatment of asthma and 
actually DP1 activation plays a role in some anti-inflammatory responses.
45
 
Another approach to dual inhibition is the development of compounds that target both 
the leukotriene and prostaglandin pathways.  Single inhibition along one of the 
pathways can cause a shift in arachidonic acid metabolism to the other uninhibited 
pathway, resulting in increased biosynthesis of either LT or PG mediators.
46
  
Compounds exhibiting dual antagonism of CysLT1 (LTD4 receptor in the leukotriene 
pathway) and TP (TXA2 receptor in the prostaglandin pathway) have been under 
development as anti-asthma drugs.  Initially Astellas Pharmaceutical reported 
compound YM158 was a selective and potent dual antagonist of LTD4/TXA2 receptors, 
and in vitro functional assays demonstrated inhibition of asthmatic responses.
47
  They 
have more recently reported a quinoline derivative 19 (Figure 1.10) as an orally active 
dual LTD4/TXA2 receptor antagonist.
48
 The design of compound 19 was based on 
combining the lipophilic chloroquinolylvinyl moiety of montelukast (CysLT1 
antagonist, Figure 1.2) with a chlorobenzenesulfonamide group present in daltroban (a 
TXA2 receptor antagonist).  However, its activity is almost 1000 fold lower at the TXA2 
receptor, so the anti-inflammatory effects may result mainly from antagonism of the 
CysLT1 receptor.   
 
 
Figure 1.10. Compounds with dual activity along the asthma inflammatory pathways. 
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1.5 Aims of the project 
Leukotriene and prostaglandin lipid mediators play important roles in the pathogenesis 
of asthma and it is anticipated that a compound with dual pharmacology, which impacts 
both the leukotriene and prostaglandin inflammatory pathways simultaneously, would 
yield compounds with an enhanced ability to treat asthma.   
An attractive novel dual target combination is the inhibition of FLAP to block the 
synthesis of all leukotrienes, and antagonism of the prostaglandin receptor CRTh2 to 
block PGD2 mediated asthma responses.  Dual FLAP/CRTh2 inhibitors have excellent 
potential as anti-asthma drugs because currently both single targeting FLAP inhibitors 
and CRTh2 antagonists are already in clinical development, but efficacy has often been 
a problem.  Therefore a dual inhibitor targeting both LT and PG pathways could 
overcome this.  In addition, many structurally diverse compounds bind to FLAP or 
CRTh2.  To date, many literature CRTh2 antagonists are lipophilic carboxylic acid 
containing compounds, features also often found in FLAP inhibitors.   
The aim of this part of the project was to identify compounds that inhibit both 
leukotriene synthesis and antagonise CRTh2 in order to discover compounds with dual 
pharmacology.  The target compounds 20 and 21 (Figure 1.11) were designed based on 
a combination of previous GlaxoSmithKline and literature SAR studies.  As well as 
featuring a phenylacetic acid group which is a known pharmacophore for CRTh2 
antagonism, the target compounds also incorporated either the polar aliphatic acyl 
indoline group present in the FLAP inhibitor AM679 (6, Figure 1.4), or the smaller acyl 
pyrrolidine group also identified by Stock et al. as enhancing potency of FLAP 
inhibition (Figure 1.12).
32  
 
 
Figure 1.11. Target compounds: potential dual FLAP inhibitors and CRTh2 antagonists. 
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 Figure 1.12. Known pharmacophores for FLAP inhibitors and CRTh2 antagonists. 
 
The first part of the project was to investigate a synthetic route towards the target 
compounds via initial synthesis of the arylboronic ester intermediates 22 (Figure 1.13), 
which would facilitate attachment of ring B by a Suzuki coupling.     
 
 
Figure 1.13. Proposed synthetic route towards target compounds. 
 
Compounds of type 20 and 21 would then be evaluated though biological assays for 
their activity against leukotriene synthesis inhibition and antagonism of the CRTh2 
receptor.  The assays would determine if the compounds showed potential FLAP 
inhibitory activity by inhibiting LTB4 production and if the compounds inhibited the 
binding of PGD2 to the CRTh2 receptor.  Compounds showing dual pharmacology 
could serve as an excellent starting point for further lead optimisation for novel anti-
asthma drugs.   
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2. Results and discussion 
 
2.1 Synthesis of boronic ester intermediates (ring A) 
2.1.1 Attempted synthesis by direct acetylation 
The first approach to the preparation of the boronic ester intermediates 22 (Figure 1.13) 
was via an initial N-acetylation.  This would allow the synthesis of the target 
compounds 20 and 21 with R
1
 = COCH3 (Figure 1.11), which was chosen because Stock 
et al. have reported SAR studies of N-acyl indoline groups which led to their discovery 
of the potent FLAP inhibitor 6 (Figure 1.4).
32
   
Following a procedure reported by Kuwano et al.,
49
 the N-acetyl indoline alcohol (S)-23 
was synthesised over 3 steps from commercially available (S)-indoline-2-carboxylic 
acid (S)-24 (Scheme 2.1).  Treatment of the carboxylic acid (S)-24 with thionyl chloride 
in methanol gave the intermediate methyl ester as the hydrochloride salt.  Subsequent 
acetylation with acetic anhydride, triethylamine and the addition of DMAP (to enable a 
shorter reaction time) afforded the amide (S)-25 in 91% yield over 2 steps, which was 
similar to the yield reported in the literature of 86%.
49
   
 
 
Scheme 2.1. Synthesis of N-acetyl indoline alcohol (S)-23. 
 
Reduction of the methyl ester moiety in compound (S)-25 (Scheme 2.1) was achieved 
using lithium borohydride in THF at room temperature, which gave the N-acetyl 
indoline alcohol (S)-23 in 50% yield after purification by column chromatography.  This 
was a lower yield than that reported in the literature, where the same product was 
isolated in 74% yield.
49
  Lithium borohydride was used rather than lithium aluminium 
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hydride because it enables the selective reduction of esters to alcohols without affecting 
amides, however a side product isolated from the reaction was indolin-2-ylmethanol
50
 in 
19% yield, where the N-acetyl group had been converted to the N-H group.  This side 
product may have formed from the N-acetyl indoline alcohol (S)-23 through an initial 
N-O intramolecular acyl transfer, resulting in the O-acetyl compound, which would then 
be reduced to the alcohol by lithium borohydride. 
The N-acetyl pyrrolidine analogue (S)-26 was prepared via the same route over 3 steps 
from readily available (S)-proline (S)-27 (Scheme 2.2).  Esterification and subsequent 
acetylation of (S)-27 gave the compound (S)-28
51
 in 93% yield over two steps.  The 
same synthesis was applied with the opposite enantiomer, (R)-proline (R)-27, where 
esterification followed by acetylation afforded the N-acetyl compound (R)-28.
52
  
Reduction of the methyl ester moiety in compound (S)-28 was carried out using lithium 
borohydride at a low temperature in order to supress the formation of side products, and 
this afforded the N-acetyl pyrrolidine alcohol (S)-26
53
 in 55% yield after purification by 
column chromatography.  It was likely that the moderate yield was due to the instability 
of (S)-26, with possible N-O acyl transfer occurring.  The use of 2-methyl THF as a 
solvent instead of THF was found to give a better separation of the aqueous and organic 
phases during the work-up and improve the yield of the product isolated.   
 
 
Scheme 2.2. Synthesis of N-acetyl pyrrolidine alcohols. 
 
The next step in the synthesis of the boronic ester intermediates was to activate the 
alcohol as a tosylate to provide a good leaving group for the subsequent coupling to a 
phenol boronic acid derivative.  Tosylation of the pyrrolidine alcohol (S)-26 to form the 
tosylate (S)-29 was not as straightforward as anticipated (Scheme 2.3).  Under standard 
tosylation conditions with equimolar amounts of pyridine and tosyl chloride (Table 2.1, 
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entry 1), unreacted tosyl chloride was recovered (42%) as well as a complex mixture of 
products.  The reaction was repeated using an excess of pyridine (Table 2.1, entry 2).  
The crude mixture of products formed from this reaction were separated using column 
chromatography, resulting in the isolation of the chloride derivative 30
53
 in 45% yield 
and the unexpected N-tosylate 31 in 7% yield (Scheme 2.3).  
 
 
Scheme 2.3. Attempted tosylation of alcohol (S)-26.  
 
Entry Base (eq) TsCl (eq) Conditions Results (yield after column 
chromatography) 
1 pyridine (1.1)  1.1 rt, 30 h Mixture
a 
Recovered TsCl (42%) 
2 pyridine (5.0)  1.2 0 
o
C to rt,  
20 h 
Chloride 31 (45%) 
N-tosylate 32 (7%) 
3 pyridine (5.0) 2.0 0 
o
C, 4 h Mixture
a
 containing 
chloride 31 and N-tosylate 
32 (ratio 43:57) 
4 2,6-lutidine (5.0) 
 
1.2 0 
o
C to rt, 
15 h 
N-tosylate 32 (10%) 
5 2,6-lutidine (5.0) 
Et3N (1.5) 
1.2 0 
o
C to rt,  
15 h 
N-tosylate 32 (19%) 
 
Table 2.1. Attempted tosylation reactions.  aCrude material contained a complex mixture of compounds. 
 
It has been established in the literature that tosylation reactions using tosyl chloride and 
pyridine as a base, can lead to the formation of undesired side products.
54
  These include 
pyridinium salts (where reactive tosylate products react with pyridine hydrochloride 
formed during the reaction) resulting in a loss of the desired tosylate with the 
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pyridinium salt lost during the work-up.  Also, the conversion of tosylate into the 
corresponding chloride product can be a problem, where the pyridine hydrochloride 
formed during the reaction acts as the chloride nucleophile.  These side products have 
often been formed at high temperatures or when a large excess of pyridine was used.
54
 
Attempts to suppress the formation of the chloride 30 by lowering the reaction 
temperature to 0 
o
C were unsuccessful (Table 2.1, entry 3), and formation of both the 
chloride 30 and the N-tosylate 31 was detected by 
1
H-NMR spectroscopy of the crude 
product.  The tosylation reaction was repeated with 2,6-lutidine as an alternative bulkier 
base compared to pyridine (Table 2.1, entry 4), that can suppress pyridinium salt 
formation.
54
  Under these conditions, the chloride 30 was not formed, however N-
tosylate 31 was still isolated in 10% yield after purification by column chromatography.  
Addition of triethylamine to the reaction (which could react with HCl to give the 
corresponding salt), also only yielded N-tosylate 31 but in a 19% yield (Table 2.1, entry 
5).  Since the reactions were carried out, the synthesis of tosylate (S)-29 was reported in 
a patent, from alcohol (S)-26 using tosyl chloride, triethylamine and DMAP.
55
  However 
limited experimental details were provided and the yield of the product was not given. 
It was possible that during the reaction the desired tosylate (S)-29 formed readily but 
was unstable, and neighbouring group participation of the N-acetyl group could lead to 
the formation of cyclic intermediate 32 (Scheme 2.4).  A chloride nucleophile could 
then attack to form the chloride 30.  It was also possible that compound 26 underwent 
an N-O acyl transfer followed by sulfonation of the amine to yield the N-tosylate 31. 
 
 
Scheme 2.4. Proposed mechanism of neighbouring group participation. 
 
An alternative strategy, still retaining the N-acetyl group (which would be useful for the 
direct preparation of the boronic ester intermediates 22 with R
1
 = COCH3, Figure 1.13), 
was to convert the alcohol (S)-26 to the alkyl bromide 33 (Scheme 2.5).  The alcohol 
(S)-26 was treated with carbon tetrabromide and triphenylphosphine at room 
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temperature, which afforded the alkyl bromide 33 in a low yield of 5% after purification 
by column chromatography.  The triphenylphosphine oxide impurities were difficult to 
separate from the product 33 by column chromatography.  After further purification by 
filtration, it was observed by 
1
H-NMR spectroscopy that bromide 33 had rearranged to 
the acetate 34.
56
  Bromination of alcohol (S)-26 with thionyl bromide resulted in the 
bromide product 33 being isolated in a low yield (10%), and 33 was also found to be 
unstable over time, rearranging to the acetate 34 (Scheme 2.5). 
 
 
Scheme 2.5. Attempted conversion of alcohol to alkyl bromide. 
 
2.1.2 Synthesis via N-Boc protection route 
An alternative synthetic approach was to prepare the boronic ester intermediates 22 
(Figure 1.13) with R
1
 = Boc.  Substitution of the acetyl group of compound 26 with a 
Boc group, which has a lower reactivity, was expected to alleviate the problem of N to 
O-acyl transfer and neighbouring group participation.  In addition, Bartoli et al. have 
reported a procedure for tosylation of an N-Boc pyrrolidine alcohol derivative which 
afforded the tosylate product in an excellent yield.
57
  Following this strategy, once the 
target compounds had been synthesised, the Boc group could then be deprotected and 
subsequent N-acetylation would yield the target compounds with the desired N-acetyl 
group. 
N-Boc-prolinol 35 was synthesised by two different methods (methods A and B, 
Scheme 2.6).  Following literature procedures, method A began with reduction of 
optically pure proline (S)-27 using lithium aluminium hydride to furnish the alcohol (S)-
36 in 96% yield, which was consistent with the yield of 94% reported in the literature.
58
  
Subsequent Boc protection using Boc anhydride and triethylamine,
59
 afforded N-Boc-
prolinol (S)-35 in 73% yield after purification by column chromatography.  Several 
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methods have been reported in the literature for the reduction of optically pure -amino 
acids to optically pure -amino alcohols.  These include reduction with LiBH4 and 
Me3SiCl,
60
 NaBH4 with iodine or H2SO4,
61
 and boron reagents.
62
  The most routinely 
used reagent for the reduction of -amino acids is lithium aluminium hydride which has 
been shown to proceed without racemisation at the -carbon63 and successfully gave the 
alcohol (S)-36 here.   
Difficulties were encountered when removing impurities from the reduction with 
lithium aluminium hydride, particularly when the reaction was scaled up to 5 g of the 
starting material (S)-proline.  An alternative synthetic route was therefore used to 
synthesise N-Boc-prolinol 35 following literature procedures (method B, Scheme 2.6).
57
  
First, (S)-proline (S)-27 was Boc protected using Boc anhydride and triethylamine to 
give the compound (S)-37 in 80% yield after purification by recrystallisation.  Selective 
reduction of the carboxylic acid moiety in (S)-37 with borane tetrahydrofuran complex, 
afforded the desired alcohol (S)-35 in 84% yield, which was comparable to the yield 
reported in the literature of 82%.
57
  Synthesis of the enantiomeric alcohol (R)-35
64
 was 
prepared using the same procedure from optically pure proline (R)-27 (Scheme 2.6).  
 
 
Scheme 2.6. Synthesis of N-Boc-prolinol using either method A or method B. 
 
Tosylate (S)-38 was next prepared from the alcohol (S)-35 using a modified version of a 
literature procedure using tosyl chloride and pyridine (Scheme 2.7).
57
  Tosylate (S)-38 
was found to be unstable if stored over long periods of time under argon at 4 
o
C.  
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Therefore the mesylates (S)-39 and (R)-39 were prepared from alcohols (S)-35 and (R)-
35 in quantitative yield, using mesyl chloride and triethylamine.
65
  Mesylates (S)-39 and 
(R)-39 were noted to be stable when stored under argon at 4 
o
C for extended periods.  
  
 
Scheme 2.7. Preparation of tosylate and mesylate prolinol derivatives. 
 
The final step in the preparation of the boronic ester intermediates was a nucleophilic 
displacement of either the tosyl group in 38, or the mesyl group in 39, with the phenol 
boronic ester 40 (Scheme 2.8).  Using similar conditions to those reported by Stock et 
al.,
32
 the tosylate (S)-38 and phenol 40 were reacted with a carbonate base overnight at 
50 
o
C (Table 2.2, entries 1-2).  No reaction occurred and only starting materials were 
recovered.  Repeating the reaction at a higher temperature, either in reluxing acetonitrile 
or in DMF at 110 
o
C (Table 2.2, entries 3-4) resulted in the formation of a complex 
mixture of products.  Shortening the reaction time to 4 hours and using acetonitrile as 
the solvent, resulted in a low yield of 12% of the desired product (S)-41 isolated after 
purification by column chromatography (Table 2.2, entry 5).  The other fractions eluted 
from the column contained mostly starting materials.  In an attempt to optimise the yield 
of the product (S)-41, the same reaction conditions using a carbonate base were 
attempted with the less bulky and more stable mesylate analogue (S)-39 (Table 2.2, 
entry 6), however the yield of the product (S)-41 achieved was low (9%).   
 
 
Scheme 2.8. Coupling the tosylate or mesylate with a phenol derivative. 
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Entry R group Base (5 eq) Solvent Conditions Yield of (S)-41 
1 Ts K2CO3 CH3CN 50 
o
C, 18 h 0% 
a 
2 Ts Cs2CO3 CH3CN 50 
o
C, 18 h 0% 
a 
3 Ts Cs2CO3 CH3CN Reflux, 18 h 0% 
b 
4 Ts Cs2CO3 DMF 110 
o
C, 18 h 0% 
b 
5 Ts Cs2CO3 CH3CN Reflux, 4 h 12% 
c 
6 Ms Cs2CO3 CH3CN Reflux, 18 h 9% 
c 
 
Table 2.2. Reaction conditions for synthesis of boronic ester intermediates. aOnly starting materials 
recovered. bNo starting materials but a mixture of products isolated.  cYield after column chromatography. 
 
One of the side products identified that was formed during the phenol coupling 
reactions was oxazolidone 42 (Scheme 2.9).  This product had also previously been 
reported as being formed from a base catalysed rearrangement of N-Boc pyrrolidine 
tosylate 38.
66
  The Boc group carbonyl can attack the electrophilic carbon and displace 
the tosylate to give the cationic intermediate 43.  Then abstraction of a proton from one 
of the tert-butyl methyl groups can lead to the loss of 2-methylpropene and the 
formation of oxazolidone 42. 
 
 
Scheme 2.9. Proposed mechanism of the base catalysed rearrangement of tosylate 38 by Curran at al.66  
 
In order to suppress the base catalysed rearrangement, the order of addition of reagents 
used in the phenol coupling reaction was investigated.  The base was first added to the 
phenol derivative to generate the phenolate, followed by the addition of mesylate (S)-39 
(Scheme 2.10).  Optimal reaction conditions were explored using the less expensive 
phenol 44 as a model substrate for the phenol boronic ester 40.  Following a literature 
procedure, the reactions were initially carried out using sodium hydride in THF (Table 
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2.3, entries 1-2).
67
  The yield of product (S)-45 obtained after 24 hours was 30%, and 
the yield increased only to 36% if the reaction was carried out for 48 hours, which was 
much lower than the yield reported in the literature of 78%.
67
  Changing the solvent to 
DMF and repeating the reaction at 95 
o
C for 4 hours, resulted in the product (S)-45 
which was isolated in 37% yield (Table 2.3, entry 3).  Using the same conditions but 
increasing the amount of sodium hydride from 1.5 equivalents to 2 equivalents resulted 
in an increase of the product yield to 69%, but using 3 equivalents of sodium hydride 
resulted in a slightly lower yield of 62% of the product (Table 2.3, entries 4-5).  
Applying the optimal reaction conditions using 2 equivalents of sodium hydride in 
DMF with the phenol boronic ester derivative 40, resulted in isolation of the desired 
boronic ester product (S)-41 in a disappointing 31% yield (Table 2.3, entry 6).    
 
 
Scheme 2.10. Optimisation of the synthesis of boronic ester compounds. 
 
 
Entry Phenol  Base Solvent Conditions Yield (%)
a 
1 44 NaH (1.5 eq) THF reflux, 22 h 30 
2 44 NaH (1.5 eq) THF reflux, 48 h 36 
3 44 NaH (1.5 eq) DMF 95 
o
C, 4 h 37 
4 44 NaH (2.0 eq) DMF 95 
o
C, 3.5 h 69 
5 44 NaH (3.0 eq) DMF 95 
o
C, 3.5 h 62 
6 40 NaH (2.0 eq) DMF 95 
o
C, 3.5 h 31 
7 44 tBuOK (1.1 eq) THF reflux, 27 h 30 
8 44 
t
BuOK (1.1 eq) DMF 75 
o
C, 6 h 70 
9 40 
t
BuOK (1.1 eq) DMF 75 
o
C, 6 h 25 
10 40 
t
BuOK (2.0 eq) DMF 75 
o
C, 6 h 46 
 
Table 2.3. Coupling reactions of phenols with mesylate (S)-39. aIsolated yield after purification by 
column chromatography. 
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The coupling reaction was repeated with a different base, potassium tert-butoxide 
(Table 2.3, entries 7-10).  It has been reported in the literature that using potassium tert-
butoxide rather than sodium hydride in DMF allows lower reaction temperatures to be 
used.
57
  Therefore the reaction temperatures were lowered to 75 
o
C.  Reaction of the 
model phenol 44 with mesylate (S)-39 in DMF at 75 
o
C for 6 hours, gave the 
corresponding product (S)-45 in 70% yield after purification by column 
chromatography (Table 2.3, entry 8).  Applying the same reaction conditions to the 
phenol boronic ester 40 afforded the desired boronic ester product (S)-41 in a low yield 
of 25% (Table 2.3, entry 9).  Repeating the reaction but increasing the amount of 
potassium tert-butoxide from 1.1 equivalents to 2 equivalents resulted in the isolation of 
the desired product (S)-41 in 46% yield (Table 2.3, entry 10).  The lower yields 
achieved with the boronic ester substrate may be due to coordination of 
t
BuOK to form 
a boronate complex.  The same procedure using the optimal conditions was repeated for 
the synthesis of the opposite enantiomer of the boronic ester intermediate (R)-41, which 
was isolated in 55% yield (Scheme 2.11).   
 
 
Scheme 2.11. Synthesis of N-Boc protected pyrrolidine boronic ester intermediate. 
 
The same synthetic route was followed to access the novel indoline N-Boc protected 
boronic ester analogues (S)-46 and (R)-46 (Scheme 2.12).  Treatment of commercially 
available indoline-2-carboxylic acid 47 with Boc anhydride and triethylamine gave the 
Boc protected compound 48 in 90% yield for the (S)-enantiomer
68
 and 58% yield for the 
(R)-enantiomer.
69
  Subsequent reduction of the carboxylic acid moiety with borane.THF 
complex resulted in the isolation of alcohol 49 in 73% yield for the (S)-enantiomer
70
 
and 61% yield for the (R)-enantiomer.
71
  Conversion of the alcohol 49 to mesylate 50 
was achieved using mesyl chloride and triethylamine.  Finally, displacement of the 
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mesyl group with phenol boronic ester 40 using potassium tert-butoxide in DMF at 75 
o
C, resulted in isolation of the indoline boronic ester intermediate 46, in 45% yield for 
the (S)-enantiomer and 52% yield for the (R)-enantiomer. 
 
 
Scheme 2.12. Synthesis of indoline N-Boc protected boronic ester intermediates. 
 
 
2.2 Synthesis of aryl iodides (ring B) 
In order to synthesise target compounds 20 and 21 (Figure 1.11), aryl halides were 
required for Suzuki coupling to the boronic ester intermediates 42 and 46.  Initially, aryl 
iodides 51 and 52 (Figure 2.1), with an iodide group meta to the acetic acid side chain 
and a methyl substituent (R2 = CH3), were chosen as the ring B structure.  These 
structural features were chosen based on literature phenylacetic acid CRTh2 antagonists 
developed by Amira (Figure 1.8) and previous GlaxoSmithKline SAR studies.
40
 
 
 
Figure 2.1. Target compounds for use in Suzuki reactions - aryl iodides. 
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Aryl iodide 51 was prepared by aromatic oxidative iodination according to a procedure 
by Skulski et al., where arenes were mono-iodinated with strong electrophilic I
+
 
reagents.
72
  p-Tolylacetic acid 53 was reacted with iodine and sodium periodate as the 
oxidant, in a strongly acidic solution (Scheme 2.13) to afford the crude aryl iodide 51 in 
69% yield.  The crude product contained a small amount of a di-iodinated product as 
confirmed by mass spectrometry.  The same procedure was followed to synthesise the 
corresponding methyl ester analogue 54 in 76% yield, from methyl 2-(p-tolyl)acetate 55 
(Scheme 2.13).  Purification of the crude aryl iodide 51 by recrystallisation and the 
crude aryl iodide methyl ester 54 by column chromatography resulted in approximately 
3-5% of the di-iodinated compound impurity remaining.  It was hoped that this could be 
removed after the next coupling step. 
 
 
Scheme 2.13. Aromatic iodination of p-tolylacetic acid and its methyl ester analogue. 
 
The synthesis of the aryl iodide with a methyl group ortho to the acetic acid side chain 
was problematic due to the ortho and para directing methyl group (Scheme 2.14).  
Using the same iodination procedure as above with methyl 2-(o-tolyl)acetate 56 resulted 
in a mixture of aryl iodide regioisomers formed in 54% yield.  The major regioisomer 
57 had the iodide group para to the methyl group, whilst the minor regioisomer was the 
desired ortho iodinated product 58.  The regioisomers were inseparable by column 
chromatography.   
 
 
Scheme 2.14. Aromatic iodination of methyl 2-(o-tolyl)acetate. 
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An alternative proposed synthetic route to aryl halides of type 52 and 58 was the Arndt-
Eistert synthesis (Scheme 2.15).
73
  Commercially available 3-bromo-2-methylbenzoic 
acid 59 could be converted to the acid chloride and reacted with diazomethane to give 
diazoketone 60. A Wolff rearrangement in the presence of water should allow for the 
formation of the homologated carboxylic acid 61.  This would yield the bromide 
analogue of compound 52, which should still be effective for the Suzuki coupling 
required in the next stage of the synthesis of the target compounds.  However it was 
decided to continue the synthesis of the target compounds with aryl iodides 51 and 54, 
and obtain the series of compounds with the methyl substituent para to the acetic acid 
side chain first. 
 
 
Scheme 2.15. Possible synthetic route to aryl bromides via an Arndt-Eistert synthesis. 
 
 
2.3 Suzuki coupling 
The boronic ester intermediates were coupled to the aryl iodides via a Suzuki reaction
74
  
to generate the biaryl products.  Initial Suzuki reactions were carried out with aryl 
iodide 51 (Figure 2.1) containing the carboxylic acid moiety.  This would have been 
useful, as it directly generated the target products with the desired carboxylic acid 
attached.  Unfortunately, using aryl iodide 51 in the Suzuki reactions resulted in very 
low yields of biaryl products.  Therefore the methyl ester aryl iodide 54 was used, 
which made the purification of the products easier and allowed higher yields of products 
to be generated.  However, this also added an additional ester hydrolysis step at the end 
of the synthesis in order to generate the desired carboxylic acids. 
The Suzuki coupling to form the biaryl compounds involved heating the boronic ester, 
aryl iodide, a palladium catalyst and a base in a suitable solvent (Scheme 2.16). 
Reaction of the N-Boc pyrrolidine boronic ester (R)-41 and aryl iodide 54, under 
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standard Suzuki conditions with potassium carbonate and Pd(PPh3)4 in a mixture of 
DME/H2O at 85 
o
C,
32
 afforded the novel biaryl product (R)-62 in 20% yield after 
purification by column chromatography (Table 2.4, entry 1). The other fractions 
collected from the column contained the starting materials, indicating that the reaction 
had not gone to completion.   
 
 
Scheme 2.16. Suzuki coupling reaction of N-Boc proline boronic esters and aryl iodide 54. 
 
Entry Catalyst  Base Solvent Conditions Yield
a
 [enantiomer] 
1 Pd(PPh3)4 K2CO3 DME/H2O 
(2:1) 
85 
o
C, 22 h 20%  [(R)-62]
 
2 Pd(dppf)Cl2.
CH2Cl2 
K3PO4 Dioxane/H2O 
(4:1) 
85 
o
C, 22 h 17% crude  [(R)-62] 
3 Pd(OAc)2 + 
PPh3 
K3PO4 Dioxane/H2O 
(4:1) 
85 
o
C, 48 h 37%  [(R)-62] 
4 Pd(PPh3)4 K3PO4 DMF 85 
o
C, 24 h 82%  [(R)-62] 
5 Pd(PPh3)4 K3PO4 DMF 85 
o
C, 24 h 74%  [(S)-62] 
 
Table 2.4. Suzuki coupling reaction conditions. aIsolated yield after purification by column 
chromatography. 
 
To optimise the yield of the biaryl product, the use of other palladium catalysts and 
bases was investigated.  A wide range of Pd(0) catalysts can be used for cross 
couplings, or the catalyst is often added as a Pd(II) complex which forms the active 
catalytic Pd(0) species in situ.  Pd(PPh3)4 is a commonly used catalyst, but others such 
as PdCl2(PPh3)2, Pd(dppf)Cl2 and Pd(OAc)2 plus phosphine ligands are also efficient as 
they are air stable.
74
  Changing the catalyst to the less air sensitive Pd(dppf)Cl2 complex 
and repeating the reaction using potassium phosphate as the base in a mixture of  
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dioxane/H2O did not improve the yield of the product (R)-62, which was obtained in 
17% crude yield (Table 2.4, entry 2).  Repeating the reaction with Pd(OAc)2 and PPh3 
(Table 2.4, entry 3) did result in a slightly improved yield of the cross-coupled product 
(R)-62 to 37% but this was only achieved after the reaction was carried out over 2 days.   
In the literature, poor product yields have previously been reported for Suzuki couplings 
using aqueous basic conditions and if the aryl boronic ester is sterically hindered or 
contains electron withdrawing substituents.
75
  This has been attributed to steric 
hinderance or hydrolytic deboronation and has been overcome by using an anhydrous 
base such as K3PO4 in DMF.
75
  Repeating the coupling reaction of boronic ester (R)-41 
with aryl iodide 54 using these reaction conditions, with Pd(PPh3)4 as the catalyst and 
K3PO4 in DMF at 85 
o
C for 24 hours, greatly improved the yield of the biaryl product 
(R)-62 to 82% (Table 2.4, entry 4).  The same conditions were applied to synthesise the 
opposite biaryl enantiomer (S)-62 in 74% yield (Table 2.4, entry 5).   
The optimised Suzuki conditions with K3PO4 and Pd(PPh3)4 in DMF were also applied 
to the synthesis of the biaryl N-Boc indoline analogues (S)-63 and (R)-63 which were 
isolated in 80% and 70% yield respectively (Scheme 2.17). 
 
 
Scheme 2.17. Suzuki coupling reaction of N-Boc indoline boronic esters and aryl iodide 54. 
 
 
2.4 Final deprotection and acetylation steps 
The final target compounds of type 20 and 21 with the nitrogen substituent R1 = H 
(Figure 1.11) were prepared using a series of deprotection steps of the N-Boc 
pyrrolidine compounds (S)-62 and (R)-62 and the N-Boc indoline compounds (S)-63 
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and (R)-63.  Removal of the Boc group from pyrrolidine derivative (S)-62 under acidic 
conditions with TFA in dichloromethane yielded the amine (S)-64 in quantitative yield 
(Scheme 2.18).  Subsequent ester hydrolysis of compound (S)-64 with lithium 
hydroxide at room temperature afforded the target compound (S)-65 in 84% yield.  
 
 
Scheme 2.18. Synthesis of target compound via Boc deprotection then ester hydrolysis. 
 
An alternative method was used for the synthesis of the opposite enantiomer (R)-65 
(Scheme 2.19).  First, ester hydrolysis of compound (R)-62 was accomplished with 
lithium hydroxide, which was then followed by Boc deprotection using 4 M HCl in 
dioxane, to afford the target compound (R)-65 in 53% yield over two steps.   
   
 
Scheme 2.19. Synthesis of target compound via ester hydrolysis then Boc deprotection. 
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It was decided to apply the route which involved Boc deprotection first, followed by the 
ester hydrolysis, to the synthesis of the target indoline analogues.  This was because the 
intermediate Boc deprotected compounds would be useful in the preparation of other 
target compounds featuring an N-acetyl group.  Deprotection of the Boc group from the 
indoline derivatives (S)-63 and (R)-63 with TFA yielded amines (S)-66 and (R)-66 in 
quantitative yields (Scheme 2.20).  This was followed by ester hydrolysis with lithium 
hydroxide to afford the target compounds (S)-67 in 48% yield, and (R)-67 in 49% yield 
after purification by column chromatography.  
 
 
Scheme 2.20. Synthesis of indoline target compound via Boc deprotection and ester hydrolysis. 
 
The final target compounds of type 20 and 21 with the nitrogen substituent R1 = COCH3 
(Figure 1.11) were prepared by acetylation and ester hydrolysis of the pyrrolidine 
compounds (S)-64 and (R)-64 and indoline compounds (S)-66 and (R)-66 (Scheme 
2.21).  Acetylation was achieved using acetic anhydride, triethylamine and DMAP, 
which resulted in the isolation of the N-acetyl intermediates in yields between 78-86%. 
Subsequent hydrolysis of the methyl ester resulted in the formation of the N-acetyl 
pyrrolidine target compounds (S)-68 and (R)-68 in 73% and 50% yields respectively, 
and the N-acetyl indoline target compounds (S)-69 and (R)-69 in 32% and 26% yields 
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after purification by column chromatography.  The low isolated yields of the indoline 
derivatives could have been improved by optimisation of the purification procedure.  
During the purification by column chromatography of indoline compounds (S)-69 and 
(R)-69, a fraction was collected that contained a mixture of the desired product and an 
impurity, but this fraction was not re-purified because enough of the clean desired 
product had already been isolated for analysis in the biological assays. 
 
 
Scheme 2.21. Synthesis of N-acetyl pyrrolidine and indoline target compounds. 
 
 
2.5 Leukotriene B4 synthesis inhibition 
2.5.1 LTB4 synthesis inhibition assay 
Compounds 65, 67, 68 and 69 were tested by GVK Bio in a cell based assay using 
human neutrophils to measure the inhibition of LTB4 synthesis, in order to determine 
the potency of the compounds in inhibiting leukotriene synthesis inhibition.
i
  All of the 
compounds tested had IC50 values in the micromolar range and were inhibitors of LTB4 
biosynthesis (Table 2.5).   
                                                             
i The LTB4 synthesis inhibition assay was carried out by GVK Bio (GVK Biosciences, Private Limited, 
Plot No. 28A, IDA Nacharam, Hyderabad – 500076, India).  The human biological samples were sourced 
ethically and their research use was in accord with the terms of the informed consents. 
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No. R Mwt calc LogP 
(ACD) 
IC50 
(M)a 
pIC50
b 
BEI
c 
(S)-65 
 
325.4 3.4 1.29 5.9 18.1 
(R)-65 
 
325.4 3.4 0.58 6.2 19.1 
(S)-68 
 
367.4 3.2 6.64 5.2 14.2 
(R)-68 
 
367.4 3.2 3.49 5.5 15.0 
(S)-67 
 
373.4 4.6 3.48 5.5 14.7 
(R)-67 
 
373.4 4.6 1.84 5.7 15.3 
(S)-69 
 
415.5 4.9 0.46 6.3 15.2 
(R)-69 
 
415.5 4.9 0.50 6.3 15.2 
Table 2.5. LTB4 synthesis inhibitory activity.   
a
Inhibition of LTB4 synthesis in human neutrophils by 
Enzyme Linked Immunosorbent Assay (ELISA) carried out by GVK Bio.  The FLAP inhibitor MK886 
was used as a reference compound and had IC50 = 0.88-0.99 nM, pIC50 = 9.1.  
bpIC50 = -log(IC50(M)).  
cBEI = Binding Efficiency Index = (pIC50/Mwt)*1000 
 
Of the compounds tested, those with the (R)-stereochemistry were slightly more active 
than those with the corresponding (S)-stereochemistry, with the exception of the N-
acetyl indoline compounds (S)-69 and (R)-69, which had the same pIC50 value of 6.3.  
Analysis of the free amine compounds (65 and 67) showed that the pyrrolidine moiety 
gave rise to a better potency than the corresponding indoline analogues, for example 
pyrrolidine (R)-65 (pIC50 = 6.2) was 3 times more potent than the indoline analogue (R)-
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67 (pIC50 = 5.7).  The opposite trend was observed for the N-acetyl compound set (68 
and 69), where the indoline analogues were more potent LTB4 synthesis inhibitors than 
the pyrrolidines, for example indoline (R)-69 (pIC50 = 6.3) had a 7 fold better potency 
than its pyrrolidine analogue (R)-68 (pIC50 = 5.5).   
The X-ray crystal structure of FLAP bound to inhibitor MK591 3 (Figure 1.3) indicated 
that the binding pocket for the quinoline moiety was restricted and positioned deep 
within the FLAP trimer.
28
  Hence it was possible some of the differences in potency 
observed between the various pyrrolidine and indoline groups were caused by limited 
space in the binding pocket.  The most potent LTB4 synthesis inhibitors were the N-
acetyl indolines (S)-69 and (R)-69 (pIC50 = 6.3).  These results corresponded well to the 
SAR reported for the FLAP inhibitor AM679 6 (Figure 1.4), where the N-acetyl 
indoline moiety enhanced the potency of LTB4 synthesis inhibition.
32
   
The ligand efficiency related to the efficiency per mass unit (BEI = binding efficiency 
index)
76
 was calculated for each compound.  One of the most potent compounds, 
pyrrolidine (R)-65, was a reasonably efficient inhibitor of LTB4 synthesis, with BEI = 
19.1.  This compared favourably to the efficiency of literature FLAP inhibitors in their 
capacity to inhibit LTB4 synthesis, such as MK886 2 (Figure 1.3) with BEI = 18.1, and 
AM679 6 (Figure 1.4) with BEI = 13.3.
27,32
 
Based on structural similarities with literature FLAP inhibitors, it was reasonable to 
hypothesise that the compounds found to be LTB4 synthesis inhibitors were targeting 
the protein FLAP.  However, in order to confirm the target, additional assays would 
need to be carried out such as a FLAP binding assay. 
 
2.5.2 Development of an in-house assay 
An investigation into the development of an in-house LTB4 inhibition assay using mass 
spectrometry for the quantification of LTB4 was undertaken.
ii
  This would have allowed 
for screening a larger number of compounds at a lower cost compared to those required 
for outsourcing.  Development of the assay was carried out in collaboration with Dr 
                                                             
ii The LTB4 inhibition assay was carried out in collaboration with Dr Dean Willis at the UCL pharmacy 
department.  The development of the MS method and analysis was carried out in collaboration with Dr 
Lisa D. Haigh in the UCL chemistry mass spectrometry facility. 
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Willis at UCL pharmacy department.  The LTB4 inhibition assay was carried out 
following published procedures.
77
  The assay involved the addition of the test 
compound to the cells (mouse leukocytes or human neutrophils were used) (Scheme 
2.22).  Then the cells were stimulated with a calcium ionophore A23187 which liberates 
arachidonic acid and activates the biosynthesis of leukotrienes.  To terminate the 
reaction, the cell supernatant was centrifuged and the supernatant extracted with a 
mixture of dichloromethane and methanol containing 1% formic acid.  After 
evaporation of the organic solvents, the resultant residue was reconstituted in methanol 
for LC-MS analysis.     
 
 
 
 
Scheme 2.22. Summary of the LTB4 inhibition assay. 
 
Key to the success of the method was development of a mass spectrometry method for 
quantitative LTB4 analysis.  This proved to be very problematic.  A calibration curve 
using LTB4 purchased from Sigma-Aldrich was established, which was based on LC-
MS methods reported in the literature (Figure 2.2).
78,79
 From the calibration curve, the 
LTB4 quantification range was 0.08-10 µg/mL, however this was not sufficiently 
sensitive. Literature methods have analysed LTB4 in the ng/mL and pg/mL 
concentration ranges.
79
   
The mass spectrometer was operated in the ESI negative mode so that LTB4 was 
detected as the deprotonated species [M - H]
-
.  Selected ion monitoring (SIM) was used 
over the mass range m/z 334-337, so only compounds with a mass corresponding to the 
LTB4 [M - H]
- 
ion at m/z 335 would be detected.  LC-MS ion chromatograms of the 
standard LTB4 solutions containing a known concentration of LTB4 in methanol, 
showed a single peak at rt = 10 min (Figure 2.3). 
 
Cells 
incubated 
with test 
compound 
Cells 
stimulated 
with calcium 
ionophore 
Centrifuge 
supernatant 
and extract 
LTB4 
 
 
LC-MS 
analysis 
39 
 
 
Figure 2.2. Calibration curve (range 0.08-10 µg/mL) of LTB4. 
 
 
Figure 2.3. LC-MS ion chromatogram of a standard LTB4 solution. 
 
To test the LTB4 inhibition assay and confirm that the cells were producing LTB4 once 
stimulated with the calcium ionophore, the assay was carried out with no test compound 
added to the cells.  It was expected that the LC-MS ion chromatogram would indicate 
the presence of LTB4 with a peak at retention time = 10 min, however this was not 
observed and peaks with retention times at 2 and 7 minutes were noted (Figure 2.4).   
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Figure 2.4. LC-MS ion chromatogram of extracts from calcium ionophore stimulated cells. 
 
The stability of LTB4 in the samples could have been an issue.  Two isomers of LTB4 
include 6-trans-LTB4 70 and 6-trans-12-epi-LTB4 71 (Figure 2.5), which are non-
enzymatic hydrolysis products of LTA4, but can also form from isomerisation of LTB4 
at low pH and high temperatures.
80
   LTB4 and its isomers have the same [M - H]
-
 ion at 
m/z 335 and so the specificity of the LC-MS detection method was likely to have been a 
problem.  The LTB4 inhibition assay was repeated with the addition of zileuton (a 
known LTB4 synthesis inhibitor, Figure 1.2) to the cells.  If the extra peaks seen in the 
LC-MS ion chromatogram disappeared then it would have been likely these peaks 
corresponded to isomers of LTB4.  However the chromatograms obtained still showed 
multiple peaks.  The data from these experiments proved to be very unreliable and 
further development of the assay was not continued. 
 
 
Figure 2.5. Structures of LTB4 and two isomers 6-trans-LTB4 and 6-trans-12-epi-LTB4. 
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2.6 CRTh2 antagonist activity assay 
Compounds 65, 67, 68 and 69 were tested in a CRTh2 functional assay by Euroscreen 
FAST, for antagonist activity on recombinant human CRTh2 (Table 2.6).
iii
  Each 
compound was tested at a single concentration of 10 µM.  The percentage inhibition 
refers to the inhibition of CRTh2 receptor activation measured by radioligand GTP35S 
binding.    
 
No. R Percentage 
inhibition
a 
 No. R Percentage 
inhibition
a 
(S)-65 
 
14%  (S)-67 
 
64% 
(R)-65 
 
-3%  (R)-67 
 
22% 
(S)-68 
 
92%  (S)-69 
 
132% 
(R)-68 
 
27%  (R)-69 
 
72% 
Table 2.6. CRTh2 antagonist activity assay results.  aAverage percentage inhibition of CRTh2 activation 
(antagonist activity) on human recombinant CRTh2 receptor, the compounds were tested at a single 
concentration of 10 µM in duplicate (n = 2). 
 
The carboxylic acid functionality was already known to be important for CRTh2 
binding because the majority of literature CRTh2 antagonists contain this moiety.  
Therefore, having retained the phenylacetic acid group, the SAR for this set of 
compounds focused on the modifications of the indole or pyrrolidine group.  The assay 
results revealed three clear trends.  The first was the (S)-stereochemistry gave rise to 
                                                             
iii The CRTh2 assay was conducted by Euroscreen (Euroscreen FAST Business Unit, Euroscreen SA, 47 
Rue Adrienne Bolland, 6041 Gosselies, Belgium).  The human biological samples were sourced ethically 
and their research use was in accord with the terms of the informed consents. 
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more potent antagonism than the corresponding (R)-stereochemistry analogues.  The 
second trend highlighted the indoline ring was a more potent pharmacophore than the 
pyrrolidine ring analogues, for example, replacement of the pyrrolidine ring in (R)-68 
with the indoline ring (R)-69, improved the percentage inhibition by 45%.  The final 
trend was that an N-acetyl group significantly improved CRTh2 antagonism compared 
to the free amines, for example the N-acetyl pyrrolidine compound (S)-68 had a 78% 
higher percentage inhibition compared to the N-H pyrrolidine compound (S)-65. 
With the current data it was only possible to conclude that the compounds showing 
antagonistic activity at CRTh2 at 10 µM were (S)-67, (S)-68, (S)-69 and (R)-69.  The 
most potent CRTh2 antagonist was the N-acetyl indoline (S)-69.  Testing these four 
active compounds in a dose response screen would provide more information about the 
effects of the compounds on the CRTh2 receptor at different concentrations, which 
would then allow comparisons to other CRTh2 antagonists reported in the literature.   
  
 
2.7 Conclusions  
A novel series of pyrrolidine and indoline biphenylacetic acids were synthesised as dual 
inhibitors of the leukotriene and prostaglandin inflammatory pathways, by targeting 
FLAP and the CRTh2 receptor.  The compounds were designed based on a combination 
of known pharmacophores for potent FLAP inhibitors and CRTh2 antagonists.  The 
compounds evaluated in the biological assays inhibited the synthesis of LTB4, with 
some also active CRTh2 antagonists.  The compound that exhibited the most promising 
dual pharmacology was indoline (S)-69, which had a pIC50 value of 6.3 for LTB4 
synthesis inhibition, and was an antagonist of CRTh2 at 10 µM.  Compound (S)-69 
could provide a good starting point for lead optimisation of dual inhibitors of 
leukotriene synthesis and the CRTh2 receptor, as potential anti-inflammatory drugs for 
diseases such as asthma.   
Future biological testing should include a FLAP binding assay to determine if this is the 
target of the compounds which leads to their LTB4 synthesis inhibitory activity.  In 
addition, dose response curves should be generated for the compounds that were active 
against the CRTh2 receptor. 
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Future medicinal chemistry studies could focus on further SAR based on the most 
promising dual inhibitor (S)-69.  Modifying aryl ring functionalities could be explored, 
as well as the positioning of the acetic acid group.  Modification of the indoline ring to 
either the indole or reverse indole (which are common pharmacophores for CRTh2 
receptor antagonists) could also be explored.   
Unfortunately the project was not able to be continued further because the required 
assays to determine the bioactivities of the compounds was very expensive to outsource.  
It would not have been possible to obtain the biological data for anymore compounds 
that were synthesised. 
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Part B:  Synthesis of tetrahydroisoquinolines, tetrahydrobenzazepines and 
profens and their antimycobacterial properties 
 
3. Introduction 
 
3.1 Antimycobacterial drug discovery 
3.1.1 Tuberculosis: drugs and resistance 
Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium 
tuberculosis that most commonly affects the lungs.  It is a serious global health problem 
that is particularly widespread in developing countries, and is the second leading cause 
of death from a single infectious agent.  In 2013 it was estimated that 9 million people 
developed TB and 1.5 million died from the disease.
81
  About one third of the world’s 
population is estimated to be infected with asymptomatic latent M. tuberculosis where 
the mycobacteria are viable but apparently non-replicating, and the risk of reactivation 
and developing infectious TB is approximately 5%.
82
  This is even higher in patients 
with compromised immune systems such as those with HIV infection, diabetes, 
malnutrition and cancer.
83
 
The current treatment for drug-susceptible TB (TB that is not drug resistant) relies on 
drugs developed over 50 years ago, and is at least a 6 month regimen of a combination 
of the four first-line anti-TB drugs: isoniazid 72, rifampicin 73, pyrazinamide 74 and 
ethambutol 75 (Figure 3.1).  A combination of drugs is used because they have different 
targets and mechanisms of action (Table 3.1), which allows for the shortest treatment 
time and reduces the risk of resistance emerging.  Successful cure rates of over 90% for 
drug-susceptible TB are achieved following the first-line drugs treatment.
81
  Despite 
this, patient adherence to the long treatment time and multiple drug combinations can be 
a problem and can result in relapse of the M. tuberculosis infection, the continuous 
spread of the disease and the emergence of drug resistance.   
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Figure 3.1 First-line anti-TB drugs. 
 
 First-line drug 
(year discovered) 
Primary target Mechanism of action 
Isoniazid (1952) Enoyl-acyl-carrier-
protein reductase 
Inhibits mycolic acid synthesis 
Rifampicin (1963) RNA polymerase Inhibits transcription 
Pyrazinamide (1954) 
 
30S ribosomal subunit Inhibits translation, acidifies 
cytoplasm 
Ethambutol (1961) Arabinosyl transferases Inhibits arabinogalactan synthesis 
Table 3.1. First-line anti-TB drugs and their targets and mechanism of action. 
 
Multi-drug resistant TB (MDR-TB) is caused by mycobacteria that are resistant to the 
two most potent first-line drugs isoniazid 72 and rifampicin 73.  In 2013 an estimated 
3.5% of new and 20.5% of previously treated TB cases were MDR-TB.
81
  The current 
treatment for MDR-TB requires a minimum of 20 months using a combination of 
second-line anti-TB drugs (Table 3.2).  These are either less effective than first-line 
drugs or have serious side effects, and include aminoglycosides, polypeptides, 
fluoroquinolones, thioamides, cycloserine and p-aminosalicylic acid.
84
  Recently two 
new drugs were approved for use against MDR-TB.  In 2012 a diarylquinoline 
compound bedaquiline 76 (Figure 3.2) was approved by the FDA, but for use only when 
no other drugs are available due to safety concerns.
85
  In 2014 a nitroimidazole 
delamanid 77 (Figure 3.2) was approved by the European Medicines Agency and is 
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undergoing clinical studies.
86
  Chemical scaffolds such as benzothiazinones and 
oxazolidinones have also been shown to have promising potency against mycobacteria 
and are in preclinical or clinical development as potential anti-TB drugs.   
 
Second-line drug 
(year discovered) 
Primary target Mechanism of action 
Aminoglycosides:  
 Streptomycin (1944) 
 Kanamycin (1957)  
30S ribosomal subunit Inhibits protein synthesis 
Polypeptides: 
 Capreomycin (1960s) 
Ribosomal subunit 
interface 
Inhibits protein synthesis 
Fluoroquinolones: 
 Levofloxacin 
 Moxifloxacin 
DNA gyrase and DNA 
topoisomerase 
Inhibits DNA supercoiling 
Thioamides: 
 Ethionamide (1961) 
Enoyl-acyl-carrier-
protein reductase 
Inhibits mycolic acid synthesis 
Cycloserine (1955) D-alanine racemase 
and ligase 
Inhibits peptidoglycan 
synthesis 
p-Aminosalicylic acid 
(1948) 
Dihydropteroate 
synthase 
Inhibits folate biosynthesis 
Bedaquiline (2005) ATP synthase Inhibits energy metabolism 
Delamanid (2006) Unknown Inhibits mycolic acid synthesis 
Table 3.2. Second-line drugs used for the treatment of tuberculosis. 
 
 
Figure 3.2. Recently approved compounds for the treatment of MDR-TB. 
 
The emergence of extremely drug resistant TB (XDR-TB) has made the disease even 
more difficult to treat.  XDR-TB is caused by mycobacteria resistant to the first-line 
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drugs isoniazid 72 and rifampicin 73, and the second-line drugs (a fluoroquinolone and 
at least one of the injectable aminoglycosides or polypeptides). The emergence of 
MDR- and XDR-TB highlights the urgent need for new anti-TB drugs that shorten the 
duration of treatment and have good efficacy and safety profiles.  
TB drugs occupy a diverse chemical space and often have physiochemical properties 
that are not typical of drug-like compounds or do not conform to Lipinski’s rules.87  For 
example, the first-line drugs include small polar molecules such as isoniazid 72 and 
ethambutol 75, but also large and complex molecules such as rifampicin 73 (Figure 
3.1).  The second-line drug bedaquiline 76 (Figure 3.2) is highly lipophilic (calc logP 
(ACD) = 7.6) with a fairly high molecular weight of 555.5.  The nitroimidazole group 
present in delamanid 77 (Figure 3.2) is essential for its antimycobacterial activity but 
not typically associated with drug-like molecules.  These examples highlight the 
diversity in physiochemical properties of some of the most potent antimycobacterial 
compounds, and it has been proposed that new lead compounds should be sought from a 
more chemically diverse space such as natural products and their derivatives.
88
 
 
3.1.2 Determining antimycobacterial potency  
Whole-cell (or phenotypic) screening involves testing series of compounds for their 
ability to inhibit the growth of mycobacteria and gives a measure of a compounds 
antimycobacterial potency.  It has proven to be a successful strategy for discovering 
new antimycobacterial compounds, such as in the discovery of bedaquiline 76 as well as 
other compounds currently in clinical trials for the treatment of tuberculosis.
89
  The 
major advantage of whole-cell screening is the ability to directly determine if a 
compound inhibits the growth of mycobacteria at a specific concentration.  In 
comparison, the alternative method of target based screening (which involves testing 
compounds for their ability to inhibit a specific target) can be limited by the potency of 
a compound for a specific target not translating into whole cell antimycobacterial 
activity.  Whole-cell screening also offers the advantage of being able to discover novel 
antimycobacterial structures with new mechanisms of action.   
Tuberculosis drug discovery is challenging because of the slow growth rate and highly 
infectious nature of M. tuberculosis which can only be handled in specialist 
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laboratories.  A way to avoid these limitations is to use different mycobacterial species 
as surrogates, such as M. aurum, M. smegmatis or M bovis BCG.  M. aurum is relatively 
fast growing and non-pathogenic and has been shown to have an antibiotic 
susceptibility profile similar to that of M. tuberculosis.
90
  This makes it an excellent 
surrogate model for the early stage screening of compounds antimycobacterial activity.  
A whole-cell screening method developed by the Bhakta group known as SPOTi (spot 
culture growth inhibition assay), is a rapid and convenient high throughput assay for 
determining antimycobacterial activity of large libraries of compounds, and has been 
used in combination with M. tuberculosis surrogates such as M. aurum.
90
  The SPOTi 
method allows for the determination of the MIC (minimum inhibitory concentration) of 
a compound.  This is defined as the minimum concentration of a compound required to 
completely inhibit the growth of the mycobacteria.  The MIC is important for assessing 
antimycobacterial potency of compounds in early stage drug discovery. 
 
3.1.3 Repurposing drugs 
The repurposing of drugs describes the discovery of new pharmacological activities for 
existing or old drugs.  Existing drugs already have known pharmacological, toxicity and 
safety profiles, so if they are repurposed for a different disease the time and expense of 
clinical development is reduced.
91
  This would be a major advantage for the 
development of new drugs for the treatment of infectious diseases such as TB.
92
  
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the treatment of 
pain and inflammation but have recently been shown to also possess interesting 
antimycobacterial properties.  In a study by Gold et al., the NSAID oxyphenbutazone 
was shown to be selectively mycobactericidal to non-replicating TB.
93
  In another study 
by the Bhakta group, NSAIDs with a 2-arylpropanoic acid structure (profens) were 
evaluated as potential anti-TB drugs.
94
  Ibuprofen 78, loxoprofen 79 and carprofen 80 
displayed growth inhibitory properties against M. tuberculosis and had MICs between 
40-75 µg/mL (Figure 3.3).  Synthetic derivatives of ibuprofen 78 with substitution of 
the carboxylic acid moiety for either the methyl ester or an amide derivative resulted in 
loss of activity or increased cytotoxicity (Figure 3.3).  This suggested a free carboxylic 
acid was required for antimycobacterial activity.  Modifying the aromatic ring of 
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ibuprofen 78 to the 3,5-dinitro analogue resulted in an improvement of activity with 
MIC = 30  µg/mL (Figure 3.3).   
 
 
Figure 3.3. Antimycobacterial activity of NSAID 2-arylpropanoic acid racemates (MIC refers to the 
minimum inhibitory concentration against M. tuberculosis H37Rv). 
 
Ibuprofen 78, carprofen 80 and the dinitro analogue of ibuprofen were also shown to 
have activity against the growth of MDR-TB strains and could have a potential novel 
mechanism of action compared to current TB treatments.  Further SAR of the 2-
arylpropanoic acids would be beneficial in the development of more potent 
antimycobacterial compounds and could help with target elucidation. 
    
3.1.4 Mycobacteria efflux pumps 
Mycobacteria such as M. tuberculosis can acquire mutations in target genes which are 
responsible for resistance to individual drugs.
95
  However, mutations are not the only 
cause of drug resistance in TB.  Other key factors play a role, including intrinsic (or 
natural) resistance from the permeability barrier of the cell wall and the active efflux of 
drugs out of the cell.  Bacterial efflux pumps are membrane proteins that can transport a 
range of substrates out of the cell, and can contribute to drug resistance by either 
preventing a drug from reaching the intended target or by decreasing the concentration 
of drug inside the cell to a sub-inhibitory level.
96
  A sub-inhibitory level of an anti-TB 
drug over the long treatment period represents a particular problem as it increases the 
chances of genetic mutations occurring.
97
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Using compounds that are efflux pump inhibitors (EPIs) in combination with anti-TB 
drugs is a possible strategy for preventing the emergence of drug resistant TB, as well 
as improving efficacy of anti-TB drugs that are subject to efflux.
98
  EPIs include 
verapamil 81, chlorpromazine 82, the plant alkaloid reserpine 83 and spectinomycin 
analogues 84 (Figure 3.4).
99
  These compounds are often used experimentally but there 
are currently no mycobacterial efflux pump inhibitors in clinical use.   
 
 
Figure 3.4. Efflux pump inhibitors of mycobacteria. 
 
Verapamil 81, when used in combination with the first-line anti-TB drug rifampicin 73, 
has been shown to reduce the MIC 4-fold against M. tuberulosis in vitro compared to 
using rifampicin 73 alone.
100
  When verapamil 81 was used in combination with the 
second-line drug bedaquiline 76, an 8-fold reduction in the MIC was reported, with 
equally promising results observed in in vivo studies.
101
  These studies highlight the 
important role EPIs could have in anti-TB drug discovery.   
 
3.2 Tetrahydroisoquinolines 
3.2.1 Structure and biological activity 
1,2,3,4-Tetrahydroisoquinoline (THIQ) derivatives are important nitrogen containing 
heterocyclic compounds in medicinal chemistry.  These compounds are abundant in 
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nature, with the THIQ ring system present in many alkaloid natural products which 
display a wide range of biological and pharmaceutical activities.  Alkaloid THIQ 
derivatives such as morphine, emetine, berberine, noscapine and tubocurarine have been 
used for various pharmaceutical applications (Figure 3.5).  The 1-substituted THIQ 
scaffold has also been used in synthetic drugs such as solifenacin (Figure 3.5).   
 
 
Figure 3.5. Tetrahydroisoquinoline derivatives and their pharmaceutical properties. 
 
THIQ derivatives are structurally diverse, ranging from the more simple 1-substituted 
THIQs to more complex structures like morphine.  Simple THIQs have a broad range of 
bioactivities which makes them attractive targets in drug discovery.  They can also be 
useful precursors for the synthesis of more complex structures and therefore the 
development of efficient strategies for their synthesis is important.   
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3.2.2 Antimycobacterial properties 
Antimycobacterial properties have been reported for both natural THIQ containing 
alkaloids
102
 and synthetic THIQs.
103
  The Bhakta group recently identified aporphine 
alkaloids (S)-leucoxine 85 and 3-methoxynordomesticine 86 (that both contain a THIQ 
moiety) that inhibited the growth of mycobacterial species including M. bovis BCG and 
M. tuberculosis (Figure 3.6).
104
 
 
 
Figure 3.6. THIQ containing aporphine alkaloids with antimycobacterial properties. 
 
To further examine the THIQ scaffold, a series of 1-substituted THIQ analogues were 
synthesised in the Hailes group using either a Bischler-Napieralski reaction (section 
3.3.1) or a biomimetic Pictet-Spengler reaction (section 3.3.4) which required a 
phosphate catalyst and was suitable for a variety of aldehyde and amine substrates.
105
  
These compounds were evaluated for their antimycobacterial properties by the Bhakta 
group.
105
  THIQs 87-90 with a 6,7-dihydroxy or a 6-hydroxy substitution inhibited the 
growth of M. bovis BCG with MIC = 80-100 µg/mL (Figure 3.7).  Compound 87 (MIC 
= 100 µg/mL) was the most structurally similar to the aporphine 86 which suggested 
that the methylenedioxybenzyl substituent at the C-1 position was contributing to the 
antimycobacterial activity.  The presence of a lipophilic chain at the C-1 position also 
conferred antimycobacterial activity in compounds 89 (MIC = 80 µg/mL) and 90 (MIC 
= 100 µg/mL). 
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Figure 3.7. 1-Substituted THIQs that inhibit the growth of mycobacterial species.  MIC values refer to 
the concentration of compound required to inhibit the growth of M. bovis BCG in a SPOTi assay.  
 
In the same study another series of THIQ compounds with a halogen at the C-5 
position, a hydroxy or methoxy group at the C-8 position, and a benzylic or phenyl 
substituent at the C-1 position were shown to inhibit the growth of M. bovis BCG 
(Figure 3.8).
105
  THIQs 91 and 92 with a 5-bromo-8-hydroxy substitution conferred 
marked antimycobacterial activity, and the benzylic derivative 92 (MIC = 20 µg/mL) 
was three times more potent than the phenyl derivative 91 (MIC = 60 µg/mL).  If the 
hydroxy group was replaced with a methoxy group, such as in compound 93, the 
antimycobacterial activity was retained (MIC = 20 µg/mL) but the cytotoxicity of the 
compound towards murine macrophage cells (RAW264.7) increased.  It was also 
observed that the 5-bromo analogue 93 conferred more potency than either the 5-chloro 
analogue 94 (MIC = 40 µg/mL) or the 5-iodo analogue 95 (MIC = 50 µg/mL).   
 
 
Figure 3.8. Halogenated 1-substituted THIQs that inhibit the growth of mycobacteria.  MIC values refer 
to the concentration of compound required to inhibit the growth of M. bovis BCG in a SPOTi assay.  
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The THIQs 87, 89 and 94 were found to be specific inhibitors of mycobacteria.  They 
were active against other species of mycobacteria such as M. smegmatis and M. aurum, 
but they were not growth inhibitors of Gram-negative bacteria such as E. coli and P. 
putida, or acid-fast Rhodococcus equi RHA1.  This suggests these compounds target a 
mechanism that is specific to mycobacteria.  A number of the THIQ compounds 
including 91 and 92 were shown to inhibit the MurE ligase of M. tuberculosis (IC50 
<111 µM), a key enzyme involved in the early stage of mycobacterial cell wall 
peptidoglycan biosynthesis.  There was a positive trend observed for the correlation 
between the growth inhibition of M. tuberculosis (MIC) and the inhibition of MurE 
(IC50) but it was not particularly strong.  Therefore it is probable that other targets are 
also involved.  The results from this study highlighted the excellent potential of the 
THIQ scaffold for the development of future anti-TB drugs.  
 
3.3 Synthesis of tetrahydroisoquinolines 
3.3.1 Bischler-Napieralski reaction 
The Bischler-Napieralski reaction is a frequently used method for the synthesis of 1-
substituted THIQs.
106
  It involves the cyclisation of a phenylethylamide such as 96 in 
the presence of a dehydrating agent to form a 1-substituted 3,4-dihydroisoquinoline 97, 
and in a second step this is reduced to the 1-substituted THIQ 98 (Scheme 3.1).  
Common dehydrating agents include phosphorus oxychloride (POCl3) and phosphorus 
pentoxide (P2O5), and the cyclisation reaction is typically carried out in refluxing 
toluene or xylene.  Many functional groups do not tolerate the harsh conditions needed 
for the reaction and so protecting groups are often required which can make this 
synthetic approach step-intensive. 
 
 
Scheme 3.1. Bischler-Napieralski cyclisation/reduction reaction for 1-substituted THIQ synthesis. 
55 
 
The intermediate 3,4-dihydroisoquinoline contains the C=N bond which has the 
potential to be reduced asymmetrically, yielding THIQs with a single enantiomeric 
configuration at the C-1 position. Metal catalysed asymmetric hydrogenation of 3,4-
dihydroisoquinoline intermediates has been used for the preparation of chiral THIQs.  
For example in a recent synthesis towards an antiepileptic compound, a chiral 
ruthenium catalyst was used to generate the THIQ 99 in 87% ee (Scheme 3.2).
107
  
Whilst this enantioselectivity was good, it would need to be higher for pharmaceutical 
compound synthesis.  Metal catalysts used in the asymmetric synthesis of 1-substituted 
THIQs can be expensive, have limited occurrence and are often toxic.  Therefore 
sustainable synthetic approaches are more desirable.  
 
 
Scheme 3.2. Ruthenium catalysed asymmetric hydrogenation of Bischler-Napieralski intermediates. 
 
3.3.2 Classical Pictet-Spengler reaction 
The Pictet-Spengler reaction is a widely used method for the synthesis of 1-substituted 
THIQs.  It was discovered in 1911 by Amé Pictet and Theodor Spengler who 
synthesised 1,2,3,4-tetrahydroisoquinoline 100 by heating phenylethylamine and 
dimethoxymethane (a formaldehyde equivalent) in hydrochloric acid (Scheme 3.3).
108
 
 
 
Scheme 3.3. The first discovered Pictet-Spengler reaction. 
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The Pictet-Spengler reaction typically involves the condensation of a phenylethylamine 
such as dopamine 101 and an aldehyde under acidic conditions to form an intermediate 
iminium ion 102 (Scheme 3.4).  This is followed by cyclisation through an 
intramolecular electrophilic aromatic substitution to form the THIQ product 103.   
 
 
Scheme 3.4. Mechanism of the acid catalysed Pictet-Spengler reaction for the synthesis of THIQs. 
 
One particular challenge in synthesising THIQs using the Pictet-Spengler method can 
be the low reactivity of the imine intermediate.  To overcome this, high temperatures 
and strong acidic conditions or even superacidic conditions have been used to promote 
the reaction, but this limits the functional group compatability.
109
  Strong Bronsted acid 
catalysts are commonly used including acetic acid, trifluoroacetic acid and p-
toluenesulfonic acid.  More recently examples of Lewis acid catalysed Pictet-Spengler 
reactions have been reported including calcium complexes and Yb(OTf)3.
110,111
  
Another strategy used to enhance the electrophilicity of the intermediate imine has been 
to generate N-acyliminium ions, commonly called acyl Pictet-Spengler reactions.
112
 
The Pictet-Spengler reaction is promoted by phenylethylamines with electron rich 
aromatic rings.  Electron donating groups on the aromatic ring (such as hydroxy or 
methoxy substituents) that are para or ortho to the cyclisation position facilitate the 
reaction by increasing the nucleophilicity at the position of cyclisation.
113
  The 
regioselectivity of a Pictet-Spengler reaction also depends on the electron donating 
substituents on the aromatic ring.  For example, for phenylethylamine 104 (Scheme 
3.5), cyclisation of the iminium intermediate can occur either at the position para to the 
hydroxy group to yield THIQ 105 or the position ortho to the hydroxy group to yield 
THIQ 106.
114
  Generally the least sterically hindered position is the predominant site for 
cyclisation (unless this position is blocked by a substituent) resulting in THIQ 105 being 
the major regioisomer formed.  The ratio of regioisomers can vary depending on 
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reaction conditions and complete regioselectivity for the THIQ product where 
cyclisation occurs para to the electron donating group is often observed.  
 
 
Scheme 3.5. Regioselectivity of the Pictet-Spengler reaction.  
 
Despite some of the requirements for Pictet-Spengler reactions, it has remained a useful 
method for the synthesis of many THIQ derived natural products and biologically active 
compounds. 
 
3.3.3 Pictet-Spengler reaction in nature 
In nature the Pictet-Spengler reaction is used to generate THIQ alkaloids.  The enzymes 
that catalyse this biosynthetic reaction are called Pictet-Spenglerases.  One of these 
enzymes is norcoclaurine synthase (NCS) which catalyses the stereospecific 
condensation of dopamine 101 and 4-hydroxyphenylacetaldehyde (4-HPAA) 107 to 
give the THIQ product (S)-norcoclaurine 108 (Scheme 3.6).
115
  This is an important 
reaction because it is the first step in the pathway to all the benzylisoquinoline alkaloids, 
which consist of more than 2500 known structures and are all synthesised from the 
central precursor (S)-norcoclaurine 108.
116
   
The proposed mechanism of the NCS catalysed Pictet-Spengler reaction (Scheme 3.6) 
begins with the initial formation of an iminium ion 109, followed by deprotonation of 
the 3-hydroxy group which promotes cyclisation onto the iminum moiety.
117
  The 
resulting quinone 110 is deprotonated irreversibly to form (S)-norcoclaurine 108. 
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Scheme 3.6. Proposed mechanism of the Pictet-Spengler reaction catalysed by NCS. 
 
In plants NCS catalyses the stereospecific formation of (S)-norcoclaurine 108, with the 
newly created chiral centre at position C-1 formed exclusively in the (S)-configuration.  
This excellent stereoselectivity has been utilised in NCS enzyme catalysis for the 
synthesis of structurally diverse (S)-THIQs, and this approach also offers a sustainable 
alternative compared to classical organic synthesis.
118,119,120
  A limitation of enzyme 
catalysis can be substrate specificity.  Several aldehydes are accepted as substrates by 
wild type NCS but dopamine tolerates less functionalisation which can limit its 
synthetic applications.  However, evaluation of the substrate scope of NCS enzymes 
remains an active area of research, with more detailed studies of the mechanism and 
kinetics of the Pictet-Spenglerase NCS being reported.
121
   
 
3.3.4 Biomimetic Pictet-Spengler reaction 
A biomimetic version of the Pictet-Spengler reaction mediated by phosphate catalysis in 
water was reported by the Hailes group.
122
  The reaction mimics the naturally occurring 
reaction in plants for the synthesis of norcoclaurine 108.  It was established that 
dopamine 101 undergoes a Pictet-Spengler condensation with 4-HPAA 107 in the 
presence of a phosphate buffer under mild reaction conditions (pH 6, 50 
o
C) to yield the 
THIQ norcoclaurine 108 (Scheme 3.7).  Phosphates were shown to have an important 
role in the reaction and act as catalysts, since when the reaction was carried out in water 
with no phosphate present, less than 1% of norcoclaurine 108 was formed.  In addition, 
carbonate, sulfate, borate and vanadate yielded the product 108 with less than 4% 
conversion.  Phosphates shown to catalyse the reaction included inorganic phosphates 
as well as uridine 5’-monophosphate (UMP) and glucose-1-phosphate. 
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  Scheme 3.7. Biomimetic phosphate mediated Pictet-Spengler reaction. 
 
The mild conditions used for the biomimetic reaction makes it suitable for a range of 
less stable amine and aldehyde substrates, and in contrast to the Bischler-Napieralski 
reaction does not require the use of protecting groups.  However, the phenylethylamines 
require an electron donating –OH or -NH2 group at the C-3 position in order sufficiently 
activate cyclisation of the imine intermediate.  A wide range of aldehydes were tolerated 
in the biomimetic Pictet-Spengler reaction with dopamine 101 including aliphatic, 
aromatic and benzylic aldehydes.  This simple one step method is suitable for the 
synthesis of structurally diverse sets of THIQ alkaloids, as demonstrated by the 
synthesis of a library of compounds for screening in antimycobacterial assays.
105
 
A proposed mechanism of the phosphate mediated Pictet-Spengler reaction involves 
two possible roles of the phosphate (Schemes 3.8 and 3.9).  Phosphate could act as a 
base and abstract a proton from the C-6 hydroxy group of the imine 111, activating the 
ring for addition to the electrophilic imine (Scheme 3.8).  Abstraction of the proton at 
position C-8a of 112 by phosphate could then facilitate rearomatisation to THIQ 113.   
 
 
Scheme 3.8. Proposed role of phosphate in the biomimetic Pictet-Spengler reaction (Pi is inorganic 
phosphate). 
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Phosphate could also act as a nucleophile (Scheme 3.9) and attack the imine 111 to 
form aminophosphate 114.  Subsequent deprotonation of the C-6 hydroxy group and 
rearomatisation could be facilitated by the phosphate group through the formation of a 
6-membered ring intermediate 115.     
 
 
Scheme 3.9. Proposed role of phosphate in the biomimetic Pictet-Spengler reaction. 
 
A recent study by the Maresh group has shown that the concentration of phosphate used 
in the biomimetic Pictet-Spengler reaction can affect the regioselectivity of the 
reaction.
119
  In their one pot procedure for the synthesis of THIQs from amino acids, 
they monitored the Pictet-Spengler reaction between propanal and dopamine 101 by 
HPLC for the formation of THIQ products 116 and 117 (Scheme 3.10).   
 
 
Scheme 3.10. One-pot biomimetic Pictet-Spengler reaction from amino acids. 
 
When a high concentration of phosphate was used (0.3 M), the THIQ 116 was formed 
as the major product where cyclisation occurred para to the electron donating hydroxy 
group.  Less than 1% of the regioisomer 117 (formed through cyclisation ortho to the 
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electron donating hydroxy group) was detected by HPLC.  When the reaction was 
repeated at a lower phosphate concentration of 0.01 M, the formation of the minor 
THIQ regioisomer 117 became more significant, with approximately 14% conversion. 
 
3.3.5 Asymmetric Pictet-Spengler reaction 
The cyclisation step in the Pictet-Spengler reaction creates a new chiral centre at the C-1 
position of the THIQ product.  The biological or pharmacological activity of 1-
substituted THIQs is often displayed by a specific enantiomer and therefore research 
into asymmetric methods for their synthesis is important for drug development.   
There are a number of diastereoselective Pictet-Spengler reactions for the synthesis of 
1-substituted THIQs using substrates containing chiral auxiliaries.
123
  For example, in a 
synthesis of (R)-salsolidine 118, a p-tolylsulfinyl chiral auxiliary was used to control the 
stereochemistry (Scheme 3.11).
124
  The Pictet-Spengler reaction of N-sulfinyl 
phenylethylamine 119 with acetaldehyde yielded THIQ 120 in 86% de, and the chiral 
auxiliary was removed in the presence of hydrochloric acid without racemisation.  
Although diastereoselective reactions allow for the synthesis of a single 1-substituted 
THIQ enantiomer, they can be step intensive requiring the installation and removal of 
chiral auxiliaries.   
 
 
Scheme 3.11. Asymmetric synthesis of a 1-substituted THIQ using a chiral auxiliary approach. 
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Asymmetric organocatalysis is the use of chiral organic molecules to catalyse 
enantioselective transformations.  The first enantioselective organocatalytic Pictet-
Spengler reaction was reported by Taylor and Jacobsen in 2004 but it was not for the 
preparation of the THIQ scaffold, instead for the synthesis of tetrahydro--carbolines 
(THBCs).
125
  Their strategy involved using a chiral thiourea catalyst 121 (a hydrogen 
bond donor catalyst) and enhancing the reactivity of the imine intermediate by 
generating the N-acyliminium ion, which afforded the N-acyl THBC products 122 in 
85-95% ee (Scheme 3.12).     
 
 
Scheme 3.12. Asymmetric acyl Pictet-Spengler reaction (R = alkyl group). 
 
A number of chiral thiourea catalysts and chiral Bronsted phosphoric acid catalysts have 
been used in the enantioselective organocatalytic Pictet-Spengler cyclisation, but most 
of these have been restricted to tryptamine derivatives.
126
  The success of these reactions 
can be attributed to the high nucleophilicity of the indole system, and the indole NH can 
hydrogen bond to the Bronsted acid catalyst enabling greater stereoselective control.  In 
comparison, the benzene ring in phenylethylamines is less nucleophilic than the indole 
in tryptamine.  Therefore the Pictet-Spengler cyclisation of phenylethylamines to 
THIQs often requires higher temperatures and stronger acidic conditions which makes 
the development of asymmetric versions more challenging.  
Only recently the enantioselective organocatalytic approach was extended to the 
synthesis of THIQs by Hiemstra and coworkers.
127
  A series of 1-substituted THIQs 123 
(Scheme 3.13) with ee up to 86% were prepared from N-(o-nitrophenylsulfenyl)-
phenylethylamines 124 using BINOL phosphoric acid catalysed Pictet-Spengler 
reactions. The phenylethylamine required a 3-hydroxy substituent in order to enhance 
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the reactivity of the ring.  The sulfenyl moiety was crucial for enantioselectivity and to 
increase reactivity of the iminium ion intermediate.  A range of aliphatic aldehydes were 
used in the reaction resulting in the chiral THIQ products 123 in yields of up to 95%. 
 
 
Scheme 3.13. Enantioselective organocatalytic Pictet-Spengler reaction. Nps = o-nitrophenylsulfenyl. 
 
The Hiemstra group also used the enantioselective phosphoric acid catalysed Pictet-
Spengler reaction to prepare 1-benzyl THIQs from N-sulfenyl phenylethylamines and 
phenylacetaldehydes (Scheme 3.14).
128
  They achieved good yields (70-85%) by 
carrying out the reactions at room temperature in the presence of a drying agent. Higher 
temperatures caused decomposition and side products of the phenylacetaldehyde 
substrates.  Using (R)-TRIP as the catalyst led to the formation of 1-benzyl THIQs in 
the (R)-configuration with ee between 85-92%.  After protecting group manipulations 
the alkaloid (R)-norcoclaurine (R)-108 was isolated in 89% ee.  This is opposite to the 
configuration produced by the NCS Pictet-Spenglerase enzyme in plants, which produce 
the (S)-configuration stereoselectively.   
 
 
Scheme 3.14. Enantioselective organocatalytic Pictet-Spengler reaction for 1-benzyl THIQs.  
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3.4 Aqueous phosphate mediated catalysis 
Water is an attractive reaction medium for organic synthesis and has a number of 
advantages over traditional organic solvents including lower costs, a reduced 
environmental impact and it is safe, non-toxic and non-flammable.
129
  In nature, 
biosynthetic reactions take place in water, and the synthesis of chiral biological 
molecules via enzymatic reactions are highly stereospecific.  For synthetic chemists, 
water compatible asymmetric catalysts are attractive as a sustainable approach for the 
preparation of enantiomerically pure compounds.
130
  However, water is a strong 
hydrogen bond donor/acceptor which can disrupt interactions between a chiral catalyst 
and a substrate and significantly influence the enantioselectivity that can be achieved.  
This is particularly a problem for catalysts that rely on non-covalent interactions such as 
hydrogen bonding or coulombic attraction between ion pairs.  Therefore asymmetric 
catalysis in aqueous media is challenging. 
Aqueous phosphate mediated catalysis has been demonstrated for a number of reactions, 
including Pictet-Spengler reactions that are promoted by a phosphate buffer
122
 (section 
3.3.4) and reactions catalysed by heterogeneous apatite catalysts featuring a phosphate 
functionalised surface.
131
  In aqueous solution phosphate exists in different ionisation 
states dependent on the pH of the solution (Figure 3.9), which can influence the 
catalytic activity of the phosphate.  In strongly acidic solution phosphoric acid is the 
predominant form.  In strong basic conditions the fully deprotonated phosphate ion 
(PO4
3-
) predominates.  Under neutral, weakly acidic or weakly basic conditions, mostly 
hydrogen and dihydrogen phosphate forms are present.   
 
 
Figure 3.9. Ionisation states of phosphate (pKa values at 25 
oC are from the CRC Handbook of Chemistry 
and Physics). 
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Chiral BINOL-derived phosphoric acids (Figure 3.10) have been established as an 
efficient and versatile class of organocatalysts for asymmetric reactions.
132
  The axially 
chiral biaryl (BINOL) moiety gives the catalyst its source of chirality, and the addition 
of bulky substituents at the 3,3’-positions of the biaryl improves enantioselectivity by 
providing a chiral environment where the substrate is activated.  Although many 
BINOL-derived phosphoric acid catalysts have been developed and used for the 
asymmetric synthesis of pharmaceutically useful structures, generally strictly anhydrous 
conditions are required to achieve high enantioselectivities.   
 
 
Figure 3.10.  General structure of chiral BINOL-derived phosphoric acids. 
 
In 2010 the Rueping group reported the first example of a BINOL-derived phosphoric 
acid catalysed asymmetric reaction in water (Scheme 3.15).
133
  They performed an 
enantioselective hydrogenation of quinolines 125 using a Hantzsch ester as the hydride 
source, to prepare 2-substituted tetrahydroquinolines 126.  The phosphoric acid catalyst 
(R)-TRIP was proposed to induce selectivity through formation of a chiral ion pair with 
the quinoline imine and direct the hydride donor to a particular face.  High 
enantioselectivities were observed when the reaction was carried out in water, and even 
higher selectivity (ee up to 97%) was achieved in a saturated NaCl solution, despite the 
fact that water is a strong hydrogen bond donor and could disrupt interactions between 
the catalyst and substrate.  This was attributed to ‘hydrophobic hydration’ where non 
polar molecules align so that the contact surface between these molecules and water is 
minimised.  This principle plays an important role in biological processes such as 
enzyme-substrate interactions.  In addition, the bulky isopropyl substituents on the 
catalyst created a hydrophobic pocket for the substrate to interact with the active 
catalytic phosphate centre.       
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Scheme 3.15.  Enantioselective hydrogenation of quinolines catalysed by a BINOL-derived phosphoric 
acid in water. 
 
An emerging class of water compatible asymmetric catalysts are chiral biological 
phosphates.  Biological molecules are an excellent starting point for the development of 
water compatible catalysts because they are typically highly soluble in water.  
Ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) have been shown to 
successfully catalyse a number of carbon-carbon bond forming reactions such as Diels-
Alder reactions, Friedel-Crafts reactions and Michael additions with high 
enantioselectivity.
134
  DNA-based asymmetric catalysts involve the binding of a 
catalytically active metal complex to the DNA through either covalent bonding or 
supramolecular interactions.
135
  Chiral catalysts lower the energy of one diastereomeric 
transition state to result in the preferential formation of a single diastereoisomer.  The 
right handed double helix structure of DNA provides the source of chirality, but the 
mechanism of how it lowers the energy of one diastereomeric transition state is not fully 
understood, and possible interactions between the DNA and the substrate include 
groove binding, intercalation or interactions with the phosphate backbone.  
Natural unmodified DNA as a catalyst has also been applied to aldol reactions, Henry 
(nitroaldol) reactions and Michael additions in water.
136
  However, currently no 
enantioselectivity has been reported for these reactions.  DNA is composed of 
nucleotides that each contain a phosphate group, a deoxyribose sugar and a nucleobase.  
These groups are capable of various interactions that could be responsible for the 
catalytic activity.  For example, Wang et al., found that the catalytic activity of DNA in 
the synthesis of dithioacetals from carbonyl compounds could be associated with the 
phosphate group.
137
  The Kumar group have reported the use of a single nucleotide as a 
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catalyst for asymmetric reductive amination of ketones (Scheme 3.16).
138
  Adenosine 
mono-, di- and triphosphate nucleotides promoted the reaction to give the amine product 
127 in excellent yields, but for good enantioselectivity to be achieved the reactions 
required anhydrous conditions.  It was proposed that the phosphate group of the 
nucleotides played a key role in the catalytic activity, through hydrogen bonding with 
the imine intermediate.   
 
 
Scheme 3.16.  Enantioselective reductive amination catalysed by a single nucleotide. 
 
The advantages of using chiral biological phosphates such as DNA or nucleotides as 
catalysts are their commercial availability and their compatibility with aqueous media.  
They are emerging as excellent catalysts for a number of organic transformations and 
show promising ability to control the stereoselectivity of reactions. 
 
3.5 Tetrahydro-2-benzazepines 
3.5.1 Structure and biological activity 
2,3,4,5-Tetrahydro-2-benzazepines (THBPs) are 7-membered ring analogues of 
tetrahydroisoquinoline.  The THBP ring system is present in both alkaloid natural 
products and synthetic drugs that possess a wide range of biological activities (Figure 
3.11).  For example, a number of Amaryllidaceae alkaloids contain the THBP structure 
such as galanthamine which is an acetylcholinesterase inhibitor used for the treatment of 
Alzheimer’s disease and haemanthidine which was recently shown to have antimalarial 
properties.
139
  Synthetic THBP derivatives include capsazepine which is a vanilloid 
receptor antagonist and BMS791325 which is undergoing clinical studies as an inhibitor 
of the hepatitis C virus.
140
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Figure 3.11. Examples of bioactive tetrahydro-2-benzazepine (THBP) derivatives. 
 
1-Substituted THBPs are interesting as potential drug molecules as they are closely 
related to the 1-substituted THIQs, of which there are many biologically active 
compounds.  For SAR studies, changing the ring size from a 6-membered ring (THIQ) 
to a 7-membered ring (THBP) can be useful because conformational changes in the ring 
can alter the position of the substituents and influence the potency against a target.
141
  In 
addition, 7-membered ring THBPs may have different metabolic profiles compared to 
the corresponding 6-membered ring THIQs and may offer improved pharmacokinetic 
properties.  
 
3.5.2 Synthesis 
Strategies reported for the synthesis of 1-substituted THBPs are fairly limited.  Ring 
expansions have been used such as the Schmidt ring expansion followed by further 
steps to incorporate a C-1 substitutent onto the benzazepine ring.
142
  More common 
routes involve a cyclisation to form the 7-membered ring system.  Reactions such as 
ring closing metathesis and a gold catalysed [2 + 5] cycloaddition have been used to 
prepare 1-substituted THBPs, but these involved multiple steps to prepare the required 
compounds for cyclisation.  The Bischler-Napieralski reaction (described in section 
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3.3.1) has been used for cyclisation to form 7-membered rings.  For example, the 
activated phenylpropylamide 128 was converted to the cyclic imine 129 in the presence 
of phosphorus oxychloride at high temperature (Scheme 3.17).  The imine was 
subsequently reduced to yield the 1-substituted THBP 130.
143
  
 
 
Scheme 3.17. Synthesis of a 1-substituted THBP by a Bischler-Napieralski/reduction method. 
 
The Pictet-Spengler cyclisation (described in section 3.3.2) has also been used for the 
synthesis of THBPs.  The cyclisation between phenylpropylamine 131 and 
benzaldehyde derivatives to generate 1-substituted THBPs 132a-c has been reported, 
but the reactions required high temperatures and the yields of the THBP products were 
low (6-22%) (Scheme 3.18).
144
  It was essential for the phenylpropylamine 131 to have 
an electron donating hydroxy substituent to activate the ring at the position para to the 
cyclisation site.   
 
 
Scheme 3.18. Synthesis of 1-substituted THBPs by a Pictet-Spengler cyclisation.  
 
Although 7-endo trig cyclisations are favoured by Baldwin’s rules, the Pictet-Spengler 
cyclisation to yield 7-membered rings is challenging.  Reported methods often rely on 
using modified Pictet-Spengler conditions involving either N-acyl or N-sulfonyl groups 
(to increase the reactivity of the imine intermediate) and are often limited to the use of 
formaldehyde.  For example in the total synthesis of lycoramine, an Amaryllidaceae 
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alkaloid, the cyclisation of compound 133 under acidic conditions yielded THBP 134, 
proceeding via an N-acyliminium intermediate (Scheme 3.19).
145
 
 
 
Scheme 3.19. Modified Pictet-Spengler cyclisation in the total synthesis of lycoramine. 
 
Cyclisation to form 7-membered rings is challenging with strategies often involving 
numerous steps that are not generally applicable to a wide range of substrates.  
Cyclisation methods that are compatible with unprotected substrates, operate under mild 
conditions and do not involve step-intensive procedures would be useful, since 
compounds containing the 1-substituted tetrahydro-2-benzazepine structure show wide 
ranging bioactivities and are interesting structures for medicinal chemistry. 
 
3.6 Aims of the project 
The aim of this part of the project was to synthesise a series of 1-substituted THIQs and 
establish their antimycobacterial properties, in order to further previous SAR studies 
where the THIQ structure was identified as a promising new pharmacophore for anti-TB 
drugs.
105
  The target compounds 135 (Scheme 3.20) were designed based on THIQs that 
were previously found to show antimycobacterial activity within the Hailes and Bhakta 
groups.  The substituents on the aromatic ring (R1-R4) included hydroxy groups (which 
were previously found to influence antimycobacterial activity but the optimal position 
was not established) and a bromide substituent (which was present in THIQs 91-93 
(Figure 3.8) and conferred excellent antimycobacterial activity).  The aim was to also 
investigate substituents at the C-1 position (R5) such as alkyl chains, benzylic groups or 
functionalised groups that could allow for further manipulation of the THIQs to 
generate new structures.  The phosphate mediated Pictet-Spengler reaction was chosen 
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for the preparation of the target compounds because this method readily allows for 
variations of the substituents at C-1 (R5) and the aromatic ring (R1-R4) through the 
choice of amine and aldehyde starting materials (Scheme 3.20). 
To determine the antimycobacterial activity of the THIQs, the aim was to evaluate the 
compounds in a number of assays by biological collaborators, including SPOTi and 
cytotoxicity assays.  Compounds showing promising antimycobacterial activity could 
then undergo further analysis for possible modes of action including an efflux pump 
inhibition assay which has been established by the Bhakta group.  In addition to the 
SAR studies, two 1-substituted THIQs 91 and 92 (Figure 3.8) that were previously 
found to be excellent inhibitors of mycobacterial growth, required synthesis for 
pharmacokinetic analysis.    
    
 
Scheme 3.20. Target THIQs to be synthesised by the phosphate mediated Pictet-Spengler reaction. 
 
The aim of the project was also to extend the use of the phosphate mediated Pictet-
Spengler reaction.  Previously the cyclisation reaction had only been used for the 
construction of racemic 6-membered ring THIQs.  Extending the reaction to generate 7-
membered ring analogues from readily accessible starting materials would generate a 
new range of 1-substituted THBPs 136 (Scheme 3.21) which may also possess 
interesting antimycobacterial activities.  In addition, extending the phosphate mediated 
Pictet-Spengler reaction to generate optically active THIQs 137 (Scheme 3.21) in 
aqueous media would be attractive as a synthetic tool.  Therefore, the aim was to screen 
chiral biological phosphates and BINOL-derived phosphoric acids as chiral catalysts, 
and to determine the enantiomeric excess of the THIQ products generated. 
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Scheme 3.21. Phosphate mediated Pictet-Spengler reaction to prepare 7-membered ring THBPs and 
optically active THIQs. 
 
The final part of this project was to prepare a small set of profens (2-arylpropionic 
acids) for antimycobacterial screening.  The aim was to improve potency compared to 
the profens reported to date.
94
  The target compounds 138 and 139 (Figure 3.12) were 
derivatives of ibuprofen and loxoprofen.  These were chosen for derivatisation because 
the Bhakta group found that they were good inhibitors of the growth of M. 
tuberculosis.
94
  Also, ibuprofen was readily available, and loxoprofen could be prepared 
following literature procedures from cheap commercially available starting materials. 
  
 
Figure 3.12. Target derivatives of ibuprofen and loxoprofen. 
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4. Tetrahydroisoquinolines 
 
4.1 SAR of C-1 and aromatic ring substituents 
4.1.1 Synthesis of first generation THIQs  
The first generation of 1-substituted THIQs incorporated various groups at the C-1 
position, with the aim of identifying substituents that conferred antimycobacterial 
activity.  The substituents included alkyl chains of varying length, a cyclic alkyl group 
and benzylic groups (Scheme 4.1).  These were selected based on the good 
antimycobacterial activities previously reported for THIQs that featured a 
methylenedioxybenzyl substituent and a nonyl substituent (section 3.2.2, Figures 3.7 
and 3.8).
105
 
The phosphate mediated Pictet-Spengler reaction (described in section 3.3.4)
122
 was 
used to synthesise the THIQs (Scheme 4.1).  Dopamine 101 was chosen as the 
phenylethylamine starting material in order to prepare THIQ compounds with a 6,7-
dihydroxy substitution pattern on the aromatic ring. Compounds featuring this moiety 
have previously shown antimycobacterial activity.
105
  In addition, dopamine 101 was 
readily available and favours Pictet-Spengler cyclisations due to the electron rich 
aromatic ring.  The aldehydes used included aliphatic aldehydes 140a-d and 
phenylacetaldehyde derivatives 140e-f. 
 
 
Scheme 4.1. Synthesis of first generation THIQs (Yields = isolated yield after purification by HPLC). 
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The Pictet-Spengler reactions were carried out in a 1:1 mixture of potassium phosphate 
buffer (pH 6) and acetonitrile at 50 
o
C.  The crude products were purified using reverse-
phase prep-HPLC, eluting with water and acetonitrile containing 0.1% TFA.  The THIQ 
products collected from the HPLC purification were subsequently washed with 
methanol to remove the TFA.  The major THIQ products 141a-f were isolated in yields 
between 32-77%.  A small amount of the regioisomers 142a-f were formed as a minor 
product in each reaction (isolated yields 3-9%).  The regioisomers were separated 
during the reverse-phase HPLC purification, but due to their structural similarity the 
compounds eluted close together.  A good separation was achieved by running the 
HPLC method for an extended period of time (methods described in Chapter 8).  
Therefore, in addition to the desired 6,7-dihydroxy THIQs 141a-f, the 7,8-dihydroxy 
THIQs 142a-f were available for evaluation for antimycobacterial activity.  
The phenylacetaldehydes used in the synthesis of the first generation THIQs were 
prepared using a Parikh-Doering oxidation.
146
  Phenylacetaldehydes can be difficult to 
prepare because they are prone to polymerisation and aldol condensations.  The Parikh-
Doering oxidation involves the activation of DMSO for the oxidation of alcohols using 
sulphur trioxide, and the reaction proceeds under mild basic conditions and has been 
used by Pesnot et al. as a general route for the synthesis of phenylacetaldehydes.
118a
  
Aldehyde 140f was prepared in two steps from commercially available phenylacetic 
acid 143 (Scheme 4.2).  The phenylacetic acid 143 underwent reduction using lithium 
aluminium hydride to afford the alcohol 144
147
 in 96% yield, followed by oxidation 
using SO3.pyridine in DMSO and dichloromethane to give the aldehyde 140f in 51% 
yield.  For optimal yields the reaction temperature needed to be kept at -15 
o
C, hence 
dichloromethane was required as a co-solvent to avoid freezing of the DMSO solution.  
The same oxidation method was used to prepare 2-(m-tolyl)acetaldehyde 140e
118b
 from 
commercially available 3-methylphenethyl alcohol in 60% yield.   
 
 
Scheme 4.2. Synthesis of 3,4-(methylenedioxy)phenylacetaldehyde 140f. 
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The aldehyde 4-HPAA 107
122
 was also synthesised following the Parikh-Doering 
oxidation method (Scheme 4.3) in 43% yield.   4-HPAA 107 was difficult to isolate in 
good yields because the phenol moiety enhances the ability of the aldehyde to undergo 
aldol condensations.  It was found that optimal yields were achieved when purification 
of the crude product by column chromatography was carried out quickly, and 
evaporation of the solvents in vacuo was performed at room temperature.  The resulting 
product 107 was stable when stored under argon at -80 
o
C in acetonitrile solution.  The 
prepared 4-HPAA 107 was subsequently used in a study of the mechanism and kinetics 
of the NCS catalysed Pictet-Spengler biosynthetic pathway (section 3.3.3) by Lichman 
et al.
121
  
 
 
Scheme 4.3. Synthesis of 4-HPAA. 
 
4.1.2 Antimycobacterial activity of first generation THIQs 
The compounds were tested for their growth inhibition of M. aurum using SPOTi (spot 
culture growth inhibition assay, described in section 3.1.2) (Table 4.1).
iv
  The MIC 
(minimum inhibitory concentration) values were determined as the concentration at 
which no growth of mycobacteria was observed.  The compounds were also evaluated 
for their effect on mammalian cells using a eukaryotic cell cytotoxicity resazurin assay 
with murine macrophage cells RAW 264.7.  The GIC (growth inhibitory concentration) 
values were determined as the concentration at which more than 90% inhibition of cell 
viability was observed (Table 4.1).  Both of these assays were carried out by biological 
collaborators in the Bhakta group at Birkbeck, University of London. 
 
                                                             
iv The SPOTi and cytotoxicity assays described in this chapter were carried out by Arundhati Maitra and 
Dr Parisa N. Mortazavi in the Bhakta group in the Mycobacterial Research Laboratory at Birkbeck, 
University of London. 
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R group THIQ Mwt calc LogP 
(ACD) 
MIC M. aurum 
(µg/mL) 
GIC RAW 
264.7 (µg/mL) 
 141a 193.3 1.72 no inhibition
a 
15.6 
 142a 193.3 1.72 250 15.6 
 141b 235.3 3.09 500 31.3 
 142b 235.3 3.09 15.6 15.6 
 141c 277.4 4.45 125 7.8 
 142c 277.4 4.45 250  15.6 
 141d 233.3 2.27 no inhibition
a 
62.5 
 142d 233.3 2.27 250 7.8 
 141e 269.3 3.05 500 31.3 
 142e 269.3 3.05 250 15.6 
 141f 299.3 2.82 500 62.5 
 142f 299.3 2.82 250 31.3 
Table 4.1. Antimycobacterial properties of the first generation THIQs.  MIC = lowest concentration at 
which no growth of mycobacteria was observed.  GIC = concentration at which more than 90% inhibition 
of cell viability (RAW 264.7) was observed.  aHighest concentration tested was 500 µg/mL. 
 
The data indicated that the 6,7-dihydroxy-THIQs with alkyl chains at the C-1 position 
(141a-c) became increasingly potent against M. aurum as the length of the alkyl chain 
increased.  For example, the 1-ethyl substituted compound 141a did not inhibit the 
growth of M. aurum at a concentration of 500 µg/mL, whereas the 1-octyl substituted 
compound 141c had a MIC = 125 µg/mL.  The 6,7-dihydroxy-THIQ 141d with a 
cyclopentyl C-1 substituent did not inhibit M. aurum growth at the maximium 
concentration tested (500 µg/mL), suggesting a more flexible alkyl chain was required 
for potency.  The 6,7-dihydroxy-THIQs 141e and 141f featuring a benzylic group at the 
C-1 position, both had MIC values of 500 µg/mL, so a high concentration of the 
compound was required in order to inhibit mycobacterial growth. 
77 
 
Previously within the Hailes and Bhakta groups the 6,7-dihydroxy-THIQ 141f had been 
evaluated for its activity against the growth of M. bovis BCG using SPOTi, and had a 
MIC of 100 µg/mL.105  In comparison with this study, the MIC of the same compound 
141f against M. aurum was significantly higher (MIC = 500 µg/mL).  The difference in 
activities was likely to arise from differences between M. bovis BCG
148
 and M. 
aurum.
149
  M. aurum is a relatively fast growing species whereas M. bovis BCG is slow 
growing and more closely related to the slow growing M. tuberculosis.   
The 7,8-dihydroxy-THIQs 142 exhibited better M. aurum growth inhibition compared 
to the corresponding 6,7-dihydroxy-THIQ 141 regioisomers.  For example, compounds 
142e-f had MIC values of 250 µg/mL and the regioisomers 141e-f had MICs of 500 
µg/mL.  An exception to this trend was seen for the compounds with an octyl 
substituent at the C-1 position, where the trend was reversed and the 6,7-dihydroxy 
derivative 141c (MIC = 125 µg/mL) was more active than the 7,8-dihydroxy derivative 
142c (MIC = 250 µg/mL).  The 7,8-dihydroxy-THIQ 142b with a pentyl chain at the C-
1 position  was the most potent compound of the series with a MIC of 15.6 µg/mL.   
The MICs of the first generation THIQs did not show a correlation with the calculated 
LogP values (Table 4.1).  The LogP values (octanol/water partition coefficient) express 
the compounds lipophilicity, and according to Lipinski’s rules, drug absorption and 
permeability is more likely when LogP is less than 5.
87
  TB drugs often do not conform 
to this rule, and a number of studies have shown the tendency for LogP to increase 
during early drug discovery.  For example, in a series of indolecarboxamide anti-TB 
compounds, the calculated LogP of the initial hit compound was 4.5, and this increased 
to 6.1 for the optimised compound.
89
  This may be linked to more lipophilic compounds 
having improved permeability across the highly waxy mycobacterial cell wall.
150
  
However this was not observed in this SAR study where there were significant 
differences in activity between the 6,7-dihydroxy-THIQ and 7,8-dihydroxy-THIQ 
regioisomers which had the same calculated LogP values.  This suggested the position 
of the hydroxy groups on the aromatic ring influenced the potency, possibly through 
interactions with an unknown target.  
Analysis of the GIC data showed that the THIQs displayed cytotoxicity against 
mammalian cells (Table 4.1).  For all of the compounds the concentration that was 
required to inhibit mycobacterial growth would also be toxic to mammalian cells.  The 
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compounds that exhibited the lowest cytotoxicity against mammalian cells (GIC = 62.5 
µg/mL) were the 6,7-dihydroxy-THIQs 141d and 141f.  In order to be useful as 
potential drug like compounds, the MICs would need to be much lower than the GIC 
values so that selective inhibition for mycobacteria growth could be achieved without 
the compounds being toxic to mammalian cells. 
 
4.1.3 Synthesis of second generation THIQs 
The most potent compound from the first generation THIQs was 142b with a pentyl 
chain at position C-1.  In order to determine if this was the optimal chain length for 
antimycobacterial activity, an investigation into the propyl, butyl, hexyl and heptyl 
chain lengths was carried out.  The second generation THIQs with varying length alkyl 
chains at the C-1 position were prepared using the phosphate mediated Pictet-Spengler 
reaction as described for the first generation THIQs (Scheme 4.4). The reaction between 
dopamine 101 and the aliphatic aldehydes yielded a mixture of 6,7-dihydroxy-THIQs 
145a-d as the major products and 7,8-dihydroxy-THIQs 146a-d as the minor products.   
 
 
Scheme 4.4. Synthesis of second generation THIQs (Yields = isolated yields after purification by HPLC). 
 
The major regioisomers with a butyl 145b, hexyl 145c and heptyl 145d chain at the C-1 
position were isolated after reverse phase prep-HPLC in good yields of between 83-
86%.  The THIQ 145a with a shorter propyl chain was isolated in a lower yield of 45%.  
This was because some of the product was lost at the purification stage in order to 
79 
 
ensure all of the product 146a was completely separated from its regioisomer.  The 
corresponding minor regioisomers 146a-d were isolated in yields of between 3-11% and 
the yields increased as the length of the alkyl chain increased.  
 
4.1.4 Antimycobacterial activity of second generation THIQs 
The second generation THIQs were screened for their growth inhibition of M. aurum 
and cytotoxicity against mammalian cells (Table 4.2).   
 
 
R group THIQ Mwt calc LogP 
(ACD)
 
MIC M. aurum 
(µg/mL) 
GIC RAW 
264.7 (µg/mL) 
 145a 207.3 2.18 >500
a 
31.3 
 146a 207.3 2.18 250 15.6 
 145b 221.3 2.63 >500
a 
125 
 146b 221.3 2.63 250 15.6 
 142b 235.3 3.09 125 15.6 
 145c 249.4 3.54 250 62.5 
 146c 249.4 3.54 250 15.6 
 145d 263.4 3.99 250 7.8 
 146d 263.4 3.99 500 15.6 
Table 4.2. Antimycobacterial properties of the second generation THIQs. aThe highest concentration of 
THIQ tested was 500 µg/mL.  MIC = lowest concentration at which no growth of mycobacteria was 
observed.  GIC = concentration at which more than 90% inhibition of cell viability was observed. 
 
The MIC values of the 6,7-dihydroxy-THIQs 145a-d decreased as the length of the 
alkyl chain was increased, as previously observed for the first generation compounds.  
Compounds 145a-b with the propyl and butyl chains at position C-1 did not completely 
inhibit the growth of M. aurum at the highest concentration tested (500 µg/mL).  
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Compounds 145c-d with a hexyl or heptyl chain at the C-1 postion had lower MIC 
values of 250 µg/mL.  This suggested that increasing the lipophilicity of the 6,7-
dihydroxy-THIQ compounds resulted in increased antimycobacterial activity. 
The 7,8-dihydroxy-THIQs 146a-d and 142b showed a different pattern of 
antimycobacterial activity compared to the corresponding 6,7-dihydroxy regioisomers.  
Compounds with a propyl 146a or butyl 146b substituent at the C-1 position had a MIC 
value of 250 µg/mL.  Increasing the chain length to the pentyl substituent 142b resulted 
in a more potent compound with a decrease in the MIC to 125 µg/mL.  Increasing the 
chain further to the hexyl 146c and heptyl 146d substituents resulted in the MICs 
increasing (MIC = 250 and 500 µg/mL respectively).   
When compound 142b was screened in the first generation compounds the MIC was 
determined as 15.6 µg/mL against M. aurum (Table 4.1).  However, when screened 
again with the second generation compounds the MIC value against M. aurum was 125 
µg/mL (Table 4.2).  To confirm the actual MIC, compound 142b was synthesised again 
and purified, and re-tested in the same assay where its MIC was found to be 125 µg/mL.  
Hence this was determined as the true MIC value, and although it was not as potent as it 
originally seemed, THIQ 142b was still the most potent compound of the series with the 
lowest MIC value.   
The GIC data (Table 4.2) showed that the least cytotoxic compound to mammalian cells 
was the 6,7-dihydroxy-THIQ 145b with a butyl C-1 substituent (GIC = 125 µg/mL).  
All of the 7,8-dihydroxy-THIQs 146a-d had a GIC of 15.6 µg/mL.  As also seen for the 
first generation THIQs, generally the GIC values were lower than the MIC values.  
Therefore the concentration of THIQ required to inhibit mycobacterial growth would 
also be toxic to mammalian cells.  To optimise these compounds, the mammalian cell 
toxicity would need to be reduced whilst enhancing or at least maintaining the level of 
antimycobacterial activities. 
 
4.1.5 Synthesis of third generation THIQs 
The significant trend observed for the first and second generation THIQs was that the 
7,8-dihydroxy-THIQs were generally more potent for M. aurum growth inhibition than 
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the 6,7-dihydroxy-THIQs.  Therefore the third generation compounds were designed to 
focus on the activity of the aromatic ring substituents and to determine if the increase in 
potency arose from the presence of a hydroxy group at position C-8 or the removal of a 
hydroxy group at position C-6.   
The target compounds (Figure 4.1) included THIQs with a single hydroxy group at 
positions C-6, C-7 and C-8, or a 6,8-dihydroxy substitution, to identify which hydroxy 
substituents increased the antimycobacterial activity of the compounds.  Also, THIQs 
with a 5-bromo-8-hydroxy substitution were synthesised because this motif was 
previously found within the group to confer good antimycobacterial properties 
(described in section 3.2.2).
105
  All of the target compounds were designed to retain the 
pentyl substituent at position C-1, which was found to confer the highest 
antimycobacterial activity in the SAR studies on the C-1 substituent. 
 
 
Figure 4.1. Target compounds for SAR of aromatic ring substituents. 
 
Most of the target compounds were synthesised using the phosphate mediated Pictet-
Spengler reaction.
122
  Initial preparation of the hydroxyphenylethylamine starting 
materials was required (Scheme 4.5).  These were prepared as previously reported via 
the reduction of commercially available methoxyphenylacetonitriles to the 
corresponding amines, followed by demethylation.
105,118a
 Reduction of 3-
methoxyphenylacetonitriles 147 and 148 was accomplished using borane (as the THF 
complex) in anhydrous tetrahydrofuran at room temperature for 24 hours.  The crude 
products were purified by column chromatography using triethylamine as an additive to 
ensure the product remained as the uncharged free amine, to give the phenylethylamines 
149
118a
 and 150
151
 in good yields (95% and 82% respectively).   
Bromination of 3-methoxyphenylethylamine 149 was carried out based on a literature 
procedure
152
 and involved the slow addition of bromine in acetic acid to the 
phenylethylamine at 15 
o
C (Scheme 4.5).  After purification of the crude product by 
column chromatography, the mono-brominated compound 151 was obtained in 88% 
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yield.  The same bromination method was followed to prepare compounds 152
153
 and 
153
154
 from amines 150 and 154 (amine 154 was commercially available).  Bromination 
of 3,5-dimethoxyphenylethylamine 150 yielded a mixture of the mono- and di-
brominated products (under a carefully controlled reaction temperature and using 1 
equivalent of bromine) that were formed due to the activation of the ring at the positions 
para to each methoxy group.  These products were separated using column 
chromatography and the mono-brominated product 152 was isolated in 34% yield.    
The final step was demethylation of the methoxy groups of the 3-
methoxyphenylethylamine derivatives using boron tribromide in anhydrous 
dichloromethane (Scheme 4.5).
105,118a
 When the reactions were complete they were 
quenched with methanol, and subsequent evaporation of the volatiles led to isolation of 
the 3-hydroxyphenylethylamine products 155-159 as the hydrobromide salt in good 
yields (89-100%).  This work-up procedure proved to be more facile than quenching the 
reactions with water, as otherwise it was difficult to isolate the desired products from 
the aqueous phase.  The dihydroxyphenylethylamine 158 was further purified by 
reverse phase prep-HPLC to remove any oxidised impurities.  The phenylethylamine 
155 prepared for this SAR study was also used by biological collaborators in a one-pot 
synthesis of an (S)-benzylisoquinoline alkaloid, using the enzymes transaminase (TAm) 
and norcoclaurine synthase (NCS) in a ‘triangular’ cascade.120 
 
 
  Scheme 4.5. Synthesis of hydroxyphenylethylamines. aIsolated yield of the TFA salt after HPLC. 
83 
 
The target THIQ compounds 160 and 161 were prepared from the phosphate mediated 
Pictet-Spengler reaction between phenylethylamine 155 and hexanal (Scheme 4.6).  The 
reaction was carried out in a mixture of potassium phosphate buffer (pH 6, 0.5 M) and 
acetonitrile at 50 
o
C.  Two regioisomers were generated and were separated by reverse 
phase prep-HPLC.  The major product 6-hydroxy-THIQ 160 was isolated in 81% yield 
and the minor product 8-hydroxy-THIQ 161 in 12% yield.   
 
 
Scheme 4.6. Synthesis of target compounds 160 and 161 with a single hydroxy group. 
  
The target THIQ compounds 162 and 163 with a 5-bromo-8-hydroxy substitution were 
also synthesised using the phosphate mediated Pictet-Spengler reaction (Scheme 4.7).  
The reaction between phenylethylamines 157 and 159 with hexanal yielded the desired 
products 162 and 163 in low yields of 14% and 7%.  The low yields were most likely to 
result from a combination of sterics and electronics of the intermediate imine.  
Cyclisation of the imine proceeds at the more sterically hindered position ortho to the 
hydroxy group, and the aromatic ring may not be sufficiently electron rich to promote 
the cyclisation to achieve good yields.  Usually the position para to the activating 
hydroxy group would be favoured for Pictet-Spengler reactions but this position was 
blocked by the bromine substituent.  Despite the low yields, sufficient quantities of the 
products were isolated for the antimycobacterial activity assays.   
 
 
Scheme 4.7. Synthesis of target compounds with a 5-bromo-8-hydroxy substitution. 
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The 3,5-dihydroxyphenylethylamines 156 and 158 were excellent substrates for the 
phosphate mediated Pictet-Spengler reaction (Scheme 4.8).  The advantage of using 
amines with a 3,5-dihydroxy substitution was that cyclisation of the intermediate imine 
yielded one product and avoided a mixture of regioisomers.  In addition, both the 
hydroxy substituents of 156 and 158 activated the aromatic ring for cyclisation to the 
same position, so although cyclisation occurred at a position which was sterically 
hindered (ortho to a hydroxy group), the ring was sufficiently activated to achieve good 
yields of the cyclised products.  The target compound 164 was isolated after reverse 
phase HPLC in an excellent yield of 95%, and the bromo analogue 165 isolated in 72%.   
 
 
Scheme 4.8. Synthesis of target compounds with a 6,8-dihydroxy substitution. 
 
The final target compound was THIQ 166 with a single hydroxy group at the C-7 
position (Scheme 4.9).  This compound lacked an electron donating hydroxy group in a 
position which would activate the aromatic ring to cyclise in a Pictet-Spengler reaction 
(see sections 3.3.2 and 3.3.4).
113,122
  Therefore a Bischler-Napieralski reaction 
(described in section 3.3.1) was employed to prepare THIQ 166.
155
  The synthesis began 
with the preparation of phenylethylamide 167 (Scheme 4.9).  The commercially 
available phenylacetonitrile 168 was reduced to amine 169
156
 in 76% yield and then 
reacted with hexanoyl chloride to form the desired amide 167 in 90% yield.   
The Bischler-Napieralski cyclisation of phenylethylamide 167 required forcing 
conditions (Scheme 4.9).  Initially phosphorus oxychloride was employed as the 
dehydrating agent and used in acetonitrile at reflux.  These conditions did not produce 
any of the cyclised product.  The solvent was changed to toluene to enable a higher 
reaction temperature but also using these conditions did not yield any cyclised product.  
Next, a procedure reported for the synthesis of similar 7-methoxy-THIQs was 
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followed.
155
  A mixture of phosphorus oxychloride and phosphorus pentoxide in 
refluxing xylene, followed by reduction of the cyclic imine intermediate with sodium 
borohydride produced a mixture of the 7-methoxy-THIQ 170 and the unexpected 
regioisomer 6-methoxy-THIQ 171.  The regioisomers could not be separated by HPLC 
and were isolated as a mixture in 37% yield (ratio 170/171, 1.6:1).  The desired 7-
methoxy-THIQ 170 was assigned as the major product as determined by 
1
H-NMR 
spectroscopy.  The final step was the demethylation of the methoxy groups using boron 
tribromide to yield the hydroxy-THIQs 166 and 160.  These regioisomers could be 
separated by reverse phase prep-HPLC and the target compound 166 was isolated in 
43% yield. 
 
 
Scheme 4.9. Synthesis of the target compound with a 7-hydroxy substitution. 
 
A mechanism for the formation of the unexpected regioisomer 171 generated in the 
Bischler-Napieralski reaction has been reported.
157
  It was proposed that the use of 
phosphorus pentoxide would generate a nitrile intermediate (Scheme 4.10).  Attack of 
the aromatic ipso carbon onto the nitrile in a 5-endo dig cyclisation forms a spirocyclic 
carbocation which rearranges to the cyclic imine with the methoxy substituent at the C-
6 position. 
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Scheme 4.10. Proposed mechanism by S. Doi et al. for the formation of 6-methoxy- and 7-methoxy-
THIQs under Bischler-Napieralski reaction conditions. 
 
4.1.6 Antimycobacterial activity of third generation THIQs 
The third generation THIQs were screened for their growth inhibition of M. aurum and 
cytotoxicity against mammalian cells as previously described for the first and second 
generation compounds (Table 4.3).  Analysis of the MIC values revealed three key 
trends.  The first trend was that a hydroxy group at the C-8 position (THIQ 161, MIC = 
250 µg/mL) enhanced the antimycobacterial activity more than a hydroxy group at 
position C-6 or C-7 (THIQs 160 and 166, MICs = 500 µg/mL).  The second important 
SAR was that despite the C-8 hydroxy group conferring optimal mycobacteria growth 
inhibition, the presence of a hydroxy group at the C-6 position was tolerated without 
loss of activity.  This was demonstrated by the comparison of inhibition data for the 8-
hydroxy-THIQ 161 with 6,8-dihydroxy-THIQ 164 which both had a MIC of 250 
µg/mL.  The 6,8-dihydroxy-THIQ derivatives could be synthesised using the phosphate 
mediated Pictet-Spengler reaction in excellent yields and further series of compounds 
containing this pharmacophore could easily be prepared for further SAR studies. 
The third key trend was that the presence of a bromine substituent at the C-5 position on 
the THIQs improved the mycobacteria growth inhibition activity.  This was consistent 
with previous studies in the group for 5-bromo-8-hydroxy analogues of phenyl or 
benzyl C-1 substituted THIQs (described in section 3.2.2).
105
  For example, when 
comparing 8-hydroxy-THIQ 161 to 5-bromo-8-hydroxy-THIQ 162, a decrease in MIC 
from 250 µg/mL to 62.5 µg/mL was observed.  Similarly, when comparing 6,8-
dihydroxy-THIQ 164 to 5-bromo-6,8-dihydroxy-THIQ 165, a decrease in the MIC from 
250 µg/mL to 125 µg/mL was observed.  The most potent compound was THIQ 162 
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(MIC = 62.5 µg/mL) and was also the most lipophilic compound of the series with a 
calculated LogP (ACD) of 4.16.  It was possible that the higher lipophilicity of THIQ 
162 improved its permeability across the highly waxy mycobacterial cell wall.
150
   
 
THIQ Mwt calc LogP 
(ACD)
 
MIC M. aurum 
(µg/mL) 
GIC RAW 264.7 
(µg/mL) 
 
160 
219.3 3.42 500
 
62.5 
 
166 
219.3 3.42 500 125 
 
161 
219.3 3.42 250
 
31.3 
 
162 298.2 4.16 62.5 15.6 
 
163 314.2 3.81 250 31.3 
 
165 314.2 3.81 125 31.3 
 
164 
235.3 3.09 250 62.5 
Table 4.3. Antimycobacterial properties of the third generation THIQs.  MIC = lowest concentration at 
which no growth of mycobacteria was observed.  GIC = concentration at which more than 90% inhibition 
of cell viability (RAW 264.7) was observed. 
 
The GIC data showed that the THIQs displayed some cytotoxicity towards mammalian 
cells (Table 4.3), and were therefore not selectively toxic towards mycobacterial cells.  
The least cytotoxic compound was the 7-hydroxy-THIQ 166 with a GIC of 125 µg/mL.  
The THIQs containing a bromo substituent (162, 163 and 165) that were the most active 
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against the growth of M. aurum also displayed the most cytotoxicity towards 
mammalian cells (GIC = 15.6-31.3 µg/mL).  In order to be useful as potential anti-
mycobacterial drugs, the concentration of the THIQs required for antimycobacterial 
activity would need to be at least two fold lower than the GIC values. 
 
4.2 Efflux pump inhibition 
The first, second and third generation THIQ compounds were screened in a 
mycobacterial efflux pump inhibition assay, to probe whether efflux pump inhibition 
(described in section 3.1.4) was a possible mode of action.  The screening was carried 
out by biological collaborators in the Bhakta group at Birkbeck.
v
  A real-time 
fluorometric method based on a protocol reported by Rodrigues et al. was employed to 
evaluate the efflux pump inhibition ability of the THIQs against M. aurum.
158
   
The assay involved the use of ethidium bromide 172 (Figure 4.2), a commonly used 
efflux pump substrate.
158
  Ethidium bromide 172 has a low fluorescent signal when 
outside the mycobacterial cell, but becomes strongly fluorescent once inside the cell in a 
concentration dependent manner.  When the test compound and ethidium bromide 172 
were added to M. aurum, an increase in fluorescence over time indicated that ethidium 
bromide was accumulating inside the M. aurum cells, suggesting that efflux pump 
activity was inhibited.  Two known potent efflux pump inhibitors (verapamil 81 and 
chlorpromazine 82, Figure 3.4) were used as positive controls.  Experiments containing 
only the viable mycobacterial cells and ethidium bromide 172 served as negative 
controls.  In order to ensure mycobacterial cell viability were unaffected, a 
concentration of quarter the MIC of the THIQ compounds was used in the assay. 
 
 
Figure 4.2. Efflux pump substrate ethidium bromide 172. 
                                                             
v The efflux pump inhibition assays were carried out by Arundhati Maitra and Dr Parisa N. Mortazavi in 
the Bhakta group in the Mycobacterial Research Laboratory at Birkbeck, University of London. 
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A number of the first and second generation THIQs showed mycobacterial efflux pump 
inhibitory activity (Figure 4.3 shows an example of the data obtained from the efflux 
inhibition assay.  For the complete set of results and graphs see Appendix chapter 9).  
To compare the efflux inhibitory activity of the THIQ compounds, an efflux value was 
assigned using a scale of 0 to 4 (Table 4.4).  The efflux value reflected the amount of 
accumulation of ethidium bromide 172 in M. aurum after 60 minutes (Figure 4.3).  The 
positive control containing the efflux pump inhibitor verapamil 81 had the highest 
fluorescence intensity in the experiments and was assigned an efflux value of 4 (efflux 
value 4 = accumulation of ethidium bromide comparable with verapamil, representing 
compounds with potent efflux pump inhibitory activity).  The negative control 
containing no efflux pump inhibitor was assigned a value of 0 (efflux value 0 = 
accumulation of ethidium bromide was not above the levels of the negative control, 
representing compounds with no efflux pump inhibitory activity).   
 
 
 
Figure 4.3. Effect of THIQs on the accumulation of ethidium bromide in M. aurum (VP = verapamil 81 
and CPZ = chlorpromazine 82)  
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R THIQ Efflux value THIQ Efflux value 
 
 
141a 0 142a 2 
 
 
145a 0 146a 2 
 
 
145b 0 146b 2 
 
 
141b 0 142b 2 
 
 
145c 1 146c 3 
 
 
145d 1 146d 0 
 
 
141c 1 142c 3 
 
 
141d 0 142d 2 
 
 
141e 0 142e 4 
 
 
141f 0 142f 3 
Table 4.4. M. aurum efflux pump inhibitory activity of the first and second generation THIQs.  Efflux 
values were assigned using a scale of 0-4, where 0 = accumulation of ethidium bromide not above the 
levels of the negative control, and 4 = accumulation of ethidium bromide comparable with the efflux 
pump inhibitor verapamil. 
 
The 6,7-dihydroxy-THIQs 141a-f and 145a-d were either poor efflux pump inhibitors 
or displayed no efflux pump inhibition with efflux values = 0-1 (Table 4.4).  In contrast, 
the data indicated that the 7,8-dihydroxy-THIQs were efflux pump inhibitors.  The 7,8-
dihydroxy-THIQs 142a-d and 146a-d with aliphatic substituents at the C-1 position had 
efflux values between 2-3 and promoted the accumulation of ethidium bromide in M. 
aurum.  An exception was compound 146d which did not show any efflux pump 
inhibitory activity (efflux value = 0).  The 7,8-dihydroxy-THIQs 142e-f containing a 
benzylic C-1 substituent also showed an increase in the fluorescence intensity, and 
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compound 142f promoted the highest accumulation of ethidium bromide (efflux value = 
4) which was comparable to verapamil 81.  A correlation between efflux pump activity 
and the MICs of the first and second generation THIQs was not observed.  The results 
strongly suggested that the 7,8-dihydroxy substitution on the THIQs was contributing to 
the whole-cell efflux pump inhibitory activity. 
The third generation THIQs were also screened in the efflux pump inhibition assay 
(Table 4.5, Figure 4.4 and for the complete set of results and graphs see Appendix 
Chapter 9).  The data for THIQs 160 (efflux value = 1), 166 (efflux value = 4) and 161 
(efflux value = 0) containing a single hydroxy group clearly indicated that a hydroxy 
group at the C-7 position promoted the highest accumulation of ethidium bromide in M. 
aurum.  The 7-hydroxy-THIQ 166 was also able to inhibit efflux slightly better than the 
known efflux pump inhibitor verapamil (Figure 4.4).  Interestingly, THIQ 161 with a 
single hydroxy group at the C-8 position (which was found to enhance the MIC values) 
showed no efflux pump inhibitory activity.  The 6,8-dihydroxy-THIQs 164 and 165 
with no C-7 hydroxy group also showed no efflux pump inhibitory activity.  The data 
indicated that the brominated 7,8-dihydroxy-THIQ 163 (efflux value = 4) inhibited 
efflux in M. aurum and suggested that the presence of an 8-hydroxy group was tolerated 
without loss of efflux inhibitory activity.  In comparison, a 6,7-dihydroxy substitution 
pattern generally resulted in THIQs with little or no efflux inhibitory activity (Table 
4.4), even though a C-7 hydroxy substituent was present.  
 
 
THIQ R1 R2 R3 R4 Efflux value 
160 H OH H H 1 
166 H H OH H 4 
161 H H H OH 0 
162 Br H H OH 2 
163 Br H OH OH 4 
165 Br OH H OH 0 
164 H OH H OH 0 
Table 4.5. M. aurum efflux pump inhibitory activity of the third generation THIQs.   
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Figure 4.4. Effect of third generation THIQs on the accumulation of ethidium bromide in M. aurum (VP 
= verapamil 81 and CPZ = chlorpromazine 82)  
 
 
4.3 Synergism 
Using efflux pump inhibitors in combination with existing anti-TB drugs represents a 
possible strategy for preventing the emergence of drug resistant TB and improving the 
efficacy of drugs that are subject to efflux (see section 3.1.4).
98
  Several efflux pumps 
have been identified in various species of mycobacteria that are associated with low 
level drug resistance.  For example, the first-line anti-TB drug rifampicin 73 (Figure 
3.1) has been found to cause low level resistance in M. smegmatis, M. aurum and M. 
tuberculosis.
159
  Also, efflux activity in M. tuberculosis has been shown to contribute to 
resistance to the first-line drugs isoniazid 72 and ethambutol 75.
160
 
The efflux pump inhibition assay results of the first, second and third generation THIQs 
(section 4.2) suggested that the 7,8-dihydroxy-THIQs and the 5-bromo-8-hydroxy-
THIQ showed M. aurum efflux pump inhibitory activity.  Six of the THIQs that showed 
efflux pump activity were selected for screening in a synergism assay (Figure 4.5), 
which was carried out by biological collaborators at Birkbeck.
vi
  In addition, the 5-
                                                             
vi The synergism assays were carried out by Arundhati Maitra in the Bhakta group in the Mycobacterial 
Research Laboratory at Birkbeck, University of London. 
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bromo-8-hydroxy-THIQ 91 (Figure 4.5) was selected for screening in the synergism 
assay because it was previously demonstrated to inhibit the growth of M. bovis BCG in 
the Hailes and Bhakta groups.
105
   
 
 
Figure 4.5. THIQ compounds selected for synergism studies. 
 
The THIQs were evaluated in combination with the anti-TB drugs isoniazid 72, 
rifampicin 73 and ethambutol 75 (Figure 3.1) for their MICs against M. aurum and 
evaluated for possible synergistic interactions (Table 4.6).        
The MIC of isoniazid 72 alone was 0.938 µg/mL.  In the presence of THIQ 162 at a 
concentration of 62.5 µg/mL the MIC of isoniazid was reduced 2-fold to 0.468 µg/mL.  
The other THIQs that were evaluated in combination with isoniazid 72 either did not 
show any reduction in the MIC or had a negative effect on the MIC (increased to 1.875 
µg/mL).  It was possible that the THIQs were involved in preventing isoniazid from its 
entry into the cell and/or any endogenous antitubercular mechanisms of actions.  
The MIC of rifampicin 73 against M. aurum alone was 0.625 µg/mL.  When rifampicin 
73 was used in combination with the THIQs 142b, 142c, 142e, 162 and 91 the MIC 
decreased 2-fold to 0.312 µg/mL.  Particularly noteworthy were THIQs 142c (featuring 
an octyl alkyl chain at the C-1 position) and 91 (featuring a 5-bromo-8-hydroxy 
substitution) because the decrease in the MIC was achieved when these compounds 
were used at a low concentration of 0.1 µg/mL.   
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Anti-TB drug 
(MIC/ µg/mL) 
THIQ MIC in combination/ µg/mL 
(THIQ conc/µg/mL) 
Fold reduction 
of MIC 
 
 
Isoniazid 72 
(MIC = 0.938) 
142b 
146c 
142c 
142e 
142f 
162 
91 
1.875  (62.5) 
1.875  (31.3) 
1.875  (125) 
0.938  
1.875  (62.5) 
0.468  (62.5) 
0.938 
0 
0 
0 
0 
0 
2  
0 
 
 
Rifampicin 73 
(MIC = 0.625) 
142b 
146c 
142c 
142e 
142f 
162 
91 
0.312  (15.6) 
0.625 
0.312  (0.1) 
0.312  (125) 
0.625 
0.312  (0.97) 
0.312  (0.1) 
2 
0 
2 
2 
0 
2 
2 
 
 
Ethambutol 75 
(MIC = 0.312) 
142b 
146c 
142c 
142e 
142f 
162 
91 
0.150  (125) 
0.150  (0.1) 
0.312  
0.312 
0.312 
0.150  (15.6) 
0.312 
2 
2 
0 
0 
0 
2 
0 
Table 4.6. Effect of selected THIQs on the MIC of first-line anti-TB drugs.   
 
The MIC of ethambutol 75 against M. aurum was 0.312 µg/mL.  The MIC of 
ethambutol 75 was reduced 2-fold when used in combination with the THIQs 142b and 
146c, both featuring an alkyl chain at the C-1 position.  THIQ 146c contributed to 
lowering the MIC when used at a lower concentration of 0.1 µg/mL compared to THIQ 
142b which required a concentration of 125 µg/mL.  The 7,8-dihydroxy-THIQs 142e 
and 142f featuring a benzylic C-1 substitutent did not show any reduction in the MIC of 
ethambutol 75.  THIQ 162 with a 5-bromo-8-hydroxy substitution reduced the MIC of 
ethambutol 75 2-fold at a low concentration of 15.6 µg/mL.   
Synergism has previously been defined as when the activity of a combination of two 
drugs against a given microorganism is greater than the sum of the individual activities 
of each drug.
100
  A combination of two compounds is said to be synergistic when the 
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FICI (fractional inhibitory concentration index) is less than or equal to 0.5.
161
  The 
combination of the THIQs with the anti-TB drugs that resulted in a 2-fold decrease in 
the MIC (compared to the MIC of the anti-TB drug alone) all had a FICI value of 0.5, 
and could be described as acting synergistically.    
THIQ 162 enhanced the activity of all three of the anti-TB drugs tested.  Other 
promising THIQs included 142b, 142c and 91 which were able to reduce the MIC of 
rifampicin 73 at a low concentration, and THIQ 146c when used in combination with 
ethambutol.  These preliminary investigations have shown the potential of THIQs to 
improve the activity of existing anti-TB drugs, possibly through whole-cell efflux pump 
inhibition.  Evaluating these compounds in a synergism study using M. tuberculosis 
would allow comparisons to other efflux pump inhibitors reported in the literature.  
 
4.4 Phenol bioisosteres 
Phenolic compounds are often prone to metabolism via oxidative reactions of the 
phenolic hydroxy group by cytochrome P450 enzymes, generating reactive quinones 
that have been associated with toxicological issues.
162
  In addition, phase II conjugation 
reactions are significant metabolic pathways such as glucuronidation (glucuronic acid is 
conjugated to the phenolic hydroxy group) and sulfation (sulfate is conjugated to the 
hydroxy group to form a phenyl sulfate).
163
  This can reduce the oral bioavailability of 
the compounds. 
The first, second and third generation THIQs all contained at least one hydroxy 
substituent on the aromatic ring.  Based on the SAR results, the hydroxy group appeared 
to play an important role in the antimycobacterial activities of these compounds 
(sections 4.1.2, 4.1.4 and 4.1.6).  An investigation into bioisosteres (defined as groups 
which have physiochemical similarities producing broadly similar biological effects) of 
phenols would be useful to identify compounds that may be less susceptible to 
metabolic inactivation and have an improved safety profile, whilst retaining 
antimycobacterial activity.  This could lead to the development of more clinically 
relevant drug-like compounds. 
The presence of a hydroxy group at the C-8 position of the THIQ scaffold resulted in 
compounds with the best antimycobacterial activities.  Therefore target bioisosteric 
96 
 
analogues were designed by replacing the C-8 hydroxy group (Figure 4.6).  THIQ 173 
featured an 8-amino group which represents a classical bioisosteric replacement of a 
hydroxy group, but does affect acid-base properties.  Alternative bioisosteres that have 
been reported include methanesulfonamides or ureas, and the sulfonamide N-H has been 
shown to closely resemble the phenol O-H in terms of acidity and hydrogen bond donor 
properties.
164
  Replacement of phenols with heterocyclic rings such as indoles has also 
been used, as indoles can form hydrogen bonds in a similar manner to phenol hydroxy 
groups.
165
  The target compounds 174-176 were designed based on these known 
bioisosteric replacements (Figure 4.6). 
 
 
Figure 4.6. Target THIQ phenol bioisosteres. 
 
Investigating a route to prepare the 8-amino-THIQ 173 was initially undertaken 
(Scheme 4.11).  The phosphate mediated Pictet-Spengler reaction has been shown to 
extend to the use of aminophenylethylamine substrates for the preparation of amino-
THIQs.
122
  It was anticipated that using this method might yield a mixture of the 
regioisomers 6-amino-THIQ 177 and the desired 8-amino-THIQ 173, as was observed 
previously for the hydroxy-THIQ series (section 4.1.1).  3-Aminophenylethylamine 178 
was first prepared by hydrogenation of 3-nitrophenylethylamine using a Pd/C 
catalyst.
122
  The Pictet-Spengler reaction between amine 178 and hexanal was then 
carried out under standard conditions in a 1:1 mixture of phosphate buffer (pH 6) and 
acetonitrile at 50 
o
C.  After purification of the product by reverse phase prep-HPLC, the 
6-amino-THIQ 177 was isolated in 61% yield, but unfortunately the regioisomer 8-
amino-THIQ 173 was not detected. 
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Scheme 4.11. Phosphate mediated Pictet-Spengler reaction of aniline derivatives. 
 
In an attempt to block the cyclisation occurring at the position para to the amino group, 
a bromine substituent was added at this position to ensure cyclisation occurred at the 
position ortho to the amino group.  The required brominated starting material 179 was 
first prepared from 3-aminophenylethylamine 178 using N-bromosuccinimide in 
acetonitrile (Scheme 4.12).
166
  The Pictet-Spengler reaction was carried out in a 1:1 
mixture of phosphate buffer (pH 6, 0.1 M) and acetonitrile at 50 
o
C (Scheme 4.12, Exp. 
1).  After 24 hours an aliquot of the reaction mixture was analysed by mass 
spectrometry.  The desired 8-amino-THIQ 180 was not detected.  A further equivalent 
of hexanal was added to the reaction mixture and after 24 hours the reaction was 
analysed by mass spectrometry again.  Only starting materials were detected, and none 
of the desired product.  The reaction was repeated under more forcing conditions at a 
temperature of 80 
o
C and using a higher concentration of phosphate buffer (0.5 M), but 
again none of the desired 8-amino-THIQ 180 was formed (Scheme 4.12, Exp. 2).  
 
 
Scheme 4.12. Attempted phosphate mediated Pictet-Spengler reaction for the synthesis of THIQ 180. 
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A further three experiments were carried out on a small scale to study the effect of 
lowering the phosphate concentration and performing the reactions at room temperature 
for a longer period of time (Scheme 4.12, Exp. 3-5).  These conditions were 
investigated because the Maresh group have reported that for the phosphate mediated 
Pictet-Spengler synthesis of hydroxy-THIQs, lowering the phosphate concentration and 
carrying out the reaction at room temperature yielded higher amounts of products where 
cyclisation occurred ortho to the activating group.
119
  However under these conditions 
no amino-THIQ 180 was detected when the reactions were monitored by mass 
spectrometry.  Mostly the starting material 179 was detected, as well as side products 
which were not characterised.   
In order to determine why the Pictet-Spengler reaction did not occur at the position 
ortho to the activating amino group, an analysis of the side products formed would be 
beneficial.  It was possible that the aniline was reacting with the aldehyde and forming 
an imine which would increase steric hinderance at the position ortho to the aniline 
group, as well as decreasing the electrophilicity of the aromatic ring.  The 8-amino-
THIQs 173 and 180 would have been a good starting point for the preparation of the 
phenol bioisostere compounds 174 and 175 (Figure 4.6).  Therefore further exploration 
of these bioisosteres was not continued.  
 
4.5 Lactam/lactone synthesis from 1-substituted THIQs 
Benzo[a]quinolizines and pyrroloisoquinolines are tricyclic THIQ derivatives.  These 
structures are found in a number alkaloids including schulzeines A-C, (-)-trolline and 
crispine A as well as in pharmaceuticals such as tetrabenazine, and display a variety of 
pharmacological activities including antibacterial activity (Figure 4.7).   
The δ-lactam and γ-lactam rings present in compounds such as schulzeines A-C and 
trolline (Figure 4.7) have previously been constructed via intramolecular cyclisation 
reactions.  These include a trifluoromethanesulfonic acid mediated imide carbonyl 
activation and cyclisation strategy,
167
 an acid catalysed acyl-Pictet-Spengler reaction
168
 
and intramolecular amidation reactions,
169
 and often require protecting groups for 
phenolic hydroxy groups and multi-step procedures. 
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Figure 4.7. Benzo[a]quinolizine and pyrroloisoquinoline bioactive alkaloids. 
 
It was envisioned that the phosphate mediated Pictet-Spengler reaction between a 
phenylethylamine and methyl 5-oxopentanoate 181 containing an ester functional group 
would yield the 1-substituted THIQ 182 (Scheme 4.13).  The ester functionality could 
then spontaneously cyclise via an intramolecular amidation to form the δ-lactam 183, 
generating the benzo[a]quinolizin-4-one tricyclic structure.  To explore this hypothesis, 
the 3,5-dihydroxyphenylethylamine 156 was chosen as the starting material because it 
was already shown to cyclise under the phosphate mediated Pictet-Spengler conditions 
in excellent yields to generate a single THIQ product (see section 4.1.5).   
 
 
Scheme 4.13. Potential one-pot Pictet-Spengler/lactamisation reaction. 
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Aldehyde 181 was prepared following literature procedures (Scheme 4.14).
170
  The 
commercially available δ-valerolactone 184 was opened to the corresponding alcohol 
185, and then a Swern oxidation afforded aldehyde 181 in 31% yield over the two steps.  
This yield was significantly lower than that reported in the literature.  The actual yield 
of the aldehyde was likely to have been higher but some material was lost due to the 
volatility of the aldehyde and during purification by column chromatography.  
 
 
Scheme 4.14. Synthesis of methyl 5-oxopentanoate. 
 
The phosphate mediated Pictet-Spengler reaction between phenylethylamine 156 and 
aldehyde 181 was carried out at 50 
o
C overnight, yielding the 1-substituted THIQ 182 as 
the major product and a small amount of lactam 183 (Scheme 4.15).  The mixture of 
products was separated by reverse phase prep-HPLC, and THIQ 182 was isolated in 
87% yield and lactam 183 in 4% yield.  Therefore under these conditions, the 
cyclisation of THIQ 182 to the lactam 183 was not favoured.   
 
 
Scheme 4.15. Pictet-Spengler cyclisation of amine 156 with aldehyde 181. 
 
Published procedures for lactam synthesis from esters often require basic reaction 
conditions.
169
  Taylor et al. have reported the cyclisation of amino esters to the 
corresponding lactams in excellent yields when using potassium carbonate in a mixture 
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of methanol and water.
171
  These reaction conditions were interesting because after 
formation of THIQs from the phosphate mediated Pictet-Spengler reaction, the addition 
of potassium carbonate could then facilitate lactam formation in one pot.  To investigate 
this, THIQ 182 was added to a mixture of phosphate buffer (pH 6, 0.1 M) and 
acetonitrile, then 1 equivalent of potassium carbonate was added (Scheme 4.16).  After 
stirring at room temperature for 24 hours, lactam 183 was isolated in 31% yield.   
 
 
Scheme 4.16. Lactam synthesis using basic conditions. 
 
It was probable that the conditions used for the construction of the δ-lactam would be 
able to be optimised by exploring various parameters such as the effect of pH, the 
equivalents of base and the reaction temperature.  However due to only having a small 
amount of THIQ 182 remaining towards the end of the project, the one-pot synthesis of 
the lactam from phenylethylamine 156 and aldehyde 181 was attempted at this stage 
(Scheme 4.17).  The Pictet-Spengler reaction was carried out under the standard 
conditions, and after 5 hours all of the phenylethylamine 156 starting material had 
converted to the THIQ intermediate 182 (monitored by LC-MS).  Subsequent addition 
of potassium carbonate to the reaction mixture promoted the lactamisation to generate 
lactam 183 which was isolated in 40% yield.  To improve the yield, optimisation of the 
lactamisation step would be necessary, as described above.   
 
 
Scheme 4.17. One-pot Pictet-Spengler/lactamisation reaction. 
102 
 
In addition to investigating δ-lactam synthesis from 1-substituted THIQs, an 
intramolecular cyclisation to form lactones was also explored.  It was anticipated that 
the phosphate mediated Pictet-Spengler reaction between a phenylethylamine and 
methyl 3-oxopropanoate 186 would yield the 1-substituted THIQ 187 (Scheme 4.18).  
The ester functionality could spontaneously cyclise onto the C-8 hydroxy group to 
produce lactone 188, generating a tricyclic structure.  The synthesis of tricyclic THIQ 
lactone structures such as 188 have not previously been reported in the literature. 
 
 
Scheme 4.18. Potential one-pot Pictet-Spengler/lactonisation reaction. 
 
Aldehyde 186 was prepared from the commercially available dimethyl acetal 189 based 
on a literature procedure (Scheme 4.19).
172
  The 
1
H-NMR spectrum of the crude product 
confirmed the complete conversion of starting material to the product.  However the 
purification of aldehyde 186 was not straightforward.  Purification by column 
chromatography resulted in product decomposition and none of the aldehyde 186 was 
isolated.  Therefore the crude product was used directly in the next step without 
purification. 
 
 
Scheme 4.19. Synthesis of methyl 3-oxopropanoate. 
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The phosphate mediated Pictet-Spengler reaction between phenylethylamine 156 and 
aldehyde 186 yielded the 1-substituted THIQ 187 in a moderate yield of 58% (Scheme 
4.20).  No formation of lactone 188 was observed.  Lactone formation from esters and 
phenolic hydroxy groups is often promoted by acidic conditions and high 
temperatures.
173
  Therefore, THIQ 187 was stirred in dilute hydrochloric acid, but after 
24 hours, analysis of the reaction mixture by LC-MS revealed that only starting material 
was present.  The THIQ 187 was then dissolved in a mixture of TFA and 
dichloromethane and heated at reflux, but again only the starting material was isolated 
from the reaction after purification of the crude material using reverse phase prep-
HPLC.  It was possible that lactone 188 did form using these conditions, but was 
hydrolysed back to the starting materials during reverse phase HPLC purification or 
LC-MS analysis under the aqueous conditions.  Therefore attempts to synthesise the 
lactone were not continued. 
 
 
Scheme 4.20. Pictet-Spengler cyclisation of amine 156 with aldehyde 186 and attempted lactonisation. 
 
4.6 Pharmacokinetic and pharmacodynamic properties 
The THIQs 91 and 92 have previously been identified within the Hailes group as 
possessing potent antimycobacterial activity and moderate selectivity for mycobacterial 
cells (Figure 3.8, section 3.2.2).
105
  These compounds were selected for pharmacokinetic 
analysis to determine their potential for progress into further drug development.  THIQs 
91 and 92 were prepared using the phosphate mediated Pictet-Spengler reaction as 
previously described (Scheme 4.21), but would also be possible to prepare via a 
Bischler-Napieralski route.
105
  The reaction between amine 157 and commercially 
available 2,3-(methylenedioxy)benzaldehyde 190 generated the THIQ product 91 in 
12% isolated yield after purification by reverse phase prep-HPLC.  The reaction 
104 
 
between amine 157 and aldehyde 140f generated THIQ 92 in only 3% isolated yield.  
The Pictet-Spengler cyclisation can only proceed ortho to the electron donating hydroxy 
group, and it was likely that the low yields resulted from steric hinderance around the 
newly formed carbon-carbon bond as well as competition with undesired side reactions. 
 
 
Scheme 4.21. Synthesis of THIQs for pharmacokinetic analysis. 
 
The following assays were performed by Pharmidex: aqueous solubility assay, 
metabolic stability assays, permeability assay and CYP450 inhibition assay.
vii
  The 
aqueous kinetic solubility of compounds 91 and 92 was measured at a concentration of 
1 mg/mL.  Compound 91 had a solubility of 0.31 mg/mL and compound 92 had a 
higher solubility of 0.82 mg/mL.  Both of the compounds showed encouraging aqueous 
solubility, particularly THIQ 92.    
The metabolic stability of compounds 91 and 92 were evaluated in a human microsome 
stability assay and a human hepatocyte stability assay.  The microsomal assay gave an 
indication of whether the compounds were susceptible to phase I metabolism by 
measuring the amount of compound remaining that was exposed to microsomes over 
time (Figure 4.8).  Compound 92 had a shorter half-life of 9.81 min compared to 91 
which had a half-life of 110 min.  This suggested the benzylic substituent at position C-
1 of compound 92 was prone to rapid metabolism.   
                                                             
vii The solubility assay, metabolic stability assays, permeability assay and CYP450 inhibition assay were 
carried out by Pharmidex (Pharmidex Pharmaceuticals Ltd, 14 Hanover Street, London, W1S 1YH). 
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Figure 4.8. Results from the human microsome stability assay. t1/2 = half-life. 
 
The hepatocyte stability assay gave an indication of whether the compounds were 
susceptible to phase I and II metabolism (Figure 4.9).  The same trend as seen in the 
microsome assay was also observed in the hepatocyte assay.  Compound 92 had a 
shorter half-life of 23.2 min in comparison to compound 91 (half-life = 78.6 min), and 
therefore 92 had a higher metabolic instability.  The hepatic extraction ratio was also 
evaluated which gave an indication of the amount of drug removed when passing 
through the liver, and refers to the ratio of the hepatic clearance to the blood flow.  A 
high hepatic extraction ratio was defined as greater than 0.35.  Both compounds 91 and 
92 had a high extraction ratio of greater than 0.6, indicating these compounds would be 
rapidly metabolised by the liver. 
 
 
Figure 4.9. Results from the human hepatocyte stability assay. t1/2 = half-life.  
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The CYP450 (cytochrome P450) inhibition assay showed that compound 92 inhibited 
the activity of CYP450 enzymes to a greater extent than compound 91 (Table 4.7).  The 
high inhibition of these enzymes by compound 92 (greater than 80% inhibition) could 
be a problem, as drug-drug interactions would be more likely because CYP450 oxidase 
enzymes are involved in the metabolism of many commonly prescribed drugs.  
Compound 91 also displayed a high inhibition of CYP2C19, CYP2D6 and CYP3A4, 
but a lower inhibition of CYP1A2 and CYP2C (inhibition less than 50%).     
 
THIQ   % Inhibition   
 CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
91 37% 45% 98% 81% 80% 
92 81% 82% 97% 93% 93% 
Table 4.7. Results from the CYP450 inhibition assay.  
 
The Madin Darby Canine Kidney (MDCK) cell line transfected with the human 
multidrug resistant-1 gene (MDR1) was used to study the transcellular permeability of 
the compounds and to assess the effect of efflux by P-glycoprotein (Pgp) on compound 
permeability (Table 4.8).  Compound 91 was moderately permeable in the MDCK 
monolayer assay (3.2 x 10
-6
 cm/s), while compound 92 had a lower permeability (1.7 x 
10
-6
 cm/s).  The high aqueous solubility of 92 and more probable hydrophilic nature 
would explain its lower cellular permeability compared to compound 91.  The efflux 
permeability ratios classified both compounds as Pgp efflux substrates.  Therefore drug 
efflux was occurring, which could lead to poor exposure for oral drug development. 
 
THIQ          Papp (x 10
-6
 cm/s)
a 
     A-B                      B-A 
Efflux ratio
 
(B-A/A-B) 
Pgp substrate
b 
91      3.2 (medium)       38.0              11.9 Yes 
92      1.7 (low)              18.8 11.3 Yes 
Table 4.8. Results from the MDR1-MDCK permeability assay. aPapp = apparent permeability of a 
compound for apical to basal (A-B) and basal to apical (B-A) permeation. Permeability (A-B): Papp < 2 
(low), Papp  > 20 (high).  
bCompounds with efflux ratio > 1.5 were classed as Pgp substrates. 
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To evaluate any off-target activities of compounds 91 and 92, a hit profiling screen was 
contracted to and carried out by Eurofins Panlabs.
viii
   The hit profiling screen indicated 
any adverse activity of the compounds against 35 targets including ion channels, 
adrenergic receptors, GPCRs and CYP450 enzymes (Table 4.9 highlights the targets 
where greater than 50% inhibition was observed.  For the complete list of targets see 
Chapter 8 experimental).  The compounds were tested at a single concentration of 10 
µM (IC50 data was not determined) and results were for ligand binding data 
(agonist/antagonist mode of action was not determined).  The responses were 
considered significant if greater than 50% inhibition of a target was observed.   
 
Assay Species THIQ 92 
% inhibition 
THIQ 91 
% inhibition 
CYP450, 1A2 human 60 - 
CYP450, 2C19 human 99 73 
CYP450, 2C9 human 63 - 
CYP450, 2D6 human 96 - 
CYP450, 3A4 human 94 - 
Adrenergic 1A rat 83 67 
Adrenergic 1B rat 78 55 
Adrenergic 2A human 93 65 
Adrenergic 1 human 93 85 
Adrenergic 2 human 91 75 
Dopamine D1 human 57 - 
Imidazoline I2, central rat 69 - 
Opiate µ (OP3, MOP) human 70 - 
Serotonin 5-HT2B human 99 - 
Sigma σ1 human 86 52 
Sodium channel, site 2 rat 88 88 
Transporter, norepinephrine (NET) human 72 - 
Table 4.9. Results from Eurofins Panlabs hit profiling screen, showing >50% inhibition. 
 
Both compounds displayed a number of off-target activities, but compound 92 
displayed significantly greater off-target activity compared to compound 91.  The 
                                                             
viii The hit profiling screen was carried out by Eurofins Panlabs (Eurofins Panlabs Taiwan Ltd, 
Pharmacology Laboratories, 158 Li-The Road, Peitou, Taipei, Taiwan 112, Taiwan R.O.C.).  
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results showed compound 92 displayed a significant response in 17 of the 35 assays, 
whereas compound 91 showed a significant response for 8 out of the 35 assays (Table 
4.9).  The widespread off-target activities on adrenergic receptors and other off-target 
activities would need to be reduced in order to develop a promising lead compound 
whilst still retaining potency against mycobacteria.   
In conclusion the results from the pharmacokinetic analysis of THIQ compounds 91 and 
92 have highlighted compound 91 as a more promising structure to develop further as 
an anti-TB scaffold.    
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5. Tetrahydrobenzazepines and profens 
 
5.1 Tetrahydrobenzazepine synthesis  
5.1.1 Cyclisation of 3,4-dihydroxyphenylpropylamines 
An investigation into applying the phosphate mediated Pictet-Spengler reaction 
(described in section 3.3.4) to the synthesis of 7-membered ring tetrahydro-2-
benzazepines (THBPs) was conducted.  The aim was to prepare novel 1-substituted 
THBPs that were analogues of the 6-membered ring THIQs that have previously been 
shown to possess interesting antimycobacterial activity.
105
    
First, a synthetic route for the preparation of 3-hydroxyphenylpropylamine derivatives 
was required. A number of 3-methoxyphenylpropanoic acids were commercially 
available including compounds 191 and 192, and so these were used as the starting 
materials (Scheme 5.1).  Based on a literature procedure,
174
 the carboxylic acid 191 was 
treated with thionyl chloride to produce an acyl chloride intermediate.  This was then 
dissolved in anhydrous THF and added dropwise to an excess of 28% ammonium 
hydroxide solution (to ensure the acyl chloride did not hydrolyse back to the acid) at 0 
o
C to give the amide 193 in 95% yield.  Amide 193 was reduced to the amine 194
175
 
using lithium aluminium hydride in THF, and subsequent demethylation with boron 
tribromide yielded the desired 3,4-dihydroxyphenylpropylamine 195 in quantitative 
yield as the hydrobromide salt (Scheme 5.1).  The demethylation step was initially 
attempted using hydrobromic acid and acetic acid which had previously been described 
for the preparation of compound 195.
176
  However it was found that it was difficult to 
purify the product using this method due to excess acetic acid in the crude material.   
The same synthetic route was also applied to the synthesis of the analogue 3,5-
dihydroxyphenylpropylamine 196 (Scheme 5.1).  Commercially available carboxylic 
acid 192 was converted to the amide 197
177
 in 54% yield.  Reduction of amide 197 to 
the amine 198 followed by the demethylation step yielded the product 196 as the 
hydrobromide salt in quantitative yield.   
110 
 
 
Scheme 5.1. Synthesis of hydroxyphenylpropylamines. 
 
The phosphate mediated Pictet-Spengler reaction was initially attempted using 3,4-
dihydroxyphenylpropylamine 195 and phenylacetaldehyde 199 (Scheme 5.2).  These 
starting materials were chosen because they were close analogues of dopamine and 4-
HPAA, that are the natural substrates for the enzymatic Pictet-Spengler reaction to 
generate the 6-membered ring THIQ norcoclaurine (described in section 3.3.3).  The 
Pictet-Spengler reaction was carried out in a 1:1 mixture of 0.1 M potassium phosphate 
buffer at pH 6 and acetonitrile at 50 
o
C.  Analysis of the reaction mixture by LC-MS 
after 18 hours revealed the presence of mainly unreacted amine starting material 195 
and a small amount of side products.  The desired 7-membered ring THBP 200 was not 
detected.  The reaction was repeated using a higher concentration of phosphate but the 
same result was observed.   
 
 
Scheme 5.2. Attempted Pictet-Spengler reaction for the synthesis of THBP 200. 
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These initial results suggested that the formation of a 7-membered ring via the 
phosphate mediated Pictet-Spengler reaction would be significantly more challenging 
than for the analogous 6-membered ring formation.  In general, 7-membered rings are 
more difficult to construct than the smaller 5- or 6-membered ring analogues because of 
entropic costs of the ring closure, transannular interactions and increased ring strain in 
the cyclic product.
178
  Only a limited number of Pictet-Spengler type cyclisations to 
form 7-membered rings have previously been reported (examples in section 3.5.2). 
Due to the instability of phenylacetaldehyde and its potential to form unwanted side 
products, further investigations into Pictet-Spengler reactions were carried out using 
either benzaldehyde or an aliphatic aldehyde.  Phenylpropylamine 195 and 
benzaldehyde 201 were reacted at 50 
o
C overnight in a 1:1 solution of potassium 
phosphate buffer (pH 6) and acetonitrile, and the effect of changing the concentration of 
phosphate buffer from 0.1 to 0.5 M was explored (Table 5.1, entries 1-3).  In all three 
experiments analysis of the crude products by LC-MS showed that mostly starting 
materials were present.  When the reaction was repeated at a higher temperature of 80 
o
C the mass of the desired THBP 202 was detected in the crude product (Table 5.1, 
entry 4).  However, very little product was formed and the majority of the crude mixture 
consisted of the unreacted starting materials.  It was not possible to isolate any of the 
THBP 102 from this reaction. 
 
 
Entry Phosphate conc. Temperature LC-MS of crude product 
1 0.1 M 50 
o
C Mixture of starting materials 
2 0.25 M 50 
o
C Mixture of starting materials 
3 0.5 M 50 
o
C Mixture of starting materials 
4 0.1 M 80 
o
C Mixture of starting materials and a 
mass corresponding to that of 
THBP 202 was detected. 
Table 5.1. Attempted phosphate mediated Pictet-Spengler reactions for the synthesis of THBP 202.  
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In parallel to investigating the Pictet-Spengler reactions, the alternative Bischler-
Napieralski reaction (described in section 3.3.1) was used to prepare THBP 202 
(Scheme 5.3).  The dimethoxy analogue 203 of the desired THBP 202 was first 
prepared according to a literature procedure.
143
  Amidation of phenylpropylamine 194 
with benzoyl chloride gave the amide 204 in 85% yield.  The Bischler-Napieralski 
cyclisation of amide 204 was achieved using phosphorus oxychloride in refluxing 
acetonitrile, which was followed by reduction of the intermediate imine with sodium 
borohydride, producing the dimethoxy-THBP 203 in 92% yield.  This was similar to the 
yield reported in the literature of 90%.
143
  The dimethoxy-THBP 203 was treated with 
boron tribromide in dichloromethane and once the demethylation reaction had gone to 
completion water was added, however it proved difficult to extract the product from the 
aqueous phase.  The small amount of product which was extracted was purified by 
reverse phase prep-HPLC to remove impurities, and the THBP 202 was isolated in a 
low yield of 11%.  It is likely that a higher yield could be achieved using an alternative 
work-up involving quenching the boron tribromide with methanol and evaporating the 
volatiles generated.   
 
 
Scheme 5.3. Bischler-Napieralski route to prepare THBP 202. 
 
The preparation of the novel 1-phenyl-THBP 202 via the Bischler-Napieralski route 
indicated that compounds with this type of structure were accessible, and therefore 
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investigations into the phosphate mediated Pictet-Spengler synthesis of 1-substituted 
THBPs was continued.  The next Pictet-Spengler reactions were attempted using the 
more reactive and less sterically demanding aliphatic aldehyde hexanal 140b (Table 
5.2).  This aldehyde was selected because it would result in THBP products with a 
pentyl substituent at the C-1 position, and the 6-membered ring THIQ analogues with 
this substitution displayed good antimycobacterial properties (Chapter 4).   
 
 
Entry Phosphate buffer Co-solvent Yield of 205
a 
Yield of 206
a 
1 water (no phosphate) CH3CN 0%
b
 0%
b 
 
2 0.5 M, pH 6 CH3CN 5% 3% 
3 0.5 M, pH 6 CH3OH 2% 1% 
Table 5.2. Pictet-Spengler reactions for the synthesis of 1-pentyl-THBPs. aIsolated yield after HPLC.  
bThe mass of the THBP product was not seen in the MS analysis of the crude mixture.  
 
Phenylpropylamine 195 and hexanal 140b were reacted at 80 
o
C in a mixture of water 
and acetonitrile with no phosphate present (Table 5.2, entry 1).  Analysis of the mass 
spectrum of the crude product showed that there was no mass corresponding to the 
THBP product, but mostly starting materials present.  When the reaction was repeated 
using the same conditions but with phosphate buffer (pH 6, 0.5 M) instead of water, the 
THBP 205 was detected in the mass spectrum of the crude reaction product (Table 5.2, 
entry 2).  The crude product was purified by reverse phase prep-HPLC and two products 
were isolated.  The first eluted product was the 7,8-dihydroxy-THBP 205, formed from 
the cyclisation occurring para to the activating hydroxy group, and was isolated in 5% 
yield.  The second eluted product was the 8,9-dihydroxy-THBP 206, formed from the 
cyclisation occurring ortho to the activating hydroxy group, and was isolated in 3% 
yield.  The reaction was also repeated using methanol as the co-solvent (Table 5.2, entry 
3), but after separation of the THBPs 205 and 206 using reverse phase-HPLC an even 
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lower yield of 1-2% was obtained.  Therefore acetonitrile was considered to be a better 
co-solvent than methanol. 
In general, for the synthesis of the analogous 6-membered ring THIQs via the Pictet-
Spengler reaction, the para cyclised THIQs (6,7-dihydroxy-THIQs) were formed as the 
major product and the ortho cyclised THIQs (7,8-dihydroxy-THIQs) were only formed 
as a minor product (discussed in section 3.3.2 and 4.1.1).  It was therefore interesting 
that for the 7-membered rings, the 8,9-dihydroxy-THBP 206 was formed in a similar 
quantity to the 7,8-dihydroxy-THBP 205, even though the yields of both the 
regioisomers were very low.  The 8,9-dihydroxy-THBP structure was novel and 
exploring biological activities including antimycobacterial activity would be interesting. 
 
5.1.2 Cyclisation of 3,5-dihydroxyphenylpropylamines 
It was found for the synthesis of 6-membered ring THIQs that using 3,5-
dihydroxyphenylethylamine substrates with a highly activated electron rich ring, 
resulted in excellent yields of the cyclised products and no regioisomer formation 
(section 4.1.5).  It was therefore anticipated that for 7-membered ring synthesis, using 
3,5-dihydroxyphenylpropylamine substrates would result in higher yields of THBP 
products.   
The phosphate mediated Pictet-Spengler reaction between amine 196 and hexanal was 
carried out in a 1:1 solution of phosphate buffer at pH 6 and acetonitrile at 50 
o
C 
(Scheme 5.4).  The 7,9-dihydroxy-THBP 207 was isolated from this reaction in 72% 
yield after purification by reverse-phase prep-HPLC.  The reaction was then repeated 
with different aldehydes.  Using benzaldehyde provided the THBP 208 in 26% yield, 
and using phenylacetaldehyde resulted in the formation of THBP 209 which was 
isolated in 21% yield (Scheme 5.4).  These results were a significant improvement in 
comparison to the reactions carried out with 3,4-dihydroxyphenylpropylamine 195, 
where less than 5% of THBP products were isolated.  This indicated that for the 
cyclisation to form a 7-membered ring to occur, a highly activated aromatic ring was 
needed.  The 3,5-dihydroxy substitution on the aromatic ring of 196 would activate 
position C-6 towards cyclisation (by increasing the nucleophilicity at this position) more 
than the 3,4-dihydroxy substitution on amine 195.    
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Scheme 5.4. Pictet-Spengler reaction for the synthesis of 7,9-dihydroxy-THBPs.  Yields refer to the 
isolated yield of THBP after purification by HPLC. 
 
The aldehyde used also affected the yield of the 7,9-dihydroxy-THBP products (Scheme 
5.4).  Higher yields were obtained with the aliphatic aldehyde hexanal.  The lower yield 
of THBP 208 when benzaldehyde was used, was possibly because the intermediate 
imine was more sterically hindered by the bulky phenyl group.  The lower yield of 
THBP 209 when phenylacetaldehyde was used was attributed to unwanted side product 
formation which lowered the amount of aldehyde available for the phosphate mediated 
Pictet-Spengler reaction. 
The novel 7,9-dihydroxy-THBPs with various 1-substituents would be good candidates 
for antimycobacterial screening and work is ongoing to test the activities of these 7-
membered ring compounds and compare them to the corresponding 6-membered ring 
THIQ analogues. 
 
5.1.3 Lactam synthesis from 1-substituted THBPs 
It was previously found for the 6-membered ring THIQs that if the substituent at 
position C-1 contained an appropriate ester functionality, cyclisation onto the amine (N-
2) produced lactam tricyclic derivatives (section 4.5).  It was proposed that a similar 
reaction could occur with the 7-membered ring THBP analogues. 
The phosphate mediated Pictet-Spengler reaction between phenylpropylamine 196 and 
aldehyde 181 at 50 
o
C yielded THBP 210 as the major product and lactam 211 as the 
minor product (Scheme 5.5).  The products were separated using reverse phase HPLC, 
and THBP 210 was isolated in 80% yield and lactam 211 in 12% yield.  In comparison, 
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the Pictet-Spengler reaction to prepare the 6-membered ring THIQ analogues yielded 
the 1-substituted THIQ 182 in 87% yield and lactam 183 in 4% yield (Scheme 4.15).  
Similar to the THIQ reaction, under the Pictet-Spengler reaction conditions cyclisation 
of THBP 210 to generate the lactam 211 was not favoured.  However, a higher yield of 
lactam 211 (12%) was formed compared to the THIQ analogue lactam 183 (4% yield).    
 
 
Scheme 5.5. Pictet-Spengler cyclisation of amine 196 with aldehyde 181. 
 
To establish whether THBP 210 could be cyclised to the lactam 211 under aqueous 
basic conditions, 210 was dissolved in a phosphate buffer and acetonitrile solution and 
treated with potassium carbonate (Scheme 5.6).  The reaction was stirred at room 
temperature and analysed by LC-MS to monitor the disappearance of THBP 210.  After 
36 hours most of the THBP 210 had been converted to product.  After 48 hours the LC-
MS trace appeared the same as when run at 36 hours, so the reaction was stopped at this 
time.  Purification of the crude product by prep-HPLC resulted in isolation of lactam 
211 in only 29% yield.  A side product which was detected in the LC-MS analysis of 
the reaction mixture corresponded to the hydrolysed product 212.       
 
 
Scheme 5.6. Lactam synthesis under basic conditions. 
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The cyclisation to form the δ-lactam from THBP 210 was not optimised due to only 
having a small quantity of the THBP 210 and the amine 196 remaining towards the end 
of the PhD.  However, a one-pot synthesis of lactam 211 from phenylpropylamine 196 
and aldehyde 181 was attempted (Scheme 5.7).  The Pictet-Spengler reaction was 
carried out under the standard conditions and after 8 hours all of the phenylpropylamine 
196 had converted to the THBP intermediate 210 (monitored by LC-MS).  Subsequent 
addition of potassium carbonate to the reaction mixture promoted the cyclisation to 
form lactam 211, which was isolated in 39% yield.    
 
 
Scheme 5.7. One-pot Pictet-Spengler/lactamisation reaction. 
 
It was likely that the reaction conditions (such as pH, equivalents of base and 
temperature) used for the construction of the δ-lactam ring in the second step of the one-
pot synthesis would be able to be optimised in order to improve the yield of the product.  
The tricyclic THBP derivative 211 represents a novel structure and testing of its 
antimycobacterial properties would be interesting for future studies.  
 
5.2 Profen synthesis 
5.2.1 Ibuprofen analogues 
A set of analogues of the non-steroidal anti-inflammatory drugs ibuprofen 78 and 
loxoprofen 79 were prepared for antimycobacterial screening.  The Bhakta group have 
previously shown profens (2-arylpropionic acids) including 78 and 79 to be good 
inhibitors of the growth of M. tuberculosis as well as MDR-TB strains (described in 
section 3.1.3).
94
  The target compounds included nitro- and amino-ibuprofen derivatives 
138 (Figure 3.12).  These were selected because a dinitro-ibuprofen derivative was 
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previously shown to improve the antimycobacterial potency against the growth of M. 
tuberculosis compared to ibuprofen.
94
   
The nitration of ibuprofen 78 was carried out according to a literature procedure,
179
 
using 70% nitric acid and concentrated sulfuric acid (Scheme 5.8).  This afforded a 
mixture of the starting material 78, the mono-nitrated product 213 and the di-nitrated 
product 214, in the ratio 3:75:22 as determined by 
1
H-NMR spectroscopy.  The di-
nitrated compound 214 was removed from the mixture using column chromatography.  
This left a mixture of the mono-nitrated product 213 containing approximately 5% of 
the starting material 78.  Recrystallisation from ethyl acetate/hexane successfully 
removed the starting material to yield the mono-nitrated product 213 in 31% yield.  The 
nitro group added ortho to the activating iso-butyl group and this regioisomer was 
confirmed by NMR spectroscopy. 
 
 
Scheme 5.8. Nitration of ibuprofen. 
 
The nitro compound 213 was reduced to the aniline 215 via catalytic hydrogenation 
with a palladium on carbon catalyst in methanol (Scheme 5.9).
180
  After purification by 
reverse phase prep-HPLC, the aniline 215 was isolated as the TFA salt in 37% yield.  
The ibuprofen derivatives 213 and 215 will be screened for their antimycobacterial 
activity by biological collaborators (Bhakta group) to determine the influence of the 
nitro and amino aromatic ring substituents on the antimycobacterial properties. 
 
 
Scheme 5.9. Reduction of nitro-ibuprofen. 
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5.2.2 Loxoprofen analogues 
In order to prepare the loxoprofen derivative target compounds (139, Figure 3.12), first 
loxoprofen 79 was synthesised following a similar route to that reported by Yamakawa 
et al.
181
  Methyl esterification of commercially available 2-(p-tolyl)propanoic acid 216 
under acidic conditions gave the methyl ester 217 in 94% yield (Scheme 5.10, Method 
A).   Compound 217 was subsequently treated with N-bromosuccinimide (NBS) and 
azo(bis)isobutyronitrile (AIBN) in carbon tetrachloride.  Heating the mixture at reflux 
for 5 hours gave the bromo derivative 218 in 84% yield after filtration of the reaction 
mixture and purification of the product by column chromatography.  The bromo 
derivative 218 was also synthesised by an alternative route starting from 2-(4-
(bromomethyl)phenyl)propanoic acid 219 (Scheme 5.10, Method B).  Methyl 
esterification of compound 219 by stirring at room temperature in methanol with 
sulfuric acid as a catalyst yielded the bromo derivative 218 in 77% yield after 
purification by column chromatography.  A minor side product from the reaction was 
characterised as the methoxy derivative 220,
182
 which eluted as a second fraction from 
the column.  
 
 
Scheme 5.10. Synthesis of the bromo intermediate 218 for the preparation of loxoprofen. 
 
The bromo derivative 218 was next added to a solution of ethyl 2-oxocyclopentane 
carboxylate 221 in acetone in the presence of potassium carbonate (Scheme 5.11).  
After heating at reflux for 16 hours, the diester 222 was isolated in 61% yield.  Finally, 
decarboxylation and hydrolysis of the diester 222 under strong acidic conditions 
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afforded loxoprofen 79 in 76% yield as a mixture of stereoisomers with NMR data 
consistent with literature reports.
183
 
 
 
Scheme 5.11. Synthesis of loxoprofen. 
 
Loxoprofen 79 contains two chiral centres and is used clinically as an anti-inflammatory 
drug as a racemic mixture of all four stereoisomers (Figure 5.1).  It is a prodrug, and in 
humans is metabolised through reduction of the ketone moiety to the corresponding 
alcohol metabolites, of which there are 8 possible stereoisomers.
184
  The most 
pharmacologically active metabolite, the (2S,1’R,2’S)-trans-alcohol 223 (Figure 5.1), is 
formed in larger amounts than the other stereoisomers and is also derived from the 
metabolic inversion of the cis-alcohol metabolites.
185
  Therefore, interesting target 
loxoprofen derivatives to prepare for antimycobacterial screening included compounds 
accessible via reduction of the ketone.   
 
 
Figure 5.1. Prodrug loxoprofen and its bioactive alcohol metabolite. 
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The ketone moiety of loxoprofen 79 was reduced with sodium borohydride in methanol, 
which afforded the alcohol derivative 224 in 95% yield (Scheme 5.12).  Alcohol 224 
was isolated as a 3:1 mixture of the trans/cis stereoisomers as determined from 
1
H-
NMR spectroscopy data.
183
  Depending on the results of the antimycobacterial 
evaluation of compound 224, future investigations into the preparation of single 
stereoisomers may be useful.  Asymmetric syntheses of single enantiomers of alcohol 
224 have been reported using either asymmetric hydrogenation
186
 or chemoenzymatic 
routes involving the reduction of the ketone with a ketoreductase.
187
   
 
 
Scheme 5.12. Reduction of loxoprofen to the alcohol analogue. 
 
The second analogue of loxoprofen 79 that was prepared was the novel amino 
compound 225 (Scheme 5.13).  Reductive amination was carried out by treatment of 
loxoprofen 79 in methanol with ammonium acetate and sodium cyanoborohydride at 
room temperature.
188
  Purification of the crude product by reverse phase prep-HPLC, 
followed by recrystallisation afforded the amino compound 225 in 46% yield.  Similar 
to the alcohol derivative 224, the amino compound 225 was isolated as a mixture of 
stereoisomers in a 6:1 ratio at the 1’/2’ positions, determined by 1H-NMR spectroscopy. 
 
 
Scheme 5.13. Reductive amination of loxoprofen. 
 
A method for the asymmetric reductive amination of loxoprofen 79 was also desirable 
as it would enable the preparation of either the (2’R)- or (2’S)-chiral amine 225, which 
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would then be able to be evaluated separately in the antimycobacterial assays.  
Transaminases (TAms) have been used in the asymmetric synthesis of chiral amines for 
pharmaceutically relevant compounds.  They catalyse the transfer of an amino group 
(from an amine donor substrate) to a carbonyl such as a ketone, generating a chiral 
amine.  The Arthrobacter sp. transaminase is (R)-selective and has previously been 
reported for the amination of ketones for compounds including steroids and 1,3-
ketoamides.
189
  The potential of using Arthrobacter TAm for the asymmetric amination 
of loxoprofen 79 was tested using (R)-methylbenzylamine 226 as the amine donor and 
the cofactor pyridoxal-5’-phosphate (PLP) (Scheme 5.14).  The production of 
acetophenone 227 was monitored by analytical HPLC.  When the transaminase reaction 
was carried out, only a small amount of acetophenone 227 was detected.  This 
suggested that an alternative amine donor such as isopropylamine should be used, or 
that loxoprofen 79 was not accepted by the enzyme as a substrate.  
 
 
Scheme 5.14. Attempted (R)-selective transaminase catalysed amination of loxoprofen 
 
The transaminase Chromobacterium violaceum (CV-TAm) has previously been shown 
to accept a wide range of ketones and is an (S)-selective transaminase.
190
  The amination 
reaction of loxoprofen 79 was carried out using CV-TAm, however problems were 
encountered with the HPLC monitoring of the production of acetophenone 227.  The 
results were not reliable and would need to be repeated, however due to the limited time 
available at the end of the PhD this was not further investigated.   
An evaluation of the antimycobacterial properties of the ibuprofen analogues 213 and 
215 and the loxoprofen derivatives 224 and 225 is currently ongoing by biological 
collaborators (Bhakta group).   
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6. Asymmetric phosphate mediated Pictet-Spengler reaction 
 
6.1 Chiral sugar phosphates 
Water is an attractive reaction medium for organic synthesis, but asymmetric catalysis 
in water is challenging because of its strong hydrogen bond donor/acceptor properties, 
which can disrupt interactions between a chiral catalyst and a substrate.  An emerging 
class of water compatible asymmetric catalysts are chiral biological phosphates such as 
DNA, RNA and nucleotides (described in section 3.4).  Previous work published by the 
Hailes group demonstrated that a range of phosphates including the chiral uridine 5’-
monophosphate (UMP) 228 and glucose-1-phosphate 229 (Figure 6.1), acted as 
efficient catalysts in the biomimetic phosphate mediated Pictet-Spengler reaction for the 
synthesis of norcoclaurine 108 (Section 3.3.4, Scheme 3.7).
122
  The stereoselectivity of 
the reaction was not analysed, but UMP 228 and glucose-1-phosphate 229 both contain 
multiple chiral centres within the single isomer molecule which could potentially 
influence the stereoselectivity.  Asymmetric versions of the Pictet-Spengler reaction 
have been reported for the synthesis of THIQs with a chiral centre at the C-1 position 
(described in section 3.3.5), but to date there are no examples where the reactions have 
been performed in aqueous media.   
 
 
Figure 6.1. Structure of uridine 5’-monophosphate and glucose-1-phosphate. 
 
A range of commercially available single isomer sugar phosphates were selected to 
screen in the phosphate mediated Pictet-Spengler reaction between dopamine 101 and 
phenylacetaldehyde 199, generating the THIQ product 230 (Table 6.1).  
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Phenylacetaldehyde 199 was selected because it was a close analogue of 4-HPAA 107, 
the natural substrate for the NCS enzyme catalysed Pictet-Spengler reaction (Scheme 
3.7, section 3.3.4).  In contrast to 4-HPAA 107 (which was unstable and required 
synthesis from the corresponding alcohol, Scheme 4.3), phenylacetaldehyde 199 was 
commercially available and more chemically stable.  The Pictet-Spengler reactions were 
carried out using standard conditions in a 1:1 mixture of aqueous phosphate solution 
(pH 6) and acetonitrile at 50 
o
C.  After 4 hours the crude product was purified by 
reverse phase prep-HPLC to obtain the THIQ product 230 (Table 6.1).   
 
 
Entry Phosphate Yield
a  
(%) 
ee
c 
(%) 
1S/1R  
ratio 
1 No phosphate added 0
b 
- - 
2 Potassium phosphate 64  2   51/49 
3 -D-Glucose-1-phosphate 71  2   49/51 
4 D-Glucose-6-phosphate  69  0   50/50 
5 D-Fructose-6-phosphate  64 2   51/49 
6 Uridine 5’-monophosphate (UMP)  67  2   49/51 
7 Cytidine 5’-monophosphate (CMP)  19  0   50/50 
8 2’-Deoxyuridine 5’-monophosphate (dUMP) 45  2   49/51 
9 2’-Deoxythymidine 5’-monophosphate (dTMP) 69  2   49/51 
10 Inosine 5’-monophosphate (IMP) 41 6    47/53  
11 Guanosine 5’-monophosphate (GMP) 34  8   46/54 
12 2’-Deoxyguanosine 5’-monophosphate (dGMP)  57  6   47/53 
13 Adenosine 5’-monophosphate (5’-AMP) 25 6   47/53 
14 Adenosine 3’-monophosphate (3’-AMP) 43  6   53/47 
15 Cyclic adenosine monophosphate (cAMP) 17 0   50/50 
 
Table 6.1. Screening sugar phosphates in the biomimetic Pictet-Spengler reaction. aIsolated yield after 
purification by reverse phase HPLC. bLC-MS of the reaction mixture showed a very small amount of 
THIQ product had formed which was not isolated. cDetermined by chiral HPLC. 
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A chiral analytical HPLC method for the separation of THIQs (1R)-230 and (1S)-230 
was developed at GSK by Dr Eric Hortense, which was then also adopted at UCL.
ix
  
The assignment of enantiomers was made by comparison of a racemic sample of THIQ 
230 with a sample of the enantiopure (1S)-230, which was synthesised by collaborators 
via an enzymatic route.
120,121
  The enantiomeric excess (ee) of 230 was determined from 
the chiral HPLC analysis. 
All of the phosphates used successfully promoted the Pictet-Spengler cyclisation to 
yield THIQ 230 (Table 6.1), highlighting the key role that the phosphate has in 
mediating the reaction.  When the reaction was performed without the addition of 
phosphate (Table 6.1, entry 1), only negligible amounts of the product 230 were 
detected by LC-MS and therefore it was not isolated or purified.  As a positive control, 
the reaction was carried out using potassium phosphate as the catalyst to generate the 
racemic THIQ 230 in 64% yield (Table 1, entry 2).  The glucose and fructose mono-
phosphorylated sugars did not induce stereoselectivity in the product (Table 6.1, entries 
3-5), but were as effective in mediating the reactions as potassium phosphate, 
generating THIQ 230 in 64-71% yields.   
A set of commercially available pyrimidine nucleotides were screened in the Pictet-
Spengler reaction, including uridine, cytidine and thymidine 5’-monophosphates (Table 
6.1, entries 6-9).  These phosphates did not induce stereoselectivity in the product 230.  
The isolated yields of THIQ 230 were between 45-69% when uridine or thymidine 
nucleotides were used as the phosphate source, but reduced to 19% yield when cytidine 
monophosphate was used.  A set of purine nucleotides were also screened in the Pictet-
Spengler reaction (Table 6.1, entries 10-15).  For these reactions the product 230 was 
isolated in lower yields ranging from 25-57%, but a small stereoselectivity was 
observed (6-8% ee).  An exception was when cyclic adenosine monophosphate was 
used, where no stereoselectivity was observed (0% ee).  The purine nucleotides that 
were mono-phosphorylated at the 5’-position (IMP, GMP, dGMP and 5’-AMP, Table 
6.1, entries 10-13) induced the same stereoselectivity in the product, with (1R)-230 as 
the predominant configuration.  This was opposite to the stereoselectivity of the 
enzymatic reaction, which gives rise to THIQs with a (1S)-configuration.
115
  When the 
                                                             
ix Chiral HPLC analysis for reaction entries 1-9 and 11-14 in table 6.1 were performed by Dr. Eric 
Hortense at GSK, Stevenage.  All other chiral HPLC analysis described in chapter 6 were carried out at 
UCL. 
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purine nucleotide was mono-phosphorylated at the 3’-position (3’-AMP), the (1S)-
stereoisomer was favoured with a small enantiomeric excess of 6% (Table 1, entry 14).  
This was opposite to that observed with adenosine 5’-monophosphate, suggesting that 
the stereoselectivity may be influenced by the position of attachment of the phosphate 
group on the furanose ring.   
The role of phosphate in mediating the Pictet-Spengler reaction has previously been 
proposed as either acting as a general base (abstracting a proton from the C-6 hydroxy 
group of the intermediate imine) or forming an intermediate aminophosphate (section 
3.3.4, Schemes 3.8 and 3.9).  The phosphate group in 5’-AMP 231 (Figure 6.2) lies on 
the same face of the furanose ring as the adenine group.  In 3’-AMP 232 (Figure 6.2), 
the phosphate group lies on the opposite side of the furanose ring to the adenine group.  
Therefore, the intermediate imine/aminophosphate group could be held either above or 
below the furanose ring which may influence stereoselectivity, as well as possible π-π 
interactions between the phenyl groups of the substrate and the adenine ring of the 
nucleotide.  Interactions between catecholamines and adenine nucleotides in aqueous 
solution have previously been demonstrated in 
1
H-NMR studies by Granot et al., 
through stacking interactions between the catechol and the adenine ring.
191
   
The phosphate group in cAMP 233 (Figure 6.2) is held in a ring in a rigid position, 
which may have not allowed the intermediate imine/aminophosphate group to form any 
stabilising interactions with the adenine ring.  It was also possible the ionisation 
properties of the phosphate moiety played a role.  cAMP 233 is a phosphodiester and at 
pH 6 exists as the monoanion.  In comparison, the other purine nucleotides screened 
including 5’-AMP 231 and 3’-AMP 232 would have existed as a mixture of the mono- 
and di-anion species. 
 
 
Figure 6.2. Structure of adenosine monophosphates. 
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DNA was also screened in the phosphate mediated Pictet-Spengler reaction (Scheme 
6.1).  The reaction was carried out at pH 6 or pH 2.3 (the pH of the DNA when 
dissolved in water).  The yield of THIQ 230 from these reactions after 4 hours was low 
(6-11%).  The chiral environment of the DNA helix did not induce stereoselectivity in 
the product 230 (0% ee determined by chiral HPLC analysis).  DNA is a 
polynucleotide, with the 5’-phosphate group of one nucleotide linked to the 3’-hydroxy 
group of an adjacent nucleotide.  Similar to cAMP 233 (Figure 6.2) the phosphate group 
is part of a more rigid structure than the phosphate groups present in single nucleotides 
and may be less accessible to promote the Pictet-Spengler cyclisation.   
 
 
Scheme 6.1. DNA (herring sperm) as the phosphate source in the biomimetic Pictet-Spengler reaction. 
 
6.2 Modified adenosine monophosphates 
The general trend found from screening chiral single isomer nucleotides as mediators 
for the biomimetic Pictet-Spengler reaction, was that purine 5’-monophosphates 
induced a small enantiomeric excess in the THIQ product, which was not observed with 
pyrimidine nucleotides.  This suggested the stereoselectivity could be influenced by the 
presence of the purine moiety.  
Purine heterocycles are larger than pyrimidines and exhibit restricted rotation about the 
N-glycosidic bond, giving rise to the syn- and anti-conformations (Figure 6.3).  Purine 
nucleotides generally favour the anti-conformation, but the syn/anti equilibrium can be 
altered by the addition of substituents at the C-8 position of the purine ring.  For 
example, adenosine 5’-monophosphate with a bromo substituent at the C-8 position has 
been shown to favour the syn-conformation in water, due to increased steric hinderance 
between the bromo group and the sugar (Figure 6.3).
192
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Figure 6.3. Syn- and anti-conformations of purine nucleotides. 
 
In order to investigate the steric effects of the nucleotide purine ring on the 
stereoselectivity of the phosphate mediated Pictet-Spengler reaction, it was decided to 
prepare analogues of 5’-AMP 231 with various substituents at the C-8 position 
following literature procedures.  First, 8-bromo adenosine 5’-monophosphate (8-Br-
AMP) 234 was prepared according to a procedure by the Wagner group, where the 
unprotected nucleotide 5’-AMP 231 in sodium acetate buffer was directly modified by 
the addition of a saturated aqueous bromine solution (Scheme 6.2).
193
  The crude 
product contained a small amount of residual sodium acetate, and could be used directly 
in the next step without further purification. 
 
 
Scheme 6.2. Synthesis of 8-Br-AMP. 
 
8-Br-AMP 234 was next used in Pd-catalysed cross couplings to introduce aryl groups 
at position C-8 (Scheme 6.3).  According to a procedure described by the Wagner 
group, the cross-coupling reactions between 8-Br-AMP 234 and aryl-boronic acids were 
carried out in water, using a catalytic system involving the water soluble ligand TPPTS 
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(triphenylphosphine-3,3’,3’’-trisulfonic acid sodium salt) and the Pd source, sodium 
tetrachloropalladate(II).
193
  Purification of the crude 8-phenyl-AMP 235 product was 
initially attempted by passing the material through a short column of reverse phase 
silica, and eluting with 
i
PrOH/H2O/NH4OH.  Unfortunately this purification method 
was unsuccessful, and the isolated product 235 contained impurities.  In the literature, 
ion pair chromatography was used to afford 8-phenyl-AMP 235 in 82% yield.
193
  
Therefore for the purification of 8-phenyl-AMP 235, reverse phase prep-HPLC was 
carried out using a gradient of 0.05 M TEAB (triethylammonium bicarbonate) against 
acetonitrile as the mobile phase.  It was very difficult to optimise the HPLC conditions 
to separate the compounds in the mixture, and minor impurities were still present in the 
product as observed by 
1
H-NMR spectroscopy.  The isolated yield of compound 235 
was 84% but this contained impurities. 
The cross coupling method
193
 was also applied to the synthesis of four novel 8-aryl-
AMP analogues 236-239 (Scheme 6.3).  The isolated yields ranged from 10-39%, which 
were low due to the loss of material when purifying the nucleotides by reverse phase 
HPLC.  The 8-naphthyl-AMP analogue 236 was prepared so that the effects of sterics 
on the stereoselectivity of the phosphate mediated Pictet-Spengler reaction could be 
studied.  The 8-aryl-AMP analogues 237-239 featured either an electron donating 
hydroxy or methoxy group or an electron withdrawing nitro group on the aryl ring, so 
that electronic effects could be explored.  
 
 
Scheme 6.3. Synthesis of 8-aryl-AMP compounds. 
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The modified adenosine 5’-monophosphate nucleotides were used as the phosphate 
source in the phosphate mediated Pictet-Spengler reaction between dopamine 101 and 
phenylacetaldehyde 199 (Table 6.2).  The reactions were performed using standard 
conditions of a 1:1 mixture of the aqueous phosphate solution (0.067 M, pH 6) and 
acetonitrile at 50 
o
C.  After 4 hours the crude product was purified by reverse phase 
prep-HPLC to obtain the THIQ 230, which was analysed by chiral HPLC to determine 
the enantiomeric excess.     
 
 
Entry Phosphate Yield
a  
(%) 
ee
b
  
(%) 
1S/1R  
ratio 
1 8-Bromo-AMP  234 49 10 45/55 
2 8-Phenyl-AMP  235 31 10 45/55 
3 8-Naphthyl-AMP  236 59  8 46/54 
4 8-Hydroxyphenyl-AMP  237 49 10 45/55 
5 8-Methoxyphenyl-AMP  238 43  12 44/56 
6 8-Nitrophenyl-AMP  239 45 14 43/57 
Table 6.2. Screening modified adenosine 5’-monophosphates in the biomimetic Pictet-Spengler reaction. 
aIsolated yield after purification by reverse phase HPLC. bDetermined by chiral HPLC. 
 
The modified adenosine 5’-monophosphates 234-239 mediated the Pictet-Spengler 
reaction to generate the THIQ product 230 in isolated yields between 31-59% (Table 
6.2).  The enantiomeric excess of product 230 for these reactions was between 8-14%, 
with (1R)-230 as the predominant configuration.  These were slightly higher than the 
stereoselectivity induced by the unmodified adenosine 5’-monophosphate (6% ee, Table 
6.1).  Sterics appeared to have little effect on the stereoselectivity.  For example, the 8-
phenyl-AMP analogue 235 and the 8-naphthyl-AMP analogue 236 gave rise to a similar 
enantiomeric excess of the product 230 (Table 6.2, entries 2-3).  Comparing AMP 
derivatives 237, 238 and 239 (Table 6.2, entries 4-6) showed that the electron donating 
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or electron withdrawing substituent attached to the phenyl ring at the C-8 position also 
had little effect on the stereoselectivity. 
Overall the modified adenosine 5’-monophosphates did induce a small stereoselectivity 
in the phosphate mediated Pictet-Spengler reaction between dopamine 101 and 
phenylacetaldehyde 199.  Although the enantiomeric excess values of the product 230 
were too small to make the reaction useful, it was still interesting that only the purine 
5’-monophosphate nucleotides were able to induce this stereoselectivity for the (1R)-
stereoisomer.  It may be possible to increase the stereoselectivity in future investigations 
by exploring the reaction conditions, such as the effects of temperature, reaction time 
and the amount of nucleotide added to the reaction.    
 
6.3 BINOL phosphoric acids  
BINOL-derived phosphoric acids are a versatile class of organocatalysts for asymmetric 
reactions, and have been used in the Pictet-Spengler reaction but only under strictly 
anhydrous conditions (section 3.3.5).  The phosphoric acid (R)-TRIP (Figure 6.4) has 
successfully been utilised as an asymmetric catalyst in aqueous media for the 
enantioselective hydrogenation of quinolines (section 3.4).  A structurally simpler 
analogue of (R)-TRIP, was compound 240 (Figure 6.4), which was screened in the 
phosphate mediated Pictet-Spengler reaction in order to determine if BINOL phosphoric 
acids were able to promote the reaction.  Phosphoric acid 240 was selected because it 
was readily available, whereas (R)-TRIP was expensive from commercial sources or 
would have required a multistep synthesis.  
 
 
Figure 6.4. Structure of BINOL-derived phosphoric acids. 
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The Pictet-Spengler reaction was initially performed using a 1:1 mixture of an aqueous 
solution of phosphoric acid (S)-240 (0.1 M, pH 6) and acetonitrile (Table 6.3, entry 1).  
After 30 hours the crude product was purified by reverse phase HPLC, generating the 
THIQ 230 in 33% isolated yield.  A problem that was encountered when carrying out 
the reaction was that phosphoric acid (S)-240 was not completely soluble in water, and 
the accurate preparation of the 0.1 M solution at pH 6 was difficult.  It was encouraging 
however that the THIQ product 230 was isolated from the reaction.   
 
 
Entry Aq. phosphoric acid ((S)-240)/ 
co-solvent, ratio 
Time (h) Yield (%) 
1 (S)-240/acetonitrile, 1:1 30 33
a 
2 (S)-240 (no co-solvent) 4 0 
3 (S)-240/acetonitrile, 2:1 4 0 
4 (S)-240/acetonitrile, 1:1 4 0 
5 (S)-240/acetonitrile, 1:2 4 0 
6 (S)-240/methanol, 2:1 4 0 
7 (S)-240/methanol, 1:1 4 0 
8 (S)-240/methanol, 1:2 4 0 
9 (S)-240/DMF, 2:1 4 0 
10 (S)-240/DMF, 1:1 4 0 
11 (S)-240/DMF, 1:2 4 0 
Table 6.3. Screening BINOL-derived phosphoric acid (S)-240 in the biomimetic Pictet-Spengler reaction. 
aIsolated yield after reverse phase HPLC. 
 
A number of reactions were next carried out in parallel (Table 6.3, entries 2-11).  As the 
solubility of phosphoric acid (S)-240 was a problem, the co-solvent was investigated 
including acetonitrile, methanol and DMF, which have previously been shown to result 
in high conversions when used in the biomimetic Pictet-Spengler reaction.
122
  The 
reactions were carried out for 4 hours (the same length of time as previously used when 
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investigating the stereoselectivity of the sugar phosphate mediators), with the aim of 
isolating the THIQ product 230 and analysing the enantiomeric excess. However, in all 
of the reactions none of the desired product 230 was isolated.  This suggested that the 
reactions required a longer reaction time for conversion to THIQ 230 to be achieved. 
The BINOL phosphoric acid (S)-240 was not effective at promoting the Pictet-Spengler 
reaction and therefore was not investigated further during this project. 
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7. Conclusions and future work 
 
A series of 1-substituted THIQs were synthesised and their antimycobacterial properties 
evaluated against M. aurum.  Most of the 1-substituted THIQs displayed 
antimycobacterial activity, but also exhibited high cytotoxicities.  Structure activity 
relationships (regarding the compounds ability to inhibit the growth of M. aurum) 
revealed that THIQs featuring an 8-hydroxy substitution were generally more potent 
inhibitors than THIQs without this group.  This included compounds with a 6,8- and 
7,8-dihydroxy substitution.  The addition of a bromine substituent at the C-5 position 
also increased the potency of the compounds, consistent with results from previous 
studies.
105
  The 5-bromo-8-hydroxy-THIQ 162 (Figure 7.1) which had a 1-pentyl chain 
was identified as the most compound of the series (MIC = 62.5 µg/mL). 
Structure activity relationships regarding M. aurum efflux pump inhibition showed that 
most of the THIQs with a 7,8-dihydroxy substitution displayed efflux pump inhibitory 
activity, whereas the 6,7-dihydroxy-THIQs did not.  Among the THIQs showing efflux 
pump inhibitory activity, some also showed synergistic activity when used in 
combination with current anti-TB drugs.  In particular, THIQ 162 was very promising 
as a synergistic drug and enhanced the activity of all three first-line anti-TB drugs tested 
(isoniazid, rifampicin and ethambutol).  THIQs 142b, 146c, 142c and 91 (Figure 7.1) 
also displayed synergistic activity when used in combination with rifampicin or 
ethambutol at a low concentration of 0.1 µg/mL.  These preliminary studies highlight 
the potential of the THIQ scaffold as a novel class of mycobacterial efflux pump 
inhibitors, and provide a good starting point for further exploration of these compounds. 
 
 
Figure 7.1. Structures of promising antimycobacterial THIQ compounds. 
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The phosphate mediated Pictet-Spengler reaction was an efficient method for the 
preparation of the 1-substituted THIQs.  The scope of this reaction was extended to the 
preparation of THIQs with 1-substituents containing an ester functional group, which 
could be further cyclised to form a tricyclic structure through a second intramolecular 
lactamisation reaction.  The phosphate mediated Pictet-Spengler reaction was also used 
to prepare a series of novel 7-membered ring THBPs.  Cyclisation to generate 7-
membered rings was more difficult than cyclisation to form the 6-membered ring 
THIQs, and the substrate scope was limited to phenylpropylamines with a highly 
activated ring (3,5-dihydroxy substitution).  Finally it was demonstrated that chiral 
single isomer sugar phosphates promoted the phosphate mediated Pictet-Spengler 
reaction for the preparation of 1-benzyl-THIQs.  A study into the stereoselectivity of 
these reactions demonstrated that generally the sugar phosphates did not induce 
stereoselectivity.  However purine nucleotides were able to induce a very small 
stereoselectivity, with the enantiomeric excess of the product THIQ between 6-14%.    
Evaluation of the synthesised 7-membered ring THBPs and profen analogues as 
potential anti-TB compounds is ongoing.  Future antimycobacterial testing should also 
include screening the most active THIQs such as compound 162 against M. 
tuberculosis, as currently the compounds have only been screened against M aurum.  
Future Medicinal Chemistry studies could focus on further SAR based around the THIQ 
structure, including functionalisation of aromatic ring substituents.  For example, 
hydroxy substituents at either the C-6 or C-8 position could be converted to the triflate 
to enable Suzuki cross coupling reactions to be performed with a range of commercially 
available boronic acids (Scheme 7.1).
194
   
 
 
Scheme 7.1. Functionalisation of THIQs via a Suzuki cross coupling reaction. PG = protecting group. 
 
Also, 8-hydroxy-THIQs could be further functionalised with various groups at the C-5 
position (para to the phenol hydroxy group), such as the introduction of an acyl group 
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via a triflic anhydride mediated para acylation reaction (Scheme 7.2).
195
  The 
antimycobacterial properties of these compounds could then be compared to the 5-
bromo-8-hydroxy-THIQ 162.   
 
 
Scheme 7.2. Functionalisation of THIQs via a triflic anhydride mediated acylation. PG = protecting 
group. 
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8. Experimental 
 
8.1 General experimental 
All reagents and solvents were purchased from Sigma-Aldrich, Alfa Aesar, Acros and 
Fisher scientific, and were used as provided unless otherwise indicated.  
Dichloromethane, THF, diethyl ether and toluene were obtained from an anhydrous 
solvent system providing high quality, oxygen free solvents.  Petrol refers to petroleum 
ether (40-60 
o
C fraction). For non-aqueous chemistry, reactions were carried out in 
oven-dried glassware under a nitrogen or argon atmosphere unless otherwise indicated.  
Thin layer chromatography (TLC) was carried out using Macherey-Nagel Polygram
®
 
silica 60 polyester sheets, 0.2 mm layer thickness, UV254 indicator, 40 x 80 mm plate 
size.  TLC plates were visualised under UV or stained with a potassium permanganate 
solution.  Flash column chromatography was performed using Merck silica gel 60, 40-
63 µm as the stationary phase.   
1
H and 
13
C NMR spectra were obtained using either a Bruker AMX300, Bruker Avance 
400, Bruker Avance 500 or Bruker Avance 600 spectrometer.  Chemical shifts (δ) were 
quoted in parts per million (ppm) relative to residual solvent peaks, CDCl3 (
1
H NMR δ 
7.26 and 
13
C NMR δ 77.2) and CD3OD (
1
H NMR δ 3.31 and 13C NMR δ 49.0), using 
the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad.  The coupling constants (J) were measured in Hertz (Hz).  Where 
appropriate, COSY HMQC and HMBC experiments were carried out to aid assignment.  
The numbering systems used for assigning NMR spectra for THIQ, THBP and 
nucleotide structures were as follows: 
 
Melting points were determined using the Stuart Scientific SMP11 analogue apparatus 
and are uncorrected.  Infra-red spectra were obtained using a Perkin Elmer Spectrum 
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100 FT-IR spectrometer or a Thermo Scientific Nicolet 6700 FT-IR spectrometer.  
Optical rotations were determined using a Perkin Elmer 343 polarimeter and units for 
specific rotation are 10
-3 
deg cm
2
 g
-1
.  Mass spectra were obtained using either a Fisons 
VG70-SE, a Thermo Finnigan MAT 900XP, or a Waters LCT Premier XE 
spectrometer.  The pH meter used was a Mettler-Toledo model MP225. 
Mass Directed AutoPreparative HPLC (MDAP):  MDAP was conducted on a Sunfire 
C18 column (150 mm length x 30 mm i.d., 5 m packing diameter) at ambient 
temperature, eluting with solvents A/B (A: 0.1% v/v solution of trifluoroacetic acid in 
water, B: 0.1% v/v solution of trifluoroacetic acid in acetonitrile), according to one of 
the following gradients.  Gradient A: 5-30% B in A.  Gradient B: 15-55% B in A.  
Gradient C: 30-85% B in A.  Gradient D: 50-99% B in A.  The flow rate was 40 
mL/min.  The run time was 20 min unless otherwise stated.  The UV detection was a 
summed/averaged signal from wavelength of 210 nm to 350 nm. The mass spectra were 
recorded using positive mode electrospray ionisation.  
Preparative HPLC Method 1:  HPLC was conducted on a Varian Prostar or Dionex 
instrument equipped with a UV-visible detector, using a Phenomenex Onyx Monolithic 
semi-prep C18 column (100 mm length x 10 mm i.d.) at room temperature, eluting with 
solvents A/B (A: 0.1% v/v solution of trifluoroacetic acid in water, B: 0.1% v/v solution 
of trifluoroacetic acid in acetonitrile).  The gradient employed was 5-40% B in A.  The 
run time was 20 min and the flow rate was 8 mL/min unless otherwise stated.  The UV 
detection was at wavelength 280 nm and 254 nm. 
Preparative HPLC Method 2:  HPLC was conducted on a Varian Prostar or Dionex 
instrument equipped with a UV-visible detector, using an Acentis C18 column (150 mm 
length x 21.2 mm i.d., 5 µm) at room temperature, eluting with solvents A/B (A: 0.1% 
v/v solution of trifluoroacetic acid in water, B: 0.1% v/v solution of trifluoroacetic acid 
in acetonitrile), according to one of the following gradients.  Gradient A: 5-15% B in A, 
Gradient B: 5-20% B in A, Gradient C: 5-30% B in A, Gradient D: 10-15% B in A, 
Gradient E: 10-25% B in A, Gradient F: 15% B in A.  The run time was 40 min and the 
flow rate was 7 mL/min unless otherwise stated.  The UV detection was at wavelength 
280 nm and 254 nm. 
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Preparative HPLC Method 3:  HPLC was conducted on a Varian Prostar instrument 
equipped with a UV-visible detector, using a Supelco Discovery Bio Wide Pore C18 
column (250 mm length x 21.1 mm i.d., 10 µm) at room temperature, eluting with 
solvents A/B (A: 0.05 M triethylammonium bicarbonate buffer, B: acetonitrile), 
according to one of the following gradients.  Gradient A: 0-15% B in A, Gradient B: 0-
25% B in A, Gradient C: 0-30% B in A, Gradient D: 0-60% B in A, Gradient E: 0-98% 
B in A.  The flow rate was 8 mL/min.  The run time was 25 min unless otherwise stated.  
The UV detection was at wavelength 254 nm and 214 nm. 
Analytical chiral HPLC: Chiral HPLC analysis was performed on a Varian Prostar 
instrument equipped with an autosampler and a UV-visible detector, using a Supelco 
Astec Chirobiotic T2 column (250 mm length x 4.6 mm i.d., 5 m packing diameter) at 
ambient temperature, eluting with an isocratic mobile phase of methanol (0.1% acetic 
acid, 0.2% triethylamine).  The flow rate was 1 mL/min.  The injection volume was 10 
µL.  The run time was 40 min.  Compounds were detected by UV absorbance at 
wavelength 230 nm.   
LC-MS: UPLC analysis was performed using a Waters Acquity UPLC-MS system, 
using a Zorbax SB-C18 column (2.1 x 2.0 mm i.d., 1.8 µm packing diameter), eluting 
with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of 
formic acid in acetonitrile).  The flow rate was 1 mL/min, and the gradient employed 
was: 0 min (A: 100%, B: 0%), 4 min (A: 5%, B: 95%), 4.5 min (A: 5%, B: 95%), 5.0 
min (A: 100%, B: 0%).  The UV detection was at wavelength 254 nm.  The mass 
spectra were recorded on a single quadrupole (SQD) mass spectrometer using positive 
ion electrospray ionisation mode.   
 
8.2 (S)-1-(2-(Hydroxymethyl)indolin-1-yl)ethan-1-one ((S)-23)
49
 
 
The title compound was prepared following a literature procedure.
49
  Lithium 
borohydride (46.8 mg, 2.15 mmol) was added portionwise to a stirred solution of (S)-25 
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(254 mg, 1.16 mmol) in THF (2 mL) at 0 
o
C and stirred at rt for 7 h.  The reaction was 
quenched by addition of 10% HCl and extracted with EtOAc (3 x 15 mL).  The 
combined organic extracts were washed with sat. Na2CO3, brine, dried (Na2SO4), and 
solvent removed in vacuo to give a yellow oil, which was purified by column 
chromatography (EtOAc/hexane, 2:1) to afford the alcohol (S)-23
 
as a pale brown solid 
(111 mg, 50%), as a mixture of amide rotamers (2:1 in CDCl3).  Rf 0.19 (EtOAc/hexane, 
2:1);  m.p. 99-100 
o
C;  []D
25
 -50.3 (c 0.89, EtOH);  δH (500 MHz; CDCl3) 8.18-6.92 
(4H, m, 4 x Ar-H), 4.97-4.40 (1H, m, 2-CH), 3.75-3.50 (2H, m, CH2O), 3.35-2.57 (2H, 
m, 3-CH2), 2.50-2.25 (3H, m, CH3);  m/z (CI) 192 ([M + H]
+
, 100%);  HRMS 
C11H14O2N, calcd 192.1025, found 192.1028.  
 
8.3 Methyl (S)-1-acetylindoline-2-carboxylate ((S)-25)
49
  
 
The title compound was prepared using a modified version of a literature procedure.
49
  
Thionyl chloride (4 mL, 54.8 mmol) was added dropwise to a stirred solution of (S)-
indoline-2-carboxylic acid (3.01 g, 18.4 mmol) in methanol (35 mL) at 0 
o
C.  The 
solution was stirred at rt for 1 h and heated at reflux for 3 h.  The mixture was 
concentrated in vacuo to a brown residue, which was washed with methanol (3 x 35 
mL) and after each methanol addition concentrated in vacuo to remove residual thionyl 
chloride to give the intermediate methyl (S)-indoline-2-carboxylate hydrochloride as a 
brown solid (4.37 g) which was then dissolved in THF (30 mL) and DMAP (244 mg, 
1.99 mmol) and triethylamine (10 mL, 71.7 mmol) were added.  After 30 min, acetic 
anhydride (4.30 mL, 45.5 mmol) was added to the reaction mixture at 0 
o
C, and stirred 
at rt for 10 min, then heated at reflux for 5 h.  The mixture was diluted with water (100 
mL) and extracted with EtOAc (3 x 50 mL).  The combined organic extracts were 
washed with 1 M HCl (2 x 50 mL), sat. Na2CO3 (2 x 50 mL), brine (50 mL), passed 
through a hydrophobic frit and solvent removed in vacuo to give the product (S)-25 as a 
brown solid (3.68 g, 91%), as a mixture of amide rotamers (1.2:1 in CDCl3).  Rf 0.37 
(hexane/EtOAc, 1:1);  m.p. 75-77 
o
C;  []D
25
 -115.6 (c 0.90, EtOH), lit
196
 []D
26
 -48.0 (c 
0.80, CHCl3);  δH (500 MHz; CDCl3) 8.23-7.14 (3H, m, 3 x Ar-H), 7.02 (1H, t, J = 7.0 
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Hz, Ar-H), 5.16-4.91 (1H, m, 2-CH), 3.76-3.73 (3H, m, OCH3), 3.62-3.10 (2H, m, 3-
CH2), 2.48-2.17 (3H, m, COCH3);  δC (125 MHz; CDCl3) 174.6 (CO2CH3), 171.7 and 
171.3 (COCH3), 145.4 and 144.1 (Ar-C), 133.6 and 131.2 (Ar-C), 130.8 and 130.6 (Ar-
CH), 128.5 and 127.0 and 126.8 and 126.2 (2 x Ar-CH), 120.2 and 116.6 (Ar-CH), 64.2 
and 63.0 (2-CH), 55.8 and 55.3 (OCH3), 36.4 and 34.3 (3-CH2), 27.3 and 26.5 
(COCH3);  m/z (CI) 220 ([M + H]
+
, 100%);  HRMS C12H14O3N, calcd 220.0974, found 
220.0965.  
 
8.4 (S)-1-(2-(Hydroxymethyl)pyrrolidin-1-yl)ethan-1-one ((S)-26)
53
   
 
Lithium borohydride (760 mg, 34.9 mmol) was added portionwise to a stirred solution 
of (S)-28 (3.78 g, 22.1 mmol) in 2-MeTHF (38 mL) at 0 
o
C and stirred at 0 
o
C for 20 h.  
The reaction was quenched by addition of 1 M HCl, then brine (40 mL), and extracted 
with CH2Cl2 (2 x 50 mL).  The aqueous phase was adjusted to pH 11 by addition of sat. 
Na2CO3, then extracted with CH2Cl2 (2 x 50 mL).  Combined organic extracts were 
washed with sat. Na2CO3, brine, passed through a hydrophobic frit, and solvent 
removed in vacuo to give a yellow oil, which was purified by column chromatography 
(EtOAc/CH3OH, 95:5) to afford the alcohol (S)-26
 
as a pale yellow oil (1.73 g, 55%), as 
a mixture of amide rotamers (16:1 in CDCl3).  Rf 0.14 (EtOAc/CH3OH, 95:5);  []D
25
 -
61.0 (c 0.90, EtOH), lit
197
 []D -69.5 (c 1.07, EtOH);  δH (500 MHz; CDCl3) 4.65 (1H, 
br s, OH), 4.21-4.14 (1H, m, 2-CH), 3.63 (1H, dd, J = 11.0 and 3.0 Hz, CHHO), 3.56 
(1H, dd, J = 11.0 and 8.0 Hz, CHHO), 3.53-3.43 (2H, m, 5-CH2), 2.08 (3H, s, CH3), 
2.06-1.98 (1H, m, 3-CHH), 1.98-1.81 (2H, m, 4-CH2), 1.63-1.55 (1H, m, 3-CHH);  δC 
(125 MHz; CDCl3) major amide rotamer, 172.1 (COCH3), 67.4 (CH2O), 61.2 (2-CH), 
49.1 (5-CH2), 28.5 (3-CH2), 24.4 (4-CH2), 23.0 (CH3);  m/z (CI) 144 ([M + H]
+
, 100%);  
HRMS C7H14O2N, calcd 144.1025, found 144.1022. 
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8.5 Methyl acetyl-(S)-prolinate ((S)-28)
51
   
 
Thionyl chloride (9.50 mL, 130 mmol) was added dropwise to a stirred solution of (S)-
proline (5.08 g, 44.1 mmol) in methanol (50 mL) at 0 
o
C.  The solution was stirred at rt 
for 1 h and heated at reflux for 3 h.  The mixture was concentrated in vacuo to give a 
yellow oil, which was washed with methanol (3 x 20 mL) and after each methanol 
addition concentrated in vacuo to remove residual thionyl chloride, to yield the 
intermediate methyl (S)-prolinate hydrochloride as a yellow oil (8.09 g), which was then 
dissolved in THF (60 mL) and DMAP (500 mg, 4.09 mmol) and triethylamine (25.0 
mL, 179 mmol) were added.  After 30 min, acetic anhydride (11.5 mL, 122 mmol) was 
added to the reaction mixture at 0 
o
C, which was stirred at rt for 10 min, then heated at 
reflux for 3 h.  The mixture was diluted with brine (130 mL) and extracted with CH2Cl2 
(3 x 50 mL).  The combined organic extracts were washed with brine (50 mL), passed 
through a hydrophobic frit, and solvent removed in vacuo to give a yellow oil, which 
was purified by column chromatography (EtOAc) to yield the product (S)-28 as a pale 
yellow oil (7.06 g, 93%), as a mixture of amide rotamers (4:1 in CDCl3).  Published 
data assigns the major rotamer as the one with the acetamide carbonyl pointing towards 
the ester (trans).
198
  Rf 0.31 (EtOAc);  []D
25
 -93.4 (c 0.88, EtOH), lit
199
 []D
21
 –101.7 (c 
1.00, EtOH);  δH (500 MHz; CDCl3) 4.48-4.33 (1H, m, 2-CH), 3.74-3.70 (3H, m, 
OCH3), 3.66-3.44 (2H, m, 5-CH2), 2.31-2.01 (2H, m, 3-CH2), 2.07-1.85 (5H, m, 4-CH2, 
COCH3);  δC (125 MHz; CDCl3) 173.0 and 172.7 (CO2CH3), 169.7 and 169.5 (COCH3), 
60.2 and 58.5 (2-CH), 52.6 and 52.3 (OCH3), 47.8 and 46.4 (5-CH2), 31.5 and 29.5 (3-
CH2), 24.8 and 22.9 (4-CH2), 22.3 (COCH3);  m/z (EI) 171 (M
+
, 22%), 112 (M
+ 
- 
CO2CH3, 100%);  HRMS C8H13O3N, calcd 171.0890, found 171.0883. 
 
8.6 Methyl acetyl-(R)-prolinate ((R)-28)
52
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The title compound was prepared according to the procedure described in section 8.5, 
from (R)-proline (2.51 g, 21.8 mmol).  The crude product was purified by column 
chromatography (EtOAc) to yield (R)-28 as an orange oil (3.49 g, 93%).  
Characterisation data was identical to that of (S)-28 except []D
25
 +80.5 (c 0.96, EtOH). 
 
8.7 (S)-1-(2-(Chloromethyl)pyrrolidin-1-yl)ethan-1-one (30)
53
 and (S)-(1-
tosylpyrrolidin-2-yl)methyl acetate (31).   
 
Compounds 30 and 31 were isolated as side products from an attempted tosylation 
reaction.  Tosyl chloride (620 mg, 3.25 mmol) was added portionwise to a stirred 
solution of alcohol (S)-26 (356 mg, 2.49 mmol) and anhydrous pyridine (1.0 mL, 12.4 
mmol) in CH2Cl2 (5 mL) at 0 
o
C.  The reaction mixture was stirred at rt for 20 h, then 
diluted with CH2Cl2 (5 mL) and washed with water, 1 M HCl, sat. Na2CO3 and brine, 
passed through a hydrophobic frit, and solvent removed in vacuo to give a mixture of 
products as a bright yellow-orange oil, which were separated by column 
chromatography (EtOAc).  The first product eluted was the N-tosyl product 31 as a pale 
yellow oil (52.0 mg, 7%).  Rf 0.91 (EtOAc);  m.p. 53-54 
o
C;  υmax/cm
-1
 (KBr, CDCl3 
cast) 2986, 2971, 2886, 1741, 1600;  δH (500 MHz; CDCl3) 7.72 (2H, d, J = 8.0 Hz, 2 x 
6-Ar-H), 7.31 (2H, d, J = 8.0 Hz, 2 x 7-Ar-H), 4.19 (1H, dd, J = 11.0 and 5.0 Hz, 
CHHO), 4.10 (1H, dd, J = 11.0 and 7.0 Hz, CHHO), 3.90-3.84 (1H, m, 2-CH), 3.46-
3.40 (1H, m, 5-CHH), 3.19-3.12 (1H, m, 5-CHH), 2.42 (3H, s, Ar-CH3), 2.06 (3H, s, 
COCH3), 1.89-1.78 (1H, m, 4-CHH), 1.74-1.66 (1H, m, 3-CHH), 1.64-1.53 (2H, m, 4-
CHH, 3-CHH);  δC (125 MHz; CDCl3) 170.9 (COCH3), 143.7  (Ar-C), 134.5 (Ar-C), 
129.9 (2 x 7-Ar-CH), 127.7 (2 x 6-Ar-CH), 66.3 (CH2O), 57.9 (2-CH), 49.2 (5-CH2), 
28.7 (3-CH2), 24.0 (4-CH2), 21.6 (Ar-CH3), 21.0 (COCH3);  m/z (CI) 298 ([M + H]
+
, 
100%);  HRMS C14H20O4NS, calcd 298.1113, found 298.1118.  The second product 
eluted was the chloride product 30 as a pale yellow oil (181 mg, 45%).  Rf 0.23 
(EtOAc);  δH (300 MHz; CDCl3) 4.35-4.24 (1H, m, 2-CH), 3.78-3.60 (2H, m, CH2Cl), 
3.55-3.38 (2H, m, 5-CH2), 2.06 (3H, s, CH3), 2.06-1.80 (4H, m, 3-CH2, 4-CH2);  m/z 
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(EI) 161 ((
35
Cl)M
+
, 15%), 112 (M
+
 - CH2Cl, 100%);  HRMS C7H12ON
35
Cl, calcd 
161.0602, found 161.0604.   
 
8.8 (S)-1-(2-(Bromomethyl)pyrrolidin-1-yl)ethan-1-one (33) 
 
Thionyl bromide (0.300 mL, 3.87 mmol) was added dropwise to a stirred solution of 
alcohol (S)-26 (212 mg, 1.48 mmol) in CH2Cl2 (10 mL) at 0 
o
C.  The reaction mixture 
was stirred at rt for 22 h, then concentrated to give a bright orange solid which was 
dissolved in ethyl acetate (25 mL).  The mixture was filtered to remove the precipitate.  
The solvent was removed in vacuo and the resulting orange oil was purified by column 
chromatography (EtOAc) to yield the bromide 33 as a yellow oil (29.3 mg, 10%), as a 
mixture of amide rotamers (5:1 in CDCl3).  Rf 0.40 (EtOAc);  δH (500 MHz; CDCl3) 
major rotamer, 4.31-4.26 (1H, m, 2-CH), 3.63 (1H, dd, J = 9.5 and 3.0 Hz, CHHBr), 
3.55 (1H, dd, J = 9.5 and 8.0 Hz, CHHBr), 3.47 (2H, m, 5-CH2), 2.06 (3H, s, CH3), 
2.05-1.84 (4H, m, 3-CH2, 4-CH2);  δC (125 MHz; CDCl3) major rotamer, 170.0 
(COCH3), 57.5 (2-CH), 48.7 (5-CH2), 34.5 (CH2Br), 29.0 (CH2), 24.0 (CH2), 23.0 
(CH3);  m/z (CI) 208 ([(
81
Br)M + H]
+
, 15%), 206 ([(
79
Br)M + H]
+
, 15%);  HRMS 
C7H13ON
79
Br, calcd 206.0190, found 206.0185.  The bromide 33 was unstable and 
rearranged to the acetate 34 (pyrrolidin-2-ylmethyl acetate) at room temperature as 
observed by 
1
H-NMR spectroscopy with the appearance of signals consistent with those 
reported in the literature.
56
   
 
8.9 tert-Butyl (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate ((S)-35)
57
  
 
The title compound was prepared following a literature procedure.
57
  Borane 
tetrahydrofuran complex (1 M, 38.0 mL, 38.0 mmol) was added dropwise to a solution 
of (S)-37 (4.01 g, 18.6 mmol) in THF (30 mL) at 0 
o
C.  The solution was stirred at 0 
o
C 
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for 2 h, then rt for 1.5 h.  The reaction mixture was cooled in an ice bath and cold water 
(70 mL) was added.  The aqueous phase was extracted with EtOAc and the organic 
extracts were washed with brine, sat. NaHCO3 and water, dried (Na2SO4) and solvent 
removed in vacuo to give a yellow oil which was purified by column chromatography 
(hexane/EtOAc, 3:2) to yield the product (S)-35 as a white solid (3.16 g, 84%).  Rf 0.43 
(EtOAc/hexane, 2:3);  m.p. 54-55 
o
C (lit
200
 58-59 
o
C, EtOAc);  []D
25
 -43.8 (c 1.00, 
CHCl3), lit
57
 []D -47.3 (c 1.00, CHCl3);  δH (500 MHz; CDCl3) 4.73 (1H, br s, OH), 
3.98-3.91 (1H, m, 2-CH), 3.65-3.54 (2H, m, CH2O), 3.47-3.27 (2H, m, 5-CH2), 2.03-
1.96 (1H, m, 3-CHH), 1.85-1.75 (2H, m, 4-CH2), 1.55-1.50 (1H, m, 3-CHH), 1.46 (9H, 
s, C(CH3)3);  δC (125 MHz; CDCl3) 157.3 (CO2
t
Bu), 80.4 (C(CH3)3), 67.9 (CH2O), 60.3 
(2-CH), 47.7 (5-CH2), 28.8 (3-CH2), 28.6 (C(CH3)3), 24.2 (4-CH2);  m/z (CI) 202 ([M + 
H]
+
, 100%);  HRMS C10H20O3N, calcd 202.1443, found 202.1445. 
 
8.10 tert-Butyl (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate ((R)-35)
64
  
 
The title compound was prepared according to the procedure described in section 8.9, 
from (R)-37 (3.99 g, 18.5 mmol). The crude product was purified by column 
chromatography (hexane/EtOAc, 3:2) to yield the product (R)-35 as white crystals (3.29 
g, 88%). M.p. 53-55 
o
C (lit
64
 59-60 
o
C, hexane).  NMR and MS data identical to that of 
(S)-35.  
 
8.11 (tert-Butoxycarbonyl)-(S)-proline ((S)-37)
57
  
 
The title compound (S)-37 was prepared following a literature procedure.
57
  
Triethylamine (9.40 mL, 67.4 mmol) was added to a mixture of (S)-proline (6.43 g, 55.8 
mmol) in CH2Cl2 (130 mL) at 0 
o
C.  Boc anhydride (15.7 g, 71.9 mmol) in CH2Cl2 (6.5 
mL) was added to the reaction mixture over 10 min at 0 
o
C, and stirred for 3 h at 0 
o
C.  
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The reaction was quenched by adding saturated aq. citric acid (35 mL) and the organic 
phase washed with brine, dried (Na2SO4) and solvent removed in vacuo.  The crude 
product was dissolved in hot EtOAc, followed by addition of hexane (300 mL).  The 
crystallised product was collected by filtration to yield (S)-37 as white crystals (9.58 g, 
80%), as a mixture of amide rotamers (55:45 in CDCl3).  M.p. 129-131 
o
C (lit
57
 135-137 
o
C, EtOAc/hexane);  []D
25
 -89.1 (c 1.00, CHCl3) lit
201
 []D
20
 -92.0 (c 1.10, CHCl3);  δH 
(500 MHz; CDCl3) 7.35 (1H, br s, OH), 4.40-4.20 (1H, m, 2-CH), 3.60-3.30 (2H, m, 5-
CH2), 2.36-2.00 (2H, m, 3-CH2), 1.99-1.81 (2H, m, 4-CH2), 1.53-1.36 (9H, m, 
C(CH3)3);  δC (125 MHz; CDCl3) 178.8 and 175.0 (CO2H), 156.6 and 154.0 (CO2
t
Bu), 
81.5 and 80.4 (C(CH3)3), 59.2 and 59.0 (2-CH), 47.1 and 46.4 (5-CH2), 30.9 and 28.6 
(3-CH2), 28.5 and 28.3 (C(CH3)3), 24.4 and 23.7 (4-CH2);  m/z (CI) 216 ([M + H]
+
, 
5%), 114 ([M + H]
+
 - C5H10O2, 100%);  HRMS C10H18O4N, calcd 216.1236, found 
216.1233. 
 
8.12 (tert-Butoxycarbonyl)-(R)-proline ((R)-37)
202
   
 
The title compound was prepared according to the procedure described in section 8.11, 
from (R)-proline (3.02 g, 26.2 mmol).  The crude product was purified by 
recrystallisation (EtOAc/hexane) to yield the product (R)-37 as white crystals (4.34 g, 
77%).  Characterisation data was identical to that of (S)-37 except []D
25
 +88.0 (c 1.00, 
CHCl3), lit
202
 []D
25
 +66.5 (c 7.29, CHCl3). 
 
8.13 tert-Butyl (S)-2-((tosyloxy)methyl)pyrrolidine-1-carboxylate ((S)-38)
57
 
 
Tosyl chloride (412 mg, 2.16 mmol) was added portionwise to a solution of (S)-35 (344 
mg, 1.71 mmol) in CH2Cl2 (3.5 mL) and anhydrous pyridine (0.80 mL) at 0 
o
C.  The 
solution was stirred at rt for 17 h after which time a precipitate formed.  The solution 
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was diluted with CH2Cl2 (5 mL), washed with water, 0.5 M HCl, and brine, dried 
(Na2SO4) and solvent removed in vacuo to give a yellow oil, which was purified by 
column chromatography (hexane/EtOAc, 4:1) to yield the tosylate (S)-38 as a colourless 
oil (478 mg, 79%).  Rf 0.38 (hexane/EtOAc, 3:1);  δH (500 MHz; CDCl3) broadening of 
signals due to amide rotamers, 7.77 (2H, d, J = 8.0 Hz, 2 x Ar-H), 7.33 (2H, d, J = 8.0 
Hz, 2 x Ar-H), 4.18-3.78 (3H, m, 2-CH, CH2O), 3.40-3.18 (2H, m, 5-CH2), 2.48 (3H, s, 
Ar-CH3), 2.01-1.69 (4H, m, 3-CH2, 4-CH2), 1.37 (9H, s, C(CH3)3);  m/z (ESI) 378 ([M + 
Na]
+
, 100%);  HRMS C17H25O5NSNa, calcd 378.1351, found 378.1361.  
 
8.14 tert-Butyl (S)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate ((S)-
39)
65
 
 
Triethylamine (3.20 mL, 23.0 mmol) followed by methanesulfonyl chloride (1.30 mL, 
16.8 mmol) were added dropwise to a solution of the alcohol (S)-35 (3.00 g, 14.9 mmol) 
in CH2Cl2 (35 mL) at 0 
o
C and stirred at 0 
o
C for 1 h and rt for 1 h, after which time a 
precipitate had formed.  The reaction mixture was diluted with CH2Cl2 (40 mL), washed 
with sat. NaHCO3 (2 x 40 mL) and brine (2 x 40 mL), dried (Na2SO4) and solvent 
removed in vacuo to yield the mesylate (S)-39 as a yellow oil (4.17 g, 100% crude) as a 
mixture of amide rotamers, which was used without further purification.  Rf 0.40 
(EtOAc/hexane, 2:3);  []D
25
 -51.9 (c 1.00, CHCl3);  δH (500 MHz; CDCl3) broadening 
of signals due to amide rotamers, 4.37-3.91 (3H, m, 2-CH, CH2O), 3.47-3.25 (2H, m, 5-
CH2), 3.00 (3H, s, SCH3), 2.10-1.76 (4H, m, 3-CH2, 4-CH2), 1.45 (9H, s, C(CH3)3);  δC 
(125 MHz; CDCl3) 154.7 and 154.2 (CO2
t
Bu), 80.3 and 79.9 (C(CH3)3), 69.8 and 69.5 
(CH2O), 55.8 (2-CH), 47.1 and 46.7 (5-CH2), 37.5 and 37.0 (SCH3), 28.7 and 27.9 (3-
CH2), 28.5 (C(CH3)3), 23.8 and 23.0 (4-CH2);  m/z (CI) 280 ([M + H]
+
, 85%), 224 ([M 
+ H]
+ 
- C4H8, 100%), 180 ([M + H]
+
 - C5H8O2, 80%);  HRMS C11H22O5NS, calcd 
280.1219, found 280.1212. 
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8.15 tert-Butyl (R)-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate ((R)-
39)
65
  
 
The title compound was prepared according to the procedure described in section 8.14, 
from (R)-35 (3.23 g, 16.0 mmol).  The crude product (R)-39 was isolated as a yellow oil 
(4.68 g, 100% crude) and used without further purification.  NMR and MS data was 
identical to that of (S)-39.
 
 
8.16 tert-Butyl (S)-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)methyl) pyrrolidine-1-carboxylate ((S)-41)
203
   
 
To a solution of 4-hydroxyphenylboronic acid pinacol ester (411 mg, 1.87 mmol) in 
DMF (2.5 mL) with molecular sieves, was added 
t
BuOK (300 mg, 2.67 mmol) 
portionwise at rt, and stirred for 40 min.  A solution of mesylate (S)-39 (347 mg, 1.24 
mmol) in DMF (2.5 mL) was added dropwise and heated at 75 
o
C for 6 h.  The resulting 
dark brown mixture was diluted with EtOAc (75 mL) and water (25 mL).  The aqueous 
phase was extracted with EtOAc (2 x 20 mL).  The combined organic extracts were 
washed with water (4 x 20 mL), 1 M NaOH (3 x 15 mL), brine (15 mL), passed through 
a hydrophobic frit, and solvent removed in vacuo to give an orange oil, which was 
purified by column chromatography (petrol/EtOAc, 9:1) to yield the boronic ester (S)-
41 as a yellow oil (231 mg, 46%).  Rf 0.40 (hexane/EtOAc, 4:1);  []D
25
 -35.1 (c 0.70, 
CHCl3);  δH (500 MHz; CDCl3) broadening/splitting of signals due to amide rotamers, 
7.73 (2H, d, J = 8.0 Hz, 2 x 7-Ar-H), 6.91 (2H, d, J = 8.0 Hz, 2 x 6-Ar-H), 4.23-3.73 
(3H, m, 2-CH, CH2O), 3.50-3.26 (2H, m, 5-CH2), 2.11-1.80 (4H, m, 3-CH2, 4-CH2), 
1.47 (9H, s, C(CH3)3), 1.33 (12H, s, 2 x C(CH3)2);  δC (125 MHz; CDCl3) 161.4 (Ar-
CO), 154.6 (CO2
t
Bu), 136.6 (2 x 7-Ar-CH), 120.7 (Ar-C), 114.0 (2 x 6-Ar-CH), 83.6 (2 
x C(CH3)2), 79.8 and 79.4 (C(CH3)3), 68.0 (CH2O), 56.2 and 55.8 (2-CH), 47.0 and 46.6 
(5-CH2),  28.6 (C(CH3)3), 28.1 (3-CH2), 24.9 (2 x C(CH3)2), 24.0 and 22.9 (4-CH2);  m/z 
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(EI) 403 (M
+
, 5%), 114 (M
+
 - C4H8 – C13H18O3B, 100%);  HRMS C22H34O5NB, calcd 
403.2525, found 403.2528. 
 
8.17 tert-Butyl (R)-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)methyl) pyrrolidine-1-carboxylate ((R)-41)
203 
 
 
The title compound was prepared according to the procedure described in section 8.16, 
from mesylate (R)-39 (809 mg, 2.90 mmol).  The crude product was purified by column 
chromatography (hexane/EtOAc, 9:1) to yield the product (R)-41 as a pale yellow oil 
(644 mg, 55%).  NMR and MS data was identical to that of (S)-41. 
 
8.18 tert-Butyl (S)-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)methyl) indoline-1-carboxylate ((S)-46)  
 
The title compound was prepared according to the procedure described in section 8.16, 
from mesylate (S)-50 (798 mg, 2.44 mmol). The crude product was purified by column 
chromatography (hexane/EtOAc, 95:5) to yield the product (S)-46 as a pale yellow solid 
(499 mg, 45%).  Rf 0.25 (hexane/EtOAc, 9:1); m.p. 122-124 
o
C;  υmax/cm
-1
 (CDCl3 cast) 
2977, 2932, 1701, 1604, 1571, 1484, 1391, 1361;  δH (500 MHz; CDCl3) 8.10-7.34 (1H, 
br m, 7-Ar-H), 7.74 (2H, d, J = 8.0 Hz, 2 x 9-Ar-H), 7.23-7.12 (2H, m, 4-Ar-H, 6-Ar-
H), 6.97 (1H, t, J = 7.5 Hz, 5-Ar-H), 6.90 (2H, d, J = 8.0 Hz, 2 x 8-Ar-H), 4.91-4.70 
(1H, m, 2-CH), 4.28 (1H, dd, J = 9.0 and 3.5 Hz, CHHO), 3.98-3.81 (1H, m, CHHO), 
3.34 (1H, dd, J = 16.5 and 10.0 Hz, 3-CHH), 3.12 (1H, dd, J = 16.5 and 1.5 Hz, 3-
CHH), 1.59 (9H, s, C(CH3)3), 1.34 (12H, s, 2 x C(CH3)2);  δC (125 MHz; CDCl3) 161.3 
(Ar-C), 152.3 (CO2
t
Bu), 142.2 (Ar-C), 136.6 (2 x 9-Ar-CH), 130.0 (Ar-C), 127.5 (4-Ar-
150 
 
CH), 125.1 (6-Ar-CH), 122.8 (5-Ar-CH), 121.2 (Ar-C), 115.5 (7-Ar-CH), 114.1 (2 x 8-
Ar-CH), 83.6 (2 x C(CH3)2), 81.5 (C(CH3)3), 67.7 (CH2O), 57.8 (2-CH), 31.4 (3-CH2), 
28.6 (C(CH3)3), 24.9 (2 x C(CH3)2);  m/z (ESI) 474 ([M + Na]
+
, 80%), 352 (M
+
 - 
C5H8O2, 100%);  HRMS C26H34BNO5Na, calcd 474.2428, found 474.2420. 
 
8.19 tert-Butyl (R)-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)methyl) indoline-1-carboxylate ((R)-46)  
 
The title compound was prepared according to the procedure described in section 8.16, 
from mesylate (R)-50 (814 mg, 2.49 mmol). The crude product was purified by column 
chromatography (hexane/EtOAc, 95:5) to yield the product (R)-46 as a white solid (587 
mg, 52%).  Characterisation data was identical to that of (S)-46. 
 
8.20 (S)-1-(tert-Butoxycarbonyl)indoline-2-carboxylic acid ((S)-48)
68
  
 
The title compound was prepared according to the procedure described in section 8.11, 
from (S)-indoline-2-carboxylic acid (2.00 g, 12.3 mmol). The crude product was 
recrystallised (EtOAc/hexane) to yield compound (S)-48 as a pale brown solid (2.90 g, 
90%) as a mixture of amide rotamers (7:4 in CDCl3).  M.p. 124-126 
o
C (lit
68
 124-125 
o
C, EtOAc/hexane);  δH (500 MHz; CDCl3) 10.60 (1H, br s, OH), 8.00-7.37 (1H, m, 7-
Ar-H), 7.24-7.06 (2H, m, 4-Ar-H, 6-Ar-H), 7.00-6.91 (1H, m, 5-Ar-H), 5.07-4.78 (1H, 
m, 2-CH), 3.63-3.09 (2H, m, 3-CH2), 1.68-1.50 (9H, m, C(CH3)3); δC (150 MHz; 
CDCl3) 178.4 and 177.0 (CO2H), 151.6 and 153.4 (CO2
t
Bu), 142.5 and 141.3 (Ar-C), 
128.2 and 128.0 (Ar-CH), 128.9 and 127.7 (Ar-C), 125.0 and 124.5 (Ar-CH), 122.9 (Ar-
CH), 114.9 and 114.7 (Ar-CH), 83.2 and 81.8 (C(CH3)3), 60.1 (2-CH), 32.7 and 31.6 (3-
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CH2), 28.5 and 28.3 (C(CH3)3);  m/z (ESI) 262 ([M - H]
-
, 100%);  HRMS C14H16NO4, 
calcd 262.1079, found 262.1092. 
 
8.21 (R)-1-(tert-Butoxycarbonyl)indoline-2-carboxylic acid ((R)-48)
69
  
 
The title compound was prepared according to the procedure described in section 8.11, 
from (R)-indoline-2-carboxylic acid (1.94 g, 11.9 mmol). The crude product was 
recrystallised (EtOAc/hexane) to yield compound (R)-48 as a pale brown solid (1.81 g, 
58%).  Characterisation data was identical to that of (S)-48. 
 
8.22 tert-Butyl (S)-2-(hydroxymethyl)indoline-1-carboxylate ((S)-49)
70
  
 
The title compound was prepared according to the procedure described in section 8.9, 
from (S)-48 (1.80 g, 6.84 mmol). The crude product was purified by column 
chromatography (hexane/EtOAc, 4:1) to yield the product (S)-49 as a yellow oil (1.24 g, 
73%).  Rf 0.43 (hexane/EtOAc, 2:1);  δH (500 MHz; CDCl3) 7.55 (1H, br s, 7-Ar-H), 
7.19-7.11 (2H, m, 4-Ar-H, 6-Ar-H), 6.95 (1H, t, J = 7.0 Hz, 5-Ar-H), 4.69-4.51 (1H, m, 
2-CH), 3.76 (1H, dd, J = 11.0 and 6.5 Hz, CHHO), 3.69 (1H, dd, J = 11.0 and 4.5 Hz, 
CHHO), 3.33 (1H, dd, J = 16.0 Hz and 10.5 Hz, 3-CHH), 2.95-2.60 (2H, m, 3-CHH, 
OH), 1.59 (9H, s, C(CH3)3);  δC (150 MHz; CDCl3) 154.6 (CO2
t
Bu), 141.8 (Ar-C), 130.0 
(Ar-C), 127.5 (Ar-CH), 125.0 (Ar-CH), 122.9 (Ar-CH), 115.7 (Ar-CH), 82.5 (C(CH3)3), 
66.9 (CH2O), 61.2 (2-CH), 31.2 (3-CH2), 28.5 (C(CH3)3);  m/z (EI) 249 (M
+
, 10%), 118 
(M
+
 - C6H11O3, 100%);  HRMS C14H19O3N, calcd 249.1360, found 249.1362.  
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8.23 tert-Butyl (R)-2-(hydroxymethyl)indoline-1-carboxylate ((R)-49)
71
   
 
The title compound was prepared according to the procedure described in section 8.9, 
from (R)-48 (1.70 g, 6.46 mmol). The crude product was purified by column 
chromatography (hexane/EtOAc, 4:1) to yield the alcohol (R)-49 as a yellow oil (0.987 
g, 61%).  Characterisation data was identical to that of (S)-49. 
 
8.24 tert-Butyl (S)-2-(((methylsulfonyl)oxy)methyl)indoline-1-carboxylate ((S)-50) 
 
The title compound was prepared according to the procedure described in section 8.14, 
from (S)-49 (1.12 g, 4.49 mmol). The crude product (S)-50 was isolated as a brown 
solid (1.33 g, 90% crude), and used without further purification.  M.p. 50-55 
o
C;  
υmax/cm
-1
 (CDCl3 cast) 2976, 2938, 1698, 1603, 1484;  δH (500 MHz; CDCl3) 7.98-7.36 
(1H, br m, 7-Ar-H), 7.20-7.14 (2H, m, 4-Ar-H, 6-Ar-H),  6.96 (1H, t, J = 7.5 Hz, 5-Ar-
H), 4.73-4.66 (1H, m, 2-CH), 4.38 (1H, dd, J = 10.0 and 3.5 Hz, CHHO), 4.35-4.30 
(1H, m, CHHO), 3.37 (1H, dd, J = 16.5 and 10.0 Hz, 3-CHH), 3.03 (1H, dd, J = 16.5 
and 2.5 Hz, 3-CHH), 2.89 (3H, s, SO2CH3), 1.58 (9H, s, C(CH3)3);  δC (150 MHz; 
CDCl3) 152.1 (CO2
t
Bu), 142.1 (Ar-C), 129.6 (Ar-C), 127.8 (4-Ar-CH), 125.1 (6-Ar-
CH), 123.1 (5-Ar-CH), 115.3 (7-Ar-CH), 81.9 (C(CH3)3), 69.3 (CH2O), 57.6 (2-CH), 
37.5 (SO2CH3), 31.2 (3-CH2), 28.5 (C(CH3)3);  m/z (EI) 327 (M
+
, 20%), 272 (M
+
 - 
C4H7, 60%), 228 (M
+
 - C5H7O2, 85%), 176 (M
+
 - C5H11O3S, 100%);  HRMS 
C15H21O5NS, calcd 327.1135, found 327.1134. 
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8.25 tert-Butyl (R)-2-(((methylsulfonyl)oxy)methyl)indoline-1-carboxylate ((R)-50)   
 
The title compound was prepared according to the procedure described in section 8.14, 
from (R)-49 (891 mg, 3.57 mmol). The crude product was isolated as a brown solid 
(1.02 g, 87% crude) and used without further purification.  Characterisation data was 
identical to that of (S)-50.   
 
8.26 2-(3-Iodo-4-methylphenyl)acetic acid (51)
204
   
 
The title compound was prepared based on a literature procedure.
72
  Sodium periodate 
(281 mg, 1.31 mmol) and powdered iodine (224 mg, 0.883 mmol) were added to a 
stirred solution of glacial acetic acid (2 mL) and acetic anhydride (1 mL) at 5 
o
C under 
argon.  Concentrated H2SO4 (0.90 mL, 17.7 mmol) was added slowly dropwise to the 
vigorously stirred reaction mixture at 5 
o
C.  p-Tolylacetic acid 53 (408 mg, 2.72 mmol) 
was added portionwise to the reaction mixture at 5 
o
C and stirred for 1 h at rt, then 
heated at 40 
o
C for 3 h, during which time the dark brown solution turned yellow.  The 
reaction mixture was slowly poured into an ice cold solution of Na2SO3 (2.21 g, 17.6 
mmol) in water (30 mL) and stirred for 15 min.  The solid was collected by filtration, 
yielding the crude product 51 as a pale yellow solid (516 mg, 69% crude).  A portion of 
the crude product was purified by recrystallisation (hexane) to give 51 as a white solid.  
δH (600 MHz; CDCl3) 11.0 (1H, br s, OH), 7.73 (1H, s, 2-Ar-H), 7.20-7.15 (2H, m, 5-
Ar-H, 6-Ar-H), 3.57 (2H, s, CH2CO2H), 2.40 (3H, s, CH3);  δC (150 MHz; CDCl3) 176.9 
(CO2H), 140.7 (4-Ar-C), 139.7 (2-Ar-CH), 132.5 (1-Ar-C), 129.9 (Ar-CH), 129.4 (Ar-
CH), 101.3 (3-Ar-C), 39.8 (CH2CO2H), 27.8 (CH3);  m/z (EI) 276 (M
+
, 100%), 231 (M
+
 
- CO2H, 100%);  HRMS C9H9O2I, calcd 275.9642, found 275.9646. 
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8.27 Methyl 2-(3-iodo-4-methylphenyl)acetate (54) 
 
The title compound was prepared according to the procedure described in section 8.26 
from methyl ester 55 (4.55 g, 27.7 mmol).  The crude yellow-brown oil was purified by 
column chromatography (petrol/EtOAc, 95:5) to yield the product 54 as a pale yellow 
oil (6.07 g, 76%).  Rf 0.27 (petrol/EtOAc, 95:5);  υmax/cm
-1
 (CDCl3 cast) 2950, 1737, 
1601, 1557, 1484;  δH (500 MHz; CDCl3) 7.73 (1H, s, 2-Ar-H), 7.20-7.14 (2H, m, 5-Ar-
H, 6-Ar-H), 3.69 (3H, s, OCH3), 3.54 (2H, s, CH2CO2CH3), 2.40 (3H, s, Ar-CH3);  δC 
(125 MHz; CDCl3) 171.7 (CO2CH3), 140.3 (4-Ar-C), 139.6 (2-Ar-CH), 133.2 (1-Ar-C), 
129.8, (Ar-CH), 129.2 (Ar-CH), 101.2 (3-Ar-C), 52.2 (OCH3), 40.0 (CH2CO2CH3), 27.7 
(Ar-CH3);  m/z (EI) 290 (M
+
, 80%), 231 (M
+
 - CO2CH3, 100%);  HRMS C10H11O2I 
calcd 289.9798, found 289.9799.   
 
8.28 Methyl 2-(p-tolyl)acetate (55)
205
 
 
To a solution of p-tolylacetic acid (5.01 g, 33.4 mmol) in methanol (65 mL) was added 
concentrated H2SO4 (0.40 mL, 7.50 mmol) and heated at reflux for 6 h.  The solution 
was concentrated in vacuo, and the residue dissolved in EtOAc (180 mL) and washed 
with NaHCO3, brine, dried (MgSO4) and solvent removed in vacuo to yield the product 
55 as a pale yellow oil (5.21 g, 95%).  δH (500 MHz; CDCl3) 7.17 (2H, d, J = 8.0 Hz, 2 
x 2-Ar-H), 7.13 (2H, d, J = 8.0 Hz, 2 x 3-Ar-H), 3.68 (3H, s, OCH3), 3.59 (2H, s, 
CH2CO2CH3), 2.33 (3H, s, Ar-CH3);  δC (125 MHz; CDCl3) 172.3 (CO2CH3), 136.8 
(Ar-C), 131.0 (Ar-C), 129.4 (2 x 2-Ar-CH), 129.2 (2 x 3-Ar-CH), 52.1 (OCH3), 40.9 
(CH2CO2CH3), 21.2 (Ar-CH3);  m/z (EI) 164 (M
+
, 30%), 105 (M
+
 - CO2CH3, 100%);  
HRMS C10H12O2, calcd 164.0832, found 164.0827.  
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8.29 Methyl 2-(o-tolyl)acetate (56)
206
   
 
The title compound was prepared according to the procedure described in section 8.28, 
from o-tolylacetic acid (5.04 g, 33.6 mmol), to yield the product 56 as a pale yellow oil 
(5.27 g, 96%).  δH (500 MHz; CDCl3) 7.23-7.14 (4H, m, 4 x Ar-H), 3.69 (3H, s, OCH3), 
3.65 (2H, s, CH2CO2CH3), 2.32 (3H, s, Ar-CH3);  δC (125 MHz; CDCl3) 172.0 
(CO2CH3), 136.9 (Ar-C), 132.8 (Ar-C), 130.4 (Ar-CH), 130.2 (Ar-CH), 127.5 (Ar-CH), 
126.2 (Ar-CH), 52.1 (OCH3), 39.1 (CH2CO2CH3), 19.7 (Ar-CH3);  m/z (EI) 164 (M
+
, 
100%), 105 (M
+
 - CO2CH3, 60%);  HRMS C10H12O2, calcd 164.0832, found 164.0828. 
 
8.30 Methyl 2-(5-iodo-2-methylphenyl)acetate (57)
207
 and methyl 2-(3-iodo-2-
methylphenyl)acetate (58)
208
   
 
The mixture of aryl iodide regioisomers were synthesised following the procedure 
described in section 8.26, from methyl ester 56 (501 mg, 3.05 mmol).  The crude brown 
oil was purified by column chromatography (hexane/EtOAc, 9:1) yielding a mixture of 
inseparable regioisomers 57 and 58 as a colourless oil (482 mg, 54%, ratio 57/58 = 3:1).  
Rf 0.69 (hexane/EtOAc, 4:1);  δH (500 MHz; CDCl3) major regioisomer 57: 7.52 (1H, d, 
J = 1.5 Hz, Ar-H), 7.49 (1H, dd, J = 8.0 and 1.5 Hz, Ar-H), 6.91 (1H, d, J = 8.0 Hz, Ar-
H), 3.69 (3H, s, OCH3), 3.57 (2H, s, CH2CO2CH3), 2.25 (3H, s, Ar-CH3), minor 
regioisomer 58: 7.77 (1H, d, J = 7.5 Hz, Ar-H), 7.15 (1H, d, J = 7.5 Hz, Ar-H), 6.84 
(1H, t, J = 7.5 Hz, Ar-H), 3.71 (2H, s, CH2CO2CH3), 3.69 (3H, s, OCH3), 2.44 (3H, s, 
Ar-CH3). 
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8.31 tert-Butyl (S)-2-(((5’-(2-methoxy-2-oxoethyl)-2’-methyl-[1,1’-biphenyl]-4-
yl)oxy)methyl)pyrrolidine-1-carboxylate ((S)-62)   
 
To a solution of boronic ester (S)-41 (260 mg, 0.645 mmol) in DMF (11 mL) was added 
aryl iodide 54 (250 mg, 0862 mmol) and K3PO4 (414 mg, 1.95 mmol).  Argon was 
bubbled through the solution for 10 min.  Tetrakis(triphenylphosphine)palladium(0) 
(96.5 mg, 0.0835 mmol) was added to the reaction mixture and heated at 85 
o
C for 24 h.  
The reaction mixture was diluted with EtOAc (100 mL) and washed with water (6 x 50 
mL) and brine (50 mL), dried (phase separator) and solvent removed in vacuo to give a 
crude orange-brown oil, which was purified by column chromatography 
(hexane/EtOAc, 9:1) to afford the biaryl product (S)-62 as a yellow oil (211 mg, 74%).  
Rf 0.31 (hexane/EtOAc, 4:1);  υmax/cm
-1
 (CDCl3 cast) 2973, 1740, 1691, 1609, 1516; δH 
(600 MHz; CDCl3) broadening/splitting of signals due to amide rotamers, 7.25-7.19 
(3H, m, 2 x 7-Ar-H, 9-Ar-H), 7.15 (1H, d, J = 8.0 Hz, 10-Ar-H), 7.12 (1H, s, 8-Ar-H), 
6.97 (2H, d, J = 7.0 Hz, 2 x 6-Ar-H), 4.25-3.76 (3H, m, 2-CH, CH2O), 3.69 (3H, s, 
OCH3), 3.62 (2H, s, CH2CO2CH3), 3.48-3.29 (2H, m, 5-CH2), 2.25 (3H, s, Ar-CH3), 
2.12-1.82 (4H, m, 3-CH2, 4-CH2), 1.49 (9H, s, C(CH3)3);  δC (150 MHz; CDCl3) 172.3 
(CO2CH3), 158.0 and 157.9 (Ar-C), 154.8 and 154.7 (CO2
t
Bu), 141.9 and 141.8 (Ar-C), 
134.5 (Ar-C), 134.3 and 134.1 (Ar-C), 131.4 (Ar-C), 130.9 (8-Ar-CH), 130.7 (9-Ar-
CH), 130.4 (2 x 7-Ar-CH), 127.9 (10-Ar-CH), 114.2 (2 x 6-Ar-CH), 79.9 and 79.5 
(C(CH3)3), 68.4 and 68.1 (CH2O), 56.1 and 56.0 (2-CH), 52.2 (OCH3), 47.1 and 46.7 (5-
CH2), 40.9 (CH2CO2CH3), 28.9 and 28.1 (3-CH2), 28.7 (C(CH3)3), 24.0 and 22.9 (4-
CH2), 20.3 (Ar-CH3);  m/z (EI) 439 (M
+
, 15%), 114 (M
+
 - C4H8 - C17H17O3, 100%);  
HRMS C26H33O5N, calcd 439.2353, found 439.2350. 
 
 
 
 
157 
 
8.32 tert-Butyl (R)-2-(((5’-(2-methoxy-2-oxoethyl)-2’-methyl-[1,1’-biphenyl]-4-
yl)oxy)methyl)pyrrolidine-1-carboxylate ((R)-62)  
 
The title compound was prepared according to the procedure described in section 8.31, 
from the boronic ester (R)-41 (60.0 mg, 0.149 mmol).  The crude brown oil was purified 
by column chromatography (hexane/EtOAc, 9:1) to yield the biaryl product (R)-62 as a 
pale yellow oil (53.5 mg, 82%).  Characterisation data was identical to that of (S)-62. 
 
 
8.33 tert-Butyl (S)-2-(((5’-(2-methoxy-2-oxoethyl)-2’-methyl-[1,1’-biphenyl]-4-
yl)oxy)methyl)indoline-1-carboxylate ((S)-63) 
 
The title compound was prepared according to the procedure described in section 8.31, 
from the boronic ester (S)-46 (0.288 g, 0.638 mmol).  The crude brown oil was purified 
by column chromatography (hexane/EtOAc, 9:1) to yield the biaryl product (S)-63 as a 
yellow oil (0.248 g, 80%).  Rf 0.18 (hexane/EtOAc, 9:1);  υmax/cm
-1
 (CDCl3 cast) 2975, 
2951, 1738, 1692, 1607, 1576, 1515;  δH (500 MHz; CDCl3) δH (500 MHz; CDCl3) 
broadening/splitting of signals due to amide rotamers,  8.05-7.32 (1H, br m, 7-Ar-H), 
7.25-7.14 (6H, m, 4-Ar-H, 6-Ar-H, 2 x 9-Ar-H, 11-Ar-H, 12-Ar-H), 7.12 (1H, d, J = 1.5 
Hz, 10-Ar-H), 6.98 (1H, t, J = 7.5 Hz, 5-Ar-H), 6.95 (2H, d, J = 8.5 Hz, 2 x 8-Ar-H), 
4.94-4.77 (1H, m, 2-CH), 4.37-4.23 (1H, m, CHHO), 4.01-3.87 (1H, m, CHHO), 3.70 
(3H, s, OCH3), 3.62 (2H, s, CH2CO2CH3), 3.37 (1H, dd, J = 16.5 and 9.5 Hz, 3-CHH), 
3.16 (1H, dd, J = 16.5 and 1.5 Hz, 3-CHH), 2.25 (3H, s, Ar-CH3), 1.60 (9H, s, 
C(CH3)3);  δC (125 MHz; CDCl3) major rotamer, some Ar-C signals obscured by Ar-CH 
signals, 172.2 (CO2CH3), 157.8 (Ar-C), 152.4 (CO2
t
Bu), 142.3 (Ar-C), 141.7 (Ar-C), 
134.5 (Ar-C), 134.4 (Ar-C), 131.4 (Ar-C), 130.8 (10-Ar-CH), 130.7 (11-Ar-CH), 130.3 
(2 x 9-Ar-CH), 127.9 (12-Ar-CH), 127.5 (4-Ar-CH), 125.1 (6-Ar-CH), 122.8 (5-Ar-
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CH), 115.5 (7-Ar-CH), 114.3 (2 x 8-Ar-CH), 81.4 (C(CH3)3), 68.0 (CH2O), 57.9 (2-
CH), 52.1 (OCH3), 40.8 (CH2CO2CH3), 31.4 (3-CH2), 28.6 (C(CH3)3), 20.2 (Ar-CH3);  
m/z (ESI) 510 ([M + Na]
+
, 25%), 388 (M
+
 - C5H7O2, 100%);  HRMS C30H33NO5Na, 
calcd 510.2256, found 510.2260. 
 
8.34 tert-Butyl (R)-2-(((5’-(2-methoxy-2-oxoethyl)-2’-methyl-[1,1’-biphenyl]-4-
yl)oxy)methyl)indoline-1-carboxylate ((R)-63) 
 
The title compound was prepared according to the procedure described in section 8.31, 
from the boronic ester (R)-46 (480 mg, 1.06 mmol).  The crude brown oil was purified 
by column chromatography (hexane/EtOAc, 9:1) to yield the biaryl product (R)-63 as a 
yellow-brown oil (360 mg, 70%).  Characterisation data was identical to that of (S)-63. 
 
8.35 Methyl (S)-2-(6-methyl-4’-(pyrrolidin-2-ylmethoxy)-[1,1’-biphenyl]-3-
yl)acetate ((S)-64) 
 
Trifluoroacetic acid (1 mL) was added dropwise to a solution of (S)-62 (158 mg, 0.358 
mmol) in CH2Cl2 (1 mL) at 0 
o
C, and stirred for 1 h at rt.  The solution was concentrated 
in vacuo to give the crude product as the TFA salt (165 mg, 100% crude) as an orange 
oil, which was used without further purification. υmax/cm
-1
 (CDCl3 cast) 2956, 2775, 
1778, 1734, 1670, 1610, 1516, 1496;  δH (500 MHz; CDCl3) 9.69 (1H, br s, NH), 8.30 
(1H, br s, NH), 7.25-7.18 (3H, m, 2 x 7-Ar-H, 9-Ar-H), 7.15 (1H, dd, J = 8.0 and 1.5 
Hz, 10-Ar-H), 7.08 (1H, d, J = 1.5 Hz, 8-Ar-H), 6.90 (2H, d, J = 8.0 Hz, 2 x 6-Ar-H), 
4.27 (1H, dd, J = 10.0 and 3.0 Hz, CHHO), 4.17 (1H, dd, J = 10.0 and 5.5 Hz, CHHO), 
4.13-4.04 (1H, m, 2-CH), 3.69 (3H, s, OCH3), 3.61 (2H, s, CH2CO2CH3), 3.45-3.35 
(2H, m, 5-CH2), 2.21 (3H, s, Ar-CH3), 2.30-1.99 (4H, m, 3-CH2, 4-CH2);  δC (125 MHz; 
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CDCl3) 172.5 (CO2CH3), 156.5 (Ar-C), 141.4 (Ar-C), 135.6 (Ar-C), 134.4 (Ar-C), 
131.4 (Ar-C), 130.7 and 130.5 (2 x 7-Ar-CH, 8-Ar-CH, 9-Ar-CH), 128.0 (10-Ar-CH), 
114.2 (2 x 6-Ar-CH), 66.1 (CH2O), 59.2 (2-CH), 52.2 (OCH3), 46.2 (5-CH2), 40.8 
(CH2CO2CH3), 26.8 (CH2), 24.0 (CH2), 20.1 (Ar-CH3);  m/z (ESI) 340 ([M + H]
+
, 
100%);  HRMS C21H26NO3, calcd 340.1913, found 340.1907. 
 
8.36 Methyl (R)-2-(6-methyl-4’-(pyrrolidin-2-ylmethoxy)-[1,1’-biphenyl]-3-
yl)acetate ((R)-64) 
 
The title compound was prepared according to the procedure described in section 8.35, 
from (R)-62 (153 mg, 0.348 mmol).  The crude product (R)-64 was isolated as a yellow-
brown oil as the TFA salt (164 mg, 100% crude), and used without further purification.  
Characterisation data was identical to that of (S)-64.   
 
8.37 (S)-2-(6-Methyl-4’-(pyrrolidin-2-ylmethoxy)-[1,1’-biphenyl]-3-yl)acetic acid 
((S)-65) 
 
A solution of lithium hydroxide (3.45 mg, 0.144 mmol) in water (0.1 mL) was added to 
a solution of the ester (S)-64 (16.3 mg, 0.0434 mmol, HCl salt) in methanol (0.1 mL) 
and THF (0.1 mL).  The solution was stirred at rt for 19 h, then concentrated in vacuo.  
The resulting residue was dissolved in water (5 mL) and pH adjusted to 7 by addition of 
0.2 M HCl.  The aqueous phase was extracted with EtOAc (2 x 10 mL), CH2Cl2 (2 x 10 
mL) and 20% methanol in CH2Cl2 (2 x 10 mL).  The combined organic extracts were 
passed through a hydrophobic frit and evaporated in vacuo.  None of the desired 
compound was extracted.  The aqueous phase was concentrated in vacuo and the residue 
was dissolved in CH3OH:DMSO (1:1, 1 mL), filtered and purified by MDAP (Gradient 
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B, rt = 9.82 min).  Appropriate fractions were combined and evaporated in vacuo to 
yield (S)-65 as the TFA salt as a colourless oil (16.1 mg, 84%).  []D
25
 +9.9 (c 0.81, 
CHCl3);  υmax/cm
-1
 (CDCl3 cast) 2976, 1672, 1610, 1516;  δH (600 MHz; CDCl3) 10.33 
(1H, br s, NH), 8.83 (1H, br s, NH), 7.18 (1H, d, J = 8.0 Hz, 10-Ar-H), 7.11-7.07 (3H, 
m, 2 x 7-Ar-H, 9-Ar-H), 6.94 (1H, s, 8-Ar-H), 6.79 (2H, d, J = 8.0 Hz, 2 x 6-Ar-H), 
4.14 (1H, dd, J = 10.5 and 4.0 Hz, CHHO), 4.07 (1H, dd, J = 10.5 and 6.0 Hz, CHHO), 
3.99-3.92 (1H, m, 2-CH), 3.50 (2H, s, CH2CO2H), 3.40-3.29 (2H, m, 5-CH2), 2.18 (3H, 
s, Ar-CH3), 2.20-1.91 (4H, m, 3-CH2, 4-CH2);  δC (150 MHz; CDCl3) 176.5 (CO2H), 
156.7 (Ar-C), 141.4 (Ar-C), 135.2 (Ar-C), 134.4 (Ar-C), 131.3 (Ar-C), 130.8 (8-Ar-
CH), 130.7 (9-Ar-CH), 130.5 (2 x 7-Ar-CH), 128.2 (10-Ar-CH), 114.3 (2 x 6-Ar-CH), 
66.3 (CH2O), 58.7 (2-CH), 45.7 (5-CH2), 40.7 (CH2CO2H), 26.9 (3-CH2), 24.1 (4-CH2), 
20.2 (Ar-CH3);  m/z (ESI) 326 ([M + H]
+
, 100%);  HRMS C20H24NO3, calcd 326.1756, 
found 326.1771. 
 
8.38 (R)-2-(6-Methyl-4’-(pyrrolidin-2-ylmethoxy)-[1,1’-biphenyl]-3-yl)acetic acid 
((R)-65) 
 
A solution of lithium hydroxide (5.86 mg, 0.132 mmol) in water (0.2 mL) was added to 
a stirred solution of the ester (R)-62 (36.0 mg, 0.0819 mmol) in methanol (0.2 mL) and 
THF (0.2 mL).  The solution was stirred at rt for 21 h, then concentrated in vacuo to 
give a pale yellow residue, which was dissolved in CH3OH:DMSO (1:1, 1 mL), filtered 
and purified by MDAP (Gradient D, rt = 13.9 min, m/z 426 [M + H]
+
).  Appropriate 
fractions were combined and solvent removed in vacuo to yield a pale yellow oil (22.0 
mg), which was dissolved in 4 M HCl in 1,4-dioxane (1 mL, 4.00 mmol) and stirred at 
rt for 21 h.  The volatiles were removed from the reaction under a stream of N2 to give 
the crude product as a pale yellow oil which was dissolved in CH3OH:DMSO (1:1, 1 
mL), filtered and purified by MDAP (run time 10 min, Gradient B, rt = 9.78 min).  
Appropriate fractions were combined and evaporated in vacuo to yield the product (R)-
65 as the TFA salt as a colourless oil (19.1 mg, 53%).  Characterisation data was 
identical to that of (S)-65 except []D
25
 -6.0 (c 0.96, CHCl3). 
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8.39 Methyl (S)-2-(4’-(indolin-2-ylmethoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetate 
((S)-66) 
 
The title compound was prepared following the same procedure as described in section 
8.35, from (S)-63 (190 mg, 0.391 mmol).  The crude product was isolated as an orange 
oil as the TFA salt (0.198 g, 100% crude) and used without further purification.  
υmax/cm
-1
 (CDCl3 cast) 2954, 2543, 1778, 1735, 1666, 1610, 1516;  δH (500 MHz; 
CDCl3) 7.41-7.35 (3H, m, 4-Ar-H, 6-Ar-H, 7-Ar-H), 7.31-7.26 (1H, m, 5-Ar-H), 7.23 
(2H, d, J = 9.0 Hz, 2 x 9-Ar-H), 7.21 (1H, d, J = 8.0 Hz, 11-Ar-H), 7.15 (1H, d, J = 8.0 
Hz, 12-Ar-H), 7.09 (1H, s, 10-Ar-H), 6.93 (2H, d, J = 9.0 Hz, 2 x 8-Ar-H), 4.80-4.70 
(1H, m, 2-CH), 4.43-4.31 (2H, m, CH2O), 3.69 (3H, s, OCH3), 3.61 (2H, s, 
CH2CO2CH3), 3.51 (1H, dd, J = 16.5 and 9.0 Hz, 3-CHH), 3.30 (1H, dd, J = 16.5 and 
7.5 Hz, 3-CHH), 2.21 (3H, s, Ar-CH3);  δC (125 MHz; CDCl3) 172.5 (CO2H), 156.5 
(Ar-C), 141.4 (Ar-C), 136.4 (Ar-C), 135.6 (Ar-C), 134.4 (Ar-C), 133.6 (Ar-C), 131.4 
(Ar-C), 130.8 (Ar-CH), 130.7 (Ar-CH), 130.5 (2 x 9-Ar-CH), 129.4 (Ar-CH), 128.9 
(Ar-CH), 128.0 (Ar-CH), 126.0 (Ar-CH), 119.0 (Ar-CH), 114.3 (2 x 8-Ar-CH), 66.5 
(CH2O), 59.6 (2-CH), 52.2 (OCH3), 40.8 (CH2CO2CH3), 32.1 (3-CH2), 20.1 (Ar-CH3);  
m/z (ESI) 388 ([M + H]
+
, 100%);  HRMS C25H26NO3, calcd 388.1913, found 388.1921. 
 
8.40 Methyl (R)-2-(4’-(indolin-2-ylmethoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetate 
((R)-66)  
 
The title compound was prepared following the same procedure as described in section 
8.35, from (R)-63 (290 mg, 0.597 mmol).  The crude product was isolated as a yellow 
oil as the TFA salt (0.303 g, 100% crude) and used without further purification.  
Characterisation data was identical to that of (S)-66.   
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8.41 (S)-2-(4’-(Indolin-2-ylmethoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetic acid ((S)-
67) 
 
To a solution of compound (S)-66 (55.0 mg, 0.110 mmol) in THF (0.3 mL) and CH3OH 
(0.3 mL), was added a suspension of LiOH.H2O (20.0 mg, 0.477 mmol) in water (0.3 
mL), and the mixture stirred at rt for 24 h.  The reaction mixture was diluted with water 
(10 mL) and 1 M HCl was added dropwise until the pH ~ 3.  The aqueous phase was 
extracted with EtOAc (3 x 15 mL).  The combined organic extracts were washed with 
brine (15 mL), dried (Na2SO4) and solvent removed in vacuo to give a crude brown oil 
which was purified by column chromatography (EtOAc) to give the product (S)-67 as a 
yellow oil (19.6 mg, 48%).  Rf 0.89 (EtOAc);  []D
25
 +49.0 (c 0.80, CHCl3);  υmax/cm
-1
 
(CDCl3 cast) 3035, 2924, 2858, 1708, 1608, 1515;  δH (500 MHz; CDCl3) 7.25-7.20 
(3H, m, 2 x 9-Ar-H, 11-Ar-H), 7.16 (1H, d, J = 8.0 Hz, 12-Ar-H), 7.14-7.10 (2H, m, 4-
Ar-H, 10-Ar-H), 7.05 (1H, t, J = 7.5 Hz, 6-Ar-H), 6.95 (2H, d, J = 8.5 Hz, 2 x 8-Ar-H), 
6.74 (1H, t, J = 7.5 Hz, 5-Ar-H), 6.67 (1H, d, J = 7.5 Hz, 7-Ar-H), 4.36-4.27 (1H, m, 2-
CH), 4.04-3.98 (2H, m, CH2O), 3.64 (2H, s, CH2CO2H), 3.27 (1H, dd, J = 15.5 and 9.0 
Hz, 3-CHH), 2.85 (1H, dd, J = 15.5 and 6.5 Hz, 3-CHH), 2.25 (3H, s, Ar-CH3);  δC (125 
MHz; CDCl3) 177.5 (CO2H), 157.8 (Ar-C), 150.2 (Ar-C), 141.8 (Ar-C), 134.7 (Ar-C), 
134.4 (Ar-C), 131.0 (10-Ar-CH), 130.8 (Ar-C), 130.7 (11-Ar-CH), 130.4 (2 x 9-Ar-
CH), 128.0 (12-Ar-CH), 127.9 (Ar-C), 127.7 (6-Ar-CH), 125.0 (4-Ar-CH), 119.0 (5-Ar-
CH), 114.2 (2 x 8-Ar-CH), 109.9 (7-Ar-CH), 71.4 (CH2O), 58.1 (2-CH), 40.6 
(CH2CO2H), 32.6 (3-CH2), 20.3 (Ar-CH3);  m/z (ESI) 374 ([M + H]
+
, 100%);  HRMS 
C24H24NO3, calcd 374.1756, found 374.1750. 
 
 
 
 
 
 
163 
 
8.42 (R)-2-(4’-(Indolin-2-ylmethoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetic acid ((R)-
67)   
 
The title compound was prepared following the same procedure as described in section 
8.41, from (R)-66 (56.0 mg, 0.112 mmol).  The crude product was purified by column 
chromatography (EtOAc) to yield the product (R)-67 as a yellow oil (20.6 mg, 49%).  
Characterisation data was identical to that of (S)-67 except []D
25
 -44.6 (c 0.70, CHCl3). 
 
8.43 (S)-2-(4’-((1-Acetylpyrrolidin-2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-
yl)acetic acid ((S)-68) 
 
DMAP (6.00 mg, 0.0491 mmol) followed by anhydrous triethylamine (0.10 mL, 0.717 
mmol) were added to a solution of (S)-64 (60.4 mg, 0.158 mmol) in CH2Cl2 (2 mL).  
The solution was stirred at rt for 45 min, then cooled to 0 
o
C and acetic anhydride (0.05 
mL, 0.529 mmol) was added.  The solution was stirred at rt for 21 h and then diluted 
with CH2Cl2 (10 mL) and brine (10 mL).  The aqueous phase was extracted with 
CH2Cl2 (2 x 10 mL).  The combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4) and solvent removed in vacuo to give a yellow oil which was purified 
by column chromatography (EtOAc) to yield the intermediate methyl (S)-2-(4’-((1-
acetylpyrrolidin-2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetate as a pale yellow 
oil (51.0 mg, 84%), as a mixture of amide rotamers (4:1 in CDCl3).  Rf 0.30 (EtOAc);  
υmax/cm
-1
 (CDCl3 cast) 2952, 2876, 1738, 1641, 1610, 1516;  δH (500 MHz; CDCl3) 
7.25-7.08 (5H, m, 2 x 7-Ar-H, 8-Ar-H, 9-Ar-H, 10-Ar-H), 7.00-6.89 (2H, m, 2 x 6-Ar-
H), 4.50-3.82 (3H, m, 2-CH, CH2O), 3.69 (3H, s, OCH3), 3.61 (2H, s, CH2CO2CH3), 
3.60-3.40 (2H, m, 5-CH2), 2.25-2.20 (3H, m, Ar-CH3), 2.19-1.92 (7H, m, COCH3, 3-
CH2, 4-CH2);  m/z (ESI) 404 ([M + Na]
+
, 85%), 382 ([M + H]
+
, 100%);  HRMS 
164 
 
C23H27NO4Na, calcd 404.1838, found 404.1825.  Methyl (S)-2-(4’-((1-acetylpyrrolidin-
2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetate (31.0 mg, 0.0813 mmol) was 
dissolved in THF (0.2 mL) and CH3OH (0.2 mL), and a suspension of LiOH.H2O (10.0 
mg, 0.238 mmol) in water (0.2 mL) was added.  The reaction mixture was stirred at rt 
for 24 h, then concentrated in vacuo and the resulting residue diluted with water (8 mL) 
and pH adjusted to 3 by addition of 1 M HCl.  The aqueous phase was extracted with 
EtOAc (4 x 10 mL).  The combined organic extracts were washed with brine, dried 
(Na2SO4) and solvent removed in vacuo to yield a crude yellow oil which was dissolved 
in CH3OH/DMSO (1:1, 1 mL), filtered and purified by MDAP (Gradient C, rt = 10.8 
min).  Appropriate fractions were combined and evaporated in vacuo to yield (S)-68 as a 
pale yellow oil (21.9 mg, 73%), as a mixture of amide rotamers (4:1 in CDCl3).  []D
25
 -
56.5 (c 1.10, CHCl3);  υmax/cm
-1
 (CDCl3 cast) 2956, 2878, 1723, 1606, 1516;  δH (400 
MHz; CDCl3) 7.31-7.14 (5H, m, 2 x 7-Ar-H, 8-Ar-H, 9-Ar-H, 10-Ar-H), 7.05-6.91 (2H, 
m, 2 x 6-Ar-H), 4.60-4.28 (1H, m, 2-CH), 4.27-3.88 (2H, m, CH2O), 3.67 (2H, s, 
CH2CO2H), 3.64-3.45 (2H, m, 5-CH2), 2.28 (3H, s, Ar-CH3), 2.26-1.97 (7H, m, 
COCH3, 3-CH2, 4-CH2);  δC (100 MHz; CDCl3) 176.1 (CO2H), 170.3 (COCH3), 157.7 
and 157.3 (Ar-CO), 141.7 and 141.5 (Ar-C), 134.4 (Ar-C), 134.1 (Ar-C), 131.2 (Ar-C), 
130.9 (Ar-CH), 130.6 (Ar-CH), 130.4 and 130.3 (2 x 7-Ar-CH), 128.0 and 127.8 (Ar-
CH), 114.1 and 114.0 (2 x 6-Ar-CH), 68.9 and 67.3 (CH2O), 57.1 and 56.1 (2-CH), 48.3 
and 45.8 (5-CH2), 40.7 (CH2CO2H), 28.9 and 27.7 (CH2), 24.3 and 22.1 (CH2), 22.7 and 
22.2 (COCH3), 20.2 (Ar-CH3);  m/z (ESI) 390 ([M + Na]
+
, 100%), 368 ([M + H]
+
, 
80%);  HRMS C22H25NO4Na, calcd 390.1681, found 390.1688. 
 
8.44 (R)-2-(4’-((1-Acetylpyrrolidin-2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-
yl)acetic acid ((R)-68) 
 
The title compound was prepared according to the procedure described in section 8.43.  
The intermediate methyl (R)-2-(4’-((1-acetylpyrrolidin-2-yl)methoxy)-6-methyl-[1,1’-
biphenyl]-3-yl)acetate was prepared from (R)-64 (113 mg, 0.249 mmol).  The crude oil 
was purified by column chromatography (EtOAc/CH3OH, 99:1) to yield the 
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intermediate compound as a yellow oil (74.3 mg, 78%).  Characterisation data of 
intermediate methyl (R)-2-(4’-((1-acetylpyrrolidin-2-yl)methoxy)-6-methyl-[1,1’-
biphenyl]-3-yl)acetate was identical to the corresponding (S)-enantiomer described in 
section 8.43.  The title compound was prepared from the intermediate (52.0 mg, 0.136 
mmol) and purified according to the procedure described in section 8.43.  The product 
(R)-68 was a pale yellow oil (32.2 mg, 50%).  Characterisation data was identical to that 
of (S)-68 except []D
25
 +56.5 (c 1.60, CHCl3). 
 
8.45 (S)-2-(4’-((1-Acetylindolin-2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetic 
acid ((S)-69) 
 
The title compound was prepared according to the procedure described in section 8.43.  
The intermediate methyl (S)-2-(4’-((1-acetylindolin-2-yl)methoxy)-6-methyl-[1,1’-
biphenyl]-3-yl) acetate was prepared from (S)-66 (0.120 g, 0.239 mmol).  The crude oil 
was purified by column chromatography (hexane/EtOAc, 2:1) to yield the intermediate 
compound as a yellow oil (80.8 mg, 79%), as a mixture of amide rotamers (3:2 in 
CDCl3).  Rf 0.26 (hexane/EtOAc, 2:1);  υmax/cm
-1
 (CDCl3 cast) 2951, 2925, 1736, 1655, 
1608, 1515, 1480;  δH (500 MHz; CDCl3) 8.22-7.17 (6H, m, 4-Ar-H, 6-Ar-H, 7-Ar-H, 2 
x 9-Ar-H, 11-Ar-H), 7.15 (1H, d, J = 8.0 Hz, 12-Ar-H), 7.10 (1H, s, 10-Ar-H), 7.06 
(1H, t, J = 7.5 Hz, 5-Ar-H), 6.97-6.84 (2H, m, 2 x 8-Ar-H), 5.23-4.74 (1H, m, 2-CH), 
4.40-4.00 (1H, m, CHHO), 3.93 (1H, t, J = 7.0 Hz, CHHO), 3.69 (3H, s, OCH3), 3.61 
(2H, s, CH2CO2CH3), 3.53-2.95 (2H, m, 3-CH2), 2.44 (3H, s, COCH3), 2.23 (3H, s, Ar-
CH3);  m/z (ESI) 452 ([M + Na]
+
, 20%), 430 ([M + H]
+
, 50%), 429 (M
+
, 55%), 388 (M
+
 
- C2HO, 100%);  HRMS C27H27NO4Na, calcd 452.1838, found 452.1819.  The title 
compound was prepared from the intermediate (56.9 mg, 0.132 mmol).  The crude 
product was purified by column chromatography (EtOAc) to yield the product (S)-69 as 
a yellow oil (17.6 mg, 32%), as a mixture of amide rotamers (7:4 in CDCl3).  Rf 0.58 
(EtOAc);  []D
25
 -53.0 (c 0.72, CHCl3);  υmax/cm
-1
 (CDCl3 cast) 3020, 2962, 2850, 1715, 
1657, 1611, 1590, 1515;  δH (500 MHz; CDCl3) 10.57 (1H, br s, CO2H), 8.19-7.17 (6H, 
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m, 4-Ar-H, 6-Ar-H, 7-Ar-H, 2 x 9-Ar-H, 11-Ar-H), 7.15 (1H, d, J = 8.0 Hz, 12-Ar-H), 
7.10 (1H, s, 10-Ar-H), 7.06 (1H, t, J = 7.5 Hz, 5-Ar-H), 6.93-6.85 (2H, m, 2 x 8-Ar-H), 
5.26-4.73 (1H, m, 2-CH), 4.37-4.00 (1H, m, CHHO), 3.92 (1H, t, J = 8.0 Hz, CHHO), 
3.63 (2H, s, CH2CO2H), 3.53-2.96 (2H, m, 3-CH2), 2.45 (3H, s, COCH3), 2.23 (3H, s, 
Ar-CH3);  δC (150 MHz; CDCl3) major rotamer, some Ar-C signals obscured by the Ar-
CH signals, 176.6 (CO2H), 169.3 (COCH3), 157.3 (Ar-C), 142.1 (Ar-C), 141.6 (Ar-C), 
134.9 (Ar-C), 134.7 (Ar-C), 131.0 (Ar-CH), 130.8 (Ar-CH), 130.5 (2 x 9-Ar-CH), 128.1 
(Ar-CH), 127.9 (Ar-CH), 125.1 (Ar-CH), 124.4 (Ar-CH), 118.4 (Ar-CH), 114.1 (2 x 8-
Ar-CH), 69.0 (CH2O), 59.6 (2-CH), 40.5 (CH2CO2H), 32.3 (3-CH2), 23.8 (COCH3), 
20.3 (Ar-CH3);  m/z (ESI) 438 ([M + Na]
+
, 40%), 416 ([M + H]
+
, 100%), 374 (M
+
 - 
C2HO, 50%);  HRMS C26H26NO4, calcd 416.1862, found 416.1858. 
 
8.46 (R)-2-(4’-((1-Acetylindolin-2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-yl)acetic 
acid ((R)-69)   
 
The title compound was prepared according to the procedure described in section 8.43.  
The intermediate methyl (R)-2-(4’-((1-acetylindolin-2-yl)methoxy)-6-methyl-[1,1’-
biphenyl]-3-yl) acetate was prepared from (R)-66 (232 mg, 0.463 mmol).  The crude oil 
was purified by column chromatography (hexane/EtOAc, 2:1) to yield the intermediate 
compound as a yellow oil (170 mg, 86%).  Characterisation data of methyl (S)-2-(4’-
((1-acetylindolin-2-yl)methoxy)-6-methyl-[1,1’-biphenyl]-3-yl) acetate was identical to 
that of the corresponding (S)-enantiomer described in section 8.45.  The title compound 
was prepared from the intermediate compound (119 mg, 0.277 mmol).  The crude 
product was purified by column chromatography (EtOAc) to yield the product (R)-69 as 
a yellow oil (30.4 mg, 26%).  Characterisation data was identical to that of (S)-69 except 
[]D
25
 +52.3 (c 1.20, CHCl3). 
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8.47 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid (loxoprofen) (79)
181
 
 
Loxoprofen was prepared based on a procedure reported by Yamakawa et al. for similar 
analogues.
181
  Concentrated HCl (24.0 mL) was added to a solution of diester 222 (440 
mg, 1.32 mmol) in acetic acid (12.0 mL) and the mixture heated at reflux for 5 h.  After 
cooling to rt the reaction mixture was diluted with water (150 mL) and extracted with 
CH2Cl2 (3 x 100 mL).  The organic extracts were combined, washed with brine, dried 
(Na2SO4) and solvent removed in vacuo to give the crude product as a yellow oil which 
was purified by column chromatography (hexane/EtOAc, 4:1) to give the product as a 
pale yellow oil (249 mg, 76%).  Rf   0.19 (hexane/EtOAc, 4:1);  δH (500 MHz; CDCl3) 
7.22 (2H, d, J = 8.0 Hz, 2 x Ar-H), 7.12 (2H, d, J = 8.0 Hz, 2 x Ar-H), 3.70 (1H, q, J = 
7.0 Hz, CHCO2H), 3.12 (1H, dd, J = 14.0 and 4.0 Hz, 1-CHCHH), 2.50 (1H, dd, J = 
14.0 and 9.5 Hz, 1-CHCHH), 2.38-1.50 (7H, m, 1-CH, 3 x CH2), 1.49 (3H, d, J = 7.0 
Hz, CH3);  δC (125 MHz; CDCl3) 220.1 (CO), 180.1 (CO2H), 139.3 (Ar-C), 137.7 (Ar-
C), 129.3 (2 x Ar-CH), 127.7 (2 x Ar-CH), 51.1 (1-CH), 44.9 (CHCO2H), 38.2 (CH2), 
35.3 (1-CHCH2), 29.3 (CH2), 20.6 (CH2), 18.2 (CH3);  m/z (ESI) 269 ([M + Na]
+
, 
100%);  HRMS C15H18O3Na, calcd 269.1154, found 269.1159.  
 
8.48 1-(Benzo[d][1,3]dioxol-4-yl)-5-bromo-1,2,3,4-tetrahydroisoquinolin-8-ol (91)
105
 
 
A solution of 2,3-(methylenedioxy)benzaldehyde (36.4 mg, 0.242 mmol) in acetonitrile 
(3 mL) was added to a solution of amine 157 (60.0 mg, 0.202 mmol) in potassium 
phosphate buffer (3 mL, 0.5 M, pH 6) under argon and stirred at 80 
o
C for 21 h.  The 
reaction mixture was concentrated in vacuo.  CH2Cl2/CH3OH (1:1, 10 mL) was added to 
the resultant residue and the suspension filtered to remove the solid.  The filtrate was 
evaporated to dryness under vacuum to give the crude product as a yellow oil, which 
was purified by prep-HPLC (Method 1, rt = 4.4 min).  Product containing fractions were 
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concentrated and co-evaporated with methanol (x3) to give the product as a pale yellow 
oil (8.7 mg, 12%).  δH (600 MHz; CD3OD) 7.48 (1H, d, J = 8.5 Hz, 6-Ar-H), 6.89 (1H, 
d, J = 8.0 Hz, 4’-Ar-H), 6.82 (1H, t, J = 8.0 Hz, 5’-Ar-H), 6.68 (1H, d, J = 8.5 Hz, 7-Ar-
H), 6.43 (1H, d, J = 8.0 Hz, 6’-Ar-H), 6.08 (1H, d, J = 1.0 Hz, OCHHO), 6.03 (1H, d, J 
= 1.0 Hz, OCHHO), 5.90 (1H, s, 1-CH), 3.51-3.28 (2H, m, 3-CH2), 3.21-3.01 (2H, m, 4-
CH2);  δC (150 MHz; CD3OD) 155.2 (Ar-CO), 149.4 (Ar-CO), 147.6 (Ar-CO), 134.2 (6-
Ar-CH), 133.7 (Ar-C), 123.4 (6’-Ar-CH), 123.0 (5’-Ar-CH), 120.3 (Ar-C), 118.0 (Ar-
C), 115.9 (7-Ar-CH), 114.2 (Ar-C), 110.7 (4’-Ar-CH), 103.1 (OCH2O), 50.4 (1-CH), 
38.0 (3-CH2), 27.5 (4-CH2);  m/z (ESI) 350 ([(
81
Br)M + H]
+
, 95%), 348 ([(
79
Br)M + 
H]
+
, 100%);  HRMS C16H15NO3
79
Br, calcd 348.0235, found 348.0235. 
 
8.49 1-(Benzo[d][1,3]dioxol-5-ylmethyl)-5-bromo-1,2,3,4-tetrahydroisoquinolin-8-ol 
(92)
105
 
 
A solution of aldehyde 140f (106 mg, 0.646 mmol) in acetonitrile (8 mL) was added to 
a solution of amine 157 (160 mg, 0.538 mmol) in potassium phosphate buffer (8 mL, 
0.5 M, pH 6) under argon and stirred at 50 
o
C for 21 h.  The reaction mixture was 
concentrated in vacuo.  CH2Cl2/CH3OH (1:1, 10 mL) was added to the resultant residue 
and the suspension filtered to remove the solid.  The filtrate was evaporated to dryness 
under vacuum to give the crude product as a brown oil, which was purified by prep-
HPLC (Method 1, rt = 7.5 min).  Product containing fractions were concentrated and co-
evaporated with methanol (x3) to give the product as a pale yellow oil (6.2 mg, 3%).  H 
(600 MHz; CD3OD) 7.45 (1H, d, J = 8.5 Hz, 6-Ar-H), 6.89-6.83 (3H, m, 2’-Ar-H, 5’-
Ar-H, 6’-Ar-H), 6.76 (1H, d, J = 8.5 Hz, 7-Ar-H), 5.97 (2H, s, OCH2O), 4.89-4.85 (1H, 
m, 1-CH), 3.66-3.59 (1H, m, 3-CHH), 3.49 (1H, dd, J = 15.0 and 3.5 Hz, 1-CHCHH), 
3.44-3.38 (1H, m, 3-CHH), 3.13-2.93 (3H, m, 1-CHCHH, 4-CH2);  C (150 MHz; 
CD3OD) 154.9 (Ar-CO), 149.9 (Ar-CO), 148.8 (Ar-CO), 133.8 (Ar-CH), 132.8 (Ar-C), 
130.4 (Ar-C), 123.6 (Ar-CH), 122.7 (Ar-C), 116.1 (Ar-CH), 114.6 (Ar-C), 110.2 (Ar-
CH), 109.8 (Ar-CH), 102.6 (OCH2O), 54.3 (1-CH), 37.5 (1-CHCH2), 37.3 (3-CH2), 
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27.5 (4-CH2);  m/z (ESI) 364 ([M(
81
Br) + H]
+
, 100%), 362 ([M(
79
Br) + H]
+
, 100%);  
HRMS C17H17NO3
79
Br, calcd 362.0392, found 362.0370. 
 
8.50 2-(4-Hydroxyphenyl)acetaldehyde (107)
122
 
 
Tyrosol (500 mg, 3.62 mmol) was dissolved in CH2Cl2 (10 mL) and DMSO (5 mL) and 
the solution was cooled to -15 
o
C.  DIPEA (1.26 mL, 7.24 mmol) was added dropwise 
to the stirred reaction mixture at -15 
o
C.  A fully dissolved solution of SO3.pyridine 
(1.15 g, 7.24 mmol) in DMSO (4 mL) was added to the reaction mixture dropwise over 
25 min.  The reaction was stirred for 1 h 15 min at -15 
o
C and quenched by the addition 
of ice cold water (50 mL).  The aqueous layer was extracted with CH2Cl2 (3 x 50 mL).  
The combined organic extracts were washed with ice cold water (2 x 40 mL), dried 
(Na2SO4) and solvent evaporated.  The residue was co-evaporated with CH2Cl2 (3 x 30 
mL) to give the crude product as yellow oil, which was purified by column 
chromatography (hexane/EtOAc, 3:1) to give the product as a pale yellow oil (211 mg, 
43%).  The product was stored in degassed acetonitrile (0.5 M) at -80 
o
C.  Rf  0.40 
(hexane/EtOAc, 2:1);  δH (600 MHz; CDCl3) 9.72 (1H, t, J = 2.5 Hz, CHO), 7.08 (2H, 
d, J = 8.0 Hz, 2 x 2-Ar-H), 6.83 (2H, d, J = 8.0 Hz, 2 x 3-Ar-H), 5.09 (1H, br s, OH), 
3.62 (2H, d, J = 2.5 Hz, CH2CHO);  δC (150 MHz; CDCl3) 200.2 (CHO), 155.2 (Ar-
COH), 131.0 (2 x 2-Ar-CH), 123.8 (Ar-C), 116.0 (2 x 3-Ar-CH), 49.8 (CH2CHO);  m/z 
(CI) 137 ([M + H]
+
, 100%);  HRMS C8H9O2, calcd 137.0603, found 137.0597. 
 
8.51 2-(m-Tolyl)acetaldehyde (140e)
118b 
 
3-Methylphenethyl alcohol (500 mg, 3.59 mmol) was dissolved in DMSO/CH2Cl2 1:1 
(14 mL) and cooled to -15 
o
C.  DIPEA (1.88 mL, 10.8 mmol) was added to the reaction 
mixture at -15 
o
C, followed by a solution of SO3.pyridine (1.43 g, 8.98 mmol) in DMSO 
(7 mL) over 15 min and stirred for 1 h at -15 
o
C.  The reaction was quenched by the 
addition of ice cold water (40 mL).  The aqueous layer was extracted with CH2Cl2 (3 x 
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40 mL).  The combined organic extracts were washed with ice cold water (5 x 25 mL), 
brine (25 mL), dried (Na2SO4) and solvent evaporated to give the crude product as a 
yellow oil, which was purified by column chromatography (hexane/EtOAc, 95:5) to 
give the product as a pale yellow oil (294 mg, 60%).  Rf  0.68 (hexane/EtOAc, 2:1);  δH 
(600 MHz; CDCl3) 9.74 (1H, t, J = 2.5 Hz, CHO), 7.26 (1H, t, J = 7.5 Hz, Ar-H), 7.12 
(1H, d, J = 7.5 Hz, Ar-H), 7.05-7.00 (2H, m, 2 x Ar-H), 3.65 (2H, d, J = 2.5 Hz, 
CH2CHO), 2.36 (3H, s, CH3);  δC (150 MHz; CDCl3) 199.8 (CHO), 138.9 (Ar-C), 131.8 
(Ar-C), 130.8 (Ar-CH), 129.0 (Ar-CH), 128.3 (Ar-CH), 126.8 (Ar-CH), 50.7 
(CH2CHO), 21.5 (CH3);  m/z (CI) 135 ([M + H]
+
, 100%);  HRMS C9H11O, calcd 
135.0810, found 135.0804. 
 
8.52 3,4-(Methylenedioxy)phenylacetaldehyde (140f)
118a 
 
The title compound was prepared according to the procedure described in section 8.51, 
from alcohol 144 (500 mg, 3.01 mmol).  The crude product was purified by column 
chromatography (hexane/EtOAc, 85:15) to give the product as a pale yellow oil (254 
mg, 51%).  Rf  0.50 (hexane/EtOAc, 2:1);  δH (600 MHz; CDCl3) 9.70 (1H, s, CHO), 
6.80 (1H, d, J = 8.0 Hz, Ar-H), 6.69 (1H, s, Ar-H), 6.66 (1H, d, J = 8.0 Hz, Ar-H), 5.97 
(2H, s, OCH2O), 3.60 (2H, s, CH2CHO);  δC (150 MHz; CDCl3) 199.5 (CHO), 148.3 
(Ar-CO), 147.1 (Ar-CO), 125.4 (Ar-C), 123.0 (Ar-CH), 110.1 (Ar-CH), 109.0 (Ar-CH), 
101.4 (OCH2O), 50.3 (CH2CHO);  m/z (CI) 165 ([M + H]
+
, 100%);  HRMS C9H9O3, 
calcd 165.0552, found 165.0550. 
 
8.53 1-Ethyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (141a)
209
 and 1-Ethyl-1,2,3,4-
tetrahydroisoquinoline-7,8-diol (142a)
119
 
 
 
Propionaldehyde (92.0 µL, 1.27 mmol) was added to a solution of dopamine 
hydrochloride (200 mg, 1.05 mmol) in potassium phosphate buffer (10 mL, 0.1 M, pH 
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6) and acetonitrile (10 mL) under argon.  The solution was stirred at 50 
o
C for 18 h.  
The reaction was concentrated under vacuum.  CH2Cl2/CH3OH (1:1, 20 mL) was added 
to the resultant residue and the suspension filtered to remove the solid.  The filtrate was 
evaporated to dryness under vacuum to give the crude product as a brown oil.  The 
regioisomers were separated by prep-HPLC (Method 1, run time: 10 min, flow rate: 5 
mL/min) and appropriate fractions were combined, concentrated and co-evaporated with 
methanol (x3) to give 141a as a pale brown oil (rt = 1.5 min, 156 mg, 77%) and 142a as 
a pale yellow oil (rt = 2.6 min, 8.3 mg, 4%).    
Major regioisomer 141a:  H (500 MHz; CD3OD) 6.67 (1H, s, 8-Ar-H), 6.63 (1H, s, 5-
Ar-H), 4.33-4.29 (1H, m, 1-CH), 3.56-3.29 (2H, m, 3-CH2), 3.05-2.87 (2H, m, 4-CH2), 
2.17-1.88 (2H, m, 1-CHCH2), 1.12 (3H, t, J = 7.5 Hz, CH3);  C (125 MHz; CD3OD) 
145.2 (Ar-COH), 144.4 (Ar-COH), 122.5 (Ar-C), 122.2 (Ar-C), 114.7 (5-Ar-CH), 112.4 
(8-Ar-CH), 56.4 (1-CH), 39.6 (3-CH2), 26.4 (CH2), 24.2 (CH2), 8.5 (CH3);  m/z (CI) 194 
([M + H]
+
, 10%);  HRMS C11H16O2N, calcd 194.1181, found 194.1179. 
Minor regioisomer 142a: H (500 MHz; CD3OD) 6.73 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.55 
(1H, d, J = 8.0 Hz, 5-Ar-H), 4.57-4.51 (1H, m, 1-CH), 3.51-3.27 (2H, m, 3-CH2), 3.04-
2.89 (2H, m, 4-CH2), 2.25-1-81 (2H, m, 1-CHCH2), 1.11 (3H, t, J = 7.5 Hz, CH3);  C 
(125 MHz; CD3OD) 144.4 (Ar-COH), 143.4 (Ar-COH), 123.3 (Ar-C), 121.1 (Ar-C), 
120.4 (5-Ar-CH), 116.0 (6-Ar-CH), 54.8 (1-CH), 38.8 (3-CH2), 26.1 (CH2), 25.5 (CH2), 
10.7 (CH3);  m/z (CI) 194 ([M + H]
+
, 30%), 164 ([M + H]
+ 
- C2H6, 100%);  HRMS 
C11H16O2N, calcd 194.1181, found 194.1180. 
 
8.54 1-Pentyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (141b)
209
 and 1-Pentyl-1,2,3,4-
tetrahydroisoquinoline-7,8-diol (142b) 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (100 mg, 0.527 mmol) and hexanal (77.2 µL, 0.632 
mmol).  The crude mixture of products were separated and purified by prep-HPLC 
(Method 1, run time: 30 min) to give 141b as a white solid (rt = 17.2 min, 92.7 mg, 
75%) and 142b as an orange oil (rt = 22.6 min, 11.3 mg, 9%).   
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Major regioisomer 141b:  M.p. 166-168 
o
C (lit
209
 164-170 
o
C, Et2O);  H (500 MHz; 
CD3OD) 6.64 (1H, s, 8-Ar-H), 6.60 (1H, s, 5-Ar-H), 4.36-4.30 (1H, m, 1-CH), 3.51-
3.26 (2H, m, 3-CH2), 3.02-2.84 (2H, m, 4-CH2), 2.08-1.81 (2H, m, 1-CHCH2), 1.56-
1.33 (6H, m, 3 x CH2), 0.94 (3H, t, J = 6.5 Hz, CH3);  C (125 MHz; CD3OD) 146.7 
(Ar-COH), 145.9 (Ar-COH), 124.3 (Ar-C), 123.6 (Ar-C), 116.2 (5-Ar-CH), 113.9 (8-
Ar-CH), 56.7 (1-CH), 41.0 (3-CH2), 35.1 (1-CHCH2), 32.7 (CH2), 26.1 (4-CH2), 25.7 
(CH2), 23.5 (CH2), 14.3 (CH3);  m/z (CI) 236 ([M + H]
+
, 85%), 164 ([M + H]
+ 
- C5H12, 
100%);  HRMS C14H22O2N, calcd 236.1645, found 236.1644. 
Minor regioisomer 142b:  υmax/cm
-1 
3039 br, 2961, 2932, 1662, 1617, 1578, 1501;  H 
(600 MHz; CD3OD) 6.74 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.55 (1H, d, J = 8.0 Hz, 5-Ar-H), 
4.62 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.51-3.28 (2H, m, 3-CH2), 3.04-2.92 (2H, m, 
4-CH2), 2.17-1.80 (2H, m, 1-CHCH2), 1.62-1.47 (2H, m, 1-CHCH2CH2), 1.45-1.35 (4H, 
m, CH2CH2CH3), 0.94 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 144.6 (Ar-
COH), 143.3 (Ar-COH), 123.3 (Ar-C), 121.3 (Ar-C), 120.4 (5-Ar-CH), 116.0 (6-Ar-
CH), 53.4 (1-CH), 38.7 (3-CH2), 33.0 (1-CHCH2), 32.5 (CH2), 26.6 (1-CHCH2CH2), 
25.5 (4-CH2), 23.4 (CH2), 14.3 (CH3);  m/z (CI) 236 ([M + H]
+
, 35%), 164 ([M + H]
+ 
- 
C5H10, 100%);  HRMS C14H22O2N, calcd 236.1645, found 236.1644. 
 
8.55 1-Octyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (141c) and 1-Octyl-1,2,3,4-
tetrahydroisoquinoline-7,8-diol (142c) 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (200 mg, 1.05 mmol) and nonanal (218 µL, 1.27 
mmol).  The mixture of products in ¾ of the crude material were separated and purified 
by prep-HPLC (Method 2, Gradient F, flow rate: 8 mL/min) to give 141c as a black oil 
(rt = 17.3 min, 168 mg, 77%) and 142c as a yellow oil (rt = 23.9 min, 18.0 mg, 8%). 
Major regioisomer 141c:  υmax/cm
-1 
3047 br, 2927, 2859, 1669, 1617, 1530;  H (500 
MHz; CD3OD) 6.64 (1H, s, 8-Ar-H), 6.60 (1H, s, 5-Ar-H), 4.35-4.29 (1H, m, 1-CH), 
3.52-3.25 (2H, m, 3-CH2), 3.01-2.83 (2H, m, 4-CH2), 2.07-1.80 (2H, m, 1-CHCH2), 
1.55-1.22 (12H, m, 6 x CH2), 0.89 (3H, t, J = 7.0 Hz, CH3);  C (125 MHz; CD3OD) 
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146.7 (Ar-COH), 145.9 (Ar-COH), 124.3 (Ar-C), 123.7 (Ar-C), 116.2 (5-Ar-CH), 113.9 
(8-Ar-CH), 56.7 (1-CH), 41.0 (3-CH2), 35.1 (CH2), 33.0 (CH2), 30.5 (CH2), 30.4 (CH2), 
30.3 (CH2), 26.4 (CH2), 25.7 (4-CH2), 23.7 (CH2), 14.4 (CH3);  m/z (ESI) 278 ([M + 
H]
+
, 100%), 261 ([M + H]
+
 - OH, 60%);  HRMS C17H28NO2, calcd 278.2120, found 
278.2124. 
 Minor regioisomer 142c:  υmax/cm
-1 
3320, 3047, 2928, 2852, 1664, 1625, 1506;  H 
(500 MHz; CD3OD) 6.73 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.54 (1H, d, J = 8.0 Hz, 5-Ar-H), 
4.64-4.58 (1H, m, 1-CH), 3.51-3.25 (2H, m, 3-CH2), 3.03-2.90 (2H, m, 4-CH2), 2.17-
1.77 (2H, m, 1-CHCH2), 1.61-1.21 (12H, m, 6 x CH2), 0.89 (3H, t, J = 7.0 Hz, CH3);  C 
(125 MHz; CD3OD) 144.6 (Ar-COH), 143.3 (Ar-COH), 123.4 (Ar-C), 121.3 (Ar-C), 
120.5 (5-Ar-CH), 116.0 (6-Ar-CH), 53.4 (1-CH), 38.8 (3-CH2), 33.1 (CH2), 33.0 (CH2), 
30.4 (CH2), 30.3 (2 x CH2), 26.9 (CH2), 25.5 (CH2), 23.7 (CH2), 14.4 (CH3);  m/z (ESI) 
278 ([M + H]
+
, 100%), 261 ([M + H]
+
 - OH, 40%);  HRMS C17H28NO2, calcd 278.2120, 
found 278.2114. 
 
8.56 1-Cyclopentyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (141d)
210
 and 1-
Cyclopentyl-1,2,3,4-tetrahydroisoquinoline-7,8-diol (142d) 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (150 mg, 0.791 mmol) and 
cyclopentanecarboxaldehyde (155 mg, 1.58 mmol).  The mixture of products in the 
crude material were separated and purified by prep-HPLC (Method 2, Gradient F, flow 
rate: 8 mL/min) to give 141d as a white solid (rt = 10.0 min, 59.2 mg, 32%) and 142d as 
a colourless oil (rt = 26.5 min, 6.5 mg, 4%). 
Major regioisomer 141d:  M.p. 207-210 
o
C;  υmax/cm
-1 
3135 br, 2969, 1675, 1612, 1531;  
H (600 MHz; CD3OD) 6.69 (1H, s, 8-Ar-H), 6.62 (1H, s, 5-Ar-H), 4.22 (1H, d, J = 8.0 
Hz, 1-CH), 3.56-3.32 (2H, m, 3-CH2), 3.02-2.92 (2H, m, 4-CH2), 2.44-2.35 (1H, m, 1-
CHCH), 1.92-1.60 (6H, m, 3 x CH2), 1.53-1.31 (2H, m, CH2);  C (150 MHz; CD3OD) 
146.9 (Ar-COH), 145.5 (Ar-COH), 124.2 (Ar-C), 123.6 (Ar-C), 116.2 (5-Ar-CH), 114.8 
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(8-Ar-CH), 60.4 (1-CH), 44.6 (1-CHCH), 39.8 (3-CH2), 31.4 (CH2), 29.8 (CH2), 26.0 
(CH2), 25.7 (CH2), 25.3 (4-CH2);  m/z (EI) 233 (M
+
, 30%), 165 (M
+
 - C5H8, 100%);  
HRMS C14H19O2N, calcd 233.1416, found 233.1419. 
Minor regioisomer 142d:  υmax/cm
-1 
3063 br, 2969, 2924, 2875, 1668, 1633, 1516;  H 
(600 MHz; CD3OD) 6.75 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.57 (1H, d, J = 8.0 Hz, 5-Ar-H), 
4.70 (1H, d, J = 8.5 Hz, 1-CH), 3.64-3.24 (2H, m, 3-CH2),  3.09-2.94 (2H, m, 4-CH2), 
2.51-2.41 (1H, m, 1-CHCH), 1.96-1.42 (8H, m, 4 x CH2);  C (CD3OD, 150 MHz) 
144.7 (Ar-COH), 143.8 (Ar-COH), 123.8 (Ar-C), 121.3 (Ar-C), 120.4 (5-Ar-CH), 116.1 
(6-Ar-CH), 55.8 (1-CH), 44.0 (1-CHCH), 38.6 (3-CH2), 30.5 (CH2), 30.4 (CH2), 25.9 
(CH2), 25.6 (CH2), 24.7 (4-CH2);  m/z (CI) 234 ([M + H]
+
, 20%), 164 ([M + H]
+ 
- 
C5H10, 100%);  HRMS C14H20O2N, calcd 234.1494, found 234.1491. 
 
8.57 1-(3-Methylbenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol (141e)
118b
 and 1-(3-
Methylbenzyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol (142e) 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (150 mg, 0.791 mmol) and aldehyde 140e (127 mg, 
0.949 mmol).  The mixture of products in the crude material were separated and purified 
by prep-HPLC (Method 2, Gradient F) to give 141e as a yellow oil (rt = 13.0 min, 148 
mg, 69%) and 142e as a yellow oil (rt = 29.4 min, 6.1 mg, 3%). 
Major regioisomer 141e:  M.p. 60-64 
o
C;  υmax/cm
-1 
3034 br, 2859, 1667, 1617, 1530;  
H (500 MHz; CD3OD) 7.27 (1H, t, J = 7.5 Hz, 5’-Ar-H),  7.17-7.07 (3H, m, 2’-Ar-H, 
4’-Ar-H, 6’-Ar-H), 6.63-6.59 (2H, m, 5-Ar-H, 8-Ar-H), 4.66-4.40 (1H, m, 1-CH), 3.50-
3.20 (3H, m, 3-CH2, 1-CHCHH), 3.06-2.85 (3H, m, 4-CH2, 1-CHCHH), 2.35 (3H, s, 
CH3);  C (125 MHz; CD3OD) 146.9 (Ar-COH), 145.8 (Ar-COH), 140.1 (Ar-C), 136.5 
(Ar-C), 131.2 (Ar-CH), 130.1 (Ar-CH), 129.5 (Ar-CH), 127.6 (Ar-CH), 123.7 (2 x Ar-
C), 116.2 (5-Ar-CH), 114.2 (8-Ar-CH), 57.8 (1-CH), 41.2 (CH2), 41.0 (CH2), 25.7 (4-
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CH2), 21.4 (CH3);  m/z (CI) 270 ([M + H]
+
, 15%), 164 ([M + H]
+
 - C8H10, 100%);  
HRMS C17H20O2N, calcd 270.1494, found 270.1485. 
Minor regioisomer 142e:  υmax/cm
-1 
3063 br, 2945, 2924, 2844, 1672, 1617, 1502;  H 
(600 MHz; CD3OD) 7.28 (1H, t, J = 7.5 Hz, 5’-Ar-H), 7.21 (1H, s, 2’-Ar-H), 7.20-7.13 
(2H, m, 4’-Ar-H, 6’-Ar-H), 6.79 (1H, d, J = 8.5 Hz, 6-Ar-H), 6.59 (1H, d, J = 8.5 Hz, 5-
Ar-H), 4.95.4.85 (1H, m, 1-CH), 3.67-3.60 (1H, m, 1-CHCHH), 3.53-3.23 (2H, m, 3-
CH2), 3.05-2.93 (3H, m, 4-CH2, 1-CHCHH), 2.36 (3H, s, CH3);  C (150 MHz; CD3OD) 
144.8 (Ar-COH), 143.4 (Ar-COH), 140.1 (Ar-C), 137.3 (Ar-C), 131.0 (2’-Ar-CH), 
130.2 (5’-Ar-CH), 129.4 (Ar-CH), 127.3 (Ar-CH), 123.4 (Ar-C), 120.6 (5-Ar-CH), 
120.4 (Ar-C), 116.3 (6-Ar-CH), 55.0 (1-CH), 38.7 (3-CH2), 38.1 (1-CHCH2), 25.5 (4-
CH2), 21.5 (CH3);  m/z (CI) 270 ([M + H]
+
, 70%), 164 ([M + H]
+
 - C8H10, 100%);  
HRMS C17H20O2N, calcd 270.1494, found 270.1488.  
 
8.58 1-(Benzo[d][1,3]dioxol-5-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol 
(141f)
105
 and 1-(Benzo[d][1,3]dioxol-5-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-7,8-
diol (142f) 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (145 mg, 0.765 mmol) and aldehyde 140f (150 mg, 
0.917 mmol).  The mixture of products in the crude material were separated and purified 
by prep-HPLC (Method 2, Gradient D) to give 141f as a yellow oil (rt = 16.0 min, 112 
mg, 49%) and 142f as a pale yellow oil (rt = 23.0 min, 6.2 mg, 3%). 
Major regioisomer 141f:  M.p. 64-66 
o
C;  υmax/cm
-1 
3018 br, 2859, 1668, 1617, 1531;  
H (600 MHz; CD3OD) 6.85 (1H, d, J = 1.5 Hz, 2’-Ar-H), 6.83 (1H, d, J = 8.0 Hz, 5’-
Ar-H), 6.78 (1H, dd, J = 8.0 and 1.5 Hz, 6’-Ar-H), 6.64-6.61 (2H, m, 5-Ar-H, 8-Ar-H), 
5.97 (2H, s, OCH2O), 4.62-4.58 (1H, m, 1-CH), 3.51-3.45 (1H, m, 3-CHH), 3.40 (1H, 
dd, J = 14.5 and 5.5 Hz, 1-CHCHH), 3.29-3.23 (1H, m, 3-CHH), 3.04-2.88 (3H, m, 4-
CH2, 1-CHCHH);  C (150 MHz; CD3OD) 149.9 (Ar-CO), 148.8 (Ar-CO), 146.9 (Ar-
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CO), 145.8 (Ar-CO), 130.1 (Ar-C), 123.9 (6’-Ar-CH), 123.6 (2 x Ar-C), 116.2 (Ar-CH), 
114.1 (Ar-CH), 110.5 (2’-Ar-CH), 109.7 (5’-Ar-CH), 102.6 (OCH2O), 57.8 (1-CH), 
40.9 (3-CH2, 1-CHCH2), 25.7 (4-CH2);  m/z (ESI) 300 ([M + H]
+
, 100%), 283 ([M + 
H]
+
 - OH, 80%), 164 ([M + H]
+
 - C8H8O2, 100%);  HRMS C17H18NO4, calcd 300.1236, 
found 300.1221. 
Minor regioisomer 142f:  υmax/cm
-1 
3029 br, 1667, 1625;  H (600 MHz; CD3OD) 6.88-
6.83 (3H, m, 2’-Ar-H, 5’-Ar-H, 6’-Ar-H), 6.79 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.59 (1H, d, 
J = 8.0 Hz, 5-Ar-H), 5.96 (2H, s, OCH2O), 4.85 (1H, dd, J = 10.5 and 3.0 Hz, 1-CH), 
3.59-3.48 (2H, m, 3-CHH, 1-CHCHH), 3.30-3.24 (1H, m, 3-CHH), 3.05-2.92 (3H, m, 
4-CH2, 1-CHCHH);  C (150 MHz; CD3OD) 149.9 (Ar-CO), 148.7 (Ar-CO), 144.8 (Ar-
CO), 143.3 (Ar-CO), 130.9 (Ar-C), 123.6 (Ar-CH), 123.3 (Ar-C), 120.6 (5-Ar-CH), 
120.3 (Ar-C), 116.3 (6-Ar-CH), 110.3 (Ar-CH), 109.7 (Ar-CH), 102.5 (OCH2O), 55.1 
(1-CH), 38.6 (3-CH2), 37.8 (1-CHCH2), 25.5 (4-CH2);  m/z (ESI) 300 ([M + H]
+
, 40%), 
164 ([M + H]
+
 - C8H8O2, 100%);  HRMS C17H18NO4, calcd 300.1236, found 300.1236. 
 
8.59 3,4-(Methylenedioxy)phenethyl alcohol (144)
147
 
 
A solution of 3,4-(methylenedioxy)phenylacetic acid (2.00 g, 11.1 mmol) in THF (50 
mL) was added slowly to a gently stirred solution of lithium aluminium hydride in THF 
(1 M, 24.4 mL, 24.4 mmol) at 0 
o
C and stirred at rt for 5 h.  The reaction mixture was 
cooled to 0 
o
C and quenched with water (25 mL).  EtOAc (100 mL) was added and the 
mixture was filtered to remove the solids.  The solids were washed with EtOAc (3 x 50 
mL).  The combined organic extracts were washed with brine (40 mL), dried (MgSO4) 
and solvent removed in vacuo to yield the product as a pale yellow oil (1.77 g, 96%) 
which was used without further purification.  Rf  0.2 (hexane/EtOAc, 2:1);  δH (300 
MHz; CDCl3) 6.81-6.65 (3H, m, 3 x Ar-H), 5.93 (2H, s, OCH2O), 3.81 (2H, t, J = 6.5 
Hz, CH2OH), 2.78 (2H, t, J = 6.5 Hz, CH2CH2OH);  m/z (CI) 166 (M
+
, 20%), 149 (M
+ 
- 
OH, 100%);  HRMS C9H10O3, calcd 166.0630, found 166.0623. 
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8.60 1-Propyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (145a)
209
 and 1-Propyl-
1,2,3,4-tetrahydroisoquinoline-7,8-diol (146a) 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (200 mg, 1.05 mmol) and butyraldehyde (114 µL, 
1.27 mmol). The mixture of products in the crude material were separated and purified 
by prep-HPLC (Method 2, Gradient A) to give 145a as a pale brown solid (rt = 17.8 
min, 99.0 mg, 45%) and 146a as a pale yellow oil (rt = 30.4 min, 7.65 mg, 3%). 
Major regioisomer 145a:  M.p. 193-195 
o
C;  H (600 MHz; CD3OD) 6.65 (1H, s, 8-Ar-
H), 6.61 (1H, s, 5-Ar-H), 4.37-4.32 (1H, m, 1-CH), 3.54-3.28 (2H, m, 3-CH2), 3.02-2.87 
(2H, m, 4-CH2), 2.05-1.81 (2H, m, 1-CHCH2), 1.59-1.47 (2H, m, 1-CHCH2CH2), 1.05 
(3H, t, J = 7.5 Hz, CH3);  C (150 MHz; CD3OD) 146.7 (Ar-COH), 145.9 (Ar-COH), 
124.2 (Ar-C), 123.5 (Ar-C), 116.2 (5-Ar-CH), 113.8 (8-Ar-CH), 56.4 (1-CH), 40.9 (3-
CH2), 37.3 (1-CHCH2), 25.7 (4-CH2), 19.8 (1-CHCH2CH2), 14.1 (CH3);  m/z (CI) 208 
([M + H]
+
, 50%), 131 ([M + H]
+
 - C3H9O2, 40%);  HRMS C12H18NO2, calcd 208.1338, 
found 208.1331. 
Minor regioisomer 146a:  υmax/cm
-1 
3330 br, 3047, 2813, 1665, 1633, 1586, 1506;  H 
(600 MHz; CD3OD) 6.74 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.55 (1H, d, J = 8.0 Hz, 5-Ar-H), 
4.63 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.51-3.28 (2H, m, 3-CH2), 3.04-2.92 (2H, m, 
4-CH2), 2.13-1.80 (2H, m, 1-CHCH2), 1.65-1.47 (2H, m, 1-CHCH2CH2), 1.03 (3H, t, J 
= 7.5 Hz, CH3);  C (150 MHz; CD3OD) 144.6 (Ar-COH), 143.3 (Ar-COH), 123.2 (Ar-
C), 121.2 (Ar-C), 120.4 (5-Ar-CH), 116.0 (6-Ar-CH), 53.1 (1-CH), 38.7 (3-CH2), 35.2 
(1-CHCH2), 25.4 (4-CH2), 20.3 (1-CHCH2CH2), 14.0 (CH3);  m/z (CI) 208 ([M + H]
+
, 
45%), 164 ([M + H]
+
 - C3H8, 40%);  HRMS C12H18NO2, calcd 208.1338, found 
208.1331. 
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8.61 1-Butyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (145b)
210
 and 1-Butyl-1,2,3,4-
tetrahydroisoquinoline-7,8-diol (146b)  
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (200 mg, 1.05 mmol) and valeraldehyde (135 µL, 
1.27 mmol).  The mixture of products in the crude material were separated and purified 
by prep-HPLC (Method 2, Gradient A, run time: 50 min) to give 145b as a pale brown 
solid (rt = 22.5 min, 193 mg, 83%) and 146b as a pale yellow oil (rt = 31.7 min, 11.4 
mg, 5%). 
Major regioisomer 145b:  M.p. 185-186 
o
C;  H (600 MHz; CD3OD) 6.65 (1H, s, 8-Ar-
H), 6.61 (1H, s, 5-Ar-H), 4.36-4.32 (1H, m, 1-CH), 3.54-3.28 (2H, m, 3-CH2), 3.03-2.87 
(2H, m, 4-CH2), 2.09-1.84 (2H, m, 1-CHCH2), 1.53-1.39 (4H, m, CH2CH2CH3), 0.99 
(3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 146.7 (Ar-COH), 145.9 (Ar-COH), 
124.2 (Ar-C), 123.6 (Ar-C), 116.2 (5-Ar-CH), 113.8 (8-Ar-CH), 56.6 (1-CH), 41.0 (3-
CH2), 34.8 (1-CHCH2), 28.6 (CH2), 25.7 (4-CH2), 23.6 (CH2), 14.2 (CH3);  m/z (CI) 222 
([M + H]
+
, 80%), 164 ([M + H]
+
 - C4H10, 85%), 131 ([M + H]
+
 - C4H11O2, 40%);  
HRMS C13H20NO2, calcd 222.1494, found 222.1490. 
Minor regioisomer 146b:  υmax/cm
-1 
3047 br, 2962, 2875, 1664, 1625, 1586, 1500;  H 
(600 MHz; CD3OD) 6.74 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.55 (1H, d, J = 8.0 Hz, 5-Ar-H), 
4.62 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.51-3.28 (2H, m, 3-CH2), 3.04-2.92 (2H, m, 
4-CH2), 2.19-1.80 (2H, m, 1-CHCH2), 1.59-1.37 (4H, m, CH2CH2CH3), 0.98 (3H, t, J = 
7.5 Hz, CH3);  C (150 MHz; CD3OD) 144.6 (Ar-COH), 143.3 (Ar-COH), 123.3 (Ar-C), 
121.3 (Ar-C), 120.4 (5-Ar-CH), 116.0 (6-Ar-CH), 53.8 (1-CH), 38.7 (3-CH2), 32.7 (1-
CHCH2), 29.1 (CH2), 25.5 (4-CH2), 23.3 (CH2), 14.0 (CH3);  m/z (CI) 222 ([M + H]
+
, 
95%), 164 ([M + H]
+
 - C4H10, 100%);  HRMS C13H20NO2, calcd 222.1494, found 
222.1488. 
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8.62 1-Hexyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (145c)
118a
 and 1-Hexyl-1,2,3,4-
tetrahydroisoquinoline-7,8-diol (146c)
118a 
 
The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (200 mg, 1.05 mmol) and heptanal (177 µL, 1.27 
mmol).  The mixture of products in the crude material were separated and purified by 
prep-HPLC (Method 2, Gradient F) to give 145c as a pale brown oil (rt = 18.2 min, 225 
mg, 86%) and 146c as a pale yellow oil (rt = 28.8 min, 25.1 mg, 10%). 
Major regioisomer 145c:  H (600 MHz; CD3OD) 6.65 (1H, s, 8-Ar-H), 6.61 (1H, s, 5-
Ar-H), 4.36-4.32 (1H, m, 1-CH), 3.54-3.28 (2H, m, 3-CH2), 3.02-2.86 (2H, m, 4-CH2), 
2.07-1.83 (2H, m, 1-CHCH2), 1.55-1.33 (8H, m, 4 x CH2), 0.93 (3H, t, J = 7.0 Hz, 
CH3);  C (150 MHz; CD3OD) 146.7 (Ar-COH), 145.9 (Ar-COH), 124.2 (Ar-C), 123.6 
(Ar-C), 116.2 (5-Ar-CH), 113.8 (8-Ar-CH), 56.7 (1-CH), 41.0 (3-CH2), 35.2 (1-
CHCH2), 32.8 (CH2), 30.0 (CH2), 26.5 (CH2), 25.7 (4-CH2), 23.4 (CH2), 14.3 (CH3);  
m/z (ESI) 250 ([M + H]
+
, 100%);  HRMS C15H24NO2, calcd 250.1807, found 250.1809. 
Minor regioisomer 146c:  H (600 MHz; CD3OD) 6.74 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.55 
(1H, d, J = 8.0 Hz, 5-Ar-H), 4.61 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.51-3.28 (2H, m, 
3-CH2), 3.03-2.92 (2H, m, 4-CH2), 2.17-1.79 (2H, m, 1-CHCH2), 1.61-1.27 (8H, m, 4 x 
CH2), 0.91 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 144.6 (Ar-COH), 143.3 
(Ar-COH), 123.2 (Ar-C), 121.2 (Ar-C), 120.4 (5-Ar-CH), 116.0 (6-Ar-CH), 53.4 (1-
CH), 38.7 (3-CH2), 33.0 (1-CHCH2), 32.7 (CH2), 30.0 (CH2), 27.0 (CH2), 25.4 (4-CH2), 
23.6 (CH2), 14.3 (CH3);  m/z (ESI) 250 ([M + H]
+
, 100%), 233 ([M + H]
+
 - OH, 90%);  
HRMS C15H24NO2, calcd 250.1807, found 250.1810. 
 
8.63 1-Heptyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (145d) and 1-Heptyl-1,2,3,4-
tetrahydroisoquinoline-7,8-diol (146d) 
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The title compounds were prepared according to the procedure described in section 
8.53, from dopamine hydrochloride (200 mg, 1.05 mmol) and octanal (198 µL, 1.27 
mmol).  The mixture of products in the crude material were separated and purified by 
prep-HPLC (Method 2, Gradient D) to give 145d as a yellow oil (rt = 22.8 min, 238 mg, 
85%) and 146d as a yellow oil (rt = 33.3 min, 30.9 mg, 11%). 
Major regioisomer 145d:  υmax/cm
-1 
2929, 2875, 1664, 1625, 1519;  H (600 MHz; 
CD3OD) 6.65 (1H, s, 8-Ar-H), 6.61 (1H, s, 5-Ar-H), 4.36-4.32 (1H, m, 1-CH), 3.53-
3.28 (2H, m, 3-CH2), 3.02-2.86 (2H, m, 4-CH2), 2.97-1.83 (2H, m, 1-CHCH2), 1.55-
1.28 (10H, m, 5 x CH2), 0.91 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 146.7 
(Ar-COH), 145.9 (Ar-COH), 124.3 (Ar-C), 123.6 (Ar-C), 116.2 (5-Ar-CH), 113.8 (8-
Ar-CH), 56.7 (1-CH), 41.0 (3-CH2), 35.2 (1-CHCH2), 32.9 (CH2), 30.5 (CH2), 30.2 
(CH2), 26.4 (CH2), 25.7 (4-CH2), 23.7 (CH2), 14.4 (CH3);  m/z (CI) 264 ([M + H]
+
, 
100%), 164 ([M + H]
+
 - C7H16, 60%);  HRMS C16H26NO2, calcd 264.1964, found 
264.1967. 
Minor regioisomer 146d:  υmax/cm
-1 
3031 br, 2969, 2928, 2852, 1662, 1578, 1500;  H 
(600 MHz; CD3OD) 6.74 (1H, d, J = 8.0 Hz, 6-Ar-H), 6.55 (1H, d, J = 8.0 Hz, 5-Ar-H), 
4.61 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.51-3.28 (2H, m, 3-CH2), 3.04-2.92 (2H, m, 
4-CH2), 2.17-1.79 (2H, m, 1-CHCH2), 1.61-1.27 (10H, m, 5 x CH2), 0.91 (3H, t, J = 7.0 
Hz, CH3);  C (150 MHz; CD3OD) 144.6 (Ar-COH), 143.4 (Ar-COH), 123.2 (Ar-C), 
121.2 (Ar-C), 120.4 (5-Ar-CH), 116.0 (6-Ar-CH), 53.4 (1-CH), 38.7 (3-CH2), 33.0 (1-
CHCH2), 32.9 (CH2), 30.3 (CH2), 30.2 (CH2), 27.0 (CH2), 25.5 (4-CH2), 23.7 (CH2), 
14.4 (CH3);  m/z (CI) 264 ([M + H]
+
, 100%), 164 ([M + H]
+
 - C7H16, 50%);  HRMS 
C16H26NO2, calcd 264.1964, found 264.1962. 
 
8.64 2-(3-Methoxyphenyl)ethan-1-amine (149)
118a 
 
To a stirred solution of 3-methoxyphenylacetonitrile (2.50 g, 17.0 mmol) in THF (35 
mL) at 0 
o
C, was added a 1 M borane tetrahydrofuran complex solution in THF (42.5 
mL, 42.5 mmol) and the reaction mixture was gradually allowed to warm to rt.  After 24 
h, the reaction was cooled to 0 
o
C and methanol (50 mL) was added dropwise.  The 
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resulting clear solution was stirred at rt overnight and concentrated in vacuo.  The 
residue was co-evaporated with methanol (3 x 20 mL), and the resulting crude product 
was purified by column chromatography (gradient of 5-15% CH3OH (+1% Et3N) in 
CH2Cl2) to yield the product as a pale yellow oil (2.44 g, 95%).  Rf  0.16 
(CH2Cl2/CH3OH(+1% Et3N), 4:1);  υmax/cm
-1 
(CDCl3 cast) 2937, 2836, 1582;  δH (500 
MHz; CDCl3) 7.22 (1H, t, J = 7.5 Hz, 5-Ar-H), 6.83-6.72 (3H, m, 2-Ar-H, 4-Ar-H, 6-
Ar-H), 3.80 (3H, s, OCH3), 2.96 (2H, t, J = 6.5 Hz, CH2N), 2.72 (2H, t, J = 6.5 Hz, 
CH2CH2N), 1.28 (2H, br s, NH2);  δC (125 MHz; CDCl3) 159.8 (Ar-CO), 141.6 (Ar-C), 
129.5 (5-Ar-CH), 121.3 (Ar-CH), 114.7 (2-Ar-CH), 111.5 (Ar-CH), 55.2 (OCH3), 43.5 
(CH2N), 40.3 (CH2CH2N). 
 
8.65 2-(3,5-Dimethoxyphenyl)ethan-1-amine (150)
151
 
 
The title compound was prepared according to the procedure described in section 8.64, 
from (3,5-dimethoxyphenyl)acetonitrile (700 mg, 3.95 mmol) and a 1 M borane 
tetrahydrofuran complex solution in THF (11.9 mL, 11.9 mmol).  The crude yellow oil 
was purified by column chromatography (CH2Cl2/CH3OH(+1% Et3N), 9:1) to give the 
product as a pale yellow oil (584 mg, 82%).  Rf 0.24 (CH2Cl2/CH3OH(+1% Et3N), 9:1);  
δH (500 MHz; CDCl3) 6.36 (2H, d, J = 2.0 Hz, 2 x 2-Ar-H), 6.32 (1H, t, J = 2.0 Hz, 4-
Ar-H), 3.78 (6H, s, 2 x OCH3), 2.96 (2H, t, J = 6.5 Hz, CH2N), 2.69 (2H, t, J = 6.5 Hz, 
CH2CH2N), 1.51 (2H, br s, NH2);  δC (125 MHz; CDCl3) 160.9 (2 x Ar-C), 142.2 (Ar-
C), 107.0 (2 x 2-Ar-CH), 98.2 (4-Ar-CH), 55.3 (2 x OCH3), 43.4 (CH2N), 40.0 
(CH2CH2N);  m/z (CI) 182 ([M + H]
+
, 40%), 165 ([M + H]
+
 - NH3, 100%);  HRMS 
C10H16O2N calcd 182.1176, found 182.1167. 
 
8.66 2-(2-Bromo-5-methoxyphenyl)ethan-1-amine (151)
152
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The title compound was prepared following a literature procedure with modifications to 
the work-up.
152
  A solution of amine 149 (1.50 g, 9.92 mmol) in glacial acetic acid (21 
mL) was treated with a solution of bromine (0.56 mL, 10.9 mmol) in acetic acid (8.50 
mL) over 45 min at -15 
o
C.  After stirring for a further 5 min, the resulting orange 
solution was treated with Et2O (80 mL) and cooled to 0 
o
C.  The product did not 
precipitate from the solution, so water was added (80 mL) and the aqueous phase 
separated.  The organic phase was extracted with water (2 x 80 mL).  The combined 
aqueous extracts were washed with Et2O (2 x 50 mL).  The aqueous phase was adjusted 
to pH 10 by addition of 2 M NaOH and extracted with CH2Cl2 (3 x 150 mL).  The 
combined organic extracts were dried (MgSO4) and solvent removed in vacuo to yield 
the product as a pale yellow oil (2.00 g, 88%), which was used without further 
purification.  υmax/cm
-1 
(CDCl3 cast) 2934, 2836, 1594, 1571;  δH (500 MHz; CDCl3) 
7.42 (1H, d, J = 8.5 Hz, 3-Ar-H), 6.78 (1H, d, J = 3.0 Hz, 6-Ar-H), 6.64 (1H, dd, J = 8.5 
and 3.0 Hz, 4-Ar-H), 3.77 (3H, s, OCH3), 2.96 (2H, t, J = 7.0 Hz, CH2N), 2.84 (2H, t, J 
= 7.0 Hz, CH2CH2N), 1.25 (2H, br s, NH2);  δC (125 MHz; CDCl3) 159.0 (Ar-CO), 
140.2 (Ar-C), 133.5 (3-Ar-CH), 116.7 (6-Ar-CH), 115.2 (Ar-CBr), 113.5 (4-Ar-CH), 
55.5 (3H, s, OCH3), 42.2 (CH2N), 40.6 (CH2CH2N). 
 
8.67 2-(2-Bromo-3,5-dimethoxyphenyl)ethan-1-amine (152)
153
 
 
The title compound was prepared according to the procedure described in section 8.66, 
from amine 150 (245 mg, 1.35 mmol).  The crude yellow oil was purified by column 
chromatography (CH2Cl2/CH3OH(+1% Et3N), 9:1).  The first product eluted was the di-
brominated compound 2-(2,6-dibromo-3,5-dimethoxyphenyl)ethan-1-amine
153
 as a pale 
yellow oil (138 mg), δH (500 MHz; CDCl3) 6.41 (1H, s, Ar-H), 3.88 (6H, s, 2 x OCH3), 
3.39-3.20 (2H, m, CH2N), 2.98-2.88 (2H, m, CH2CH2N), 2.22 (2H, br s, NH2).  The 
second product eluted was the mono-brominated product 152 as a pale yellow oil (150 
mg, 34%).  Rf 0.34 (CH2Cl2/CH3OH(+1% Et3N), 4:1);  υmax/cm
-1 
(CDCl3 cast) 2938, 
2844, 1584;  δH (500 MHz; CDCl3) 6.43 (1H, d, J = 2.5 Hz, Ar-H),  6.37 (1H, d, J = 2.5 
Hz, Ar-H), 3.86 (3H, s, OCH3), 3.80 (3H, s, OCH3), 3.08-2.90 (4H, m, CH2CH2N), 2.01 
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(2H, br s, NH2);  δC (125 MHz; CDCl3) 159.6 (Ar-CO), 156.9 (Ar-CO), 140.8 (Ar-C), 
107.3 (Ar-CH), 105.0 (Ar-CBr), 97.9 (Ar-CH), 56.4 (OCH3), 55.6 (OCH3), 41.9 
(CH2N), 40.4 (CH2CH2N);  m/z (ESI) 262 ([(
81
Br)M + H]
+
, 30%), 260 ([(
79
Br)M + H]
+
, 
35%), 245 ([(
81
Br)M + H]
+ 
- OH, 100%);  HRMS C10H15O2N
79
Br, calcd 260.0286, 
found 260.0264. 
 
8.68 2-(2-Bromo-4,5-dimethoxyphenyl)ethan-1-amine (153)
154
 
 
The title compound was prepared according to the procedure described in section 8.66, 
from 2-(3,4-dimethoxyphenyl)ethan-1-amine (1.80 g, 9.93 mmol).  The crude brown oil 
was purified by column chromatography (CH2Cl2/CH3OH(+1% Et3N), 9:1) to yield the 
product as a yellow oil (1.12 g, 43%).  Rf 0.33 (CH2Cl2/CH3OH(+1% Et3N), 4:1);  
υmax/cm
-1
 (CDCl3 cast) 2934, 2844, 1617, 1586, 1507;  δH (500 MHz; CDCl3) 6.96 (1H, 
s, 3-Ar-H), 6.74 (1H, s, 6-Ar-H), 3.85 (3H, s, OCH3), 3.84 (3H, s, OCH3), 2.95 (2H, t, J 
= 7.0 Hz, CH2N), 2.82 (2H, t, J = 7.0 Hz, CH2CH2N), 1.43 (2H, br s, NH2);  δC (125 
MHz; CDCl3) 148.4 (Ar-CO), 148.2 (Ar-CO), 131.1 (Ar-C), 115.8 (3-Ar-CH), 114.4 
(Ar-CBr), 113.5 (6-Ar-CH), 56.2 (2 x OCH3), 42.4 (CH2N), 39.9 (CH2CH2N);  m/z (CI) 
262 ([(
81
Br)M + H]
+
, 90%), 260 ([(
79
Br)M + H]
+
, 100%);  HRMS C10H15O2N
79
Br, calcd 
260.0286, found 260.0283. 
 
8.69 2-(3-Hydroxyphenyl)ethan-1-amine hydrobromide (155)
120
 
 
A solution of 1 M boron tribromide in CH2Cl2 (10.2 mL, 10.2 mmol) was added to a 
stirred solution of amine 149 (700 mg, 4.63 mmol) in CH2Cl2 (20 mL) at -78 
o
C.  The 
reaction was warmed to rt and stirred for 24 h.  The reaction was then cooled to 0 
o
C 
and quenched by addition of methanol (40 mL).  The solution was stirred at rt for 3 h 
and then concentrated in vacuo to give a brown oil.  Further methanol (20 mL) was 
added to the oil, and solvent evaporated.  This was repeated until no white fumes were 
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observed upon addition of methanol, to give the product as a pale brown solid as the 
hydrobromide salt (899 mg, 89%).  M.p. 102-104 
o
C (lit
211
 102.5-103 
o
C, EtOH);  δH 
(600 MHz; CD3OD) 7.16 (1H, t, J = 7.5 Hz, 5-Ar-H), 6.73 (1H, d, J = 7.5 Hz, 6-Ar-H), 
6.72-6.68 (2H, m, 2-Ar-H, 4-Ar-H), 3.15 (2H, t, J = 8.0 Hz, CH2N), 2.88 (2H, t, J = 8.0 
Hz, CH2CH2N);  δC (150 MHz; CD3OD) 159.1 (Ar-COH), 139.3 (Ar-C), 131.0 (Ar-
CH), 120.7 (Ar-CH), 116.6 (Ar-CH), 115.2 (Ar-CH), 41.9 (CH2N), 34.5 (CH2CH2N);  
m/z (CI) 138 ([M + H]
+
, 70%), 121 ([M + H]
+
 - OH/NH3, 100%);  HRMS C8H12ON, 
calcd 138.0919, found 138.0912. 
 
8.70 2-(3,5-Dihydroxyphenyl)ethan-1-amine hydrobromide (156)
212
 
 
The title compound was prepared according to the procedure described in section 8.69, 
from amine 150 (300 mg, 1.66 mmol) and 1 M boron tribromide in CH2Cl2 (4.97 mL, 
4.97 mmol).  The product was isolated as an orange solid as the hydrobromide salt (390 
mg, 100%).  M.p. 124-126 
o
C;  δH (500 MHz; CD3OD) 6.20 (2H, d, J = 2.0 Hz, 2 x 2-
Ar-H), 6.18 (1H, t, J = 2.0 Hz, 4-Ar-H), 3.12 (2H, t, J = 7.5 Hz, CH2N), 2.80 (2H, t, J = 
7.5 Hz, CH2CH2N);  δC (125 MHz; CD3OD) 160.0 (2 x Ar-COH), 139.9 (Ar-C), 108.1 
(2 x 2-Ar-CH), 102.4 (4-Ar-CH), 41.9 (CH2N), 34.6 (CH2CH2N). 
 
8.71 2-(2-Bromo-5-hydroxyphenyl)ethan-1-amine hydrobromide (157)
105
 
 
The title compound was prepared according to the procedure described in section 8.69, 
from amine 151 (2.00 g, 8.69 mmol) and 1 M boron tribromide in CH2Cl2 (19.1 mL, 
19.1 mmol).   The product was isolated as a pale brown solid as the hydrobromide salt 
(2.40 g, 93%).  M.p. 162-172 
o
C (decomposed);  υmax/cm
-1 
3348, 2924, 1588;  δH (500 
MHz; CD3OD) 7.36 (1H, d, J = 8.5 Hz, 3-Ar-H), 6.79 (1H, d, J = 3.0 Hz, 6-Ar-H), 6.65 
(1H, dd, J = 8.5 and 3.0 Hz, 4-Ar-H), 3.20-3.11 (2H, m, CH2N), 3.05-2.97 (2H, m, 
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CH2CH2N);  δC (125 MHz; CD3OD) 158.8 (Ar-COH), 138.0 (Ar-C), 134.9 (3-Ar-CH), 
119.0 (6-Ar-CH), 117.4 (4-Ar-CH), 113.7 (Ar-CBr), 40.4 (CH2N), 35.0 (CH2CH2N). 
 
8.72 2-(2-Bromo-4,5-dihydroxyphenyl)ethan-1-amine trifluoroacetic acid salt (158) 
 
The title compound was prepared according to the procedure described in section 8.69, 
from amine 152 (140 mg, 0.538 mmol) and 1 M boron tribromide in CH2Cl2 (1.61 mL, 
1.61 mmol).  The crude black oil was purified by prep-HPLC (Method 2, Gradient B, 
run time: 30 min, rt = 14.6 min) to yield the product as a yellow oil as the TFA salt (110 
mg, 59%).  δH (300 MHz; CD3OD) 6.36 (1H, d, J = 2.5 Hz, Ar-H), 6.32 (1H, d, J = 2.5 
Hz, Ar-H), 3.28-3.08 (2H, m, CH2N), 3.05-2.95 (2H, m, CH2CH2N);  δC (150 MHz; 
CD3OD) 159.0 (Ar-COH), 156.7 (Ar-COH), 138.6 (Ar-C), 110.1 (Ar-CH), 103.4 (Ar-
CH), 102.4 (Ar-CBr), 40.4 (CH2N), 35.3 (CH2CH2N);  m/z (CI) 234 ([(
81
Br)M + H]
+
, 
100%), 232 ([(
79
Br)M + H]
+
, 95%);  HRMS C8H11NO2
79
Br, calcd 231.9973, found 
231.9973. 
 
8.73 2-(2-Bromo-4,5-dihydroxyphenyl)ethan-1-amine hydrobromide (159)
213
  
 
The title compound was prepared according to the procedure described in section 8.69, 
from amine 153 (655 mg, 2.52 mmol) and 1 M boron tribromide in CH2Cl2 (7.55 mL, 
7.55 mmol).  The product was isolated as a pale brown solid as the hydrobromide salt 
(716 mg, 91%).  δH (600 MHz; CD3OD) 6.97 (1H, s, 3-Ar-H), 6.77 (1H, s, 6-Ar-H), 
3.12-3.07 (2H, m, CH2N), 2.96-2.90 (2H, m, CH2CH2N);  δC (150 MHz; CD3OD) 147.0 
(Ar-COH), 146.7 (Ar-COH), 127.7 (Ar-C), 120.4 (3-Ar-CH), 118.4 (6-Ar-CH), 113.3 
(Ar-CBr), 40.7 (CH2N), 34.3 (CH2CH2N);  m/z (ESI) 234 ([(
81
Br)M + H]
+
, 95%), 232 
([(
79
Br)M + H]
+
, 100%);  HRMS C8H11NO2
79
Br, calcd 231.9973, found 231.9978.  
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8.74 1-Pentyl-1,2,3,4-tetrahydroisoquinolin-6-ol (160) and 1-Pentyl-1,2,3,4-
tetrahydroisoquinolin-8-ol (161) 
 
The title compounds were prepared according to the procedure described in section 
8.49, from amine 155 (150 mg, 0.688 mmol) and hexanal (126 µL, 1.03 mmol).  The 
crude mixture of products were separated and purified by prep-HPLC (Method 2, 
Gradient A, run time: 30 min) to give 160 as a pale yellow oil (rt = 24.5 min, 121 mg, 
81%) and 161 as a pale yellow oil (rt = 28.8 min, 17.3 mg, 12%). 
Major regioisomer 160: υmax/cm
-1 
3031 br, 2958, 2927, 2867, 1668, 1617, 1523;  H 
(600 MHz; CD3OD) 7.10 (1H, d, J = 8.5 Hz, 8-Ar-H), 6.72 (1H, dd, J = 8.5 and 2.5 Hz, 
7-Ar-H), 6.64 (1H, d, J = 2.5 Hz, 5-Ar-H), 4.42-4.38 (1H, m, 1-CH), 3.55-3.31 (2H, m, 
3-CH2), 3.10-2.95 (2H, m, 4-CH2), 2.10-1.84 (2H, m, 1-CHCH2), 1.55-1.35 (6H, m, 3 x 
CH2), 0.94 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 156.8 (Ar-COH), 132.4 
(Ar-C), 127.2 (8-Ar-CH), 122.6 (Ar-C), 114.5 (5-Ar-CH), 114.2 (7-Ar-CH), 55.2 (1-
CH), 39.1 (3-CH2), 33.5 (1-CHCH2), 31.2 (CH2), 24.8 (4-CH2), 24.5 (CH2), 21.9 (CH2), 
12.7 (CH3);  m/z (CI) 220 ([M + H]
+
, 80%), 148 ([M + H]
+
 - C5H12, 20%);  HRMS 
C14H22NO, calcd 220.1701, found 220.1706. 
Minor regioisomer 161: υmax/cm
-1 
3039 br, 2961, 2930, 2867, 1667, 1633, 1592;  H 
(600 MHz; CD3OD) 7.11 (1H, t, J = 8.0 Hz, 6-Ar-H), 6.72-6.68 (2H, m, 5-Ar-H, 7-Ar-
H), 4.60 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.55-3.32 (2H, m, 3-CH2), 3.12-3.00 (2H, 
m, 4-CH2), 2.14-1.79 (2H, m, 1-CHCH2), 1.62-1.34 (6H, m, 3 x CH2), 0.94 (3H, t, J = 
7.0 Hz, CH3);  C (150 MHz; CD3OD) 155.3 (Ar-COH), 133.5 (Ar-C), 129.8 (6-Ar-
CH), 121.1 (Ar-C), 120.8 (Ar-CH), 114.1 (Ar-CH), 53.1 (1-CH), 38.3 (3-CH2), 33.0 (1-
CHCH2), 32.5 (CH2), 26.7 (CH2), 25.9 (4-CH2), 23.5 (CH2), 14.3 (CH3);  m/z (CI) 220 
([M + H]
+
, 30%), 148 ([M + H]
+
 - C5H12, 100%);  HRMS C14H22NO, calcd 220.1701, 
found 220.1698. 
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8.75 5-Bromo-1-pentyl-1,2,3,4-tetrahydroisoquinolin-8-ol (162) 
 
Hexanal (49.0 µL, 0.404 mmol) was added to a solution of amine 157 (100 mg, 0.337 
mmol) in potassium phosphate buffer (5 mL, 0.5 M, pH 6) and acetonitrile (5 mL) 
under argon.  The solution was stirred at 50 
o
C for 18 h.  Hexanal (21.0 µL, 0.169 
mmol) was added to the reaction mixture and stirred at 50 
o
C for 5 h.  The reaction was 
concentrated under vacuum. CH2Cl2/CH3OH (1:1, 15 mL) was added to the resultant 
residue and the suspension filtered to remove the solid.  The filtrate was evaporated to 
dryness under vacuum to give the crude product, which was purified by prep-HPLC 
(Method 1, rt = 6.5 min).  Appropriate fractions were combined and co-evaporated with 
methanol (x3) to give the product as a pale yellow oil (14.2 mg, 14%).  υmax/cm
-1 
3031 
br, 2953, 2928, 2859, 1666, 1641, 1581;  H (600 MHz; CD3OD) 7.39 (1H, d, J = 8.5 
Hz, 6-Ar-H), 6.70 (1H, d, J = 8.5 Hz, 7-Ar-H), 4.62 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 
3.57-3.42 (2H, m, 3-CH2), 3.09-2.95 (2H, m, 4-CH2), 2.10-1.79 (2H, m, 1-CHCH2), 
1.64-1.47 (2H, m, 1-CHCH2CH2), 1.45-1.34 (4H, m, CH2CH2CH3), 0.94 (3H, t, J = 7.0 
Hz, CH3);  C (150 MHz; CD3OD) 154.8 (Ar-COH), 133.4 (6-Ar-CH), 132.6 (Ar-C), 
123.8 (Ar-C), 115.9 (7-Ar-CH), 114.4 (Ar-CBr), 52.7 (1-CH), 37.6 (3-CH2), 32.6 (1-
CHCH2), 32.4 (CH2), 27.4 (4-CH2), 26.7 (1-CHCH2CH2), 23.4 (CH2), 14.3 (CH3);  m/z 
(CI) 300 ([(
81
Br)M + H]
+
, 20%), 298 ([(
79
Br)M + H]
+
, 25%), 219 ([M + H]
+ 
- Br, 35%), 
131 ([M + H]
+ 
- C5H12BrO, 35%);  HRMS C14H21NO
79
Br, calcd 298.0811, found 
298.0807.  
 
8.76 5-Bromo-1-pentyl-1,2,3,4-tetrahydroisoquinoline-7,8-diol (163)  
 
The title compound was prepared according to the procedure described in section 8.53, 
from amine 159 (200 mg, 0.639 mmol) and hexanal (117 µL, 0.958 mmol).  The crude 
product was purified by prep-HPLC (Method 2, Gradient C, rt = 30.0 min) to give the 
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product as a yellow oil (13.2 mg, 7%).  υmax/cm
-1 
3039 br, 2953, 2930, 2859, 1667, 
1625;  H (600 MHz; CD3OD) 7.02 (1H, s, Ar-H), 4.63 (1H, dd, J = 9.5 and 3.5 Hz, 1-
CH), 3.53-3.38 (2H, m, 3-CH2), 3.00-2.87 (2H, m, 4-CH2), 2.12-1.79 (2H, m, 1-
CHCH2), 1.63-1.35 (6H, m, 3 x CH2), 0.94 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; 
CD3OD) 144.2 (Ar-COH), 141.6 (Ar-COH), 121.7 (Ar-C), 120.7 (Ar-C), 117.7 (Ar-
CH), 112.0 (Ar-C), 51.3 (1-CH), 36.3 (3-CH2), 31.0 (CH2), 30.9 (CH2), 25.1 (4-CH2, 
CH2), 21.9 (CH2), 13.0 (CH3);  m/z (ESI) 316 ([(
81
Br)M + H]
+
, 90%), 314 ([(
79
Br)M + 
H]
+
, 100%);  HRMS C14H21NO2
79
Br, calcd 314.0756, found 314.0708. 
 
8.77 1-Pentyl-1,2,3,4-tetrahydroisoquinoline-6,8-diol (164) 
 
The title compound was prepared according to the procedure described in section 8.53, 
from amine 156 (100 mg, 0.427 mmol) and hexanal (78.0 µL, 0.641 mmol).  The crude 
product was purified by prep-HPLC (Method 2, Gradient B, rt = 23.1 min) to give the 
product as a yellow oil (95.2 mg, 95%).  υmax/cm
-1 
3055 br, 2959, 2938, 2867, 1667, 
1599, 1523;  H (600 MHz; CD3OD) 6.22 (1H, d, J = 2.5 Hz, 7-Ar-H), 6.15 (1H, d, J = 
2.5 Hz, 5-Ar-H), 4.50 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.51-3.28 (2H, m, 3-CH2), 
3.02-2.90 (2H, m, 4-CH2), 2.10-1.75 (2H, m, 1-CHCH2), 1.59-1.33 (6H, m, 3 x CH2), 
0.94 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 159.1 (Ar-COH), 156.5 (Ar-
COH), 134.1 (Ar-C), 122.4 (Ar-C), 107.2 (5-Ar-CH), 102.0 (7-Ar-CH), 53.1 (1-CH), 
38.3 (3-CH2), 33.3 (1-CHCH2), 32.5 (CH2), 26.6 (CH2), 26.1 (4-CH2), 23.5 (CH2), 14.4 
(CH3);  m/z (ESI) 236 ([M + H]
+
, 100%), 219 ([M + H]
+ 
- OH, 70%), 149 ([M + H]
+ 
- 
C5H11O, 80%);  HRMS C14H22NO2, calcd 236.1651, found 236.1660. 
 
8.78 5-Bromo-1-pentyl-1,2,3,4-tetrahydroisoquinoline-6,8-diol (165) 
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The title compound was prepared according to the procedure described in section 8.53, 
from amine 158 (100 mg, 0.289 mmol) and hexanal (53.0 µL, 0.433 mmol).  The crude 
product was purified by prep-HPLC (Method 2, Gradient E, run time: 20 min, flow rate: 
8 mL/min, rt = 7.8 min) to give the product as a yellow oil (65.0 mg, 72%).  υmax/cm
-1 
3039 br, 2959, 2938, 2867, 1666, 1588;  H (600 MHz; CD3OD) 6.45 (1H, s, 7-Ar-H),  
4.53 (1H, dd, J = 9.5 and 3.5 Hz, 1-CH), 3.54-3.39 (2H, m, 3-CH2), 3.08-2.93 (2H, m, 
4-CH2), 2.08-1.76 (2H, m, 1-CHCH2), 1.61-1.44 (2H, m, 1-CHCH2CH2), 1.43-1.34 (4H, 
m, CH2CH2CH3), 0.94 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 155.7 (Ar-
COH), 155.4 (Ar-COH), 133.1 (Ar-C), 114.6 (Ar-C), 102.6 (7-Ar-CH), 102.5 (Ar-CBr), 
52.6 (1-CH), 37.7 (3-CH2), 33.0 (1-CHCH2), 32.5 (CH2), 27.6 (4-CH2), 26.7 (1-
CHCH2CH2), 23.5 (CH2) 14.3 (CH3);  m/z (ESI) 316 ([(
81
Br)M + H]
+
, 100%), 314 
([(
79
Br)M + H]
+
, 100%), 229 ([(
81
Br)M + H]
+ 
- C5H11O, 65%), 227 ([(
79
Br)M + H]
+ 
- 
C5H11O, 65%);  HRMS C14H21NO2
79
Br, calcd 314.0756, found 314.0801. 
 
8.79 1-Pentyl-1,2,3,4-tetrahydroisoquinolin-7-ol (166) 
 
The title compound was prepared according to the procedure described in section 8.69, 
from the 1.6/1 mixture of THIQ regioisomers 170 and 171 (34.0 mg, 0.146 mmol) and a 
1 M solution of boron tribromide in CH2Cl2 (0.364 mL, 0.364 mmol).  The crude 
mixture of products were separated and purified by prep-HPLC (Method 2, Gradient A) 
to give 166 as a pale yellow oil (rt = 32.6 min, 13.8 mg, 43%) and 160 as a colourless 
oil (rt = 37.1 min, 7.3 mg, 23%). 
Major regioisomer 166: υmax/cm
-1 
3039 br, 2959, 2938, 2867, 1668, 1625, 1506;  H 
(600 MHz; CD3OD) 7.06 (1H, d, J = 8.0 Hz, 5-Ar-H), 6.74 (1H, dd, J = 8.0 and 2.5 Hz, 
6-Ar-H), 6.68 (1H, d, J = 2.5 Hz, 8-Ar-H), 4.45-4.41 (1H, m, 1-CH), 3.57-3.29 (2H, m, 
3-CH2), 3.07-2.93 (2H, m, 4-CH2), 2.11-1.88 (2H, m, 1-CHCH2), 1.57-1.36 (6H, m, 3 x 
CH2), 0.95 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 157.7 (Ar-COH), 134.4 
(Ar-C), 131.4 (5-Ar-CH), 123.0 (Ar-C), 116.7 (6-Ar-CH), 113.6 (8-Ar-CH), 56.9 (1-
CH), 41.0 (3-CH2), 35.0 (1-CHCH2), 32.7 (CH2), 26.2 (CH2), 25.5 (4-CH2), 23.5 (CH2), 
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14.3 (CH3);  m/z (CI) 220 ([M + H]
+
, 100%), 148 ([M + H]
+
 - C5H12, 50%);  HRMS 
C14H22NO, calcd 220.1701, found 220.1699. 
Minor regioisomer 160: Characterisation data listed in section 8.74. 
 
8.80 N-(4-Methoxyphenethyl)hexanamide (167) 
 
Triethylamine (4.15 mL, 29.8 mmol) was added to a stirred solution of amine 169 (900 
mg, 5.95 mmol) in CH2Cl2 (65 mL) at 0 
o
C.  After 5 min, a solution of hexanoyl 
chloride (1 mL, 7.14 mmol) in CH2Cl2 (15 mL) was added to the reaction mixture 
dropwise at 0 
o
C.  After stirring the reaction at rt for 24 h, water (100 mL) was added.  
The aqueous phase was extracted with CH2Cl2 (3 x 50 mL).  The combined organic 
extracts were washed with brine, dried (Na2SO4) and solvent removed in vacuo to give 
the crude product as a white solid, which was purified by column chromatography 
(EtOAc/petrol, 1:1) to give the product as a white solid (1.34 g, 90%).  Rf 0.34 
(EtOAc/petrol, 1:1);  m.p. 78-79 
o
C;  υmax/cm
-1 
(CDCl3 cast) 3308, 2961, 2929, 2891, 
1637, 1617, 1544, 1514;  δH (500 MHz; CDCl3) 7.10 (2H, d, J = 8.5 Hz, 2 x 2-Ar-H), 
6.84 (2H, d, J = 8.5 Hz, 2 x 3-Ar-H), 5.41 (1H, br s, NH), 3.79 (3H, s, OCH3), 3.52-3.45 
(2H, m, CH2N), 2.75 (2H, t, J = 7.0 Hz, CH2CH2N), 2.11 (2H, t, J = 7.5 Hz, COCH2), 
1.62-1.20 (6H, m, 3 x CH2), 0.88 (3H, t, J = 7.0 Hz, CH3);  δC (125 MHz; CDCl3) 173.2 
(CONH), 158.4 (Ar-CO), 131.0 (Ar-C), 129.8 (2 x 2-Ar-CH), 114.1 (2 x 3-Ar-CH), 
55.3 (OCH3), 40.7 (CH2N), 36.9 (COCH2), 34.9 (CH2CH2N), 31.5 (CH2), 25.5 (CH2), 
22.5 (CH2), 14.0 (CH3);  m/z (EI) 249 (M
+
, 5%), 134 (M
+
 - C7H15O, 100%);  HRMS 
C15H23NO2, calcd 249.1729, found 249.1728. 
 
8.81 2-(4-Methoxyphenyl)ethan-1-amine (169)
156
 
 
The title compound was prepared according to the procedure described in section 8.64, 
from 4-methoxyphenylacetonitrile (1.50 g, 10.2 mmol) and a 1 M borane 
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tetrahydrofuran complex solution in THF (25.5 mL, 25.5 mmol).  The crude product 
was purified by column chromatography (CH2Cl2/CH3OH(+1% Et3N), 85:15) to give 
the product as a pale yellow oil (1.17 g, 76%).  Rf 0.14 (CH2Cl2/CH3OH(+1% Et3N), 
4:1);  δH (500 MHz; CDCl3) 7.11 (2H, d, J = 8.5 Hz, 2 x 2-Ar-H), 6.84 (2H, d, J = 8.5 
Hz, 2 x 3-Ar-H), 3.83 (3H, s, OCH3), 2.93 (2H, t, J = 7.0 Hz, CH2N), 2.68 (2H, t, J = 
7.0 Hz, CH2CH2N), 1.26 (2H, br s, NH2);  δC (125 MHz; CDCl3) 158.1 (Ar-CO), 132.0 
(Ar-C), 129.8 (2 x 2-Ar-CH), 114.0 (2 x 3-Ar-CH), 55.3 (OCH3), 43.8 (CH2N), 39.3 
(CH2CH2N).  
 
8.82 7-Methoxy-1-pentyl-1,2,3,4-tetrahydroisoquinoline (170) and 6-Methoxy-1-
pentyl-1,2,3,4-tetrahydroisoquinoline (171) 
 
To a solution of amide 167 (100 mg, 0.401 mmol) in xylene (5 mL), was added P2O5 
(142 mg, 1.00 mmol) and POCl3 (0.336 mL, 3.61 mmol), and the mixture was heated at 
reflux for 20 h.  After cooling to rt, the reaction mixture was quenched with water (10 
mL), then 2 M NaOH was added until the solution was basic.  The aqueous phase was 
extracted with EtOAc (3 x 20 mL).  The organic extracts were combined, washed with 
brine, dried (Na2SO4) and solvent removed in vacuo to yield the intermediate imine as a 
yellow oil which was used in the next step without further purification.  To a solution of 
the imine in methanol (10 mL) at 0 
o
C, was added sodium borohydride (121 mg, 3.21 
mmol) portionwise and the mixture was stirred at rt for 2 h.  The mixture was 
concentrated under vacuum.  To the resulting residue, water (15 mL) was added, and 
extracted with EtOAc (3 x 25 mL).  The organic extracts were combined, washed with 
brine, dried (Na2SO4) and solvent evaporated in vacuo to give the crude product as a 
mixture of products 170 and 171 (56.7 mg, 37%) as a yellow oil, in a ratio 1.6:1 as 
determined by 
1
H-NMR.  H (600 MHz; CD3OD) 7.20 (1H, d, J = 8.5 Hz, minor Ar-H), 
7.16 (1H, d, J = 8.5 Hz, major Ar-H), 6.90-6.85 (2H, m, major Ar-H, minor Ar-H), 6.81 
(1H, d, J = 2.5 Hz, major Ar-H), 6.79 (1H, d, J = 2.5 Hz, minor Ar-H), 4.51-4.47 (1H, 
m, major 1-CH), 4.46-4.43 (1H, m, minor 1-CH), 3.79-3.78 (6H, m, major OCH3, minor 
OCH3), 3.59-3.32 (4H, m, major 3-CH2, minor 3-CH2), 3.16-2.97 (4H, m, major 4-CH2, 
minor 4-CH2), 2.14-1.87 (4H, m, major CH2, minor CH2), 1.57-1.34 (12H, m, major 3 x 
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CH2, minor 3 x CH2), 0.98-0.91 (6H, m, major CH3, minor CH3);  m/z (ESI) 234 ([M + 
H]
+
, 100%). 
 
8.83 1-Pentyl-1,2,3,4-tetrahydroisoquinolin-6-amine (177) 
 
The title compound was prepared according to the procedure described in section 8.49, 
from amine 178 (2 eq HCl, 104 mg, 0.497 mmol) and hexanal (73.0 µL, 0.597 mmol).  
The crude product was purified by prep-HPLC (Method 2, Gradient A, rt = 28.0 min) to 
give the product as a yellow oil (66.2 mg, 61%).  υmax/cm
-1 
2960, 2934, 2864, 1656, 
1523;  H (600 MHz; CD3OD) 7.30 (1H, d, J = 8.0 Hz, 8-Ar-H), 7.06 (1H, d, J = 8.0 Hz, 
7-Ar-H), 7.00 (1H, s, 5-Ar-H), 4.53-4.47 (1H, m, 1-CH), 3.60-3.35 (2H, m, 3-CH2), 
3.18-3.03 (2H, m, 4-CH2), 2.13-1.87 (2H, m, 1-CHCH2), 1.56-1.35 (6H, m, 3 x CH2), 
0.94 (3H, t, J = 7.0 Hz, CH3);  C (150 MHz; CD3OD) 134.6 (Ar-C), 129.3 (8-Ar-CH), 
121.0 (5-Ar-CH), 120.0 (6-Ar-CH), 56.6 (1-CH), 40.4 (3-CH2), 35.0 (1-CHCH2), 32.7 
(CH2), 26.3 (4-CH2), 26.1 (CH2), 23.5 (CH2), 14.3 (CH3);  m/z (ESI) 219 ([M + H]
+
, 
100%);  HRMS C14H23N2, calcd 219.1861, found 219.1858. 
  
8.84 3-(2-Aminoethyl)aniline hydrochloride (178)
122
 
 
The title compound was prepared based on a literature procedure.
122
  To a solution of 3-
nitrophenethylamine hydrochloride (100 mg, 0.493 mmol) in methanol (7 mL), was 
added palladium on carbon 10% (12 mg).  The flask was evacuated and re-filled with H2 
using a H2 balloon.  The reaction was stirred at rt for 5 h and then filtered through Celite 
and washed with methanol.  The filtrate was evaporated to give the product as a yellow 
oil (104 mg, 100%) as the hydrochloride salt.  δH (600 MHz; CD3OD) 7.07 (1H, t, J = 
7.5 Hz, 5-Ar-H), 6.63-6.54 (3H, m, 2-Ar-H, 4-Ar-H, 6-Ar-H), 3.13 (2H, t, J = 7.5 Hz, 
CH2N), 2.83 (2H, t, J = 7.5 Hz, CH2CH2N);  δC (150 MHz; CD3OD) 149.4 (Ar-C), 
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138.6 (Ar-C), 130.7 (5-Ar-CH), 119.2 (Ar-CH), 116.5 (Ar-CH), 115.4 (Ar-CH), 42.0 
(CH2N), 34.7 (CH2CH2N);  m/z (ESI) 137 ([M + H]
+
, 100%);  HRMS C8H13N2, calcd 
137.1079, found 137.1079. 
   
8.85 3-(2-Aminoethyl)-4-bromoaniline (179) 
 
N-Bromosuccinimide (54.3 mg, 0.305 mmol) was added portionwise to a solution of 
amine 178 (1.2 eq HCl, 50 mg, 0.278 mmol) in acetonitrile (2 mL) and methanol (0.5 
mL) at 0 
o
C.  The reaction was stirred at 0 
o
C for 1 h, then concentrated in vacuo.  The 
resulting crude product was purified by column chromatography (CH2Cl2/CH3OH(+1% 
Et3N), 85:15) to yield the product as a pale yellow oil (41.0 mg, 69%).  Rf 0.28 
(CH2Cl2/CH3OH(+1% Et3N), 4:1);  υmax/cm
-1 
3331, 2945, 2875, 1597, 1578;  δH (600 
MHz; CD3OD) 7.20 (1H, d, J = 8.5 Hz, 5-Ar-H), 6.63 (1H, d, J = 2.5 Hz, 2-Ar-H), 6.47 
(1H, dd, J = 8.5 and 2.5 Hz, 6-Ar-H), 2.88-2.80 (2H, m, CH2N), 2.78-2.74 (2H, m, 
CH2CH2N);  δC (150 MHz; CD3OD) 148.8 (Ar-C), 140.2 (Ar-C), 134.1 (5-Ar-CH), 
118.6 (2-Ar-CH), 116.3 (6-Ar-CH), 112.2 (Ar-CBr), 42.6 (CH2N), 40.4 (CH2CH2N);  
m/z (ESI) 217 ([(
81
Br)M + H]
+
, 100%), 215 ([(
79
Br)M + H]
+
, 100%);  HRMS 
C8H12N2
79
Br, calcd 215.0184, found 215.0205. 
 
8.86 Methyl 5-oxopentanoate (181)
170
 
 
The title compound was prepared according to a literature procedure, except the product 
was purified by column chromatography rather than distillation.
170
  To a solution of -
valerolactone (500 mg, 4.99 mmol) in methanol (10 mL) was added concentrated 
sulfuric acid (1 drop) and stirred at 65 
o
C for 5 h.  The reaction mixture was cooled to 0 
o
C and solid NaHCO3 (500 mg) was added.  The mixture was filtered, and the filtrate 
was evaporated to give the intermediate alcohol 185 as a colourless oil (539 mg, δH (300 
MHz; CDCl3) 3.68-3.60 (5H, m, OCH3, CH2OH), 2.36 (2H, t, J = 7.0 Hz, CH2CO2Me), 
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1.79-1.50 (4H, m, CH2CH2CH2OH)), which was used immediately in the next step 
without further purification.  To a solution of oxalylchloride (0.470 mL, 5.50 mmol) in 
CH2Cl2 (5 mL) at -78 
o
C, was added a solution of DMSO (0.780 mL, 11.0 mmol) in 
CH2Cl2 (5 mL) dropwise.  The reaction mixture was stirred for 10 min, then a solution 
of the alcohol 185 in CH2Cl2 (5 mL) was added and the reaction stirred at -78 
o
C for 30 
min.  Triethylamine (3.69 mL, 26.5 mmol) was added and the mixture allowed to warm 
to rt.  A saturated NH4Cl solution (30 mL) was added to the mixture and then extracted 
with CH2Cl2 (3 x 20 mL).  The combined organic extracts were washed with water, 
brine, dried (Na2SO4) and the solvent evaporated under vacuum at rt to give the crude 
product as a yellow oil which was purified by column chromatography (hexane/Et2O, 
2:1) to give the product as a colourless oil (202 mg, 31%).  Rf  0.20 (hexane/Et2O, 2:1);  
δH (500 MHz; CDCl3) 9.78 (1H, s, CHO), 3.67 (3H, s, OCH3), 2.51 (2H, t, J = 7.0 Hz, 
4-CH2), 2.37 (2H, t, J = 7.0 Hz, 2-CH2), 2.00-1.90 (2H, m, 3-CH2);  δC (125 MHz; 
CDCl3) 201.5 (CHO), 173.4 (CO2CH3), 51.7 (OCH3), 43.0 (4-CH2), 33.0 (2-CH2), 17.4 
(3-CH2);  m/z (CI) 131 ([M + H]
+
, 100%);  HRMS C6H11O3, calcd 131.0708, found 
131.0704. 
 
8.87 Methyl 4-(6,8-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)butanoate (182) 
 
The title compound was prepared according to the procedure described in section 8.53 
from amine 156 (50.0 mg, 0.214 mmol) and aldehyde 181 (33.4 mg, 0.257 mmol).  The 
crude yellow oil was purified by prep-HPLC (Method 2, Gradient B, flow rate: 8 
mL/min, rt = 15.7 min) to give the product as a yellow oil (49.1 mg, 87%).  A minor 
product collected from the column was lactam 183 (rt = 20.8 min, 1.9 mg, 4%).  H (600 
MHz; CD3OD) 6.22 (1H, d, J = 2.0 Hz, 7-Ar-H), 6.15 (1H, d, J = 2.0 Hz, 5-Ar-H), 4.52 
(1H, dd, J = 9.0 and 3.5 Hz, 1-CH), 3.67 (3H, s, OCH3), 3.52-3.30 (2H, m, 3-CH2), 
3.04-2.89 (2H, m, 4-CH2), 2.44 (2H, t, J = 7.0 Hz, CH2CO2CH3), 2.10-1.72 (4H, m, 1-
CHCH2CH2);  C (150 MHz; CD3OD) 175.5 (CO2CH3), 159.2 (Ar-COH), 156.4 (Ar-
COH), 134.1 (Ar-C), 112.1 (Ar-C), 107.3 (5-Ar-CH), 102.0 (7-Ar-CH), 52.5 (1-CH), 
52.1 (OCH3), 38.3 (3-CH2), 34.0 (CH2CO2CH3), 32.7 (1-CHCH2), 26.0 (4-CH2), 22.1 
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(1-CHCH2CH2);  m/z (CI) 266 ([M + H]
+
, 100%), 235 ([M + H]
+
 - OCH3, 30%), 165 
([M + H]
+
 - C5H9O2, 30%);  HRMS C14H20NO4, calcd 266.1392, found 266.1390. 
   
8.88 9,11-Dihydroxy-1,2,3,6,7,11b-hexahydro-4H-pyrido[2,1-a]isoquinolin-4-one 
(183) 
 
A solution of aldehyde 181 (20.0 mg, 0.154 mmol) in acetonitrile (1.5 mL) was added 
to a solution of amine 156 (30.0 mg, 0.128 mmol) in potassium phosphate buffer (1.5 
mL, 0.1 M, pH 6) under argon, and the mixture was stirred at 50 
o
C for 5 h.  Sat. K2CO3 
solution (0.1 mL) was added to the reaction mixture and stirred at rt for 24 h.  The pH of 
the mixture was adjusted to 4 by addition of dilute HCl and concentrated under vacuum.  
CH2Cl2/CH3OH (1:1, 10 mL) was added to the resultant residue and the suspension 
filtered to remove the solid.  The filtrate was evaporated to dryness to give the crude 
product as an orange oil, which was purified by prep-HPLC (Method 2, Gradient D, run 
time: 30 min, rt = 22.8 min).  Product containing fractions were concentrated and co-
evaporated with methanol (x3), to yield the product as a yellow oil (12.1 mg, 40%).  
υmax/cm
-1  
3219 br, 2923, 2852, 1673, 1572;  H (600 MHz; CD3OD) 6.17 (1H, d, J = 2.0 
Hz, 10-Ar-H), 6.09 (1H, d, J = 2.0 Hz, 8-Ar-H), 4.79 (1H, d, J = 11.5 Hz, 6-CHH), 4.72 
(1H, d, J = 11.5 Hz, 11b-CH), 2.95-2.88 (1H, m, 1-CHH), 2.73-2.58 (2H, m, 6-CHH, 7-
CHH), 2.57-2.47 (2H, m, 7-CHH, 3-CHH), 2.44-2.35 (1H, m, 3-CHH), 1.91-1.80 (2H, 
m, 2-CH2), 1.35-1.20 (1H, m, 1-CHH);  C (150 MHz; CD3OD) 172.8 (NCO), 157.7 
(Ar-COH), 156.6 (Ar-COH), 138.7 (Ar-C), 115.9 (Ar-C), 107.5 (8-Ar-CH), 102.0 (10-
Ar-CH), 56.1 (11b-CH), 40.3 (6-CH2), 32.5 (3-CH2), 30.9 (7-CH2), 30.5 (1-CH2), 20.3 
(2-CH2);  m/z (ESI) 234 ([M + H]
+
, 100%);  HRMS C13H16NO3, calcd 234.1130, found 
234.1137. 
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8.89 Methyl 2-(6,8-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)acetate (187) 
 
Trifluoroacetic acid (0.5 mL) and water (0.5 mL) were added to a solution of methyl 
3,3-dimethoxypropionate (400 mg, 2.70 mmol) in CH2Cl2 (2 mL), and the reaction was 
stirred at rt for 24 h.  The reaction mixture was diluted with water (4 mL) and extracted 
with CH2Cl2 (3 x 10 mL).  The combined organic extracts were dried (Na2SO4) and 
solvent removed in vacuo at rt to give crude methyl 3-oxopropanoate 186 as a 
colourless oil (245 mg, δH (300 MHz; CDCl3) 9.81 (1H, t, J = 2.5 Hz, CHO), 3.79 (3H, 
s, OCH3), 3.42 (2H, d, J = 2.5 Hz, CH2)), which was used in the next step without 
further purification.  The title compound was prepared according to the procedure 
described in section 8.53 from amine 156 (50.0 mg, 0.214 mmol) and crude aldehyde 
186 (245 mg).  The crude yellow oil was purified by prep-HPLC (Method 2, Gradient 
C, rt = 13.5 min), to give the product as a yellow oil (29.4 mg, 58%).  H (600 MHz; 
CD3OD) 6.23 (1H, s, 7-Ar-H), 6.17 (1H, s, 5-Ar-H), 4.90-4.87 (1H, m, 1-CH), 3.78 
(3H, s, OCH3), 3.49-3.34 (2H, m, 3-CH2), 3.20-3.15 (1H, m, 1-CHCHH), 3.03-2.88 
(3H, m, 4-CH2, 1-CHCHH);  C (150 MHz; CD3OD) 171.5 (CO2CH3), 158.0 (Ar-
COH), 154.8 (Ar-COH), 133.0 (Ar-C), 108.4 (Ar-C), 105.8 (5-Ar-CH), 100.7 (7-Ar-
CH), 51.2 (1-CH, OCH3), 37.0 (CH2), 34.2 (CH2), 24.7 (4-CH2);  m/z (CI) 238 ([M + 
H]
+
, 20%), 206 ([M + H]
+
 - CH4O, 100%);  HRMS C12H16NO4, calcd 238.1079, found 
238.1073. 
 
8.90 3-(3,4-Dimethoxyphenyl)propanamide (193)
174
 
 
The title compound was prepared based on a literature procedure.
174
  To a solution of 3-
(3,4-dimethoxyphenyl)propanoic acid (4.00 g, 19.0 mmol) in CH2Cl2 (24 mL) was 
added thionyl chloride (4.17 mL, 57.1 mmol) and 8 drops of DMF as a catalyst.  The 
resulting bright yellow solution was stirred at rt for 2 h.  Thionyl chloride (0.70 mL, 
9.50 mmol) and one drop of DMF was added to the reaction and stirred at rt for 1 h.  
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The reaction was concentrated in vacuo and and the residue co-evaporated with CH2Cl2 
(x3) to remove excess thionyl chloride.  The resultant residue was dissolved in THF (40 
mL) and added dropwise to a 28% ammonium hydroxide solution (120 mL) at 0 
o
C.  
The solution was left overnight at rt.  The solvents were removed in vacuo to give a 
white solid which was partitioned between 0.1 M aqueous NaOH (40 mL) and EtOAc 
(120 mL).  The organic phase was separated and the aqueous phase extracted with 
EtOAc (2 x 100 mL).  The combined organic extracts were passed through a 
hydrophobic frit and evaporated in vacuo to yield the product as a white solid (3.80 g, 
95%).  Rf  0.33 (EtOAc);  m.p. 110-111 
o
C (lit
214
 120-121 
o
C, benzene);  δH (500 MHz; 
CDCl3) 6.81-6.73 (3H, m, 3 x Ar-H), 5.58-5.26 (2H, br m, CONH2), 3.86 (3H, s, 
OCH3), 3.85 (3H, s, OCH3), 2.92 (2H, t, J = 7.5 Hz, CH2), 2.51 (2H, t, J = 7.5 Hz, CH2);  
δC (125 MHz; CDCl3) 174.6 (CONH2), 149.0 (Ar-C), 147.6 (Ar-C), 133.3 (Ar-C), 120.2 
(Ar-CH), 111.7 (Ar-CH), 111.4 (Ar-CH), 56.0 (2 x OCH3), 37.9 (CH2), 31.1 (CH2);  m/z 
(EI) 209 (M
+
, 30%), 151 (M
+
 - CH2CONH2, 100%);  HRMS C11H15NO3, calcd 
209.1049, found 209.1045. 
 
8.91 3-(3,4-Dimethoxyphenyl)propan-1-amine (194)
175
 
 
To a stirred 1 M solution of LiAlH4 in THF (28.7 mL, 28.7 mmol) at 0 
o
C was added 
slowly a solution of amide 193 (2.00 g, 9.56 mmol) in THF (80 mL).  The solution was 
gently stirred at rt for 5 h, after which time a precipitate had formed.  The reaction was 
cooled to 0 
o
C and quenched by the dropwise addition of water (20 mL).  The solvents 
were evaporated in vacuo.  CH2Cl2 (100 mL) was added to the residue and the mixture 
passed through a hydrophobic frit.  The filtrate was concentrated in vacuo to give the 
crude product as a yellow oil which was purified by column chromatography 
(CH2Cl2/CH3OH(+1% Et3N), 85:15) to give the product as an off white oil (1.43 g, 
77%).  Rf  0.36 (CH2Cl2/CH3OH(+1% Et3N), 85:15);  δH (500 MHz; CDCl3) 6.76 (1H, 
d, J = 8.0 Hz, 6-Ar-H), 6.73-6.69 (2H, m, 2-Ar-H, 5-Ar-H), 3.86 (3H, s, OCH3), 3.84 
(3H, s, OCH3),  2.74 (2H, t, J = 7.0 Hz, CH2N), 2.60 (2H, t, J = 7.0 Hz, CH2(CH2)2N), 
2.28 (2H, br s, NH2), 1.79 (2H, quintet, J = 7.0 Hz, CH2CH2N);  δC (125 MHz; CDCl3) 
148.9 (Ar-CO), 147.3 (Ar-CO), 134.5 (Ar-C), 120.2 (6-Ar-CH), 111.8 (Ar-CH), 111.3 
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(Ar-CH), 56.0 (OCH3), 55.9 (OCH3), 41.5 (CH2N), 34.8 (CH2CH2N), 32.8 
(CH2(CH2)2N);  m/z (EI) 195 (M
+
, 50%), 178 (M
+
 - NH3, 100%);  HRMS C11H17NO2, 
calcd 195.1254, found 195.1246. 
 
8.92 3-(3,4-Dihydroxyphenyl)propan-1-amine hydrobromide (195)
176
 
 
The title compound was prepared according to the procedure described in section 8.69, 
from amine 194 (356 mg, 1.82 mmol) and a solution of 1 M boron tribromide in CH2Cl2 
(5.47 mL, 5.47 mmol).  The product was isolated as a brown oil as the hydrobromide 
salt (478 mg, >100% crude).  δH (500 MHz; CD3OD) 6.68 (1H, d, J = 7.5 Hz, 5-Ar-H), 
6.64 (1H, s, 2-Ar-H), 6.52 (1H, d, J = 7.5 Hz, 6-Ar-H), 2.89 (2H, t, J = 7.5 Hz, CH2N), 
2.55 (2H, t, J = 7.5 Hz, CH2(CH2)2N), 1.90 (2H, quintet, J = 7.5 Hz, CH2CH2N);  δC 
(125 MHz; CD3OD) 146.4 (Ar-CO), 144.7 (Ar-CO), 133.2 (Ar-C), 120.6 (6-Ar-CH), 
116.5 (Ar-CH), 116.4 (Ar-CH), 40.3 (CH2N), 32.9 (CH2(CH2)2N), 30.5 (CH2CH2N);  
m/z (ESI) 168 ([M + H]
+
, 10%), 164 ([M + H]
+
 - H4, 100%). 
 
8.93 3-(3,5-Dihydroxyphenyl)propan-1-amine hydrobromide (196) 
 
The title compound was prepared according to the procedure described in section 8.69, 
from amine 198 (190 mg, 0.947 mmol) and a solution of 1 M boron tribromide in 
CH2Cl2 (2.92 mL, 2.92 mmol).  The product was isolated as a pale brown oil as the 
hydrobromide salt (242 mg, 100%).  δH (600 MHz; CD3OD) 6.17 (2H, s, 2 x 2-Ar-H), 
6.13 (1H, s, 4-Ar-H), 2.91 (2H, t, J = 7.5 Hz, CH2N), 2.56 (2H, t, J = 7.5 Hz, 
CH2(CH2)2N), 1.93 (2H, quintet, J = 7.5 Hz, CH2CH2N);  δC (150 MHz; CD3OD) 159.7 
(2 x Ar-C), 143.8 (Ar-C), 107.8 (2 x 2-Ar-CH), 101.5 (4-Ar-CH), 40.3 (CH2N), 33.5 
(CH2(CH2)2N), 30.1 (CH2CH2N);  m/z (ESI) 168 ([M + H]
+
, 70%);  HRMS C9H14NO2, 
calcd 168.1025, found 168.1014. 
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8.94 3-(3,5-Dimethoxyphenyl)propanamide (197)
177
 
 
The title compound was prepared according to the procedure described in section 8.90, 
from 3-(3,5-dimethoxyphenyl)propanoic acid (900 mg, 4.28 mmol), to yield the product 
as a yellow solid (480 mg, 54%).  M.p. 67-69 
o
C (lit
177
 80-81 
o
C).  δH (500 MHz; 
CDCl3) 6.38 (2H, s, 2 x 2-Ar-H), 6.31 (1H, s, 4-Ar-H), 5.55-5.35 (2H, m, NH2), 3.78 
(6H, s, 2 x OCH3), 2.92 (2H, t, J = 7.5 Hz, CH2CH2CO), 2.52 (2H, t, J = 7.5 Hz, 
CH2CO);  δC (125 MHz; CDCl3) 174.4 (CONH2), 161.0 (2 x Ar-CO), 143.1 (Ar-C), 
106.4 (2 x 2-Ar-CH), 98.3 (4-Ar-CH), 55.4 (2 x OCH3), 37.4 (CH2CO), 31.7 
(CH2CH2CO);  m/z (CI) 210 ([M + H]
+
, 30%), 193 ([M + H]
+
 - NH3, 100%);  HRMS 
C11H16NO3, calcd 210.1130, found 210. 1134. 
 
8.95 3-(3,5-Dimethoxyphenyl)propan-1-amine (198) 
 
The title compound was prepared according to the procedure described in section 8.91, 
from amide 197 (425 mg, 2.03 mmol).  The crude yellow oil was purified by column 
chromatography (CH2Cl2/CH3OH(+1% Et3N), 9:1) to give the product as a pale yellow 
oil (190 mg, 48%).  Rf  0.12 (CH2Cl2/CH3OH(+1% Et3N), 9:1);  υmax/cm
-1 
(CDCl3 cast) 
2935, 2852, 1593;  δH (600 MHz; CDCl3) 6.35 (2H, d, J = 2.5 Hz, 2 x 2-Ar-H), 6.30 
(1H, d, J = 2.5 Hz, 4-Ar-H), 3.77 (6H, s, 2 x OCH3), 2.74 (2H, t, J = 7.5 Hz, CH2N), 
2.59 (2H, t, J = 7.5 Hz, CH2(CH2)2N), 1.85-1.74 (4H, m, CH2CH2NH2);  δC (150 MHz; 
CDCl3) 160.9 (2 x Ar-CO), 144.6 (Ar-C), 106.5 (2 x 2-Ar-CH), 97.8 (4-Ar-CH), 55.4 (2 
x OCH3), 41.8 (CH2N), 34.9 (CH2CH2N), 33.7 (CH2(CH2)2N);  m/z (CI) 196 ([M + H]
+
, 
100%), 179 ([M + H]
+
 - NH3, 50%);  HRMS C11H18NO2, calcd 196.1338, found 
196.1333. 
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8.96 1-Phenyl-2,3,4,5-tetrahydrobenzazepin-7,8-diol (202) 
 
A solution of 1 M boron tribromide in heptane (0.900 mL, 0.900 mmol) was added to a 
stirred solution of THBP 203 (85.0 mg, 0.300 mmol) in dichloromethane (1.5 mL) at     
-78 
o
C.  The reaction was warmed to rt and stirred for 20 h.  The reaction was cooled to 
0 
o
C and quenched by the addition of water (8 mL).  The pH of the solution was 
adjusted to 7 by addition of 1 M aqueous NaOH, and the aqueous phase was extracted 
with EtOAc (3 x 20 mL).  The aqueous phase was adjusted to pH 10 and extracted with 
EtOAc (3 x 20 mL).  The combined organic extracts were dried by passing through a 
hydrophobic frit, and solvent removed in vacuo to give the crude product as a brown oil, 
which was purified by prep-HPLC (Method 1, run time: 15 min, rt = 11.0 min).  Product 
containing fractions were concentrated and co-evaporated with methanol (x3), to give 
the product as a yellow oil (8.3 mg, 11%).  υmax/cm
-1 3064 br, 1671, 1610, 1520;  δH 
(500 MHz; CD3OD) 7.59-7.44 (3H, m, 2 x 3’-Ar-H, 4’-Ar-H), 7.39 (2H, d, J = 7.5 Hz, 
2 x 2’-Ar-H), 6.74 (1H, s, 6-Ar-H), 6.16 (1H, s, 9-Ar-H), 5.72 (1H, s, 1-CH), 3.55-3.41 
(2H, m, 3-CH2), 3.22-2.77 (2H, m, 5-CH2), 2.21-1.75 (2H, m, 4-CH2);  δC (125 MHz; 
CD3OD) 147.0 (Ar-CO), 144.6 (Ar-CO), 137.5 (Ar-C), 135.2 (Ar-C), 130.5 (2 x 3’-Ar-
CH), 130.2 (4’-Ar-CH), 128.9 (2 x 2’-Ar-CH), 127.4 (Ar-C), 118.5 (6-Ar-CH, 9-Ar-
CH), 65.5 (1-CH), 50.8 (3-CH2), 34.2 (5-CH2), 26.8 (4-CH2);  m/z (EI) 255 (M
+
, 85%), 
178 (M
+
 - C6H5, 75%);  HRMS C16H17O2N, calcd 255.1259, found 255.1250. 
 
8.97 1-Phenyl-7,8-dimethoxy-2,3,4,5-tetrahydrobenzazepine (203)
143
 
 
The title compound was prepared according to a literature procedure.
143
  POCl3 (0.27 
mL, 2.94 mmol) was added to a solution of amide 204 (110 mg, 0.367 mmol) in 
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acetonitrile (3 mL) and refluxed for 21 h.  The reaction mixture was concentrated in 
vacuo and the residue co-evaporated with CHCl3 (2 x 3 mL) to give the intermediate 
imine, which was then dissolved in methanol (6 mL) and cooled to 0 
o
C.  Sodium 
borohydride (111 mg, 2.94 mmol) was added portionwise over 15 min and the solution 
stirred at rt for 1.5 h.  The reaction mixture was concentrated in vacuo.  Water (10 mL) 
was added to the residue and extracted with CHCl3 (4 x 5 mL).  The combined organic 
extracts were dried by passing through a hydrophobic frit and solvent removed in vacuo 
to give the product as a pale yellow oil (95.7 mg, 92%).  δH (500 MHz; CDCl3) 7.41-
7.24 (5H, m, 5 x Ar-H), 6.73 (1H, s, 6-Ar-H), 6.20 (1H, s, 9-Ar-H), 5.14 (1H, s, 1-CH), 
3.86 (3H, s, OCH3), 3.59 (3H, s, OCH3), 3.38-3.11 (2H, m, 3-CH2), 3.09-2.81 (2H, m, 
5-CH2), 1.90-1.62 (3H, m, 4-CH2, NH);  δC (125 MHz; CDCl3) 147.1 (Ar-C), 146.4 
(Ar-C), 142.8 (Ar-C), 137.2 (Ar-C), 134.8 (Ar-C), 128.5 (2 x Ar-CH), 127.9 (2 x Ar-
CH), 127.0 (Ar-CH), 113.7 (6-Ar-CH), 112.6 (9-Ar-CH), 67.5 (1-CH), 56.1 (OCH3), 
55.9 (OCH3), 50.7 (3-CH2), 35.4 (5-CH2), 30.3 (4-CH2);  m/z (EI) 283 (M
+
, 60%), 253 
(M
+
 - C2H6, 100%), 206 (M
+
 - C6H5, 100%);  HRMS C18H21O2N, calcd 283.1572, found 
283.1577. 
 
8.98 N-(3-(3,4-Dimethoxyphenyl)propyl)benzamide (204)
143
 
 
The title compound was prepared according to the procedure described in section 8.80, 
from amine 194 (100 mg, 0.512 mmol) and benzoyl chloride (71.3 µL, 0.614 mmol).  
The crude yellow oil was purified by column chromatography (EtOAc/hexane, 2:3) to 
give the product as a white solid (130 mg, 85%).  Rf  0.2 (EtOAc/hexane, 2:3);  m.p. 78-
80 
o
C (lit
143
 84 
o
C, EtOAc);  δH (500 MHz; CDCl3) 7.67 (2H, d, J = 7.5 Hz, 2 x 2’-Ar-
H), 7.49 (1H, t, J = 7.5 Hz, 4’-Ar-H), 7.41 (2H, t, J = 7.5 Hz, 2 x 3’-Ar-H), 6.82-6.72 
(3H, m, 2-Ar-H, 5-Ar-H, 6-Ar-H), 6.05 (1H, br s, NH), 3.86 (6H, s, 2 x OCH3), 3.55-
3.49 (2H, m, CH2N), 2.69 (2H, t, J = 7.5 Hz, CH2(CH2)2N), 1.96 (2H, quintet, J = 7.5 
Hz, CH2CH2N);  δC (125 MHz; CDCl3) 167.7 (CONH), 149.1 (2 x Ar-C), 134.1 (2 x 
Ar-C), 131.5 (4’-Ar-CH), 128.6 (2 x Ar-CH), 126.8 (2 x Ar-CH), 120.2 (Ar-CH), 111.8 
(Ar-CH), 111.4 (Ar-CH), 56.0 (2 x OCH3), 39.9 (CH2N), 33.3 (CH2(CH2)2N), 31.4 
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(CH2CH2N);  m/z (EI) 299 (M
+
, 100%);  HRMS C18H21NO3, calcd 299.1516, found 
299.1510. 
 
8.99 1-Pentyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine-7,8-diol (205) and 1-Pentyl-
2,3,4,5-tetrahydro-1H-benzo[c]azepine-8,9-diol (206) 
 
The title compounds were prepared according to the procedure described in section 
8.48, from amine 195 (75.0 mg, 0.302 mmol) and hexanal (44.0 µL, 0.363 mmol).  The 
crude mixture of products were separated and purified by prep-HPLC (Method 1, run 
time: 30 min) to give 205 as a yellow oil (rt = 21.1 min, 3.4 mg, 5%) and 206 as a 
yellow oil (rt =  23.7 min, 2.6 mg, 3%).   
Major regioisomer 205:  δH (600 MHz; CD3OD) 6.75 (1H, s, 9-Ar-H), 6.67 (1H, s, 6-
Ar-H), 4.36-4.28 (1H, m, 1-CH), 3.44-3.28 (2H, m, 3-CH2), 2.98-2.85 (2H, m, 5-CH2), 
2.21-2.12 (1H, m, 4-CHH), 1.99-1.86 (3H, m, 4-CHH, 1-CHCH2), 1.46-1.26 (6H, m, 3 
x CH2), 0.92 (3H, t, J = 7.0 Hz, CH3);  δC (150 MHz; CD3OD) 146.9 (Ar-COH), 144.8 
(Ar-COH), 134.5 (Ar-C), 125.9 (Ar-C), 118.8 (6-Ar-CH), 117.3 (9-Ar-CH), 62.2 (1-
CH), 33.4 (5-CH2), 32.6 (CH2), 31.4 (1-CHCH2), 27.1 (CH2), 26.7 (4-CH2), 23.5 (CH2), 
14.3 (CH3);  m/z (CI) 250 ([M + H]
+
, 15%), 178 ([M + H]
+ 
- C5H12, 25%);  HRMS 
C15H24NO2, calcd 250.1802, found 250.1802. 
 Minor regioisomer 206:  δH (600 MHz; CD3OD) 6.66 (1H, d, J = 8.0 Hz, 7-Ar-H), 6.51 
(1H, d, J = 8.0 Hz, 6-Ar-H), 5.28-5.22 (1H, m, 1-CH), 3.54-3.26 (2H, m, 3-CH2),  3.17-
2.73 (2H, m, 5-CH2), 2.17-2.07 (2H, m, 4-CHH, 1-CHCHH), 1.96-1.87 (1H, m, 1-
CHCHH), 1.79-1.69 (1H, m, 4-CHH), 1.47-1.17 (6H, m, 3 x CH2), 0.88 (3H, t, J = 7.0 
Hz, CH3);  δC (150 MHz; CD3OD) 145.6 (Ar-COH), 144.9 (Ar-COH), 122.2 (6-Ar-
CH), 115.6 (7-Ar-CH), 54.6 (1-CH), 44.3 (3-CH2), 34.1 (5-CH2), 32.5 (CH2), 30.6 (1-
CHCH2), 27.2 (4-CH2), 26.6 (CH2), 23.5 (CH2), 14.3 (CH3);  m/z (CI) 250 ([M + H]
+
, 
55%), 178 ([M + H]
+ 
- C5H12, 100%);  HRMS C15H24NO2, calcd 250.1802, found 
250.1797. 
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8.100 1-Pentyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine-7,9-diol (207) 
 
The title compound was prepared according to the procedure described in section 8.53, 
from amine 196 (50.0 mg, 0.202 mmol) and hexanal (37.0 µL, 0.302 mmol).  The crude 
yellow oil was purified by prep-HPLC (Method 2, Gradient C, run time: 30 min, rt = 
17.9 min), to yield the product as a pale brown oil (36.0 mg, 72%).  δH (600 MHz; 
CD3OD) 6.23 (1H, d, J = 2.5 Hz, 8-Ar-H), 6.16 (1H, d, J = 2.5 Hz, 6-Ar-H), 5.16 (1H, 
dd, J = 10.0 and 5.5 Hz, 1-CH), 3.53-3.26 (2H, m, 3-CH2), 3.19-3.11 (1H, m, 5-CHH), 
2.71 (1H, dd, J = 15.5 and 5.5 Hz, 5-CHH),  2.17-2.06 (2H, m, 1-CHCHH, 4-CHH), 
1.92-1.84 (1H, m, 1-CHCHH), 1.81-1.71 (1H, m, 4-CHH), 1.44-1.19 (6H, m, 3 x CH2), 
0.89 (3H, t, J = 7.0 Hz, CH3);  δC (150 MHz; CD3OD) 159.6 (Ar-COH), 158.2 (Ar-
COH), 144.6 (Ar-C), 113.6 (Ar-C), 110.4 (6-Ar-CH), 101.5 (8-Ar-CH), 54.3 (1-CH), 
44.0 (3-CH2), 34.9 (5-CH2), 32.5 (CH2), 30.8 (1-CHCH2), 26.9 (4-CH2), 26.6 (CH2), 
23.5 (CH2), 14.3 (CH3);  m/z (ESI) 250 ([M + H]
+
, 70%), 233 ([M + H]
+
 - OH, 100%);  
HRMS C15H24NO2, calcd 250.1807, found 250.1805. 
 
8.101 1-Phenyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine-7,9-diol (208) 
 
The title compound was prepared according to the procedure described in section 8.53, 
from amine 196 (40.0 mg, 0.161 mmol) and benzaldehyde (24.6 µL, 0.242 mmol).  The 
crude product was purified by prep-HPLC (Method 2, Gradient C, run time: 30 min, rt = 
22.1 min), to give the product as a pale yellow oil (10.6 mg, 26%).  δH (600 MHz; 
CD3OD) 7.46-7.37 (3H, m, 2 x 3’-Ar-H, 4’-Ar-H), 7.23 (2H, d, J = 8.0 Hz, 2 x 2’-Ar-
H), 6.51 (1H, s, 1-CH), 6.32 (1H, d, J = 2.5 Hz, 8-Ar-H), 6.28 (1H, d, J = 2.5 Hz, 6-Ar-
H), 3.32-3.16 (2H, m, 3-CH2), 2.79-2.63 (2H, m, 5-CH2), 2.02-1.74 (2H, m, 4-CH2);  δC 
(150 MHz; CD3OD) 158.8 (Ar-COH), 156.9 (Ar-COH), 143.6 (Ar-C), 133.2 (Ar-C), 
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128.8 (2 x 3’-Ar-CH), 128.3 (4’-Ar-CH), 127.5 (2 x 2’-Ar-CH), 110.1 (Ar-C), 108.8 (6-
Ar-CH), 100.1 (8-Ar-CH), 55.7 (1-CH), 42.8 (3-CH2), 33.3 (5-CH2), 24.6 (4-CH2);  m/z 
(CI) 256 ([M + H]
+
, 100%), 239 ([M + H]
+ 
- OH, 25%);  HRMS C16H18NO2, calcd 
256.1338, found 256.1338. 
 
8.102 1-Benzyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine-7,9-diol (209) 
 
The title compound was prepared according to the procedure described in section 8.53, 
from amine 196 (40.0 mg, 0.161 mmol) and phenylacetaldehyde (28.3 µL, 0.242 
mmol). The crude product was purified by prep-HPLC (Method 2, Gradient C, run time: 
30 min, rt = 18.9 min) to give the product as a pale yellow oil (9.0 mg, 21%).  δH (600 
MHz; CD3OD) 7.28-7.19 (3H, m, 2 x 3’-Ar-H, 4’-Ar-H), 7.16 (2H, d, J = 7.5 Hz, 2 x 
2’-Ar-H), 6.19 (1H, d, J = 2.0 Hz, 6-Ar-H), 6.09 (1H, d, J = 2.0 Hz, 8-Ar-H), 5.42 (1H, 
t, J = 8.0 Hz, 1-CH), 3.67-3.59 (1H, m, 3-CHH), 3.38-3.23 (4H, m, 1-CHCH2, 3-CHH, 
5-CHH), 2.80 (1H, dd, J = 15.5 and 5.5 Hz, 5-CHH), 2.25-1.76 (2H, m, 4-CH2);  δC 
(150 MHz; CD3OD) 158.1 (Ar-COH), 156.5 (Ar-COH), 142.9 (Ar-C), 135.7 (Ar-C), 
128.8 (2 x 2’-Ar-CH), 128.0 (2 x 3’-Ar-CH), 127.5 (4’-Ar-CH), 111.4 (Ar-C), 108.8 (6-
Ar-CH), 99.8 (8-Ar-CH), 54.5 (1-CH), 42.7 (3-CH2), 35.3 (1-CHCH2), 33.2 (5-CH2), 
25.3 (4-CH2);  m/z (CI) 270 ([M + H]
+
, 100%), 178 ([M + H]
+ 
- C7H8, 30%);  HRMS 
C17H20NO2, calcd 270.1494, found 270.1492. 
 
8.103 Methyl 4-(7,9-dihydroxy-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-
yl)butanoate (210) 
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The title compound was prepared according to the procedure described in section 8.53, 
from amine 196 (20.0 mg, 0.0806 mmol) and aldehyde 181 (12.6 mg, 0.0967 mmol).  
The crude product was purified by prep-HPLC (Method 2, Gradient B, rt = 17.2 min) to 
give the product as a yellow oil (18.0 mg, 80%).  A minor product collected from the 
column was lactam 211 (rt = 19.5 min, 2.5 mg, 12%).  δH (600 MHz; CD3OD) 6.23 (1H, 
d, J = 2.0 Hz, 8-Ar-H), 6.17 (1H, d, J = 2.0 Hz, 6-Ar-H), 5.20-5.15 (1H, m, 1-CH), 3.64 
(3H, s, OCH3), 3.54-3.46 (1H, m, 3-CHH), 3.33-3.27 (1H, m, 3-CHH), 3.18-3.10 (1H, 
m, 5-CHH), 2.71 (1H, dd, J = 15.0 and 5.5 Hz, 5-CHH), 2.46-2.35 (2H, m, 
CH2CO2Me), 2.21-2.09 (2H, m, 4-CHH, 1-CHCHH), 1.96-1.88 (1H, m, 1-CHCHH), 
1.81-1.74 (1H, m, 4-CHH), 1.71-1.47 (2H, 1-CHCH2CH2);  δC (150 MHz; CD3OD) 
175.4 (CO2Me), 159.7 (Ar-CO), 158.2 (Ar-CO), 144.8 (Ar-C), 113.2 (Ar-C), 110.5 (6-
Ar-CH), 101.5 (8-Ar-CH), 53.8 (1-CH), 52.1 (OCH3), 44.1 (3-CH2), 34.9 (5-CH2), 33.8 
(CH2CO2Me), 30.0 (1-CHCH2), 26.8 (4-CH2), 22.2 (1-CHCH2CH2);  m/z (CI) 280 ([M 
+ H]
+
, 80%);  HRMS C15H22NO4, calcd 280.1549, found 280.1544. 
 
8.104 10,12-Dihydroxy-2,3,6,7,8,12b-hexahydrobenzo[c]pyrido[1,2-a]azepin-4(1H)-
one (211) 
 
A solution of aldehyde 181 (6.50 mg, 0.0498 mmol) in acetonitrile (0.5 mL) was added 
to a solution of amine 196 (10.3 mg, 0.0415 mmol) in potassium phosphate buffer (0.5 
mL, 0.1 M, pH 6), and the mixture was stirred at 50 
o
C for 8 h.  Sat. K2CO3 solution 
(0.1 mL) was added to the reaction mixture and stirred at rt for 48 h.  The pH of the 
mixture was adjusted to 4 by addition of dilute HCl and concentrated under vacuum to 
give the crude product, which was purified by prep-HPLC (Method 2, Gradient D, run 
time: 30 min, rt = 22.7 min).  Product containing fractions were concentrated and co-
evaporated with methanol (x3), to yield the product as a yellow oil (4.0 mg, 39%).  δH 
(600 MHz; CD3OD) 6.19 (1H, d, J = 2.5 Hz, 11-Ar-H), 6.05 (1H, d, J = 2.5 Hz, 9-Ar-
H), 5.04 (1H, dd, J = 11.0 and 4.0 Hz, 12b-CH), 4.13-4.07 (1H, m, 6-CHH), 2.87-2.78 
(2H, m, 6-CHH, 8-CHH), 2.49-2.43 (2H, m, 3-CH2), 2.36-2.29 (1H, m, 8-CHH), 2.25-
2.14 (2H, m, 1-CHH, 7-CHH), 1.90-1.77 (2H, m, 2-CH2), 1.69-1.60 (1H, m, 1-CHH), 
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1.51-1.43 (1H, m, 7-CHH);  δC (150 MHz; CD3OD) 172.6 (NCO), 158.2 (Ar-CO), 
156.3 (Ar-CO), 140.3 (Ar-C), 117.6 (Ar-C), 109.3 (9-Ar-CH), 101.9 (11-Ar-CH), 60.5 
(12b-CH), 43.1 (6-CH2), 32.9 (3-CH2), 30.6 (1-CH2, 8-CH2), 26.0 (7-CH2), 21.2 (2-
CH2);  m/z (ESI) 248 ([M + H]
+
, 100%);  HRMS C14H18NO3, calcd 248.1287, found 
248.1263. 
   
8.105 2-(4-Isobutyl-3-nitrophenyl)propanoic acid (213)
179
 
 
The title compound was prepared based on a literature procedure.
179
  70% Nitric acid 
(0.80 mL) was added dropwise to a solution of 2-(4-isobutylphenyl)propanoic acid 
(2.00 g, 9.70 mmol) in concentrated sulfuric acid (12 mL) at 0 
o
C.  The reaction mixture 
was stirred at rt for 1.5 h, then poured into ice cold water (100 mL) and extracted with 
EtOAc (4 x 50 mL).  The combined organic extracts were washed with water (30 mL), 
brine (30 mL), dried (MgSO4) and solvent removed in vacuo to give the crude product 
as a yellow oil which was purified by column chromatography (hexane/EtOAc, 5:1) to 
give a mixture of the starting material and product.  The starting material was removed 
by recrystallisation from EtOAc/hexane to give the product as a pale yellow solid (764 
mg, 31%).  Rf  0.65 (hexane/EtOAc, 1:1);  m.p 94-95 
o
C (lit
179
 84 
o
C, methanol);  δH 
(500 MHz; CDCl3) 7.82 (1H, d, J = 2.0 Hz, 2-Ar-H), 7.46 (1H, dd, J = 8.0 and 2.0 Hz, 
6-Ar-H), 7.28-7.24 (1H, m, 5-Ar-H), 3.79 (1H, q, J = 7.0 Hz, CHCO2H), 2.76 (2H, d, J 
= 7.0 Hz, CH2CH(CH3)2), 1.90-1.85 (1H, m, CH(CH3)2), 1.55 (3H, d, J = 7.0 Hz, 
CH(CH3)CO2H), 0.91 (6H, d J = 6.5 Hz, CH(CH3)2);  δC (125 MHz; CDCl3) 179.0 
(CO2H), 149.8 (Ar-C), 138.9 (Ar-C), 135.6 (Ar-C), 133.1 (5-Ar-CH), 131.7 (6-Ar-CH), 
123.9 (2-Ar-CH), 44.5 (CHCO2H), 41.5 (CH2CH(CH3)2), 29.5 (CH(CH3)2), 22.5 
(CH(CH3)2), 18.0 (CH(CH3)CO2H);  m/z (ESI) 250 ([M – H]
-
, 20%), 206 ([M – H]- - 
CO2, 100%);  HRMS C13H16NO4, calcd 250.1079, found 250.1057. 
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8.106 2-(3-Amino-4-isobutylphenyl)propanoic acid trifluoroacetic acid salt (215)
180
 
 
Pd/C 10 wt. % (10 mg) was added to a solution of the nitro compound 213 (100 mg, 
0.398 mmol) in methanol (6 mL).  The flask was evacuated and re-filled with H2 using a 
H2 balloon.  The reaction was stirred at rt for 5 h.  The reaction mixture was filtered 
through Celite and washed with methanol (2 x 15 mL).  The solvent was evaporated in 
vacuo to give the crude product which was purified by prep-HPLC (Method 2, Gradient 
C, run time: 20 min, flow rate: 8 mL/min, rt = 21.0 min) to give the product as a yellow 
oil as the TFA salt (49.1 mg, 37%).  δH (600 MHz; CD3OD) 7.35 (3H, m, 3 x Ar-H), 
3.75 (1H, q, J = 7.0 Hz, CHCO2H), 2.57 (2H, d, J = 7.5 Hz, CH2CH(CH3)3), 2.00-1.90 
(1H, m, CH2CH(CH3)2), 1.47 (3H, d, J = 7.0 Hz, CH(CH3)CO2H), 0.97 (6H, d, J = 6.5 
Hz, CH(CH3)2);  δC (150 MHz; CD3OD) 177.5 (CO2H), 142.4 (Ar-C), 134.3 (Ar-C), 
132.9 (Ar-CH), 131.8 (Ar-C), 128.6 (Ar-CH), 123.0 (Ar-CH), 45.9 (CHCO2H), 40.1 
(CH2CH(CH3)2), 29.7 (CH(CH3)2), 22.6 (CH(CH3)2), 18.9 (CH(CH3)CO2H);  m/z (EI) 
222 ([M + H]
+
, 30%), 179 ([M + H]
+ 
- CO2, 100%);  HRMS C13H19NO2, calcd 
221.1416, found 221.1419. 
 
8.107 Methyl 2-(4-bromomethyl)phenyl)propanoate (218)
215
 
 
To a solution of 2-(4-(bromomethyl)phenyl)propanoic acid (2.00 g, 8.23 mmol) in 
methanol (40 mL) was added concentrated H2SO4 (2 drops) and the solution stirred at rt 
for 19 h.  The solvent was evaporated and the residue dissolved in CHCl3 (50 mL).  The 
organic phase was washed with sat. NaHCO3 (2 x 20 mL), brine (20 mL), dried 
(Na2SO4) and solvent removed in vacuo to give the crude product as a yellow oil which 
was purified by column chromatography (hexane/EtOAc, 9:1) to yield the product as a 
colourless oil (1.64 g, 77%).  Rf  0.29 (hexane/EtOAc, 9:1);  δH (500 MHz; CDCl3) 7.38 
(2H, d, J = 8.0 Hz, 2 x Ar-H), 7.30-7.25 (2H, m, 2 x Ar-H), 4.52 (2H, s, CH2Br), 3.72 
(1H, q, J = 7.0 Hz, CHCO2Me), 3.66 (3H, s, OCH3), 1.49 (3H, d, J = 7.0 Hz, 
CH(CH3)CO2Me);  δC (125 MHz; CDCl3) 174.8 (CO2Me), 140.9 (Ar-C), 136.7 (Ar-C), 
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129.4 (2 x Ar-CH), 128.0 (2 x Ar-CH), 52.2 (OCH3), 45.2 (CHCO2Me), 33.3 (CH2Br), 
18.6 (CH(CH3)CO2Me);  m/z (CI) 259 ([(
81
Br)M + H]
+
, 15%), 257 ([(
79
Br)M + H]
+
, 
15%), 177 (M
+
 - Br, 100%);  HRMS C11H14
79
BrO2,  calcd 257.0177, found 257.0173.  
 
8.108 Ethyl 1-(4-(1-methoxy-1-oxopropan-2-yl)benzyl)-2-oxocyclopentane-1-
carboxylate (222)
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Ethyl 2-oxocyclopentanecarboxylate (0.580 mL, 3.89 mmol) was added to a stirred 
suspension of K2CO3 (0.967 g, 7.00 mmol) in acetone (50 mL).  After stirring at rt for 
15 min, compound 218 (1.00 g, 3.89 mmol) was added and the resulting mixture was 
refluxed for 16 h.  The reaction mixture was concentrated in vacuo.  The residue was 
dissolved in CH2Cl2 (100 mL) and washed with sat. NaHCO3 (2 x 50 mL), brine (50 
mL), dried (Na2SO4) and solvent removed in vacuo to give the crude product as a 
colourless oil, which was purified by column chromatography (hexane/EtOAc, 9:1) to 
give the product as a colourless oil (0.784 g, 61%).  Rf   0.18 (hexane/EtOAc, 9:1);  δH 
(500 MHz; CDCl3) 7.17 (2H, d, J = 8.0 Hz, 2 x Ar-H), 7.08 (2H, d, J = 8.0 Hz, 2 x Ar-
H), 4.16 (2H, q, J = 7.0 Hz, OCH2CH3), 3.80-3.60 (4H, m, CHCO2CH3), 3.20-3.00 (2H, 
m, CH2), 2.50-1.55 (6H, m, 3 x CH2), 1.46 (3H, d, J = 7.0 Hz, CH(CH3)CO2Me), 1.24 
(3H, t, J = 7.0 Hz, OCH2CH3);  δC (125 MHz; CDCl3) 214.9 (CO), 175.0 (CO2), 171.0 
(CO2), 139.1 (Ar-C), 135.6 (Ar-C), 130.5 (2 x Ar-CH), 127.5 (2 x Ar-CH), 61.7 and 
61.5 (CCO2CH2CH3), 52.1 (OCH3), 45.1 (CHCO2Me), 38.6 (CH2), 38.3 (CH2), 31.8 
(CH2), 19.5 (CH2), 18.6 (CH(CH3)CO2Me), 14.1 (OCH2CH3);  m/z (EI) 332 (M
+
, 30%), 
199 (M
+
 - C5H9O4, 100%);  HRMS C19H24O5, calcd 332.1624, found 332.1621. 
 
8.109 2-(4-((2-Hydroxycyclopentyl)methyl)phenyl)propanoic acid (224)
183
 
 
Sodium borohydride (9.37 mg, 0.248 mmol) was added portionwise to a solution of 
loxoprofen 79 (24.4 mg, 0.0991 mmol) in methanol (1.5 mL) at 0 
o
C, and stirred at rt 
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for 2 h.  The reaction mixture was concentrated in vacuo.  The resulting residue was 
dissolved in aqueous 1 M HCl (5 mL) and extracted with CHCl3 (3 x 10 mL).  The 
combined organic extracts were washed with brine, dried (Na2SO4) and solvent 
removed in vacuo to give the product as a white solid (23.3 mg, 95%), as a 3:1 mixture 
of the trans/cis diastereoisomers at C-1 and C-2 (determined by 
1
H-NMR and based on 
assignments reported by Naruto et al.).
183
  M.p. 84-108 
o
C (lit
183
 75-111 
o
C range for all 
8 diastereoisomers);  δH (600 MHz; CDCl3) 7.25-7.10 (4H, m, 4 x Ar-H), 4.12-3.86 
(1H, m, 2-CH), 3.71 (1H, q, J = 7.0 Hz, CHCO2H), 2.85-2.45 (2H, m, 1-CHCH2), 2.05-
1.52 (6H, m, 1-CH, 3-CH2, 4-CH2, 5-CHH), 1.51 (3H, d, J = 7.0 Hz, CH3), 1.30-1.18 
(1H, m, 5-CHH);  δC (150 MHz; CDCl3) 179.7 (CO2H), 141.1 and 140.4 (Ar-C), 137.5 
and 137.3 (Ar-C), 129.3 and 129.1 (2 x Ar-CH), 127.7 (2 x Ar-CH), 78.6 and 74.5 (2-
CH), 49.8 and 47.6 (1-CH), 44.9 (CHCO2H), 39.4 and 35.2 (1-CHCH2), 34.9 and 34.2 
(3-CH2), 29.9 and 28.8 (5-CH2), 21.9 and 21.6 (4-CH2), 18.3 (CH3);  m/z (EI) 248 (M
+
, 
30%), 230 (M
+
 - OH2, 85%), 185 (M
+
 - CH3O3, 100%);  HRMS C15H20O3, calcd 
248.1412, found 248.1411. 
 
8.110 2-(4-((2-Aminocyclopentyl)methyl)phenyl)propanoic acid trifluoroacetic acid 
salt (225) 
 
Ammonium acetate (62.6 mg, 0.812 mmol) was added to stirred solution of loxoprofen 
79 (20.0 mg, 0.0812 mmol) in methanol (2.5 mL) at rt.  After 5 min, sodium 
cyanoborohydride (6.12 mg, 0.0974 mmol) was added to the reaction mixture and 
stirred at rt for 48 h.  The solvent was removed in vacuo and the resulting residue was 
purified by prep-HPLC (Method 2, Gradient C, run time: 25 min, flow rate: 8 mL/min, 
rt = 17.8 min).  Appropriate fractions were evaporated in vacuo, and the resulting solid 
was recrystallised from Et2O/CH3OH to give the product as a white solid as the TFA 
salt (13.6 mg, 46%) as a 6:1 mixture of cis/trans diastereoisomers at C-1 and C-2 
(determined by 
1
H-NMR).  M.p. 38-42 
o
C;  υmax/cm
-1 
2970, 1668, 1513;  δH (600 MHz; 
CD3OD) 7.26 (2H, d, J = 8.0 Hz, 2 x 2’-Ar-H), 7.18 (2H, d, J = 8.0 Hz, 2 x 3’-Ar-H), 
3.72-3.65 (1H, m, CHCO2H), 3.32-3.25 (1H, m, 2-CH), 2.97-2.89 (1H, m, 1-CHCHH), 
2.53-2.39 (1H, m, 1-CHCHH), 2.20-2.11 (2H, m, 1-CH, 3-CHH), 1.88-1.61 (4H, m, 3-
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CHH, 4-CH2, 5-CHH), 1.49-1.38 (4H, m, 5-CHH, CH3);  δC (150 MHz; CD3OD) 178.4 
(CO2H), 140.6 (Ar-C), 139.9 (Ar-C), 130.1 and 129.9 (2 x 3’-Ar-CH), 128.8 (2 x 2’-Ar-
CH), 57.8 and 56.2 (2-CH), 47.8 and 45.3 (1-CH), 46.2 (CHCO2H), 39.6 and 35.5 (1-
CHCH2), 31.6 and 31.4 (3-CH2), 31.2 and 29.2 (5-CH2), 23.3 and 22.4 (4-CH2), 19.0 
(CH3);  m/z (CI) 248 ([M + H]
+
, 100%);  HRMS C15H22NO2, calcd 248.1651, found 
248.1652. 
  
8.111 1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol trifluoroacetic acid salt 
(230)
122
 
 
A 0.1 M stock phosphate solution was prepared by dissolving the required phosphate 
(0.600 mmol) in water (4 mL) and adjusting the pH to 6 by adding the appropriate 
amount of dilute aqueous HCl or NaOH solution.  The solution was then diluted to 6 
mL.  Dopamine hydrochloride (60.0 mg, 0.316 mmol) and phenylacetaldehyde (44.0 
µL, 0.380 mmol) were added to a mixture of water (1 mL), phosphate stock solution (2 
mL, 0.1 M, pH 6) and acetonitrile (3 mL).  The solution was stirred at 50 
o
C for 4 h.  
The reaction mixture was concentrated under vacuum or left in the blowdown unit 
overnight to remove the volatiles.  CH2Cl2/CH3OH 1:1 (10 mL) was added to the 
resultant residue and the suspension passed through a filter to remove the solid. The 
filtrate was evaporated to dryness and the crude product was purified by either prep-
HPLC (Method 2, Gradient E, rt = 20.4), or MDAP (Gradient A, rt = 13.9 min).  
Appropriate fractions were combined and solvent removed in vacuo to yield the product 
as a yellow solid as the TFA salt.  δH (600 MHz; CD3OD) 7.45-7.28 (5H, m, 5 x Ar-H), 
6.63 (1H, s, 5-Ar-H), 6.59 (1H, s, 8-Ar-H), 4.70-4.60 (1H, m, 1-CH), 3.50-3.23 (3H, m, 
3-CH2, 1-CHCHH), 3.11-2.87 (3H, m, 1-CHCHH, 4-CH2);  δC (150 MHz; CD3OD) 
149.9 (Ar-COH), 145.8 (Ar-COH), 136.7 (Ar-C), 130.6 (2 x Ar-CH), 130.2 (2 x Ar-
CH), 128.8 (Ar-CH), 123.6 (Ar-C), 116.2 (5-Ar-CH), 114.2 (8-Ar-CH), 57.4 (1-CH), 
41.3 (CH2), 40.9 (CH2), 25.7 (4-CH2);  m/z (ESI) 256 ([M + H]
+
, 100%). 
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8.112 8-Bromo adenosine 5’-monophosphate (234)193 
 
The title compound was prepared following a literature procedure.
193
  To a stirred 
solution of adenosine monophosphate disodium salt (2.00 g, 2.56 mmol) in sodium 
acetate buffer (0.5 M, 80 mL, pH 4) was added saturated aqueous bromine (25 mL).  
After 3 h, further saturated aqueous bromine (25 mL) was added, and stirred at rt for 21 
h.  The aqueous solution was washed with chloroform (4 x 50 mL) and evaporated to 
dryness to give the crude product as an orange solid (4.49 g, >100%), which was used 
without further purification.  A sample of the crude product was purified by prep-HPLC 
(Method 3, Gradient E, rt = 8.3 min) and was used in the synthesis of nucleotides 235 
and 236.  Residual sodium acetate was present in the crude and purified product (0.5 eq) 
as determined by 
1
H-NMR.  M.p. > 300 
o
C (decomposed);  δH (600 MHz; D2O) 8.21 
(1H, s, 2-CH), 6.12 (1H, d, J = 6.0 Hz, 1’-CH), 5.33 (1H, t, J = 6.0 Hz, 2’-CH), 4.60 
(1H, t, J = 6.0 Hz, 3’-CH), 4.30-4.25 (1H, m, 4’-CH), 4.12-3.97 (2H, m, 5’-CH2);  δC 
(150 MHz; D2O) 155.0 (C), 153.6 (2-CH), 151.0 (C), 128.9 (C), 120.0 (C), 89.9 (1’-
CH), 84.7 (4’-CH), 71.2 (2’-CH), 70.4 (3’-CH), 64.2 (5’-CH2). 
 
8.113 8-Phenyl adenosine 5’-monophosphate disodium salt (235)193 
 
The title compound was prepared following a literature procedure.
193
  8-Br-AMP 234 
(120 mg, 0.245 mmol), phenylboronic acid (37.3 mg, 0.306 mmol), potassium 
carbonate (50.9 mg, 0.368 mmol), sodium tetrachloropalladate(II) (1.80 mg, 6.13 µmol, 
2.5 mol%) and triphenylphosphine-3,3’,3”-trisulfonic acid trisodium salt (8.70 mg, 15.3 
µmol, 2.5 eq to Pd) were added to a flask and purged with argon.  Degassed water (6 
mL) was added via syringe and the reaction was stirred at 80 
o
C for 1.5 h.  The resulting 
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dark brown solution was filtered, and the filtrate was purified by prep-HPLC (Method 3, 
Gradient C, rt = 17.5 min).  Appropriate fractions were combined, concentrated and co-
evaporated with methanol to remove residual TEAB.  The resulting solid was dissolved 
in water, and pH adjusted to 8 by addition of aqueous 1 M NaOH.  The solution was 
concentrated in vacuo to give the product as a brown solid (96.2 mg, 84%).  M.p. > 300 
o
C (decomposed);  δH (600 MHz; D2O) 8.28 (1H, s, 2-CH), 7.77 (2H, d, J = 7.0 Hz, 2 x 
Ar-H), 7.70-7.61 (3H, m, 3 x Ar-H), 5.75 (1H, d, J = 6.0 Hz, 1’-CH), 5.06 (1H, t, J = 
6.0 Hz, 2’-CH), 4.12-3.92 (4H, m, 3’-CH, 4’-CH, 5’-CH2);  δC (150 MHz; D2O) 156.0 
(C), 154.0 (2-CH), 153.3 (C), 150.9 (C), 131.7 (Ar-C), 130.2 (2 x Ar-CH), 129.6 (2 x 
Ar-CH), 128.8 (Ar-CH) 119.2 (C), 91.1 (1’-CH), 85.1 (4’-CH), 71.8 (2’-CH), 70.6 (3’-
CH), 65.0 (5’-CH2);  m/z (ESI) 422 ([M – H]
-
, 100%);  HRMS C16H17N5O7P, calcd 
422.0865, found 422.0853. 
 
8.114 8-Naphthyl adenosine 5’-monophosphate triethylammonium salt (236) 
 
The title compound was prepared according to the procedure described in section 8.113, 
from 8-Br-AMP 234 (120 mg, 0.245 mmol) and 2-naphthylboronic acid (52.6 mg, 0.306 
mmol).  The crude product was purified by prep-HPLC (Method 3, Gradient D, rt = 20.0 
min).  Product containing fractions were concentrated in vacuo to give the product as a 
yellow solid as the triethylammonium salt (61.6 mg, 39%, 1.67 eq TEA as determined 
by 
1
H-NMR).  M.p. > 300 
o
C (decomposed);  δH (600 MHz; D2O) 8.01 (1H, s, 11-Ar-
H), 7.93 (1H, s, 2-CH), 7.91-7.79 (3H, m, 12-Ar-H, 15-Ar-H, 16-Ar-H), 7.61 (1H, d, J 
= 8.5 Hz, 17-Ar-H), 7.57-7.52 (2H, m, 13-Ar-H, 14-Ar-H), 5.91 (1H, d, J = 6.0 Hz, 1’-
CH), 5.18 (1H, t, J = 6.0 Hz, 2’-CH), 4.46 (1H, t, J = 6.0 Hz, 3’-CH), 4.23-4.09 (3H, m, 
4’-CH, 5’-CH2), 3.17 (10H, q, J = 7.0 Hz, CH2 TEA), 1.26 (15H, t, J = 7.0 Hz, CH3 
TEA);  δC (150 MHz; D2O) 155.1 (C), 153.0 (C), 152.7 (2-CH), 150.1 (C), 134.0 (C), 
132.6 (C), 129.9 (11-Ar-CH), 129.4 (Ar-CH), 129.1 (16-Ar-CH), 128.5 (Ar-CH), 128.2 
(Ar-CH), 127.7 (Ar-CH), 126.0 (17-Ar-CH), 125.3 (C), 118.9 (C), 89.6 (1’-CH), 83.8 
(4’-CH), 70.8 (2’-CH), 70.2 (3’-CH), 64.8 (5’-CH2), 41.2 (CH2 TEA), 8.8 (CH3 TEA);  
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m/z (ESI) 472 ([M – H]-, 100%);  HRMS C20H19N5O7P, calcd 472.1022, found 
472.1011. 
 
8.115 8-(4-Hydroxy)phenyl adenosine 5’-monophosphate triethylammonium salt 
(237) 
 
The title compound was prepared according to the procedure described in section 8.113, 
from 8-Br-AMP 234 (300 mg, 0.635 mmol) and 4-hydroxyphenylboronic acid (139 mg, 
1.01 mmol).  The crude product was purified by prep-HPLC (Method 3, Gradient A, rt = 
21.5 min).  Product containing fractions were concentrated in vacuo to give the product 
as a brown solid as the triethylammonium salt (30.5 mg, 15% over 2 steps from 5’-
AMP, 1.67 eq TEA as determined by 
1
H-NMR).  δH (600 MHz; D2O) 8.22 (1H, s, 2-
CH), 7.49 (2H, d, J = 7.0 Hz, 2 x Ar-H), 6.93 (2H, d, J = 7.0 Hz, 2 x Ar-H), 5.87 (1H, d, 
J = 6.0 Hz, 1’-CH), 5.21 (1H, t, J = 6.0 Hz, 2’-CH), 4.48-4.44 (1H, m, 3’-CH), 4.25-
4.10 (3H, m, 4’-CH, 5’-CH2), 3.21 (10H, q, J = 7.5 Hz, CH2 TEA), 1.29 (15H, t, J = 7.5 
Hz, CH3 TEA);  δC (150 MHz; D2O) 158.7 (C), 154.8 (C), 153.8 (C), 151.9 (C), 150.5 
(2-CH), 131.7 (2 x Ar-CH), 119.9 (C), 118.4 (C), 116.3 (2 x Ar-CH), 89.6 (1’-CH), 83.7 
(4’-CH), 70.8 (2’-CH), 70.2 (3’-CH), 65.2 (5’-CH2), 47.3 (CH2 TEA), 8.9 (CH3 TEA);  
m/z (ESI) 440 ([M + H]
+
, 100%);  HRMS C16H19N5O8P, calcd 440.0971, found 
440.0960. 
 
8.116 8-(4-Methoxy)phenyl adenosine 5’-monophosphate triethylammonium salt 
(238) 
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The title compound was prepared according to the procedure described in section 8.113, 
from 8-Br-AMP 234 (300 mg, 0.635 mmol) and 4-methoxyphenylboronic acid (153 mg, 
1.01 mmol).  The crude product was purified by prep-HPLC (Method 3, Gradient B, rt = 
24.0 min).  Product containing fractions were concentrated in vacuo to give the product 
as a grey solid as the triethylammonium salt (49.1 mg, 26% over 2 steps from 5’-AMP, 
1.1 eq TEA as determined by 
1
H-NMR).  δH (600 MHz; D2O) 8.17 (1H, s, 2-CH), 7.48 
(2H, d, J = 8.0 Hz, 2 x Ar-H), 6.92 (2H, d, J = 8.0 Hz, 2 x Ar-H), 5.83 (1H, d, J = 6.0 
Hz, 1’-CH), 5.20 (1H, d, J = 6.0 Hz, 2’-CH), 4.50-4.45 (1H, m, 3’-CH), 4.25-4.12 (3H, 
m, 4’-CH, 5’-CH2), 3.84 (3H, s, OCH3), 3.20 (6.6H, q, J = 7.5 Hz, CH2 TEA), 1.28 
(9.9H, t, J = 7.5 Hz, CH3 TEA);  δC (150 MHz; D2O) 161.3 (C), 154.7 (C), 153.3 (C), 
151.9 (C), 150.3 (2-CH), 131.3 (2 x Ar-CH), 120.3 (C), 118.7 (C), 114.8 (2 x Ar-CH), 
89.6 (1’-CH), 83.5 (4’-CH), 70.7 (2’-CH), 70.2 (3’-CH), 65.3 (5’-CH2), 56.0 (OCH3), 
47.3 (CH2 TEA), 8.9 (CH3 TEA);  m/z (ESI) 454 ([M + H]
+
, 100%);  HRMS 
C17H21N5O8P, calcd 454.1128, found 454.1119. 
 
8.117 8-(4-Nitro)phenyl adenosine 5’-monophosphate triethylammonium salt (239) 
 
The title compound was prepared according to the procedure described in section 8.113, 
from 8-Br-AMP 234 (300 mg, 0.635 mmol) and 4-nitrophenylboronic acid (169 mg, 
1.01 mmol).  The crude product was purified by prep-HPLC (Method 3, Gradient C, run 
time: 40 min, rt = 26.0 min).  Product containing fractions were concentrated in vacuo to 
give the product as a yellow solid as the triethylammonium salt (20.0 mg, 10% over 2 
steps from 5’-AMP, 1.2 eq TEA as determined by 1H-NMR).  δH (600 MHz; D2O) 8.32 
(2H, d, J = 8.0 Hz, 2 x 11-Ar-H), 8.22 (1H, s, 2-CH), 7.89 (2H, d, J = 8.0 Hz, 2 x 10-
Ar-H), 5.86 (1H, d, J = 6.0 Hz, 1’-CH), 5.27 (1H, t, J = 6.0 Hz, 2’-CH), 4.54-4.49 (1H, 
m, 3’-CH), 4.24-4.12 (3H, m, 4’-CH, 5’-CH2), 3.22 (7.2H, q, J = 7.5 Hz, CH2 TEA), 
1.28 (10.8H, t, J = 7.5 Hz, CH3 TEA);  δC (150 MHz; D2O) 155.0 (C), 153.5 (2-CH), 
151.4 (C), 151.1 (C), 149.1 (C), 134.7 (C), 131.2 (2 x 10-Ar-CH), 124.6 (2 x 11-Ar-
CH), 119.3 (C), 89.4 (1’-CH), 83.9 (4’-CH), 71.0 (2’-CH), 70.1 (3’-CH), 65.1 (5’-CH2), 
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47.3 (CH2 TEA), 8.9 (CH3 TEA);  m/z (ESI) 469 ([M + H]
+
, 100%);  HRMS 
C16H18N6O9P, calcd 469.0873, found 469.0874. 
 
8.118 LTB4 synthesis inhibition assay (GVK Bio) 
The assay was conducted by GVK Bio (GVK Biosciences, Private Limited, Plot No. 
28A, IDA Nacharam, Hyderabad – 500076, India). Personnel involved: Dr P. 
Arumugam and Dr R. Issac. 
Materials: LTB4 parameter six pack (R&D biosystems, SKGE006B), RPMI 1640 cell 
culture medium (Sigma-Aldrich, R6504), Hank’s Balanced Salt Solution HBSS 
(Invitrogen, 14025076), Dimethyl sulfoxide (Sigma-Aldrich, D2650), Recombinant 
human complement component C5a protein (R&D biosystems, 2037-C5-025), Foetal 
bovine serum (Gibco, 10270-106), Pencillin-Streptomycin (Gibco, 15140-122), Ficoll 
Paque PLUS (GE Healthcare, 17144002), Dextran solution (Sigma-Aldrich, D8802). 
Protocol: Neutrophils were isolated from human peripheral blood by ficoll-paque 
density gradient centrifugation and dextran sedimentation.  The freshly isolated 
neutrophils were seeded at 100,000 numbers/well in a 96-well plate.  Neutrophils were 
dosed with reference compound at a top concentration of 300 nM and test compound at 
a top concentration of 100 µM with a 1:3 step down dilution for 10 points.  Neutrophils 
were incubated at 37 
o
C in a CO2 incubator for 1 h, then stimulated with 50 ng/mL of 
recombinant human complement component C5a (1 mg/mL stock).  The neutrophils 
were incubated at 37 
o
C in a CO2 incubator overnight.  The cell supernatant was 
collected from each well and diluted down to a 1:10 dilution prior to conducting the 
ELISA.  LTB4 release from the neutrophils was assessed by using an LTB4 parameter 
kit following the manufacturer’s instructions.    
 
8.119 In-house LTB4 synthesis inhibition assay 
The assay was carried out in collaboration with Dr Dean Willis at the UCL pharmacy 
department.  The development of the MS method and analysis was carried out in 
collaboration with Dr Lisa D. Haigh in the UCL chemistry mass spectrometry facility. 
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Materials: LTB4 was purchased from Sigma-Aldrich as a 100 µg/mL solution in 
ethanol, purity ≥ 97%.  The stock solution of LTB4 was prepared by dilution of the 
purchased LTB4 sample to 10 µg/mL in methanol and was stored at –20 
o
C.  The 
standard solutions required for the calibration curve (concentrations of 10, 5, 2.5, 1.25, 
0.625, 0.313, 0.156 and 0.078 µg/mL) were prepared from the stock LTB4 solution 
through serial dilution with methanol.   
LC-MS system: LC-MS analysis was performed on an Agilent 1100 HPLC system using 
a C8 column at room temperature, eluting with solvents A/B (A: 10 mM ammonium 
acetate in water, B: 10 mM ammonium acetate in acetonitrile).  The flow rate was 200 
µL/min and the gradient employed was: 0 min (A: 99%, B: 1%), 11 min (A: 1%, B: 
99%), 11.1 min (A: 1%, B: 99%).  The sample injection volume was 5 µL.  The mass 
spectra were recorded on a Thermo Finnigan LTQ ion-trap mass spectrometer using 
negative mode electrospray ionisation.  Selected ion monitoring (SIM) was used over 
the mass range m/z 334-337.  For LTB4 concentration quantification, an eight point 
calibration plot was used (LTB4 quantification range 0.08-10 µg/mL) using the peak 
area at rt = 10 min. 
Protocol A (using mouse leukocytes):  The cells (1000 cells/mL) in Dulbecco’s 
modified Eagle’s medium (0.5 mL) were treated with the test or reference inhibitor (10 
mM in DMSO).  After 10 min the cells were treated with calcium ionophore A23187 (5 
µM) for 4 h.  The cell supernatant was collected from each well and centrifuged, and 
then treated with dichloromethane (2.7 mL) and a solution of methanol containing 1% 
formic acid (0.3 mL).   The top layer was removed.  The organic layer was passed 
through a filter (syringe filters, Klarity
TM
, PVDF, 13 mm, 0.2 µm), and concentrated in 
vacuo.  The residue was reconstituted in 50 µL methanol for LC-MS analysis. Each 
experiment was carried out in triplicate.  As a control, each experiment was repeated 
with either no stimulant (calcium ionophore) added, no inhibitor added, or both 
stimulant and inhibitor not added.    
Protocol B (using human neutrophils HL60):  Neutrophils (1000 cells/mL or 2000 
cells/mL) in Dulbecco’s modified Eagle’s medium (1 mL) were treated with calcium 
ionophore A23187 (10 µM) for 10 min.  The cell supernatant was collected from each 
well and centrifuged, and then treated with dichloromethane (4.5 mL) and a solution of 
methanol containing 1% formic acid (0.5 mL).  The top layer was removed.  The 
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organic layer was passed through a filter (syringe filters, Klarity
TM
, PVDF, 13 mm, 0.2 
µm), and concentrated in vacuo.  The residue was reconstituted in 75 µL methanol for 
LC-MS analysis.  Each experiment was carried out in triplicate.  As a control, each 
experiment was repeated where no simulant (calcium ionophore) was added.    
 
8.120 CRTh2 antagonistic activity assay (Euroscreen FAST) 
The assay was conducted by Euroscreen (Euroscreen FAST Business Unit, Euroscreen 
SA, 47 Rue Adrienne Bolland, 6041 Gosselies, Belgium). Personnel involved: Jerome 
Bernard and Sophie Brogniet. 
Materials: Assay buffer – 20 mM HEPES pH 7.4, 200 mM NaCl, 10 µg/mL saponin, 
MgCl2 at optimised concentration for the specific receptor, 0.1% BSA.  Membranes – 
CHO-K1 cells expressing recombinant human CRTh2 receptor, membrane extracts 
thawed on ice, diluted in assay buffer and kept on ice.  GDP – diluted in assay buffer to 
give optimised concentration for the specific receptor.  Beads – PVT-WGA (Amersham, 
RPNQ001) diluted in assay buffer at 50 mg/mL.  GTPγ[35S] – (PerkinElmer NEG030X) 
diluted in assay buffer to give 0.1 nM. 
Protocol: For antagonist testing, membranes were mixed with GDP (volume:volume) 
and incubated for 15 min on ice.  In parallel, GTPγ[35S] was mixed with the beads 
(volume:volume) just before starting the reaction.  The following reagents were 
successively added in the wells of an Optiplate (Perkin Elmer): 50 µL of test or 
reference ligand, 20 µL of the membranes:GDP mix, 10 µL of reference agonist (PGD2) 
at historical EC50 (12 nM) and 20 µL of the GTPγ[
35
S]:beads mix.  The plates were 
covered with a top seal, mixed on an orbital shaker for 2 min, and then incubated for 1 h 
at room temperature.  Then the plates were centrifuged for 10 min at 3000 rpm, 
incubated at room temperature for 1 h and counted for 1 min/well with a PerkinElmer 
TopCount reader. 
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8.121 High throughput SPOTi assay (Bhakta group, Birkbeck)
90
 
The assays were conducted by Arundhati Maitra and Dr Parisa N. Mortazavi in the 
Bhakta group in the Mycobacterial Research Laboratory at Birkbeck, University of 
London. 
M. aurum was grown in Middlebrook 7H9 broth supplemented with 0.02% (v/v) 
glycerol, 0.05% (v/v) tween-80 and 10% oleic acid, albumin, dextrose and catalase 
(OADC; BD Biosciences) as a shaking culture at 150 rpm at 35 C. The 
antimycobacterial activities of the compounds were tested following the SPOTi.
90
 The 
high throughput growth inhibition assay was conducted in a semi-automated 96 well 
plate format.  Compounds dissolved in DMSO at a final concentration of 50 mg/mL 
were serially diluted and dispensed in a volume of 2 µL into each well of a 96 well plate 
to which 200 µL of Middlebrook 7H10 agar medium kept at 55 C supplemented with 
0.05% (v/v) glycerol and 10% (v/v) OADC was added. A well with no compounds 
(DMSO only) and isoniazid were used as experimental controls. To all the plates, a drop 
(2 µL) of mycobacterial culture containing 2 x 10
6
 colony-forming units (CFUs) was 
spotted in the middle of each well and the plates were incubated at 37 C for 5 days. 
The minimum inhibitory concentrations (MICs) were determined as the lowest 
concentrations of the compound investigated where mycobacterial growth was 
completely inhibited by the presence of the compound. 
 
8.122 Eukaryotic cell cytotoxicity testing (Bhakta group, Birkbeck) 
The assays were conducted by Arundhati Maitra in the Bhakta group in the 
Mycobacterial Research Laboratory at Birkbeck, University of London. 
The assay was performed in 96-well cell culture flat-bottom plates in duplicate.  2 µL of 
the compounds, dissolved in DMSO to a concentration of 50 mg/L, were placed in wells 
(row - A) containing 198 µL of RPMI-1640 supplemented with 2 mM L-glutamine and 
10% heat inactivated fetal bovine serum. 2-fold serial dilutions were made (rows - B to 
H/F) and DMSO only was used as a control. To each well, 100 µL of RAW 264.7 
murine macrophage cells (5 × 10
5
 cells/mL) was added.  After 48 h of incubation, the 
monocytes were washed twice with 1 x PBS, and fresh RPMI-1640 complete medium 
was added.  Plates were then treated with 30 µL of freshly prepared 0.01% resazurin 
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solution and incubated overnight at 37 °C.  A change in colour from blue to pink 
denoted the viable cell activity. Visual colour changes were recorded and the 
fluorescence intensity was measured (Fluorstar Omega, λex 560 nm, λem 590 nm). The 
growth inhibitory concentration (GIC) is determined as the concentration at which > 
90% inhibition of cell viability is observed.  
 
8.123 Efflux pump inhibition assay (Bhakta group, Birkbeck) 
The assays were conducted by Arundhati Maitra and Dr Parisa N. Mortazavi in the 
Bhakta group in the Mycobacterial Research Laboratory at Birkbeck, University of 
London. 
The assay was modified from a previously published protocol.
158
  M. aurum was grown 
until it reached early logarithmic stage of growth (OD600 ~ 0.8).  The OD600 was then 
adjusted to 0.4 by diluting the cells with culture medium. The suspension was 
centrifuged at 3000 rpm for 10 min, the supernatant was discarded and the pellet was 
resuspended in 10 mL of sterile 1 x PBS. The test samples contained: 4-6 x 10
7
 
bacteria/mL in PBS, 0.4% glucose (as a source of energy for efflux pumps activity), 0.5 
mg/L ethidium bromide (as a substrate for efflux pumps) and the compounds being 
tested at sub-MIC concentrations. Blank samples contained all of the components 
mentioned above except the bacterial suspension, which was replaced with 1 x PBS. 
The experiment was performed in a 96-well plate (Corning) which was placed in a 
fluorimeter (FLUOstar OPTIMA, BMG Labtech) and the instrument was programmed 
with the following parameters: wavelengths of 544 nm and 590 nm for excitation and 
detection of fluorescence, gain 2200, a temperature of 37 °C, and a cycle of 
measurement every min for a total period of 60 min. The accumulation or efflux of 
ethidium bromide was monitored for the mentioned period on a real-time basis. 
 
8.124 Synergism assay (Bhakta group, Birkbeck) 
The assays were conducted by Arundhati Maitra in the Bhakta group in the 
Mycobacterial Research Laboratory at Birkbeck, University of London. 
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The synergistic effect of the THIQs was examined in combination with isoniazid, 
rifampicin and ethambutol against M aurum. The assay was conducted in a 96-well 
microtitre plate using a SPOTi checkerboard distribution. The compounds were serially 
diluted in DMSO from sub-MIC concentrations and lower. Each column of the 48-well 
plate contained different concentrations of the test compound and each row contained 
different concentrations of the first-line drug. Row 12 and column G contained drugs 
and test compounds only as controls. A row with only DMSO served as an additional 
control. The checkerboard was constructed by adding 1 µL of each of the stock 
concentrations to the corresponding well and then dispensing 200 µL of warm (55 °C) 
Middlebrook 7H10 agar medium supplemented with 10% (v/v) OADC. The plates were 
then spotted with M. aurum. The plates were incubated at 35 °C for 5 days. 
The fractional inhibitory concentration (FIC) for each compound was calculated using 
the following formula
217
: FICTB-drug = [MIC of TB-drug in the combination with 
THIQ]/[MIC of TB-drug alone] and similarly, FICTHIQ = [MIC of TB-drug in the 
combination with THIQ]/[MIC of THIQ alone].  The fractional inhibitory concentration 
index (FICI) was calculated using the following formula:  FICI = FICTB-drug + FICTHIQ.  
FICI ≤ 0.5 indicated synergism, FICI ≥ 4 indicated antagonism, and values in between 
corresponded to additivity or no interaction.
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8.125 Pharmacokinetic and Pharmacodynamic assays (Pharmidex) 
The assays were contracted to and performed at Pharmidex (Pharmidex Pharmaceuticals 
Ltd, 3
rd
 Floor, 14 Hanover Street, Mayfair, London, W1S 1YH). Personnel involved: Dr 
M. Chishty and Dr M. Yaqoob. 
Aqueous kinetic solubility assay: Aqueous kinetic solubility was measured at a 
concentration of 1 and 0.1 mg/ml.  Each experiment was carried out in triplicate, and 
pimozide (low aqueous solubility control) and propranolol (high aqueous solubility 
control) were used as reference standards.  The compounds were equilibrated in 5% 
DMSO in phosphate buffered saline (pH 7.4) at 21°C for 24 h.  The samples were 
centrifuged at 15000 g for 10 min.  A 100 μL sample of the supernatant was carefully 
collected and the soluble amount of compound quantified using LC-MS/MS.  A 
standard curve for each compound was prepared in 100% acetonitrile.  The solubility 
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results were reported as low (less than 0.1 mg/mL), medium (0.1 – 0.5 mg/mL) and high 
(greater than 0.5 mg/mL).   
Human microsome stability assay: Stock solutions of the test compounds were prepared 
in DMSO (10 mM).  The stock solutions were added to PBS to give an incubation 
concentration of 1 µM.  Microsomes (0.5 mg/mL) and NADPH were added to the 
solutions (total incubation volume was 100 µL) and the reactions was incubated at 37 
o
C for up to 60 min.  Acetonitrile (300 µL) with internal standard was added to stop the 
incubation.  The samples were centrifuged and the supernatant was analysed by HPLC-
MS/MS to detect the parent compound. 
Human hepatocyte stability assay: Stock solutions of the test compounds were prepared 
in DMSO (10 mM).  The stock solutions were added to PBS so that final incubation 
concentration was 1 mM.  Hepatocytes (70,000 per well) were added to the solution 
(total incubation volume was 100 µL) and the reaction was incubated at 37 
o
C for up to 
120 min.  Acetonitrile (300 µL) with internal standard was added to stop the incubation.  
The samples were centrifuged and the supernatant was analysed by HPLC-MS/MS to 
detect the parent compound.  
CYP450 inhibition assay: The compounds originally dissolved in DMSO were added to 
PBS to give a final incubation concentration of 10 mM.  To the microtitre plate was 
added the CYP baculosomes containing cDNA for a single human P450 isozyme, 
followed by the fluorogenic substrate and NADPH.  The reaction was incubated at 37 
o
C for at least 60 min.  Fluorogenic substrates are metabolised by CYP enzymes into 
products that are highly fluorescent in aqueous solution.  The inhibition of CYP 
prevents this metabolism, which corresponds to a decrease in the fluorescence signal, 
measured on a plate reader (Instrument: Tecan Safire2).   
MDR1-MDCK permeability and efflux assay: The compounds were dissolved in DMSO 
to provide stock solutions (10 mM) from which donor (dose) solutions were prepared in 
DMEM to give a final drug concentration of 10 µM.  All dose solutions contained 
propranolol (10 µM) as an internal standard.  The Maldin Darby Canine Kidney 
(MDCK) cells carrying the human multidrug resistant-1 gene (MDR1) were used to 
seed filters that were exposed to a fixed volume of the donor solution containing the 
compound of interest.  The compounds ability to traverse the monolayer and appear in 
the receiver compartment was measured over 30 min.  Bidirectional permeability 
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measurements were derived by examining the transfer of compound in both the apical to 
basolateral compartment and vice versa. Sample analysis was conducted using LC-
MS/MS with the detection settings optimised for each test compound.  The apparent 
permeability results (Papp) were reported as low (Papp < 2 x 10
-6 
cm/s, e.g. sucrose, 
mannitol, atenolol), medium (2 x 10
-6 
cm/s < Papp < 20 x 10
-6 
cm/s) and high (Papp > 20 x 
10
-6 
cm/s, e.g. propranolol, diazepam).  Compounds with efflux ratios above 1.5 were 
classified as Pgp substrates.  
 
8.126 Panlabs hit profiling screen 
The hit profiling screen was carried out by Eurofins Panlabs (Eurofins Panlabs Taiwan 
Ltd, Pharmacology Laboratories, 158 Li-The Road, Peitou, Taipei, Taiwan 112, Taiwan 
R.O.C.). 
The hit profiling screen included 35 assays.  Compounds were tested at a single 
concentration of 10 µM in duplicate.  The assays included: CYP450 1A2 (human), 
CYP450 2C19 (human), CYP450 2C9 (human), CYP450 2D6 (human), CYP450 3A4 
(human), Adenosine A1 (human), Adenosine A2A (human), Adrenergic α1A (rat), 
Adrenergic α1B (rat), Adrenergic α2A (human), Adrenergic β1 (human), Adrenergic β2 
(human), Calcium Channel L-Type Dihydropyridine (rat), Cannabinoid CB1 (human), 
Dopamine D1 (human), Dopamine D2S (human), GABAA Flunitrazepam Central (rat), 
GABAA Muscimol Central (rat), Glutamate NMDA Phencyclidine (rat), Histamine H1 
(human), Imidazoline I2 Central (rat), Muscarinic M2 (human), Muscarinic M3 (human), 
Nicotinic Acetylcholine (human), Nicotinic Acetylcholine α1 Bungarotoxin (human), 
Opiate μ OP3, MOP (human), Phorbol Ester (mouse), Potassium Channel [KATP] 
(hamster), Potassium Channel hERG (human), Prostanoid EP4 (human), Rolipram (rat), 
Serotonin 5-Hydroxytryptamine 5-HT2B (human), Sigma σ1 (human), Sodium Channel 
Site 2 (rat), Transporter Norepinephrine NET (human). 
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9. Appendix 
 
9.1 Efflux pump inhibition assay results 
 
Compound MIC (µg/mL) Concentration used for 
efflux assay (µg/mL) 
Efflux value 
141a >500 125 0 
142a 250 62.5 2 
141b 500 125 0 
142b 125 31.3 2 
141c 125 31.3 1 
142c 250 (some growth 
inhibition seen at 125) 
31.3 3 
141d >500 125 0 
142d 250 62.5 2 
141e 500 (some growth 
inhibition seen at 250) 
62.5 0 
142e 250 62.5 4 
141f 500 (some growth 
inhibition seen at 250) 
62.5 0 
142f 250 62.5 3 
145a >500 125 0 
146a 250 62.5 2 
145b >500 125 0 
146b 250 62.5 2 
145c 250 62.5 1 
146c 250 62.5 3 
145d 250 62.5 1 
146d 500 125 0 
162 62.5 15.6 2 
160 500 125 1 
161 250 62.5 0 
166 500 125 4 
163 250 62.5 4 
165 125 31.3 0 
164 250 62.5 0 
142b HCl 125 31.3 0 
Table 9.1. MIC and concentrations of THIQs used in the efflux pump assay.  The efflux value refers to 
the effect of the THIQs on the accumulation of ethidium bromide in M. aurum, where 4 = accumulation 
of ethidium bromide the same as that of known efflux pump inhibitor verapamil and 0 = no accumulation 
of ethidium bromide above that of normal accumulation levels when no inhibitor present.  Verapamil and 
chlorpromazine were used as positive controls at concentrations 125 µg/mL and 10 µg/mL respectively.   
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Figure 9.1. The effect of first generation THIQs on the accumulation of ethidium bromide in M. aurum. 
 
 
 
Figure 9.2. The effect of first generation THIQs on the accumulation of ethidium bromide in M. aurum. 
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Figure 9.3. The effect of first generation THIQs on the accumulation of ethidium bromide in M. aurum. 
 
 
 
Figure 9.4. The effect of first and second generation THIQs on the accumulation of ethidium bromide in 
M. aurum. 
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Figure 9.5. The effect of second and third generation THIQs on the accumulation of ethidium bromide in 
M. aurum. 
 
 
Figure 9.6. The effect of third generation THIQs on the accumulation of ethidium bromide in M. aurum. 
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Figure 9.7. The effect of third generation THIQs on the accumulation of ethidium bromide in M. aurum. 
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